<SEC-DOCUMENT>0001213900-23-067199.txt : 20230814
<SEC-HEADER>0001213900-23-067199.hdr.sgml : 20230814
<ACCEPTANCE-DATETIME>20230814170055
ACCESSION NUMBER:		0001213900-23-067199
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230814
DATE AS OF CHANGE:		20230814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		231171735

	BUSINESS ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		(646) 677-3870

	MAIL ADDRESS:	
		STREET 1:		100 PARK AVE., 23RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0623_actiniumphar.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sun Aug 13 17:17:32 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:atnm="http://actiniumpharmaceuticals.com/20230630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric><b>&#160;&#160;&#160;&#160;QUARTERLY REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the quarterly period ended <b><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">June 30, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric><b>&#160;&#160;&#160;&#160;TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period from __________ to __________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber"><b>001-36374</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>ACTINIUM PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>74-2963609</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<br/>
Incorporation or Organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<br/>
Identification No.)</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>100 Park Ave., 23<sup>rd</sup> Floor</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>New York, NY </b></p></td> <td style="vertical-align: bottom; text-align: center">&#160;</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10017</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(646)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">677-3870</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">275 Madison Avenue, 7<sup>th</sup>&#160;Fl</ix:nonNumeric>.<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">10016</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Address)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><b>Securities registered
pursuant to Section&#160;12(b) of the Act:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 1%">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b>&#160;</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common stock, par value $0.001</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: bottom; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ATNM</b></span></ix:nonNumeric></td> <td>&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NYSE</ix:nonNumeric> American</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). &#9746;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#160;No&#160;&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> </tr> <tr> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td> </tr> <tr> <td>&#160;</td> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric>&#160;</span></td> </tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards, provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744;&#160;Yes <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric>&#160;No</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of shares
outstanding of each of the issuer&#8217;s classes of common stock, as of August 14, 2023: <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">26,997,587</ix:nonFraction>&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Table of Contents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I &#8211; FINANCIAL INFORMATION</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top; width: 82%"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">41</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">41</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II &#8211; OTHER INFORMATION</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I - FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. &#160;FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The accompanying consolidated
financial statements have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (which include
only normal recurring adjustments) necessary to present fairly the financial position at June 30, 2023 and December 31, 2022, and the
results of operations and cash flows for the three months and six months ended June 30, 2023 and 2022, respectively, have been made. Certain
information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction
with the financial statements and notes thereto included in the Company&#8217;s audited financial statements for the year ended December
31, 2022 in the Company&#8217;s Annual Report on Form 10-K. The results of operations for the three months and six months ended June 30,
2023 are not necessarily indicative of the operating results for the full year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share and per share
data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 18pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">91,276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">108,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">4,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,636</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">95,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">110,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Property and equipment, net of accumulated depreciation of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">590</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">487</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">604</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Restricted cash &#8211; long term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating leases right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">2,581</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">2,341</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Finance leases right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">99,051</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">114,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">8,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">10,130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Operating leases current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">512</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">494</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 18pt">Finance leases current liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">9,151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">10,628</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenue" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Long-term operating lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermOperatingLeaseObligationsNoncurrent" scale="3" unitRef="usd">1,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="atnm:LongtermOperatingLeaseObligationsNoncurrent" scale="3" unitRef="usd">2,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">45,974</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">47,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">26,984,443</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">25,674,823</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">368,033</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">355,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">314,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">288,765</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">53,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">66,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">99,051</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">114,192</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands, except share and per share data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Three Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Six Months Ended<br/> June&#160;30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Revenue</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SubleaseIncome" scale="3" unitRef="usd">985</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">11,081</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">4,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">18,930</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">9,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">4,561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">8,296</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">4,968</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">15,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">7,895</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">27,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">13,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">15,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">7,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">27,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">13,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest income - net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">461</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">1,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">461</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">83</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">1,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">15,181</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">7,767</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">26,218</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,896</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-16; -sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14; -sec-ix-hidden: hidden-fact-13">Net loss per common share &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.33</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.01</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.56</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-20; -sec-ix-hidden: hidden-fact-19; -sec-ix-hidden: hidden-fact-18; -sec-ix-hidden: hidden-fact-17">Weighted average common shares outstanding &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">26,217,910</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">23,731,886</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">25,958,706</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">22,942,317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Period from January 1, 2023 to June
30, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholder&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, January 1, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,674,823</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">355,220</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">288,765</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">66,481</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">54,414</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">11,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">11,037</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, March 31, 2023</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">25,729,370</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">356,984</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">299,802</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">57,208</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">1,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">1,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">1,210,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">9,787</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">9,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common stock from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">44,108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">15,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">15,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">26,984,443</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">368,033</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">314,983</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">53,077</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statement of Changes
in Stockholders&#8217; Equity </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Three and Six Months Ended June 30,
2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In thousands, except share amounts)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> Paid-In</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Stockholder&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance, January 1, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">329,271</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">255,748</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">73,545</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">5,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance, March 31, 2022</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">22,143,974</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">22</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">329,692</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">260,877</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">68,837</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd">425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sale of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">2,726,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">16,683</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">16,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">7,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">7,767</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance, June 30, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">24,870,623</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">25</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">346,800</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">268,644</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">78,181</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Condensed Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(amounts in thousands)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/> Six Months Ended<br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 18pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">26,218</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,896</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">1,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">846</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Depreciation &amp; amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">2,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Payment of security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="3" sign="-" unitRef="usd">299</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">1,493</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Other revenue deferred &#8211; current liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">794</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Long-term license revenue deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInLongtermLicenseRevenuesDeferred" scale="3" unitRef="usd">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets" scale="3" sign="-" unitRef="usd">527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd">242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd">222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Net Cash Used In/Provided By Operating Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">28,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" unitRef="usd">22,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows Used In Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">277</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Net Cash Used In Investing Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">277</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash Flows Provided By Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Payments on finance leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 18pt">Sales of shares of common stock, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">10,558</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="atnm:SalesOfSharesOfCommonStockNetOfCosts" scale="3" unitRef="usd">16,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Proceeds from the exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18pt">Net Cash Provided By Financing Activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">10,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">16,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net change in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">18,025</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">38,501</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">109,608</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">78,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents, and restricted cash at end of period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">91,583</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">116,722</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18pt">Cash paid for income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the condensed consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Actinium Pharmaceuticals, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. develops targeted radiotherapies to meaningfully improve survival for patients with relapsed or refractory
disease who have failed existing oncology therapies.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2023 and December 31, 2022:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">91,276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitRef="usd">108,910</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">307</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssetsCurrent" scale="3" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">91,583</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">109,608</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p></ix:nonNumeric></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CollaborativeArrangementAccountingPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:GrantRevenuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from the National Institutes of Health (&#8220;NIH&#8221;) for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1" escape="true" name="atnm:LicenseRevenuePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement include payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4" id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="atnm_LicenseRevenuePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
June 30, 2023 and 2022, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">3,418</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">1,431</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">1,445</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">2,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">5,193</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" unitRef="shares">3,484</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, FASB issued ASU
2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock
Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#8217;s financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $<ix:nonFraction contextRef="c49" decimals="-6" format="ixt:num-dot-decimal" name="atnm:MilestonePayment" scale="6" unitRef="usd">1</ix:nonFraction> million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of <ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNetAssetsPercentage" scale="-2" unitRef="pure">2</ix:nonFraction>% of net sales will be due to FHCRC.&#160;</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a lease for corporate office space effective
June 1, 2022. The lease has a term of <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseDescription">5 years 2 months</ix:nonNumeric>, with an expiration date on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:LeaseExpirationDate1">July 30, 2027</ix:nonNumeric> and current annual rent of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="6" unitRef="usd">0.6</ix:nonFraction> million.
The Company is also responsible for certain other costs, such as insurance, utilities and maintenance. As of June 30, 2023, the Company
has two leases, a corporate office lease and an office equipment lease. Both of these leases have been capitalized in accordance with
ASC842. During the six months ended June 30, 2023, the Company spent $<ix:nonFraction contextRef="c51" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LandImprovements" scale="6" unitRef="usd">0.5</ix:nonFraction> million on improvements at its corporate office space, which
has been included in the value of the operating right-to-use asset as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of lease expense
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">183</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">141</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">345</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd">234</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">21</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Supplemental cash flow information
related to leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash flow information:</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">239</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">2,605</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOrDescriptionOfWeightedAverageTerm"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.1</ix:nonNumeric> years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">0.5</ix:nonNumeric> year</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:ScheduleOfWeightedAverageDiscountRate"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rates: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">8.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2023 (excluding six months ended June 30, 2023)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd">305</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="3" unitRef="usd">618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="3" unitRef="usd">631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="3" unitRef="usd">643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="3" unitRef="usd">380</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">2,577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="atnm:PaymentWithImputedInterestPremium" scale="3" unitRef="usd">242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">2,335</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="atnm:MaturitiesOfLeaseLiabilities" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="atnm_OtherRevenueTextBlock-c0_cont_1" escape="true" name="atnm:OtherRevenueTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 &#8211; Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s ability to terminate
the module. The consideration is recognized as revenue over each module and revenue of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="atnm:RevenueRecognized" scale="6" unitRef="usd">0.9</ix:nonFraction> million was recognized during the six months
ended June 30, 2022. There was no other revenue recognized from a collaboration during the six months ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had a grant from
the National Institutes of Health for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognized revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Other revenue recognized
from this grant for the six months ended June 30, 2022 was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="6" unitRef="usd">0.1</ix:nonFraction> million. There was no corresponding revenue for the six months ended June
30, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><ix:continuation id="atnm_OtherRevenueTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $<ix:nonFraction contextRef="c54" decimals="-6" format="ixt:num-dot-decimal" name="atnm:UpfrontPayment" scale="6" unitRef="usd">35</ix:nonFraction> million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#8211; current liability at June
30, 2023 and December 31, 2022. Long-term license revenue deferred was $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="atnm:LongtermLicenseRevenueDeferred" scale="6" unitRef="usd"><ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="atnm:LongtermLicenseRevenueDeferred" scale="6" unitRef="usd">35.0</ix:nonFraction></ix:nonFraction> million at June 30, 2023 and December 31, 2022; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which
the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $<ix:nonFraction contextRef="c55" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" unitRef="usd">200</ix:nonFraction> million of its common stock. Shares of
common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. On June 28, 2022,
the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;)
with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies the original
Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the six months ended June
30, 2023, the Company sold <ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">1.3</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">10.9</ix:nonFraction> million and net proceeds of $<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">10.6</ix:nonFraction>
million. For the six months ended June 30, 2022, the Company sold <ix:nonFraction contextRef="c57" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" unitRef="shares">2.7</ix:nonFraction> million shares of common stock, resulting in gross proceeds of $<ix:nonFraction contextRef="c57" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">17.2</ix:nonFraction>
million and net proceeds of $<ix:nonFraction contextRef="c57" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd">16.7</ix:nonFraction> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/>
 of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares">3,396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.85</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">15,204</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" unitRef="shares">151</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.85</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="3" unitRef="shares">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" unitRef="shares">85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" unitRef="shares">3,418</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.12</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">8.42</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">5,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares">1,126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">12.61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted">7.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" unitRef="usd">1,306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2023, the Company granted stock options to new employees to purchase <ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="atnm:GrantOfStockOptionsToEmployees" scale="3" unitRef="shares">151</ix:nonFraction> thousand shares of common stock with an exercise price
ranging from <ix:nonNumeric contextRef="c58" name="atnm:DescriptionOfExercisePriceRange">$8.05 to $11.60</ix:nonNumeric> per share, a term of <ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="atnm:StockOptionTerm">10</ix:nonNumeric> years, and a vesting period of <ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="atnm:VestingPeriodOfStockOption">4</ix:nonNumeric> years.&#160;The options have an aggregated fair
value of $<ix:nonFraction contextRef="c58" decimals="-5" format="ixt:num-dot-decimal" name="atnm:AggregateFairValue" scale="6" unitRef="usd">1.0</ix:nonFraction> million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from <ix:nonNumeric contextRef="c58" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription">3.5% to 4.21%</ix:nonNumeric> (2) expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric> years, (3) expected volatility range from <ix:nonNumeric contextRef="c58" name="atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription">81.1% to 81.6%</ix:nonNumeric>,
and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2023
was $<ix:nonFraction contextRef="c58" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">9.0</ix:nonFraction> million related to unvested options, which is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c58" format="ixt-sec:duryear" name="atnm:WeightedAverageTerm">3.0</ix:nonNumeric> years. During the six months
ended June 30, 2023 and 2022, the Company recorded compensation expense related to stock options of $<ix:nonFraction contextRef="c58" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">1.7</ix:nonFraction> million and $<ix:nonFraction contextRef="c59" decimals="-5" format="ixt:num-dot-decimal" name="atnm:CompensationExpenseRelatedToStockOptions" scale="6" unitRef="usd">0.8</ix:nonFraction> million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit, or RSU, activity for the six months ended June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="atnm:RSUsOutstandingBeginningBalance" scale="3" unitRef="shares">325</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">5.96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">8.31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="atnm:RSUsOutstandingBeginningBalance" scale="3" unitRef="shares">330</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">6.00</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $<ix:nonFraction contextRef="c60" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestmentsAtFairValue" scale="6" unitRef="usd">2.0</ix:nonFraction> million, was determined based on the stock
prices on the dates of the grants and each RSU grant is being recognized over its respective three-year period. The unrecognized compensation
expense at June 30, 2023 of $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="atnm:UnrecognizedCompensationExpense" scale="6" unitRef="usd">1.4</ix:nonFraction> million is expected to be expensed over a weighted average of <ix:nonNumeric contextRef="c61" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">2.2</ix:nonNumeric> years. During the six months ended
June 30, 2023, the Company recorded compensation expense related to RSUs of $<ix:nonFraction contextRef="c61" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="6" unitRef="usd">0.3</ix:nonFraction> million. There was no compensation expense related to
RSUs for the six months ended June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the six months ended June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/>
 of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="3" unitRef="shares">1,443</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">16.58</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.33</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" unitRef="shares">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="atnm:WeightedAverageRemainingContractualTermGranted">10.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="atnm:NumberOfWarrantsOutstandings" scale="3" unitRef="shares">1,445</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">16.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">0.84</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" unitRef="shares">1,440</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">15.94</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c64" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">0.83</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. &#160;MANAGEMENT&#8217;S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>FORWARD-LOOKING STATEMENT NOTICE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Form 10-Q contains certain
forward-looking statements. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may
be deemed to be forward-looking statements. &#160;Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable
terminology are intended to identify forward-looking statements. &#160;These statements by their nature involve substantial risks and
uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. &#160;These
factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within
our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business
relationships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium
Pharmaceuticals, Inc. (&#8220;Actinium&#8221;) develops targeted radiotherapies intended to meaningfully improve survival for
patients with relapsed or refractory cancer who have failed existing therapies. Our vision is to build a specialty,
hospital-focused, radiotherapeutics company that develops and markets medicines for patients who are treated primarily in large
quaternary care hospitals and their catchment areas.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Pipeline Highlights</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to leverage the
clinical data of our lead product candidates, Iomab-B and Actimab-A, to improve outcomes in patients with relapsed or refractory acute
myeloid leukemia (&#8220;r/r AML&#8221;) by launching two radiotherapy drugs over the next several years to address the significant need
for better outcomes from treatment with therapeutics or from undergoing a bone marrow transplant (&#8220;BMT&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to further
advance Iomab-B outside of acute myeloid leukemia (&#8220;AML&#8221;) based on promising data as a disease control and conditioning agent
for various other blood cancers. Based on early promising clinical trial results, we are also working on a lower dose, next generation
conditioning program, Iomab-ACT, for rapidly growing cell and gene therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Our Clinical Pipeline</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AML is an aggressive, heterogeneous
disease that is difficult-to-treat. Most AML patients develop relapsed or refractory disease within one year of being afflicted and have
an extremely poor prognosis and dismal survival. Currently, a BMT is the only curative regimen available for AML patients, however, access
is limited to AML patients who are fit enough to withstand the challenges associated with this treatment. The majority of AML patients
are considered not transplantable in routine clinical practice as they are not fit enough to withstand the rigors of the patient journey
which includes therapy to attain a remission, conditioning regimens to destroy diseased marrow, challenge of the transplant itself or
post-transplant complications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Iomab-B and
Actimab-A product candidates potentially fill the major unmet medical needs in r/r AML in a complementary fashion as they are
directed at different parts of the patient journey. Iomab-B is being developed as a targeted bridging therapy candidate that we
believe could provide both disease control and conditioning in one agent. We believe results from our Phase 3 SIERRA trial
demonstrate the possibility for unprecedented access to a BMT and improved survival in unfit patients who are currently not
considered transplantable in routine clinical practice. We are developing Actimab-A as a targeted therapy candidate for fit
patients. Actimab-A has demonstrated an extension in survival in a proof-of-concept study and is poised for advanced development in
collaboration with the NCI, or National Cancer Institute (&#8220;NCI&#8221;). Together, we believe these two product candidates
could provide us the opportunity to transform the treatment of AML, especially in the relapsed and refractory segment which
represents over 50% of AML patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We announced in October 2022
that Iomab-B met the primary endpoint of durable Complete Remission (&#8220;dCR&#8221;) with a high degree of statistical significance
(p&lt;0.0001) in the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractor AML, or &#8220;SIERRA trial.&#8221; In February
2023, we announced full trial results, demonstrating unprecedented transplant access and improved outcomes in patients with r/r AML, with
double 1-year and median overall survival (&#8220;OS&#8221;) compared to control arm patients. These data were presented at the 2023 Tandem
Meetings aka the Transplantation &amp; Cellular Therapy (&#8220;TCT&#8221;) Meetings of the American Society for Transplantation and Cellular
Therapy (&#8220;ASTCT&#8221;) and the Center for International Blood &amp; Marrow Transplant Research (&#8220;CIBMTR&#8221;). We believe
these results from the SIERRA trial may provide the opportunity, if we are able to obtain U.S. Food and Drug Administration (&#8220;FDA&#8221;)
approval, to establish Iomab-B as a new standard of care.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results from the
SIERRA trial were recently presented and discussed at major bone marrow transplant and hematology medical conferences, nuclear
medicines conference and nursing congress, which is helping to broaden the awareness of Iomab-B among members of the relevant
medical and scientific communities as we prepare for potential commercialization if we achieve FDA approval. Including TCT, the
SIERRA Phase 3 results have now been highlighted in oral presentations at four international medical conferences in the U.S. and EU
attended by key Iomab-B stakeholders including bone marrow transplant physicians, hematologists and nuclear medicine physicians. On
April 27, 2023, the results from the SIERRA trial were also showcased at the European Society for Blood and Marrow Transplantation
(&#8220;EBMT&#8221;) 49<sup>th</sup> Annual Meeting, which was well-attended by the European transplant community. Also in April
2023, two posters that detailed clinical findings from the SIERRA trial sites were presented at the 48<sup>th</sup> Annual Oncology
Nursing Society (&#8220;ONS&#8221;) Congress. We believe that the scientific community present at such events took note of the
successful administration of Iomab-B infusions at various BMT centers, which was done without increasing radiation exposure risks to
treating nursing staff. SIERRA results were also awarded an oral presentation at the European Hematology Association
(&#8220;EHA&#8221;) 2023 Hybrid Congress and presented in Frankfurt, Germany on June 10, 2023. The SIERRA results were also
presented at the Society for Nuclear Medicine and Molecule Imaging (&#8220;SNMMI&#8221;) annual meeting on June 26, 2023 and was
awarded the Henry N. Wagner, Jr., Abstract of the Year award, which represents the top selection out of more than 1,500 abstracts
accepted for presentation.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are actively working on
launching an early access program (&#8220;EAP&#8221;) for Iomab-B. We are also working towards completing and submitting our Biologics
License Application (&#8220;BLA&#8221;) for Iomab-B to the FDA by the end of 2023 and if approved, we intend to commercialize Iomab-B
in the U.S. We are committed to bringing Iomab-B to patients globally and are working with Immedica AB (&#8220;Immedica&#8221;), our
European, Middle East and North Africa (&#8220;EUMENA&#8221;) partner, for the subsequent marketing authorization application (&#8220;MAA&#8221;)
of Iomab-B with the European Medicines Agency (&#8220;EMA&#8221;). Europe represents a large commercial market opportunity with approximately
twice as many transplants performed in Europe compared to the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A is being developed
under what we believe to be the current industry-leading clinical-study program utilizing the potent alpha radiation emitting isotope
Actinium-225 (&#8220;Ac-225&#8221;) with clinical data in approximately 150 patients treated over six clinical trials. The potent linear
energy transfer emitted by Ac-225 has no known resistance mechanism. Actimab-A is being developed in combination with other regimens to
exploit mechanistic synergies and leverage the mutation-agnostic mechanism of action of Ac-225 with the objective of establishing it as
a backbone therapy in AML, an extremely heterogenous disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our Actimab-A + CLAG-M therapeutic combination trial results
in r/r AML provide validation of this approach. Such results were presented at the American Society of Hematology (&#8220;ASH&#8221;)
2022 Annual Meeting &amp; Exposition in December 2022. Phase 1 results from the Actimab-A + CLAG-M combination trial showed high response
rates and minimal residual disease (&#8220;MRD&#8221;) negativity, translating to a survival benefit of 53% and 32% at one and two years
in patients who are typically expected to live two to four months. At the same meeting, we shared Phase 1 data showing that the combination
of Actimab-A + venetoclax was well-tolerated with responses, including a Complete Remission (&#8220;CR&#8221;) and a partial response
in early dose escalation cohorts. We believe the promise of these results have paved the way for the NCI Cooperative Research and Development
Agreement (&#8220;CRADA&#8221;), announced on February 6, 2023, to develop Actimab-A for the treatment of patients with AML and other
hematologic malignancies. Under the CRADA, Actinium expects to initiate the late-stage development of Actimab-A, including a potential
pivotal trial, in combination as a backbone therapy for r/r AML and expects to update on the program and timing by end of the second half of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To explore the potential for
a broader development opportunity with our Actimab-A program, we are studying the potential use of Actimab-A in solid tumor indications
through our R&amp;D efforts. CD33-expressing myeloid derived suppressor cells (&#8220;MDSCs&#8221;) are present within the tumor microenvironment
and exert immunosuppressive effects. On April 18, 2023, we presented preclinical data at the Association for Cancer Research (&#8220;AACR&#8221;)
Annual Meeting that depicted Actimab-A&#8217;s role in the tumor microenvironment to overcome immunosuppression driven by MDSCs. We believe
that our findings thus far show Actimab-A&#8217;s potential to selectively deplete MDSCs in lung and colorectal cancer. Actimab-A also
demonstrated superior depletion of human MDSCs compared to Mylotarg, a CD33-targeted antibody-drug conjugate (&#8220;ADC&#8221;) in colorectal
cancer (p&lt;0.01), highlighting the powerful cytotoxicity and potential therapeutic benefit of radiotherapy compared to naked antibodies
or ADCs. We believe that the data we have gathered to-date continues to support our objective to demonstrate the potential for Actimab-A
to be a backbone therapy to broadly improve antitumor activity of immunotherapies and other therapeutic modalities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our differentiated R&amp;D
efforts are further exemplified by our next-generation Iomab-ACT conditioning program for rapidly growing cell and gene therapies, as
well as our solid tumor and immunotherapy collaborations with Astellas Pharma Inc. (&#8220;Astellas&#8221;), AVEO Oncology/LG Chem (&#8220;LG
Chem&#8221;) and EpicentRx, Inc. (&#8220;EpicentRx&#8221;). We have several ongoing programs in solid tumors at the pre-clinical stage
with investigational new drug (&#8220;IND&#8221;) enabling studies underway.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our platform has been used
to develop a pipeline of novel radiotherapeutic assets to drive company growth. Preclinical pharmacology studies with our targeted radiotherapeutics,
such as HER3-ARC, HER2-ARC or CD33-ARC, have shown strong improvement in tumor growth inhibition in various preclinical tumor models as
single agents or in combination with immunotherapy such as magrolimab, an anti-CD47 monoclonal antibody. These results have prompted the
team to spearhead efforts in multiple solid tumor programs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium&#8217;s lead solid
tumor program is a targeted radiotherapy against HER3, a pan-cancer target that is overexpressed in several solid tumor indications with
high unmet need. We have aligned our R&amp;D strategy of advancing solid tumors into the clinic with our Actimab-A program. We recently
presented pre-clinical data at the AACR 2023 Annual Meeting, highlighting this opportunity. We believe the results support further testing
to evaluate the anti-tumor effects of HER3-targeted radiotherapy. HER3 conjugated to either alpha-emitting Ac-225 or beta-emitting Lutetium-177
(&#8220;Lu-177&#8221;) displayed anticancer activity in ovarian and colorectal cancer preclinical models. The consistent overexpression
of HER3 in multiple solid tumor types, including ovarian, renal, prostate, urothelial, breast, and lung cancers suggests broad utility
of a HER3-targeted agent in a clinical setting, which we intend to explore further.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual
property (&#8220;IP&#8221;) portfolio includes over 200 issued patents and pending patent applications worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the approximately $91.2
million cash on hand as of June 30, 2023, we expect to fund operations through 2025 as we continue to drive ahead in executing our strategy
to realize our vision.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market opportunity for
Iomab-B and Actimab-A, as depicted in the diagram below, exists in AML and for cellular therapy conditioning in various blood cancers.
We believe that Iomab-B and Actimab-A can fill the major unmet medical needs in r/r AML in a complementary fashion as they are utilized
in different parts of the patient treatment journey. The incidence of AML is approximately 21,000 patients per year, with a prevalence
of approximately 70,000 in the U.S., (approximately 27,500 new patients per year in Europe) and the disease has an outsized economic impact
relative to its population size. Over 50% of patients diagnosed with AML will develop relapsed or refractory disease, with a median age
of 68 years at diagnosis. Despite 11 new approved therapies since 2017, no significant advancements have been made toward a cure and there
is an important unmet medical need for better therapeutics, which provide the opportunity for Actimab-A. Actimab-A is a targeted radiotherapy
for fit patients that has demonstrated an impressive improvement in survival in a proof-of-concept study and is poised for advanced development
in collaboration with the NCI. Using Actimab-A in combination with chemotherapy or a targeted therapy, we have the potential opportunity
to treat both newly diagnosed or r/r AML patients, with the potential addressable population comparable to the prevalence of patients
with AML.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Today, less than 20% of AML
patients are able to access a BMT, currently the only potentially curative option. These patients are usually younger, fit, and able to
withstand the challenges associated with this treatment, leaving the large majority of AML patients ineligible for transplant. This provides
an opportunity for Iomab-B, which has demonstrated the ability to enable unfit patients to benefit from a BMT. Thus Iomab-B can potentially
expand the market from the approximately 400 r/r AML patients who are transplanted currently to approximately 8,000 unfit patients that
could be eligible for transplant. Iomab-B has also demonstrated the ability to improve BMT access with extended survival and potentially
curative outcomes in several other hematological diseases outside of AML. Several clinical trials in over 300 patients with myelodysplastic
syndromes (&#8220;MDS&#8221;), acute lymphocytic leukemia (&#8220;ALL&#8221;), Hodgkin&#8217;s lymphoma (&#8220;HL&#8221;), Non-Hodgkin
lymphoma (&#8220;NHL&#8221;) and multiple myeloma (&#8220;MM&#8221;) have demonstrated the same value proposition as in AML. This data
provides a potential opportunity to expand the market for Iomab-B beyond AML via label expansion. In the U.S., there are approximately
185,000 patients diagnosed annually with blood cancers (e.g., leukemia, lymphoma, and myeloma) that are treatable with BMT, of which,
approximately 20,000 are transplanted, leaving greater than 165,000 patients who could potentially benefit from transplant. These patients
do not receive a BMT today primarily because they are unfit with active disease and are not considered eligible, as they cannot tolerate
the rigors of therapy required to induce a remission and the conditioning agents required to ablate the marrow prior to a BMT.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beyond BMT, the opportunity
exists for better conditioning in other areas of cellular therapy such as CAR-T as well as gene therapies. The pipeline of CAR-T and gene
therapies has rapidly expanded, with the addressable patient population expected to nearly double in the next one to five years and reach
approximately 93,000 patients in the U.S. by 2030 based on the current pipeline of cellular therapies. The CAR-T market size in terms
of dollars is estimated to grow at a CAGR of approximately 11% over the next 5 plus years. The addressable market for Iomab-ACT is in
line with the patient population for cellular therapy as all patients receive conditioning of some type prior to these treatments. We
will continue to develop Iomab-ACT, our lower dose, next generation conditioning program for rapidly growing cell and gene therapies based
on early promising results, ultimately with the value proposition of improving overall access and outcomes for patients who need cellular
or gene therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium&#8217;s strategy
is to build a fully integrated, specialty radiotherapeutics company focused on the top 100 cancer hospitals using the power of our platform
to deliver new treatment options for patient populations living with high unmet medical needs in hematology and oncology. We believe our
focus on relapsed or refractory disease in cancer indications with high unmet medical need, with limited or no competition, and where
the primary delivery of care occurs in large comprehensive cancer care centers, is the appropriate strategy for our company. The cell
killing power of linear energy transfer delivered via radiotherapeutics is unmatched by other technologies and we believe relapsed/refractory
disease is an area where radiotherapeutics can succeed over other approaches. However, radiotherapeutics must be delivered on a just-in-time
basis, and commercial and supply chain barriers are higher than with other types of medicines. The validity of our approach is demonstrated
by our product development strategy as well as the commercial and operating model that we are building for our lead product candidates,
Iomab-B and Actimab-A.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to transform the
treatment of AML with our Iomab-B and Actimab-A product candidates, each of which has demonstrated extension of survival in the most difficult-to-treat
patients who are typically expected to survive for two to four months. The r/r AML segment comprises over 50% of all AML patients. Actimab-A,
a therapeutic agent, and Iomab-B for induction and conditioning, can be used in a complementary fashion as depicted in the diagram below.
Based on solid clinical evidence with these product candidates, we intend to develop and commercialize these two radiotherapy drugs, starting
with Iomab-B in 2024 and Actimab-A in 2027, if approved, to improve survival in patients with r/r AML.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Iomab-B and Actimab-A have the potential
to significantly improve r/r AML outcomes in a complementary manner</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_003.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operating model
required to achieve our vision is attractive for several reasons, including the concentrated point of care; the top 50 transplant
centers account for approximately 75% of BMTs and the top 100 hospitals treat over 50% of r/r AML patients. Further, there is
significant overlap in the healthcare providers and ecosystem required to diagnose, treat and care for r/r AML patients within these
hospitals, which will enable us to deploy a relatively small commercial organization and operate a supply chain without the need for
large investments.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is targeting
a broader opportunity in conditioning via label expansion of Iomab-B into BMT for other blood cancers and with Iomab-ACT, our next generation
conditioning program for rapidly growing cell and gene therapies. Further, our solid tumor programs are initially directed at r/r cancers,
a stage of disease where treatment is again concentrated in large hospitals, which account for a significant portion of patients. We believe
our strategy will enable us to build a successful company with high operating efficiencies and is feasible to achieve without requiring
a commercial partner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategic priorities are to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Establish Iomab-B as the standard of care to improve BMT access and survival outcomes in r/r AML patients who are currently not considered transplantable in routine clinical practice: </i></b>We intend to file a BLA in the second half of 2023 based on the positive results from the Pivotal Phase 3 SIERRA trial and leverage our operating track record at key cancer centers to build an organization that can effectively commercialize Iomab-B. By virtue of the SIERRA trial, we have established operations at 24 leading BMT centers in the U.S (22) and Canada (2) that represent about 30% of transplant volume and have strong working partnership with Key Opinion Leaders (&#8220;KOLs&#8221;) and their teams. The SIERRA results demonstrating unprecedented access to BMT and outcomes along with our commitment to operational excellence provides a strong foundation for our commercial team in the U.S. We will also work with our partner Immedica to file the MAA for the EU and support Iomab-B&#8217;s potential approval and launch with our expertise, as well as supply drug product for commercialization.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advance Actimab-A in combinations as a backbone therapy for r/r AML:</i></b> We intend to progress late-stage development of Actimab-A to leverage its mutation-agnostic mechanism of action (&#8220;MOA&#8221;) and exploit synergies in combination with other treatments to develop it as an AML backbone therapy. This approach is validated by proof-of-concept data from our Actimab-A + CLAG-M combination trial in r/r AML, which included 57% of patients who had failed venetoclax and are expected to live two to four months on average. The results demonstrated high response rates overall and in these venetoclax failed patients&#8217; median OS was 59% at one year and 32% at two years. Our collaboration with the NCI under the CRADA could provide broad support for late-stage development of Actimab-A + CLAG-M and also other clinical trials to broaden use of Actimab-A. Actimab-A, if approved, would enable us to launch a second product that is complementary to Iomab-B and fulfill our ambition of transforming the treatment outcomes of r/r AML and expand our commercial footprint into the remaining top 100 cancer care centers outside of the leading BMT hospitals.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Expand the Iomab-B label and revenue stream via life cycle management:</i></b> We intend to leverage data from several clinical trials that demonstrate the ability of Iomab-B to improve BMT access and outcomes in five additional hematologic indications. These data in MDS, ALL, HL, NHL and MM provide the foundation to expand the label for Iomab-B and increase its market potential. In AML, we would seek label expansion into haploidentical transplants, earlier lines of treatment and younger patients below the age of 55, the cutoff in the SIERRA trial. As much as possible, we would seek to use investigator sponsored trials as the primary strategy for label expansion in order to maximize capital utilization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Further expand our conditioning franchise by developing Iomab-ACT for cell and gene therapies:</i></b> We plan to develop Iomab-ACT to be used for either lymphodepletion or reduced intensity conditioning prior to CAR-T and gene therapies. Similar to BMT, access and outcomes of patients who might benefit from these therapies is currently limited by sub-optimal chemotherapy-based conditioning agents. The number of patients potentially eligible for Iomab-ACT is growing with increased availability of commercial cell and gene therapy products, as well as the expanding number of indications. We are studying Iomab-ACT in conditioning prior to CAR-T cellular therapy via a National Institutes of Health (&#8220;NIH&#8221;) funded clinical trial with Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;). We expect to present proof-of-concept data from this study in the second half of 2023 and announce further development of this program in the CAR-T space.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage our R&amp;D capabilities and technological prowess to advance our solid tumor programs and partnerships: </i></b>We intend to continue to direct our R&amp;D effort to advance our solid tumor programs into the clinic and support life cycle management for Iomab-B and Actimab-A. Our solid tumor programs and technological capabilities are validated by our partnerships with Astellas, LG Chem, and EpicentRx. Our R&amp;D capability is demonstrated by our patent portfolio with over 200 issued and pending patent applications worldwide which include protection for Iomab-B into 2037. Our IP portfolio also includes several patent families to manufacture Ac-225 in a cyclotron and includes valuable know-how.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In keeping with our strategic
    vision over the next five years, we plan to first focus on ensuring an Iomab-B approval and successful launch into core BMT centers
    to support commercial success. We intend to expand the Iomab-B label and revenue stream while progressing the development of Actimab-A
    by leveraging the NCI CRADA. We will progress the development of Iomab-ACT to proof-of-concept and explore potential partnerships
    as a means to achieve commercialization. Our solid tumor programs will progress toward the clinic as we continue to build out our
    commercial footprint into the top 100 hospitals leaving us positioned to develop them in line with our vision. With commercial dynamics
    aligning favorably for a successful Iomab-B launch and with late-stage development of Actimab-A in collaboration with the NCI, we
    plan to deliver on our mission to transform the treatment of AML and patient outcomes, and create a highly differentiated, specialty
    radiotherapeutics company focused on the top 100 large hospitals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Product Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have strategically focused
our development efforts in areas where there is a significant unmet medical need. We are developing a portfolio of novel radiotherapeutics
that has the potential to positively impact the outcomes of people living with hard-to-treat diseases such as r/r AML via both a therapeutic
and induction/conditioning agent. Outside of AML, our pipeline development offers the opportunity to enhance the value proposition of
cell and gene therapies with our targeted conditioning programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">AML Focused Programs &#8211; Iomab-B
and Actimab-A</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Iomab-B and Actimab-A
product candidates are focused on addressing the major unmet medical needs in r/r AML in a complementary manner and are directed at different
parts of the patient journey.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-B &#8211; Targeted Radiotherapeutic
for Induction and Conditioning. A potential new standard of care enabling a curative BMT in currently non-transplantable r/r AML patients
with poor survival prognosis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Opportunity to Change the Current Paradigm
for Accessing a BMT and Improving Outcomes </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current approach in preparing
patients for a BMT is to first induce a remission with therapeutic agents to reduce the disease burden and then suppress or destroy the
patient&#8217;s immune system, including the diseased bone marrow, with conditioning regimens prior to transplanting the healthy donor
hematopoietic stem cells, which are expected to restore normal bone marrow function following engraftment. As this approach requires patients
to withstand multiple challenges from non-targeted therapies, which include chemotherapy agents and/or total body irradiation that are
highly toxic, BMT is typically limited to FIT patients. Iomab-B is a targeted therapy that provides both disease control (induction) and
conditioning in one agent and is well-tolerated even by UNFIT patients who typically are not transplanted in routine practice today. The
SIERRA trial was designed to demonstrate that UNFIT patients with active disease could be administered Iomab-B and proceed directly to
a BMT without the need for inducing a remission and that this approach could result in improved survival and curative outcomes. As seen
by the positive results of the SIERRA trial detailed below, Iomab-B represents an exciting new paradigm in the management of AML patients
and establishes a potential new standard of care especially for UNFIT patients in the relapsed or refractory setting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A similar
approach has also been tried in the Phase 3 ASAP trial but with FIT patients. However, to avoid confusion between the potential of the
approaches used in the ASAP and SIERRA trials, important distinctions between these trials are depicted in the graphic below. The ASAP
trial sought to demonstrate non-inferiority between two non-novel approaches and found that outcomes similar to those of current practice
could be achieved without first getting a patient into remission before taking them to BMT by giving them sequential conditioning or treating
them twice with non-targeted chemotherapy agents that are typically used in this setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ASAP approach is
limited to only FIT patients as the UNFIT patients treated in SIERRA could not tolerate ASAP&#8217;s highly toxic sequential
conditioning approach. Sequential conditioning is not novel as a similar trial to ASAP was conducted by the UK National Cancer
Research Institute in 2019, which did not show any benefit from this approach in high-risk AML and MDS patients (Craddock et al.
Augmented Reduced Intensity Regimen Does Not Improve Post allogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol.
2021). &#160;The SIERRA trial results therefore can change the paradigm in transplant because non-transplantable patients in routine
clinical practice can benefit from a transplant with Iomab-B and have superior outcomes. While both approaches in these trials
support increased access to BMT, only Iomab-B is applicable to the unfit patients who comprise approximately 80% of r/r AML patients
and can potentially expand the market for transplant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Schetelig et al. Results from the Randomized
Phase III ASAP Trial. ASH 2022</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Pivotal Phase 3 SIERRA Trial for Iomab-B (<sup>131</sup>Iodine-apamistamab)
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SIERRA trial was designed
to demonstrate the ability of Iomab-B to overcome challenges related to patient access to curative BMT. Unfortunately, approximately 30%
of patients with AML have primary refractory disease while 50% relapse quickly after achieving initial remission. Getting these patients
with primary r/r AML into remission is very challenging due to characteristics such as age, comorbidities, and disease features such as
high-risk mutations that contribute to lack of response to salvage therapies and limit treatment options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients must be able to overcome
several challenges related to curative BMT. The first access challenge is that the patient needs to be in complete remission prior to
BMT. The current clinical practice is not to transplant patients with active AML as outcomes are poor due to high relapse rates. The National
Comprehensive Cancer Network (&#8220;NCCN&#8221;) guidelines also recommend treatment to achieve remission prior to transplant in patients
with relapsed AML. The second challenge to access is tolerance to current conditioning regimens. For older patients, myeloablative regimens
are not an option due to intense toxicity and mortality. The third challenge is the ability to achieve post-BMT remission and successful
engraftment. Inadequate conditioning can lead to graft failure, which is associated with very high mortality. Patients who fail to achieve
a CR post-transplant have extremely poor outcomes and a survival of a few weeks. The fourth challenge relates to BMT tolerability and
post-BMT complications. The conditioning and immunosuppressive regimens given to these patients put them at high risk for infectious complications
and toxicity. In the SIERRA trial, Iomab-B addressed all four of these challenges. Access to BMT is improved as CR is not needed pre-BMT
given effective disease control and targeted myeloablation. With better post-BMT engraftment, CR and lower complications, the SIERRA trial
also addressed the challenges related to improved outcomes through Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SIERRA results, presented
in the late-breaker session at the 2023 Tandem Meetings: Transplantation &amp; Cellular Therapy Meetings of the ASTCT and the CIBMTR,
support Iomab-B&#8217;s value proposition of enabling both improved access and outcomes of a BMT, thereby providing a significant curative
option for r/r AML patients, a segment that represents approximately 50% of all AML patients and the majority not transplanted today.
The design of the SIERRA trial is provided in the figure below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIERRA: A Novel, Pivotal Phase 3 Study of
Iomab-B in r/r AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i><img alt="" src="image_006.jpg"/>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pivotal Phase 3 SIERRA
trial was a 153-patient, randomized, multi-center, controlled trial of Iomab-B in patients aged 55 and above with active r/r AML, who
were heavily pre-treated and had high-risk characteristics. Patients enrolled had blast counts of 5% or greater in the marrow or circulating
blasts suggestive of active AML. In this study, Iomab-B was compared to the control arm that allowed physician&#8217;s choice of over
20 available agents, including chemotherapies and/or targeted therapies such as venetoclax (BCL-2 inhibitor), FLT3 inhibitors, IDH inhibitors
and Mylotarg, reflecting current best treatment practices attempting to get patients to CR. The control arm included recently approved
AML therapies that were added to the SIERRA protocol as they became available. The crossover arm was designed in SIERRA for an equipoise
that offered Iomab-B to patients failing to achieve a CR on the control arm with an intent to rescue them by taking them to transplant.
Of note, SIERRA had highly restrictive optionality for post-transplant maintenance. Patients with active, r/r AML are not considered eligible
for BMT with current approaches and the SIERRA trial was the only randomized Phase 3 trial to offer BMT as a treatment option for this
patient population. These patients would not be offered BMT in standard practice and therefore have dismal survival outcomes of two to
three months. The primary endpoint of the SIERRA trial was dCR of 6-months and the secondary endpoints are OS and Event-Free Survival
(&#8220;EFS&#8221;). The comparison of OS in subjects randomized to the control arm who crossed over to receive Iomab-B versus all others
in the control group was an exploratory efficacy endpoint.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As seen in the graphic below,
the primary endpoint of 6-month dCR was met with a high degree of statistical significance (p&lt;0.0001). 75% of patients (44/59) receiving
Iomab-B achieved an initial remission 30 days after their BMT compared to 6.3% of patients (4/64) in the control arm. 22% of the patients
receiving Iomab-B maintained dCR lasting 6-months or more despite limited optionality for post-transplant maintenance, while none of the
patients on the control arm achieved dCR. The current standard practice is to administer post-transplant maintenance therapy to reduce
chances of relapse. The results presented below are on a per protocol basis, which means that only data that was in strict adherence to
the protocol without any deviations was considered for the analysis. It is important to note that the p-value of the primary endpoint
in the Intent-to-Treat (&#8220;ITT&#8221;) analysis was &lt;0.0001, the same as the per protocol analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>SIERRA Results: Iomab-B Meets Primary Endpoint
with High Significance (p&lt;0.0001)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_007.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As demonstrated in the OS
graph below, patients who achieved 6-month dCR had 92.3% 1-year survival and 59.9% 2-year survival. Median OS had not been reached in
these patients. It is worth noting that two years in CR is a significant milestone in this patient population, highly indicative of long-term
survival and a possible curative outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Overall Survival for Patients who Achieved
6-month dCR with Iomab-B</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_008.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OS was one of the secondary
endpoints of the study. The Kaplan-Meier plot in the inset of the graph below shows ITT OS results between the Iomab-B arm and the control
arm. Due to the crossover design, ITT analysis of OS was confounded by the early crossover of patients (within 28 days) from the control
arm to the Iomab-B arm (57.1%). The effective rescue of these crossover patients by Iomab-B led to an outsized contribution of the Iomab-B
effect on control arm patients. As a result, median OS in the Iomab-B arm was similar to that in the control arm and this secondary endpoint
was not met in the ITT analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to isolate the true
impact of Iomab-B on OS, one of the exploratory efficacy endpoints was the comparison of OS in subjects randomized to the control arm
who crossed over to receive Iomab-B versus all others in the control arm, as well as the control arm patients who did not crossover versus
the Iomab-B arm. The Kaplan-Meier plot of OS in the graphic below shows that this exploratory analysis demonstrated the clear benefit
of Iomab-B over the control arm. The median OS for the Iomab-B group was 6.4 months which was double the 3.2 months for the non-crossover
patients in the control arm. Patients who crossed over from the control arm to receive Iomab-B had a median OS of 7.1 months demonstrating
further the ability of Iomab-B to treat patients who are non-treatable by conventional means.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A similar pattern favoring
the Iomab-B group was seen across the pre-defined subgroups, where 1-year OS for Iomab-B was 26.1% compared with 13.1% for the non-crossover
control arm. The 1-year OS for patients in the crossover arm was 35.8%. This clearly demonstrates the OS benefit of Iomab-B over the control
arm and two to three-fold improvement in survival outcomes possible with its use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Kaplan-Meier Plot of Overall Survival &#8210;
Iomab-B, Crossover, and Non-Crossover Control Arm </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><img alt="" src="image_009.jpg"/>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B produced a significant
and clinically meaningful improvement in the secondary endpoint of EFS, with a 78% reduction in the probability of an event (Hazard Ratio=0.22,
p&lt;0.0001 for both per protocol and ITT basis). EFS at 6-months for the Iomab-B arm was 28% compared to 0.2% for the control arm. In
the SIERRA trial, an event is defined as one of the following: a patient not achieving CR/CRp or crossing over, patient not receiving
BMT, a patient relapsing or death.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the figure below comparing
EFS with Iomab-B versus the control arm, the initial vertical drop in the curve in the Iomab-B arm represents those patients who did not
achieve a remission after Iomab-B or those who did not proceed to transplant, while the initial vertical drop in the curve in the control
arm mainly represents patients who did not achieve a remission with salvage therapy and either crossed over to Iomab-B or went onto best
supportive care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Event-Free Survival with Iomab-B Versus Control
Arm</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_010.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below shows relevant
adverse events in transplanted Iomab-B patients. In these patients, incidence of sepsis was four times lower in the Iomab-B arm than the
control arm (6.1% vs. 28.6%). In addition, rates of other treatment related adverse events were lower in favor of Iomab-B, including febrile
neutropenia (43.9% vs. 50.0%), mucositis (15.2% vs. 21.4%) and acute graft versus host disease (&#8220;GVHD&#8221;) (26.1% vs. 35.7%).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Grade &#8805;3 Treatment-Emergent Adverse Events
in Transplanted Patients Through Day 100 Post-HCT</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_011.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With current treatment practice,
patients who have r/r AML with active disease, utilizing current conditioning agents have poor outcomes and very low survival rates. Using
an Iomab-B led regimen, an unprecedented number of patients were able to access transplant and were able to do so with active disease,
eliminating need for achieving a CR in order to transplant the patient. Thus, patients are also able to access BMT faster with Iomab-B,
in less than half the time compared to conventional care. Iomab-B represents an exciting new paradigm with the potential to establish
a new standard of care in r/r AML setting, making it possible for most patients to get to a successful transplant with Iomab-B with a
portion of these patients having a long-term survival benefit. As shown below, with an Iomab-B led regimen, the majority of patients who
are non-transplantable in routine clinical practice can be successfully transplanted, administering myeloablative radiation with reduced
intensity conditioning tolerability to ultimately achieve transformative survival outcome, changing the treatment paradigm for r/r AML
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Iomab-B &#8211; New Paradigm to Upend BMT
Access and Improve r/r AML Outcomes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_012.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Future Development and Life Cycle Management
for Iomab-B</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of the Pivotal
Phase 3 SIERRA trial validate the value proposition of Iomab-B, and we believe it could establish unprecedented access to transplant (currently
the only curative option) with better safety and tolerability and improved outcomes, all of which could potentially make Iomab-B the new
standard of care for patients with r/r AML. We are actively working to launch an EAP and successfully file a BLA in the second half of
2023, and if approved, we anticipate the commercial launch for Iomab-B in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to commercialize
Iomab-B in the U.S. The commercial opportunity is supported by favorable dynamics, summarized by the &#8220;Three Ps and Two Cs&#8221;:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patients</i>: With its promising profile, Iomab-B provides the opportunity for unprecedented BMT access and better outcomes for patients, with favorable safety and tolerability</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Physicians</i>: Our goal is to help physicians make BMT an option for a vast majority of r/r AML patients who currently are unable to access transplant without disruption to current practice. Patients are able to return to their referring physicians for post-BMT follow-up, and long-term care</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Payers</i>: Iomab-B potentially unlocks value through getting patients safely to effective, potentially curative transplants, with improved outcomes and a manageable safety and tolerability profile</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Competition</i>: While there have been multiple new product approvals in AML over the last several years, they primarily focus on addressing genetic mutations, with limited competition in conditioning to increase access to BMT. We do not see direct or indirect visible competition for Iomab-B in the 5-to-10-year horizon to impair the commercial success of Iomab-B</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentrated Call Points</i>: The commercialization for Iomab-B will benefit from a concentrated market. The top 50 centers perform 75% of BMTs and tend to be concentrated in metropolitan areas. These factors allow for commercialization delivered by a focused 35&#8211;50-person commercial organization. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The favorable commercial dynamics
for Iomab-B in the U.S. are further supported by the strong foundation of core competencies developed during the successful execution
of the SIERRA trial at leading high-volume BMT centers. We established and actively managed an end-to-end supply chain, never missing
a patient dose, and were able to treat 60% more patients than expected due to the high number of crossover patients. We focused on operational
excellence at the point of care, working in partnership with leading KOLs and their teams to successfully execute SIERRA at a wide array
of centers. As a result, we have broad reach across leading BMT centers that account for 30% of BMT volume, which speaks to the concentration
of the BMT market. The positive SIERRA results of unprecedented access and outcomes along with our commitment to operational excellence
provide a strong foundation for our commercial team.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, Actinium licensed
the EUMENA commercial rights for Iomab-B to Immedica, an independent pharmaceutical company headquartered in Sweden. Immedica has significant
know-how and experience in commercializing niche and specialty care products across Europe and the Middle East, with extensive regulatory
and commercial expertise and capabilities. Actinium will continue to be responsible for certain clinical development activities and Iomab-B
manufacturing and will retain commercialization rights in the U.S. and rest of the world. Currently, there an estimated ~7,200 BMTs for
AML in EUMENA, two times that of the U.S., performed in a concentrated number of centers. The incidence rate of AML in Europe is 3.7
per 100,000, or ~27,500 new patients per year. Actinium received an upfront payment of $35 million USD with the potential for an additional
$417 million USD in regulatory and sales milestones and mid-twenty percent royalties. Iomab-B has been granted Orphan Drug Designation
by the EMA and has received positive Scientific Advice from EMA that the SIERRA trial can support a marketing authorization with filing
expected in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background on Iomab-B </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B is a first-in-class targeted radiotherapy consisting of apamistamab,
an anti-CD45 mouse antibody conjugated to radioactive iodine 131 (&#8220;I-131&#8221;) designed to deliver targeted myeloablative radiation
to malignant and hematopoietic cells prior to allogeneic BMT. CD45 is uniquely expressed on blood cancer, immune and bone marrow stem
cells at high levels. Targeting CD45 enables delivery of high radiation doses directly to the bone marrow, with a median of 16 gray and
as high as 44.6 gray in the SIERRA trial, while minimizing radiation exposure to vital organs such as lungs, heart and gastrointestinal
tract, thereby producing myeloablative outcomes with an overall better safety profile and the tolerability of a reduced intensity regimen.
I-131 is a beta- and gamma-emitting radioisotope that works on the cell surface and does not need to be internalized. Developed at the
Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;), Iomab-B has been studied in multiple disease indications including leukemias,
lymphomas, MDS, and MM. Over 300 patients received Iomab-B through prior studies, demonstrating the potential for unprecedented access
to BMT, improved survival and tolerability, and we intend to leverage these data as we plan for label expansion of Iomab-B. Iomab-B has
been granted Orphan Drug Designation from the FDA and has patent protection into 2037.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Actimab-A &#8211; CD33 targeting radiotherapeutic
&#8211; mutation agnostic mechanism of action has potential as combination backbone therapy in highly radiosensitive, mutation rich AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Actimab-A <i>(<sup>225</sup>Ac-lintuzumab
satetraxetan) </i>program is focused on developing combinations with other AML treatment regimens with mechanistic synergies to establish
Actimab-A as a backbone therapy, leveraging the mutation-agnostic mechanism of action of Actimab-A. There is no known resistance mechanism
to targeted radiotherapies, making Actimab-A an attractive candidate for a variety of combinations. The scientific rationale is to use
CLAG-M, a powerful chemotherapy regimen routinely used to treat patients with r/r AML, and then use Actimab-A for its precision targeting
ability that produces double-strand-DNA breaks that lead to cancer cell death to clear out residual disease. Actimab-A has demonstrated
clinically significant survival benefit in a proof-of-concept study and is poised for advanced development in collaboration with the NCI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Actimab-A + CLAG-M Phase 1 Study Results </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In collaboration with the
Medical College of Wisconsin, the Actimab-A + CLAG-M Phase 1 trial was conducted in r/r AML patients. These patients had a median age
of 63, failed two or more lines of therapy, which includes 57% having received prior treatment with venetoclax, a BCL-2 inhibitor. 67%
of these patients had adverse cytogenetics, 52% had a TP53 mutation, and 57% had a prior BMT. Median OS is typically two to four months
for this patient population, with a median OS of less than 3 months for patients who relapsed following venetoclax and a median OS less
than 2 months for those with a TP53 mutation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These trial results were presented
as an oral presentation at the 2022 ASH Annual Meeting. In this difficult-to-treat r/r AML population, the results demonstrate its high
potential. We reported 1-year survival of 53% and 2-year survival of 32%, which are as much as double what can be expected with currently
available therapies. The trial showed an Overall Response Rate (&#8220;ORR&#8221;) of 65% across all dose cohorts, 52% complete remission
rate, and a 75% MRD negativity rate. As highlighted in the figure below, the results are highly encouraging and show that the high rates
of responses and MRD negativity are translating to a meaningful survival benefit in these difficult-to-treat patients, who would otherwise
have dismal outcomes.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Actimab-A + CLAG-M &#8211; Impressive Response
and Survival Benefit in r/r AML</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_013.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Actimab-A + CLAG-M Compared to CLAG-M Alone
in r/r AML</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efficacy of CLAG-M has been
reported in older studies (Halpern and Walter. CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia. Oncotarget
2018 and Mushtaq et al. Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. ASH 2018) in patients
with r/r AML, however, almost all of these studies were conducted in the pre-targeted therapy era where no patients enrolled had prior
venetoclax-based therapy, thus efficacy data of CLAG-M in the current era, in patients exposed to prior venetoclax, or with other high-risk
features, is limited. When combined with Actimab-A, the combination has demonstrated a clinically significant survival benefit in a proof-of-concept
study irrespective of prior targeted treatment. R/R AML after failing venetoclax-based therapy is associated with dismal survival outcomes,
with a median OS of less than 3 months. In comparison, the combination trial of Actimab-A + CLAG-M led to 1-year survival of 59% and 2-year
survival of 32% in patients who failed prior venetoclax-based therapy, which compares very favorably to the traditional outcomes in these
patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Actimab-A + venetoclax Phase 1/2 Study Results</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are conducting a Phase
1/2 multi-center trial combining Actimab-A + venetoclax in both fit and unfit patients 18 years and older with r/r AML led by UCLA Medical
Center. Data from our Actimab-A + venetoclax combination trial was presented at the 2022 ASH Annual Meeting. We have demonstrated preclinically
that combinations of Actimab-A and venetoclax have mechanistic synergies. Overexpression of MCL-1, an anti-apoptotic protein, is associated
with resistance to venetoclax in AML. Actimab-A kills tumors cells with DNA double-strand breaks and downregulates MCL-1, which can (re-)sensitize
AML cells or reduce tumor resistance to venetoclax. The Actimab-A + venetoclax combination has been well-tolerated with responses, including
a CR and a partial response in early dose escalation cohorts. In our ongoing clinical trial, we are exploring the optimal dose of Actimab-A,
as well as the dosing regimen of the combination. We expect to present proof-of-concept of this study in the second half of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Further Development for Actimab-A</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 6, 2023, we announced
that we entered into a CRADA with the NCI, part of the NIH, to develop Actimab-A for the treatment of patients with AML and other hematologic
malignancies. The NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A,
and the CRADA will provide extensive support for and accelerate the development of Actimab-A alone or in combination with chemotherapy,
immunotherapy, targeted agents and other novel combinations. The CRADA studies will be overseen by the NCI in collaboration with Actinium&#8217;s
clinical development team, where Actinium has the right to review and approval all protocols and has full right to all data. This broad
collaboration may accelerate our Actimab-A development efforts with access to NCI&#8217;s vast network of over 2,000 clinical trial sites
and its Myelomatch program. Later this year, we will provide updates on our progress as we move into late-stage development with Actimab-A
+ CLAG-M, as well as other developments with our venetoclax combination trial as part of our backbone development strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exploring the broader
opportunity with our Actimab-A program and the potential use of Actimab-A in solid tumor indications through our R&amp;D efforts. CD33-expressing
MDSCs are present within the tumor microenvironment and exert immunosuppressive effects, and we believe that Actimab-A can play an important
role in the tumor microenvironment by depleting MDSCs in a targeted manner. On April 19, 2023, we presented data at the AACR Annual Meeting,
that we believe support the potential role of Actimab-A to overcome immunosuppression by MDSCs in the tumor microenvironment. We believe
our preclinical findings show promise with regard to Actimab-A&#8217;s ability to selectively deplete CD33-expressing MDSCs in both lung
and colorectal cancer, which we intend to explore further via clinical development. Actimab-A also demonstrated superior depletion of
human MDSCs compared to Mylotarg, a CD33-targeted ADC in colorectal cancer (p&lt;0.01), highlighting the powerful cytotoxicity and potential
therapeutic benefit of radiotherapy compared to naked antibodies or ADCs. MDSCs are ubiquitous across multiple cancer indications and
with the substantial number of immunotherapies in development or currently in clinical use, we believe our data may support the potential
for Actimab-A, if ultimately approved for commercialization for such indication, to be a backbone therapy that could broadly improve antitumor
activity of immunotherapies such as checkpoint inhibitors and T and NK cell therapies and other therapeutic modalities in multiple solid
tumor indications.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Background on Actimab-A</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actimab-A is an anti-CD33
antibody linked to the potent alpha-emitting radioisotope Ac-225. Actimab-A targets CD33, which is expressed in virtually all malignant
cells in patients with AML regardless of cytogenetics or mutations and enables potent alpha radiation to be directed against radiosensitive
AML cells. These cells have no known resistance or repair mechanisms when hit with the alpha particles from the Ac-225 isotope payload
that cause double stranded DNA breaks. We believe Actimab-A is the first radiotherapeutic for r/r AML and has the unique value proposition
of broad applicability, a differentiated mechanism of action, and targeted precision that is well-tolerated with minimal toxicity. Our
CD33 development program is driven by data obtained from approximately 150 AML patients in six trials and demonstrated single agent activity
with high response rates, but was also associated with prolonged neutropenia. A combination strategy was considered appropriate given
the changing treatment landscape of AML; hence, based on presumed mechanistic synergies, an investigator-initiated trial of Actimab-A
+ CLAG-M and a company-sponsored Actimab-A + venetoclax were developed and patients were enrolled into these studies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">Conditioning Focused Programs</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-B</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will further expand the
Iomab-B franchise by focusing on lifecycle management for label enhancement and indication expansion. Iomab-B data in five additional
hematologic indications (i.e., MDS, ALL, HL, NHL, and MM) provide the foundation to explore indication expansion opportunities to increase
the total addressable market for Iomab-B. Across early trials at the FHCRC, Iomab-B demonstrated similar improved access to BMT and outcomes.
We will leverage these data with strong results from the pivotal Phase 3 SIERRA trial to execute a comprehensive life cycle management
strategy to further expand Iomab-B&#8217;s role in a variety of malignant and non-malignant hematological disorders. We will continue
to develop the Iomab-B franchise to potentially address a broader market opportunity to address the over 165,000 patients diagnosed with
cancers (e.g., leukemia, lymphoma, and myeloma), who could potentially benefit from transplant, but are unable to access one today.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Iomab-ACT</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-ACT is comprised of
apamistamab, the same anti-CD45 antibody as Iomab-B, but utilizes lower, nonmyeloablative levels of I-131 to achieve lymphodepletion for
cellular therapies such as CAR-T or reduced intensity conditioning for gene therapies. We intend to continue to develop the Iomab-ACT
program designed specifically for use prior to CAR-T and gene therapies, ultimately with a value proposition of improving overall access
and outcomes for patients who need cellular or gene therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical data showed a
single, low-dose of Iomab-ACT demonstrated lymphodepletion and as CD45 positive immune cells are implicated in major CAR-T side effects,
i.e., cytokine release syndrome (&#8220;CRS&#8221;) and immune effector cell&#8211;associated neurotoxicity syndrome (&#8220;ICANS&#8221;),
Iomab-ACT has the potential to be developed as a conditioning agent for CAR-T therapies. CRS and ICANS remain two most common toxicities
of CAR-T therapies with severe cases (&gt;Grade 3) seen in &gt;20% of patients and fatality rates between 0-10%. Due to its effect on
host monocytes/macrophages, we believe conditioning with Iomab-ACT will potentially reduce the incidence of CRS and ICANS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unlike chemotherapy, Iomab-ACT
is targeted in nature, and we expect it to potentially promote improved CAR-T cell expansion, resulting in responses that are higher and
more durable. We believe our Iomab-ACT program is highly differentiated when compared to fludarabine and cyclophosphamide (&#8220;Flu/Cy&#8221;)
or other chemotherapy-based regimens that are used as standard practice today for lymphodepletion prior to cell therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are studying Iomab-ACT
in collaboration with MSKCC, for conditioning prior to CAR-T therapy for patients with relapsed or refractory B-cell acute lymphoblastic
leukemia (&#8220;B-ALL&#8221;) or diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;). This study funded by a NIH grant is the first-of-its-kind
study to use a radiotherapeutic-based conditioning regimen with CAR-T therapy. We have completed treatment of an initial cohort of three
patients and will expand to a second cohort. This study was presented at the ASH Annual Meeting in December 2022 as a trial-in-progress.
We expect to present proof-of-concept data from this study in the second half of 2023 and look forward to sharing more on our Iomab-ACT
trial with MSKCC, along with future development plans in the CAR-T space.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span style="text-decoration:underline">R&amp;D and Preclinical Programs</span></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our R&amp;D efforts yield
differentiated, high-value programs that demonstrate our experience across multiple validated cancer targets and isotopes and cover broad
areas of focus leveraging our clinical development experience across hematology, targeted conditioning, solid tumors, and next generation
radiotherapies. Our programs also inform the advancement of our Iomab-B, Actimab-A, and Iomab-ACT programs. We have utilized our technology
platform to develop our clinical portfolio in hematology &#8211; Iomab-B and Actimab-A, in conditioning for transplant and as a therapeutic,
respectively. Our research collaborations with Astellas, LG Chem, and EpicentRx establish our work with immunotherapies and in solid tumors.
We are working on several preclinical programs which include novel approaches to established targets such as HER2 and HER3, as well as
novel targets that show immense potential for radiotherapeutic approaches. Underpinning our development programs is our expanded patent
portfolio of over 200 issued patents and pending patent applications worldwide.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our platform has been used
to develop a pipeline of novel radiotherapeutic assets to drive company growth. Preclinical pharmacology studies with our targeted radiotherapeutics,
such as HER3-ARC, HER2-ARC or CD33-ARC, have shown strong improvement in tumor growth inhibition in various preclinical tumor models as
single agents or in combination with immunotherapy such as magrolimab, an anti-CD47 monoclonal antibody. These results have prompted the
team to spearhead efforts in multiple solid tumor programs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium&#8217;s lead solid
tumor program is a targeted radiotherapy against HER3, a pan-cancer target that is overexpressed in several solid tumor indications with
high unmet need. The HER3-targeted radiotherapeutic agent showed potent tumor cell cytotoxicity, enhanced antitumor effects and significantly
improved survival with an Ac-225 radiolabeled HER3 antibody compared to a naked HER3 antibody in a preclinical non-small cell lung cancer
(&#8220;NSCLC&#8221;) model. We have also demonstrated the direct impact of targeted radiotherapy in modulating immune signals such as
calreticulin upregulation to enhance tumor cell killing. Further, we have leveraged the immunomodulatory effect(s) of targeted radiotherapy
in combination with CD47 targeting agents such as magrolimab for sustained tumor growth inhibition in mouse models of AML and NSCLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also aligned our R&amp;D
strategy of advancing solid tumors with HER3 into the clinic with our Actimab-A program. On April 19, 2023, we announced encouraging preclinical
proof-of-concept data at the AACR 2023 Annual Meeting showcasing the anti-tumor effects of HER3-targted radiotherapy using multiple therapeutic
radionuclides in preclinical models of high unmet need malignancies. Actinium&#8217;s HER3-ARC conjugated to either Ac-225 or Lu-177 showed
highly significant tumor growth suppression (p&lt;0.0001) in an ovarian cancer model compared to bevacizumab, an anti-VEGF monoclonal
antibody indicated in ovarian cancer. Data presented also showed promising antitumor activity in a preclinical model of colorectal cancer,
a highly aggressive malignancy, including a significant reduction in tumor growth (p&lt;0.0001), when dosed with 225Ac-HER3-ARC. Actinium&#8217;s
HER3-targeted radiotherapy displayed strong anticancer activity when conjugated to either alpha-emitting Actinium-225 or beta-emitting
Lutetium-177 in models of two high unmet need cancers, highlighting its therapeutic potential for HER3+ malignancies. The consistent overexpression
of HER3 in multiple solid tumor types, including ovarian, renal, prostate, urothelial, breast, and lung cancers suggests broad utility
of a HER3-targeted agent in a clinical setting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We continue to expand on capabilities
and technologies across therapeutic modalities, linker technologies and in vivo cancer models, and build visibility through presentations
at key conferences and publications in journals of high impact. Our R&amp;D efforts are centered on the advancement of our key programs
with a robust &#8220;fast-to-clinic&#8221; approach in niche indications. Underpinning our development programs is our expanded patent
portfolio of over 200 issued patents and pending patent applications worldwide.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Platform Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technology
platform is built on the core competency to produce targeted radiotherapeutics, and coupled with our know-how and IP, establishes our
company in the development of isotope-agnostic, multi-targeted products that may address the treatment of hard-to-treat diseases. In our
clinical and preclinical programs, we have utilized multiple isotopes including Ac-225, I-131 and Lu-177 directed at multiple targets
in oncology and hematology such as CD45, CD33, HER3, among others. Our targeted radiotherapies combine the cell-killing ability of radiation
via a radioisotope payload with a targeting agent, such as a monoclonal antibody.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to developing
targeted radiotherapies, we also own patents related to the manufacturing of Ac-225 in a cyclotron. We have expertise in utilizing the
alpha emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with our alpha-emitter-based therapies,
&#8220;gold standard&#8221; linker technology and five issued patents in the U.S. and 49 patents internationally related to the manufacturing
or Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of highly pure Ac-225 than current methods.
When appropriate, we are well-positioned to leverage this technology to produce Ac-225.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For Iomab-B, we have
established an actively managed end-to-end supply chain that encompasses isotope sourcing through drug administration at the point
of care. Our end-to-end supply chain did not miss a patient dose in our international, 24-site SIERRA Phase 3 clinical trial
including 40 additional patients that crossed over from the control arm to receive Iomab-B. We have scaled up and have commercially
viable manufacturing operations in place to support U.S. and international commercial sales.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actinium has commercial agreements with Contract Development and Manufacturing
Organizations (&#8220;CDMOs&#8221;) with significant experience in monoclonal antibodies (&#8220;mAbs&#8221;) and final radio-labeled
drug products. The CDMO we have selected to manufacture the finished drug product to support our commercial activity has been previously
inspected by the FDA and EMA. We have scaled deliberately for manufacturing flexibility&#160;to ensure readily available drug product
upon FDA approval and the ability to ramp up rapidly to meet commercial demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have multiple isotope
supply agreements and qualified vendors in place to supply isotopes for commercial production.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our proprietary technology
platform is supported by IP, know-how and trade secrets that cover the generation, development, methods of use and manufacture of targeted
radiotherapies and their select components. Our IP covers various methods of use in multiple diseases, including indication, dose and
scheduling, radionuclide warhead, and therapeutic combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of August 2023, our patent portfolio is comprised of over 200 issued
patents and pending patent applications worldwide, which we believe constitutes a valuable business asset. Our IP includes 45 patent families,
including key patents that relate primarily to our radiotherapeutic candidates. Our patent portfolio includes 12 issued patents and 39
pending patent applications in the U.S., and 151 that are issued or pending internationally. The effective lives of the issued patents
in our portfolio, or patents that may issue from the pending applications in our portfolio, ranges from expirations between 2024 and 2043.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our Iomab-B product candidate,
we have four issued patents in the U.S. and issued patents in Canada, Europe and Japan that relate to the composition. The basic patent
terms of these patents expire in 2036 and 2037. Related patent applications are also currently pending in the U.S. and internationally.
In addition, we own both U.S. and international pending patent applications that relate to the use of Iomab-B or Iomab-ACT in the treatment
of cancers and non-malignant conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our patents also cover key
areas of our business such as manufacturing key components of our product candidate, Actimab-A, including Ac-225 in a cyclotron. We have
expertise in utilizing the alpha emitting isotope Ac-225 including clinical experience in treating approximately 150 patients with our
alpha-emitter-based therapies, &#8220;gold standard&#8221; linker technology and five issued patents in the U.S. and 49 patents internationally
related to the manufacturing or Ac-225 in a cyclotron, which we believe has the potential to produce higher quantities of Ac-225 than
currently utilized methods. These patents will expire in the years 2024 through 2027. In addition, we also own U.S. and international
patents and pending patent applications that relate to the manufacturing of Actimab-A and its use in the treatment of cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations &#8211;
Three Months Ended June 30, 2023 Compared to Three Months Ended June 30, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For&#160;the<br/>
Three&#160;Months&#160;Ended<br/>
June 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,662</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,561</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,233</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">461</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">461</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">83</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(15,181</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,767</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the three months ended June 30, 2023 and June 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We determined that
certain collaborations with a third-party were within the scope of Topic ASC 606, <i>Revenue Recognition from Contracts with
Customers, </i>or ASC 606. The collaboration agreement was made up of multiple modules related to various research activities. While
the third party had the option to terminate the agreement at the conclusion of any module, we identified a single performance
obligation to provide research services within each module for which we received monetary consideration. The consideration was
recognized to revenue over each module and revenue of $45 thousand was recognized during the three months ended June 30, 2022. There
was no corresponding revenue recognized from a collaboration during the three months ended June 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, we
entered into a license and supply agreement with Immedica Pharma AB, or Immedica, pursuant to which Immedica licensed the exclusive product
rights for commercialization of Iomab-B in the European Economic Area, Middle East and North Africa (EUMENA) including Algeria, Andorra,
Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi
Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates, the United Kingdom, the Vatican City and Yemen. Upon signing, we
were entitled to an upfront payment of $35 million from Immedica, which was received in May 2022. Under the terms of the License Agreement,
we are eligible to receive regulatory and commercial milestone payments and are entitled to receive royalties in the mid-20 percent range
on net sales of the product in certain countries that may result from the License Agreement. We will continue to be responsible for certain
clinical development activities and the manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the
world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contract liabilities are
recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in our condensed consolidated balance
sheets depending on the short-term or long-term nature of the payments to be recognized. Our contract liabilities primarily consist of
advanced payments from licensees. There was no Other revenue deferred-current liability at June 30, 2023 and December 31, 2022. Long-term
license revenue deferred was $35.0 million at June 30, 2023 and December 31, 2022, resulting from the receipt from Immedica; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $11.1 million for the three months ended June 30, 2023 increased $6.4 million from $4.7 million for the three months ended June 30,
2022. Higher research and development expenses were primarily due to increased CMC activity related to the planned BLA filing for Iomab-B
in the second half of 2023, as well as increased compensation of $1.5 million resulting from higher headcount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses of $4.6 million for the three months ended June 30, 2023 increased by $1.4 million from $3.2 million for the three months ended
June 30, 2022. Higher expenses were primarily due to increased compensation of $0.5 million resulting from higher headcount, higher non-cash
equity compensation of $0.5 million, as well as higher professional and consulting fees, including recruiting fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the three months ended June 30, 2023 of $0.5 million increased from $0.1
million for the three months ended June 30, 2022 due to a higher average interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $15.2 million
for the three months ended June 30, 2023 increased by $7.4 million from $7.8 million for the three months ended June 30, 2022 primarily
due to higher research and development expenses and general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Results of Operations
&#8211; Six Months Ended June 30, 2023 Compared to Six Months Ended June 30, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for the periods indicated, data derived from our statements of operations:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For&#160;the<br/>
Six&#160;Months&#160;Ended<br/>
June 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Other revenue</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">985</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development, net of reimbursements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,930</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,296</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,968</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,226</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,999</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest income &#8211; net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,008</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,008</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(26,218</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,896</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recorded no commercial
revenue for the six months ended June 30, 2023 and June 30, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We determined that
certain collaborations with a third-party were within the scope of ASC 606. The collaboration agreement was made up of multiple
modules related to various research activities. While the third party had the option to terminate the agreement at the conclusion of
any module, we identified a single performance obligation to provide research services within each module for which we receive
monetary consideration. Other revenue of $0.9 million was recognized during the six months ended June 30, 2022. There was no
corresponding revenue recognized from a collaboration during the six months ended June 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The National Institutes of Health awarded us a Small Business Technology
Transfer cost reimbursable grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center, or MSK, to study Iomab-ACT,
our CD45-targeted conditioning program to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed
at MSK. We recognized other revenue from this grant for the six months ended June 30, 2022 of $0.1 million. There was no corresponding
revenue recognized for the six months ended June 30, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development Expense, net of reimbursements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
of $18.9 million for the six months ended June 30, 2023 increased $9.9 million from $9.0 million for the six months ended June 30, 2022.
Higher research and development expenses were primarily due to increased CMC activity related to the planned BLA filing for Iomab-B in
the second half of 2023, as well as increased compensation of $2.5 million resulting from higher headcount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General and administrative expense</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses of $8.3 million for the six months ended June 30, 2023 increased by $3.3 million from $5.0 million for the six months ended June
30, 2022. Higher expenses were primarily due to increased compensation of $0.9 million due to higher headcount, higher non-cash equity
compensation of $0.9 million, and higher professional and consulting fees, including recruiting fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income is comprised
of net interest income in both reporting periods. The amount for the six months ended June 30, 2023 of $1.0 million increased from $0.1
million for the six months ended June 30, 2022 due to a higher average interest rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Net loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net loss of $26.2 million
for the six months ended June 30, 2023 increased by $13.3 million from $12.9 million for the six months ended June 30, 2022 primarily
due to higher research and development expenses and general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
selected cash flow information for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For&#160;the<br/> Six&#160;Months&#160;Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>June 30,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Cash (used in)/provided by operating activities</p></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(28,720</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,137</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(277</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash provided by&#160;financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,818</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;change in cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18,025</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,501</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the six months ended June 30, 2023 of $28.7 million increased by $50.8 million from the prior-year period of $22.1 million,
as a result of the higher net loss of $13.3 million and the receipt of the $35.0 million up-front payment from Immedica included in the
prior-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $0.1 million and $0.3 million for the six months ended June 30, 2023 and 2022, respectively, due to the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities for the six months ended June 30, 2023 of $10.8 million and for the six months ended June 30, 2022 of $16.6 million was primarily
from the sale of shares of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020 we entered
into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we
may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of our common stock. On June 28, 2022, we
entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement, or the Amended Sales Agreement, with JonesTrading and B.
Riley Securities, Inc. The Amended Sales Agreement modifies the original Capital on Demand&#8482; Sales Agreement to include B. Riley
as an additional sales agent thereunder. Shares of common stock are offered pursuant to our shelf registration statement on Form S-3 filed
with the SEC on August 7, 2020. For the six months ended June 30, 2023, we sold 1.3 million shares of common stock, resulting in gross
proceeds of $10.9 million and net proceeds of $10.6 million. For the six months ended June 30, 2022, we sold 2.7 million shares of common
stock, resulting in gross proceeds of $17.2 million and net proceeds of $16.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Use of Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States, (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure
of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored
and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base
our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known.
Actual results may differ materially from these estimates under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our significant accounting
policies are described in detail in the notes to our consolidated financial statements appearing in our Annual Report filed on Form 10-K
for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value Measurement </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fair value is defined as the
price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants.
A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for
identical assets or liabilities and the lowest priority to unobservable inputs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606. Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects
the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements
within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue as we satisfy a performance obligation. We only apply
the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the
goods or services we transfer to the customer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, we assess whether the promised goods or services promised within each contract
are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not to be distinct
are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods or services are
distinct, we evaluate certain criteria, including whether (i)&#160;the customer can benefit from the good or service either on its own
or together with other resources that are readily available to the customer (capable of being distinct) and (ii)&#160;the good or service
is separately identifiable from other goods or services in the contract (distinct in the context of the contract).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires us to allocate
the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction
price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling
price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer.
We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation as each performance
obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input
method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Arrangements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We follow the accounting guidance
for collaboration agreements, which requires that certain transactions between us and collaborators be recorded in our consolidated statements
of operations on either a gross basis or net basis, depending on the characteristics of the collaborative relationship, and requires enhanced
disclosure of collaborative relationships. We evaluate our collaboration agreements for proper classification in our consolidated statements
of operations based on the nature of the underlying activity. When we conclude that we have a customer relationship with one of our collaborators,
we follow the guidance of ASC 606<i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Grant Revenue </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had a grant from the National Institutes of Health for research and development related activities that provided for payments for reimbursed costs, which included overhead and general
and administrative costs as well as an administrative fee. We recognized revenue from the grant as we performed services under this arrangement.
Associated expenses were recognized when incurred as research and development expense. Revenue and related expenses are presented gross
in the consolidated statements of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>License Revenue </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a product
licensing agreement whereby we allowed a third party to commercialize a certain product in specified territories using our trademarks.
The terms of this arrangement include payment to us for a combination of one or more of the following: upfront license fees; development,
regulatory and sales-based milestone payments; and royalties on net sales of licensed products. We use judgment to determine whether milestones
or other variable consideration should be included in the transaction price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement,
we will recognize revenue from upfront license fees allocated to the license when the license is transferred to the licensee and the licensee
is able to use and benefit from the license. For licenses that are bundled with other promises, we determine whether the combined performance
obligation is satisfied over time or at a point in time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, we evaluate whether the milestones are considered probable of being achieved
and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant
revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not
within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until regulatory
approval is received. At the end of each subsequent reporting period, we will re-evaluate the probability of achieving such development
and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such
adjustments are recorded on a cumulative catch-up basis and recorded as part of license revenues during the period of adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, we
will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate and if
such is the case, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation
to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements or when it is
probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with
any variable consideration is subsequently resolved. Amounts payable to us are recorded as accounts receivable when our right to consideration
is unconditional.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development Costs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development costs
are expensed as incurred. These costs include the costs of manufacturing drug components and final drug product, the costs of clinical
trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and equipment. Research
and development reimbursements are recorded by us as a reduction of research and development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share-Based Payments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate the fair value
of each stock option award at the grant date by using the Black-Scholes option pricing model. The fair value determined represents the
cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the
award. We account for forfeitures of stock options as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting Standards Recently Adopted </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB
issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides
guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted
for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related
to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification
and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line
items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments
of ASU 2021-10 are effective January 1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard
did not have a material impact on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance ASC
606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue contracts.
Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent
with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are effective January
1, 2023, including interim periods. We will evaluate the impact of ASU 2021-08 on any future business combinations that we may enter in
the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, the Financial
Accounting Standards Board, or FASB, issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments
(Subtopic 470-50), Compensation &#8211; Stock Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s
Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option
that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share
(EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January
1, 2022, including interim periods. We adopted this standard effective January 1, 2022 and the standard did not have a material effect
on our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently exposed
to significant market risk related to changes in interest rates. As of June 30, 2023, our cash equivalents consisted primarily of short-term
money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level
of U.S. interest rates. Due to the short-term nature of the cash equivalents in our portfolio and the low risk profile of our cash equivalents,
an immediate 10% change in interest rates would not have a material effect on the fair market value of our financial position or results
of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently exposed
to significant market risk related to changes in foreign currency exchange rates. Our operations may be subject to fluctuations in foreign
currency exchange rates in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial
condition or results of operations during the six months ended June 30, 2023 and 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Evaluation of Disclosure
Controls and Procedures</i>. &#160;Under the supervision and with the participation of our management, including our principal executive
officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness, as of June 30, 2023, of our disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange
Act. Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that, as
of June 30, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required
to disclose in our filings with the Securities and Exchange Commission, or SEC, under the Exchange Act (i) is recorded, processed, summarized
and reported within the time periods specified in the SEC&#8217;s rules and forms and (ii) accumulated and communicated to our management,
including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding
required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Changes in Internal Control
over Financial Reporting</i>. There were no changes in our system of internal controls over financial reporting during the period covered
by this report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II &#8211; OTHER INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. LEGAL PROCEEDINGS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-indent: -36pt">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-indent: -36pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><i>In analyzing our company,
you should consider carefully the following risk factors, together with all of the other information included in this Quarterly Report
on Form&#160;10-Q. Factors that could cause or contribute to differences in our actual results include those discussed in the following
subsection, as well as those discussed above in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
Operations&#8221; and in our Annual Report filed on Form 10-K for the year ended December 31, 2022. Each of the following risk factors,
either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect
the value of an investment in our company. The risks and uncertainties described below are not the only ones we face. Additional risks
not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair
our business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are providing the following
summary of the risk factors contained in this Report on Form 10-Q to enhance the readability and accessibility of our risk factor disclosures.
We encourage you to carefully review the full risk factors contained in our Annual Report on Form 10-K for the year ended December 31,
2022 in their entirety for additional information regarding the material factors that make an investment in our securities speculative
or risky. These risks and uncertainties include, but are not limited to, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a clinical-stage company and have generated no revenue from commercial sales to date;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to obtain additional financing, we will be unable to continue or complete our product development or product commercialization and you will likely lose your entire investment;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We are highly dependent on the regulatory and commercial success of
Iomab-B</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not demonstrated that any of our products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development before any of our current or future product candidates will be eligible for FDA approval, if ever;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary, Interim, and &#8220;top-line&#8221; data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative reform measures intended to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently depend on single third-party manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our patent position is highly uncertain and involves complex legal and factual questions.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The use of hazardous materials, including radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on our key personnel, and the demand for&#160;talent in the biotechnology industry is highly competitive; if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement or execute our business strategy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain provisions of our Certificate of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in our stockholders&#8217; interest; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are a clinical-stage company and have
generated no revenue from commercial sales to date. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are a clinical-stage biopharmaceutical
company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product
sales to date. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If
we do not address these risks successfully, our business will suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have incurred net losses in every year
since our inception and anticipate that we will continue to incur net losses in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are not profitable and have
incurred losses in each period since our inception. As of June 30, 2023 and December 31, 2022, we had an accumulated deficit of $315.0
million and $288.8 million, respectively. We reported a net loss of $26.2 million and $12.9 million for the six months ended June 30,
2023 and 2022, respectively. We expect to continue to operate at a net loss as we continue our research and development efforts, continue
to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no assurance that the
products under development by us will be approved for sale in the United States or elsewhere. Furthermore, there can be no assurance that
if such products are approved, they will be successfully commercialized, which would have an adverse effect on our business prospects,
financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to obtain additional financing,
we will be unable to continue or complete our product development and you will likely lose your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As of the date of filing this
report, we expect that our existing resources will be sufficient to fund our planned operations for more than 12 months following the
date of this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may be required
to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in preferred
cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable terms or indeed on any terms.
In addition, from time to time, we may not be able to secure enough capital in a timely enough manner which may cause the generation of
a going-concern opinion from our auditors which can and may impair our stock market valuation and also our ability to finance on favorable
terms or indeed on any terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">To raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal
to or greater than the price per share paid by investors, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research and development activities, clinical
studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing, including rights
to future product candidates or certain major geographic markets. We may further have to license our technology to others. This could
result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may harm our business, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The amount of funding we will
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing and scope
of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary
to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative,
licensing and other commercial relationships; and our partners&#8217; commitment of time and resources to the development and commercialization
of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited access to the capital markets
and even if we can raise additional funding, we may be required to do so on unfavorable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have limited access to the
capital markets to raise funds. The capital markets have been unpredictable in the recent past for radioisotope and other oncology companies
and unprofitable companies such as ours. In addition, it is generally difficult for development-stage companies to raise capital under
current market conditions. The amount of capital that a company such as ours is able to raise often depends on variables that are beyond
our control. As a result, we may not be able to secure financing on terms attractive to us, or at all. If we are able to consummate a
financing arrangement, the amount raised may not be sufficient to meet our future needs. If adequate funds are not available on acceptable
terms, or at all, our business, including our technology licenses, results of operations, financial condition and our continued viability
will be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the regulatory
and commercial success of Iomab-B </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">We have completed patient enrollment in the pivotal Phase 3 SIERRA
trial (Study of Iomab-B in Elderly Relapsed or Refractory AML), a 153-patient multi-center randomized trial that compared outcomes of
patients who receive Iomab-B and a BMT to those of patients receiving physician&#8217;s choice of salvage chemotherapy, defined as conventional
care, as no standard of care exists for this patient population. We have announced that Iomab-B met the primary endpoint of dCR in the
SIERRA trial with statistical significance (p&lt;0.0001) and we intend to submit a BLA with the FDA by the end of 2023. Even if Iomab-B
receives favorable regulatory approval, we may not be successful in securing adequate reimbursement or establishing successful commercial
operations. Any or all of these factors could have a material adverse impact on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to establish sales, marketing
and commercial supply capabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We do not currently have, nor
have we ever had, commercial sales and marketing capabilities. If any of our product candidates become approved, we would have to build
and establish these capabilities in order to commercialize our approved product candidates. The process of establishing commercial capabilities
will be expensive and time consuming. Even if we are successful in building sales and marketing capabilities, we may not be successful
in commercializing any of our product candidates. Any delays in commercialization or failure to successfully commercialize any product
candidate may have material adverse impacts on our business and ability to continue operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business could be adversely affected
by the effects of health epidemics, including the global COVID-19 pandemic.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The global health crisis caused
by the novel coronavirus COVID-19 pandemic and its resurgences has had and may in the future negatively impact global economic activity.
Although the Public Health Emergency for COVID-19 declared by the U.S. federal government has ended, there remains a risk that new variants
of COVID 19, or other infectious diseases, may still emerge. The full impact of such an event cannot be predicted at this time, and could
depend on numerous factors, including vaccination rates among the population, the effectiveness of COVID-19 vaccines and boosters against
the COVID-19 variants and the response by governmental bodies and regulators. Given the ongoing and dynamic nature of the circumstances,
it is difficult to predict the impact of a future pandemic on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Many countries around the world
imposed quarantines and restrictions on travel and mass gatherings in response to the COVID-19 pandemic and could reinstitute such policies
in response to future infectious disease outbreaks. In such a scenario, our ability to continue to operate our business may also be limited.
Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which
could materially affect our business, financial condition and results of operations. In response to COVID-19, we implemented hybrid working
for our office-based staff, while our research staff has been actively working in our laboratory throughout the pandemic and thus far
have not experienced a significant disruption or delay in our operations as it relates to the clinical development, preclinical development
of manufacturing of our drug candidates. Although we are adhering to health and safety protocols, an outbreak of infectious disease at
our facilities could nonetheless cause shutdowns of facilities and a reduction in our workforce, which could cause a disruption or delay
in such operations. New outbreaks may further divert the attention and efforts of the medical community to coping with such outbreaks
and may disrupt the marketplace in which we operate and may have a material adverse effect on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Market disruption and volatility
following a new outbreak of infectious disease could have an adverse effect on our ability to access capital, which could in turn negatively
affect our liquidity. In addition, a recession or market correction resulting from the spread of such disease could materially affect
our business and the value of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">A future pandemic could adversely
affect our clinical trial operations, including our ability to conduct the trials on the expected timelines and recruit and retain patients
and principal investigators and site staff who, as healthcare providers, may have heightened exposure to a future pandemic if their geography
is impacted by the pandemic. Further, future pandemic could result in delays in our clinical trials due to prioritization of hospital
resources toward the pandemic, restrictions in travel, potential unwillingness of patients to enroll in trials at this time, or the inability
of patients to comply with clinical trial protocols if quarantines or travel restrictions are reinstated that impede patient movement
or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other
third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials,
and the pandemic may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work
for us, which may result in delays or hinder our ability to collect data from our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Additionally, a future pandemic
may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB&#8217;s
or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We continue to monitor the
impacts of COVID-19 on the global economy and on our business operations. However, the ultimate impact from COVID-19 or any future pandemic
on our business operations and financial results during 2023 will depend on, among other things, the ultimate severity and scope of the
pandemic, including the new variants of the virus, and whether governmental and private travel restrictions and public concerns about
public gatherings are reinstated. We are not able to fully quantify the impact that these factors had on our financial results during
2022 and will have in 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business is subject to cybersecurity
risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our operations are increasingly
dependent on information technologies and services. Threats to information technology systems associated with cybersecurity risks and
cyber incidents or attacks continue to grow, and include, among other things, storms and natural disasters, terrorist attacks, utility
outages, theft, viruses, phishing, malware, design defects, human error, and complications encountered as existing systems are maintained,
repaired, replaced, or upgraded. Risks associated with these threats include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">theft or misappropriation of funds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss, corruption, or misappropriation of intellectual property, or other proprietary, confidential or personally identifiable information (including supplier, clinical data or employee data);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption or impairment of our and our business operations and safety procedures;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">damage to our reputation with our potential partners, patients and the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure to litigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased costs to prevent, respond to or mitigate cybersecurity events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although we utilize various
procedures and controls to mitigate our exposure to such risk, cybersecurity attacks and other cyber events are evolving and unpredictable.
Moreover, we have no control over the information technology systems of third parties conducting our clinical trials, our suppliers, and
others with which our systems may connect and communicate. As a result, the occurrence of a cyber incident could go unnoticed for a period
time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have cybersecurity insurance
coverage in the event we become subject to various cybersecurity attacks, however, we cannot ensure that it will be sufficient to cover
any particular losses we may experience as a result of such cyberattacks. Any cyber incident could have a material adverse effect on our
business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Regulation&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The FDA or comparable foreign regulatory
authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our products are subject to
rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking regulatory
approval to market an antibody radiation-conjugate product is expensive and time-consuming, and, notwithstanding the effort and expense
incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of our products from the FDA, we may never
be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits commercial distribution
of a new antibody radiation-conjugate product only after a BLA for the product has received FDA approval. The BLA process is costly, lengthy
and inherently uncertain. Any BLA filed by us will have to be supported by extensive data, including, but not limited to, technical, preclinical,
clinical trial, chemistry, manufacturing and controls (&#8220;CMC&#8221;) and labeling data, to demonstrate to the FDA&#8217;s satisfaction
the safety and efficacy of the product for its intended use. The lengthy approval process as well as the unpredictability of future clinical
trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm
our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve
any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for
our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate
with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate.
Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In June 2012, we acquired rights
to apamistamab, a clinical stage anti-CD45 monoclonal antibody with safety and efficacy data in more than 300 patients in need of a BMT.
Iomab-B is our product candidate that links I-131 to apamistamab that is being studied in the pivotal Phase 3 SIERRA trial. Product candidates
utilizing apamistamab would require BLA approval before they can be marketed in the United States. We are also evaluating Iomab-ACT, which
uses a lower dose I-131 for lymphodepletion prior to CAR-T or adoptive cell therapy. We are currently evaluating clinical trials that
would use our construct for lymphodepletion. Our CD33 Alpha program studying Actimab-A (lintuzumab-Ac-225) product candidate is also being
studied in several Phase 1 trials under our sponsorship and investigator-initiated trials in patients with r/r AML. Product candidates
utilizing the lintuzumab antibody would require BLA approval before they can be marketed in the United States. We are in the early stages
of evaluating other product candidates consisting of conjugates of Ac-225 with human or humanized antibodies for pre-clinical and clinical
development in other types of cancer. The FDA may not approve these products for the indications that are necessary or desirable for successful
commercialization. The FDA may fail to approve any BLA we submit for new product candidates or for new intended uses or indications for
approved products or future product candidates. Failure to obtain FDA approval for our products in the proposed indications would have
a material adverse effect on our business prospects, financial condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&#8217;s time and other
resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications. In addition, even if we
obtain approval to market our products in the United States or in other countries, the approval could be revoked, or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when, the FDA
or other regulatory authorities will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and cash
flow may be materially adversely affected, and our ability to grow domestically and internationally may be limited. Additionally, even
if we obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications that we
request. The Company&#8217;s products may not be approved for the specific indications that are most necessary or desirable for successful
commercialization or profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not demonstrated that any of our
products are safe and effective for any indication and will continue to expend substantial time and resources on clinical development
before any of our current or future product candidates will be eligible for FDA approval, if ever.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We expect that a substantial
portion of our efforts and expenditures over the next few years will be devoted to development of our existing and contemplated biological
product candidates. Accordingly, our business currently depends heavily on the successful development, FDA approval, and commercialization
of such candidates, which may never receive FDA approval or be successfully commercialized even if FDA approval is received. The research,
testing, manufacturing, labeling, approval, sale, marketing, and distribution of our biological product candidates are, and will remain,
subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, as applicable. We
are currently not permitted to market any of our current or future product candidates in the United States until we receive FDA approval
(of each) via the BLA process. To date, we have two product candidates in clinical development and have not-yet submitted a BLA for any
of our candidates and, for many such candidates, do not expect to be in a position to do so for the foreseeable future, as there are numerous
developmental steps that must be completed before we can prepare and submit a BLA.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In the United States, the FDA
regulates pharmaceutical and biological product candidates under the FDCA and the Public Health Service Act (&#8220;PHSA&#8221;), as well
as their respective implementing regulations. Such products and product candidates are also subject to other federal, state, and local
statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state,
local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. The process required
by the FDA before a drug or biological product may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests and animal studies in accordance with FDA&#8217;s good laboratory practices (&#8220;GLPs&#8221;) and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;), which must become effective before human clinical trials in the United States may begin;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with FDA&#8217;s IND regulations, GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA for marketing approval that meets applicable requirements to ensure the continued safety, purity, and potency of the product that is the subject of the BLA based on results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced, to assess compliance with cGMPs and assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval, or denial, of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Before testing any biological
product candidate in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations
of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate.
The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor
must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND
is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding
the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological
product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical
hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure
that submission of an IND will result in the FDA allowing clinical trials to begin or that, for those that have already commenced under
an active IND, that issues will not arise that suspend or terminate such trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Clinical trials involve the
administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events
should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be
conducted and monitored in accordance with the FDA&#8217;s regulations composing the GCP requirements, including the requirement that
all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional
review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting
the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed
consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until
completed. Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1. The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in subjects.</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to
gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">After the completion of clinical
trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA
must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition
of the product, proposed labeling and other relevant information. The FDA may grant deferrals for submission of data, or full or partial
waivers. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept
the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. Before approving a BLA, the FDA
will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical
trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant
must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Notwithstanding the submission
of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and
deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. We cannot predict with any certainty if or when we might submit a BLA for regulatory approval for our product candidates
or whether any such BLA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in
part because they are subject to rigorous regulatory requirements. For example, the FDA may not agree with our proposed endpoints for
any clinical trial we propose, which may delay the commencement of our clinical trials. The clinical trial process is also lengthy and
requires substantial time and effort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In December 2015, the FDA cleared
our IND filing for Iomab-B and we have completed patient enrollment of a randomized, controlled, pivotal Phase 3 clinical trial under
such IND to study Iomab-B in patients 55 years of age or older with relapsed or refractory AML. The Phase 3 SIERRA trial met its primary
endpoint with high statistical significance with positive results for secondary endpoints and exploratory endpoints and it is expected
to form the basis for a BLA for Iomab-B for use in preparing and conditioning AML patients for a BMT. Additionally, there are physician
IND trials at the FHCRC that have been conducted or are currently ongoing at FHCRC with Iomab-B (for other target indications) and the
apamistamab antibody (formerly known as BC8) we licensed. We have other clinical trials ongoing and others that we have planned but not-yet
commenced, for our other drug candidate Actimab-A under our own sponsorship and investigator-initiated trials ongoing. Except for Iomab-B
(for patients with AML), we expect that the clinical trials we need to conduct to be in a position to submit BLAs for our product candidates
currently in-development will take, at least, several years to complete. Moreover, failure can occur at any stage of the trials, and we
could encounter problems that cause us to abandon or repeat clinical trials. Also, the results of early preclinical and clinical testing
may not be predictive of the results of subsequent clinical trials. A number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results
in earlier studies. And, preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies
that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have, nonetheless, failed
to obtain marketing approval of their products. Success in preclinical testing and early clinical trials does not ensure that later clinical
trials, which involve many more subjects, and the results of later clinical trials may not replicate the results of prior clinical trials
and preclinical testing. Any failure or substantial delay in our product development plans may have a material adverse effect on our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may encounter substantial delays in our
clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We cannot predict whether we
will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay, suspend,
or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could delay or disrupt
the clinical development of our product candidates and potentially cause our product candidates to fail to receive regulatory approval:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving, or the inability to obtain, required approvals from IRBs or other reviewing entities at clinical sites selected for participation in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in enrolling patients into clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a lower than anticipated retention rate of patients in clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the need to repeat or discontinue clinical trials as a result of inconclusive or negative results or unforeseen complications in testing or because the results of later trials may not confirm positive results from earlier preclinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate supply, delays in distribution, deficient quality of, or inability to purchase or manufacture drug product, comparator drugs or other materials necessary to conduct our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable FDA or other foreign regulatory inspection and review of a clinical trial site or records of any clinical or preclinical investigation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials, which may occur even if they were not observed in earlier trials or only observed in a limited number of participants;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a finding that the trial participants are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the placement by the FDA or a foreign regulatory authority of a clinical hold on a trial; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in obtaining regulatory agency authorization for the conduct of our clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we or they
believe the patients participating in such clinical trials, or in independent third-party clinical trials for drugs based on similar technologies,
are being exposed to unacceptable health risks including but not limited to unacceptable or suboptimal factors related to toxicity, clinical
efficacy, imbalances in safety and efficacy profiles or for other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result in
perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation of the
study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in the analysis of clinical
data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts to obtain regulatory approval for
and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on our financial results.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated
by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB (Data Safety Monitoring
Board)/DMC (Data Monitoring Committee), overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretation of data by the FDA or similar foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to achieve primary or secondary endpoints or other failure to demonstrate efficacy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen safety issues; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of adequate funding to continue the clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modifications to our product candidates
may require federal approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United
States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products may require
additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket approvals before
we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating results.
If the products are already being used for these new indications, we may also be subject to significant enforcement actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Conducting clinical trials
and obtaining approvals is a time-consuming process, and delays in obtaining required future approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would have an adverse effect on our business prospects, financial
condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical trials necessary to support approval
of our product candidates are time-consuming and expensive. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Initiating and completing clinical
trials necessary to support FDA approval of a BLA for Iomab-B, Actimab-A, and other product candidates, is a time-consuming and expensive
process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future
results, and any product candidate we advance into clinical trials may not have favorable results in later clinical trials. We worked
with the FDA to develop the SIERRA clinical trial to test the safety and efficacy of Iomab-B in patients with relapsed or refractory AML
who are age 55 and above prior to a BMT. This trial is designed to support a BLA filing for marketing approval by the FDA. In addition
to clinical data, a BLA filing encompasses preclinical, CMC, labeling and other information. Even if the clinical data from the SIERRA
trial is positive, there can be no assurances that the BLA filing we produce will meet all of the FDA&#8217;s requirements or that they
will not request additional information or studies, which may delay the FDA&#8217;s review or we may not be able to produce. We have also
worked with the FDA to develop a regulatory pathway for lintuzumab-Ac-225 in patients with high-risk MDS that consists of a dose-confirming
Phase 1 trial that can be followed by a randomized, controlled pivotal trial that could support a BLA filing. To date, we have not initiated
this clinical trial and we may never elect or be able to do so. There can be no assurance that the data generated during the trial, or
any trial, will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing
or approval of a BLA. Even if the data from this trial are favorable, the data may not be predictive of the results of any future clinical
trials.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preliminary, Interim, and &#8220;top-line&#8221;
data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject
to audit and verification procedures that could result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;From time to time, we
may publicly disclose preliminary, interim, and top-line data from our clinical trials, which is based on a preliminary analysis of then-available
data, and the results and related findings and conclusions are subject to change as more patient data become available or following a
more comprehensive review of the data related to the particular study or trial. For example, in February 2023 we announced that Iomab-B
met the primary endpoint of dCR in the SIERRA trial with statistical significance (p&lt;0.0001) producing a durable Complete Response
rate of 22% compared to a 0% durable Complete Response rate in the control arm. We may also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data. Our clinical trials may be open label studies and certain of our clinical development and or operations staff may review interim
or preliminary safety or efficacy data during routine data collection, cleaning and analysis from time to time. Interim or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results once additional data have been received and fully evaluated. Preliminary, interim or top-line data also remain subject to audit
and verification procedures that may result in the final data being materially different from the top-line, interim or preliminary data
we previously published. As a result, top-line, interim and preliminary data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">From time to time, we may also
disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject
to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become
available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure
of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or
weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If the interim, top-line or
preliminary data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating
results, prospects or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our clinical trials may fail to demonstrate
adequately the efficacy and safety of our product candidates, which would prevent or delay regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Even if our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign
authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure
that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials
and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the
proposed indicated uses. If FDA concludes that the clinical trials for Iomab-B, Actimab-A, or any other product candidate for which we
might seek approval, have failed to demonstrate safety and effectiveness, we would not receive FDA approval to market that product candidate
in the United States for the indications sought. In addition, such an outcome could cause us to abandon the product candidate and might
delay development of others. Any delay or termination of our clinical trials will delay or preclude the filing of any submissions with
the FDA and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients
enrolled in clinical trials will experience adverse side effects that are not currently part of a product candidate&#8217;s profile.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The intellectual property related to antibodies
we have licensed has expired or likely expired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The key patents related to
the humanized antibody, lintuzumab, which we use in our Actimab-A product candidate have expired. It is generally possible that others
may be eventually able to use an antibody with the same sequence, and we will then need to rely on additional patent protection covering
alpha particle drug products comprising Ac-225. Our final drug construct, Actimab A, consists of the lintuzumab antibody labeled with
the isotope Ac-225. We currently own issued and pending patents relating to methods of manufacturing Actimab-A, methods of treatment using
Actimab-A and production of the Ac-225 isotope. In addition, we possess trade secrets and know how related to the manufacturing and use
of isotopes. Any competing product based on the lintuzumab antibody is likely to require several years of development before achieving
our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development by others is nevertheless
a possibility that could negatively impact our business in the future. We own 4 issued U.S. patents, 1 issued Canadian patent, 1 issued
European patent (validated as a national patent in several countries) and 1 issued Japanese patent that relate to the composition of our
Iomab-B product candidate. Patent applications relating to Iomab-B are also pending in the U.S. and internationally. We have and may continue
to file patents related to Iomab-B that can provide barriers to entry but there is no certainty that these patents will be granted or
such granting thereof will adequately prevent others from seeking to replicate and use the apamistamab antibody or the construct. Our
patent portfolio includes pending applications related to radioimmunoconjugate composition, formulation administration, and methods of
use in treating solid or liquid cancers. This subject matter includes composition, administration, and methods of treatment for our product
candidates Actimab-A and Iomab-B. Any competing product based on the antibody used in Iomab-B is likely to require several years of development
before achieving our product candidate&#8217;s current status and may be subject to significant regulatory hurdles but such development
by others is nevertheless a possibility that could negatively impact our business in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our CD33 program clinical trials are testing
the same drug construct. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our CD33 program is comprised
of several ongoing and planned clinical trials including investigator-initiated trials in AML studying the same drug construct consisting
of lintuzumab-Ac-225. Negative results from any of these trials could negatively impact our ability to enroll or complete our other trials
studying lintzumab-Ac-225 including future studies conducted under our CRADA with the NCI. Additionally, negative outcomes including safety
concerns, may result in the FDA discontinuing other trials utilizing lintuzumab-Ac-225.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain a sufficient
supply of isotopes to support clinical development or at commercial scale.&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Iodine-131 is a key component
of our Iomab-B drug candidate. We currently source medical grade I-131 from three suppliers including two leading global manufacturers.
Currently, there is sufficient supply of I-131 to support additional trials we may undertake utilizing I-131 and for commercialization
of Iomab-B. We continually evaluate I-131 manufacturers and suppliers and intend to have multiple qualified suppliers prior to the commercial
launch of Iomab-B. While we consider I-131 to be commoditized and obtainable through several suppliers, there can be no guarantee that
we will be able to secure I-131 or obtain I-131 on terms that are acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Actinium-225 is a key component
of our Actimab-A product candidate, technology platform, preclinical R&amp;D programs and other drug candidates that we might consider
for development with the Ac-225 payload. There are adequate quantities of Ac-225 available today to meet our current needs via our present
supplier, the Department of Energy (&#8220;DOE&#8221;). The Ac-225 currently supplied to Actinium&#8217;s clinical trials from the DOE
is derived from the natural decay of thorium-229 from so-called &#8216;thorium-cows&#8217; and is able to produce sufficient quantities
that are several multiples of the amount of Ac-225 we require to supply our clinical programs through to early commercialization phase.
The DOE is also producing Ac-225 from a recently developed alternative route for Ac-225 production via a linear accelerator that is currently
being evaluated by Actinium. Initial preclinical and modelling results have indicated that the linear accelerator sourced Ac-225 does
not impact labelling efficiency and expected distribution. In accordance with representations made by the DOE, the capacity of Ac-225
from this route is expected to be sufficient to supply all of Actinium&#8217;s pipeline and commercial Ac-225 needs and support new program
expansion by not just Actinium but also other companies that are developing Ac-225 based products. Additional routes of Ac-225 production
are being pursued by the DOE including the generation of new thorium cows and production via a cyclotron. The cyclotron production method
for Ac-225 production leverages Actinium&#8217;s proprietary technology and know-how and presents an additional path towards production
of high-quality Ac-225 at a scale that would be able to satisfy commercial needs. In addition, we are aware of at least ten other government
and non-government entities globally including the U.S., Canada, Russia, Belgium, France and Japan that have, or expect to have ability
to supply Ac-225 or equipment for its production within the timeframes relevant to the potential first commercial approval of our Ac-225-based
drug candidate.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our contract for supply of
this isotope from the DOE must be renewed yearly, and we renewed our contract to extend through the end of 2023. While we expect this
contract will continue to be renewed at the end of its term as it has since 2009, there can be no assurance that the DOE will renew the
contract or that change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities of medical grade
Ac-225 would make it impossible to effectively complete clinical trials and to commercialize any Ac-225 based drug candidates that we
may develop and would materially harm our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to conduct clinical
trials to advance our drug candidates is dependent on our ability to obtain the radioisotopes I-131, Ac-225 and other isotopes we may
choose to utilize in the future. Currently, we are dependent on third party manufacturers and suppliers for our isotopes. These suppliers
may not perform their contracted services or may breach or terminate their agreements with us. Our suppliers are subject to regulations
and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these
standards. Failure to comply with regulations and standards may result in their inability to supply isotopes and could result in delays
in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade
secrets related to the manufacturing process of Ac-225. While we have manufactured medical grade Ac-225 of a purity compared to the cyclotron
sourced material in the past, this activity was terminated due to operating cost reasons and we currently do not have experience in manufacturing
medical grade Ac-225 and may not obtain the resources necessary to establish our own manufacturing capabilities in future. Our inability
to build out and establish our own manufacturing facilities would require us to continue to rely on third party suppliers as we currently
do. However, based on our current third-party suppliers and potential future suppliers of Ac-225 we expect to have adequate isotope supply
to support our current ongoing clinical trials, current and planned preclinical R&amp;D activities and commercialization should our drug
candidates receive regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The timely completion of clinical
trials in accordance with their protocols depends on our ability to enroll a sufficient number of patients who remain in the trial until
its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility criteria defined in the protocol;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the proximity of patients to trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and expertise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing clinical trials for similar or alternate therapeutic treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinician&#8217;s and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, refractory patients,
which several of our trials are enrolling, participating in clinical trials are seriously and often terminally ill and therefore may not
complete the clinical trial due to reasons including comorbid conditions or occurrence of adverse medical events related or unrelated
to the investigational products, or death. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays
in patient enrollment will result in increased costs or affect the timing of our planned trials, which could adversely affect our ability
to advance the development of our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our product
candidates on a timely basis.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">There can be no assurance that
the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary, that
any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course of the clinical
trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification is evaluated.
In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or all of the data generated
by the clinical trial is not usable because the same protocol was not used throughout the trial. This might require the enrollment of
additional subjects, which could result in the extension of the clinical trial and the FDA delaying approval of a product candidate. If
the FDA believes that its prior approval is required for a particular modification, it can delay or halt a clinical trial while it evaluates
additional information regarding the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 19.95pt">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining required
approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays
or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause an increase in
costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our product candidates or
result in the failure of the clinical trial, which could adversely affect our business, operating results and prospects. Lengthy delays
in the completion of our Iomab-B clinical trials would adversely affect our business and prospects and could cause us to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have obtained orphan drug designation
from FDA for two of our current product candidates and intend to pursue such designation for other candidates and indications in the future,
but we may be unable to obtain such designations or to maintain the benefits associated with any orphan drug designations we have received
or may receive in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have received orphan drug
designation for Iomab-B and Actimab-A for treatment of AML in both the United States and the EU. Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects
fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will
be recovered from sales in the United States for that drug or biologic. Similarly, the EMA grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating
condition affecting not more than five in 10,000 persons in the EU.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Orphan drug designation neither
shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory
review or approval process. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities
for grant funding towards clinical trial costs, tax advantages, and application fee waivers. In addition, if a product candidate receives
the first FDA approval for the indication for which it has orphan designation, such product is entitled, upon approval, to seven years
of orphan-drug exclusivity, during which the FDA may not approve any other application to market the same drug for the same indication,
unless a subsequently approved product is clinically superior to orphan drug or where the manufacturer is unable to assure sufficient
product quantity in the applicable patient population. In the EU, orphan drug designation entitles a party to financial incentives such
as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may
be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Even if we obtain (or have
obtained) orphan drug designation for certain product candidates, we may not be the first to obtain marketing approval for such candidates
for the applicable indications due to the uncertainties inherent in the development of novel biologic products. And, an orphan drug candidate
may not receive orphan-drug exclusivity upon approval if such candidate is approved for a use that is broader than the indication for
which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines
that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product
to meet the needs of patients with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Finally, even if we successfully
obtain orphan-drug exclusivity for an orphan drug candidate upon approval, such exclusivity may not effectively protect the product from
competition because (i) different drugs with different active moieties can be approved for the same condition; and (ii) the FDA or EMA
can also subsequently approve a subsequent product with the same active moiety and for the same indication as the orphan drug if the later-approved
drug if deemed clinically superior to the orphan drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval of
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any regulatory approvals that
we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may
also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our
product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety
and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials
that we conduct post-approval. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker
information. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result
in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The FDA&#8217;s and other regulatory
authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage and reimbursement may be limited
or unavailable in certain market segments for our product candidates which could limit our sales of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The commercial success of our
product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage and reimbursement
is available for patients that use our products. However, the availability of insurance coverage and reimbursement for newly approved
cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products are approved
by the FDA as safe and efficacious. Patients using existing approved therapies are generally reimbursed all or part of the product cost
by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly
attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs, and, as a result, they may
not cover or provide adequate payment for these products. Submission of applications for reimbursement approval generally does not occur
prior to the filing of a BLA for that product and may not be granted until many months after BLA approval. In order to obtain coverage
and reimbursement for these products, we or our commercialization partners may have to agree to a net sales price lower than the net sales
price we might charge in other sales channels. The continuing efforts of government and third-party payors to contain or reduce the costs
of healthcare may limit our revenue. Initial dependence on the commercial success of our products may make our revenues particularly susceptible
to any cost containment or reduction efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures intended
to increase pressure to reduce prices of pharmaceutical products paid for by Medicare or, otherwise, affect the federal regulation of
the U.S. healthcare system could have a material adverse effect our business, future revenue, if any, and results of operations.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In the United States, there
have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The Affordable Care Act, for
example, substantially changed the way healthcare is financed by both governmental and private insurers. The Affordable Care Act contains
a number of provisions that could impact our business and operations, primarily, once we obtain FDA approval to commercialize one of our
product candidates in the United States, if ever, and may also affect our operations in ways we cannot currently predict. Affordable Care
Act provisions that may affect our business include, among others, those governing enrollment in federal healthcare programs, reimbursement
changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion of state
Medicaid programs, fees and increased discount and rebate obligations, transparency and reporting requirements, and fraud and abuse enforcement.
Such changes may impact existing government healthcare programs, industry competition, formulary composition, and may result in the development
of new programs, including Medicare payment for performance initiatives, health technology assessments, and improvements to the physician
quality reporting system and feedback program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">There have been significant
judicial, administrative, executive, and legislative initiatives to modify, limit, replace, or repeal the Affordable Care Act since its
enactment. For example, former President Trump issued several Executive Orders and other directives designed to delay the implementation
of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the
Affordable Care Act. Concurrently, Congress considered legislation that would repeal or replace all or part of the Affordable Care Act.
While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation the Affordable Care Act have
been passed. For example, the Tax Cuts and Jobs Act of 2017 eliminated the Affordable Care Act provision requiring individuals to purchase
and maintain health coverage, or the &#8220;individual mandate,&#8221; by reducing the associated penalty to zero, beginning in 2019.
In December 2018, a district court in Texas held that the individual mandate is unconstitutional and that the rest of the Affordable Care
Act is, therefore, invalid. On appeal, the Fifth Circuit Court of Appeals affirmed the holding on the individual mandate but remanded
the case back to the lower court to reassess whether and how such holding affects the validity of the rest of the Affordable Care Act.
The Fifth Circuit&#8217;s decision on the individual mandate was appealed to the U.S. Supreme Court. On June 17, 2021, the Supreme Court
held that the plaintiffs (comprised of the state of Texas, as well as numerous other states and certain individuals) did not have standing
to challenge the constitutionality of the Affordable Care Act&#8217;s individual mandate and, accordingly, vacated the Fifth Circuit&#8217;s
decision and instructed the district court to dismiss the case. As a result, the Affordable Care Act will remain in-effect in its current
form for the foreseeable future; however, we cannot predict what additional challenges may arise in the future, the outcome thereof, or
the impact any such actions may have on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition to the Affordable
Care Act, there have been numerous other Congressional initiatives and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. Pharmaceutical product prices have been the focus of increased
scrutiny by the government, including certain state attorneys general, members of Congress and the United States Department of Justice.
State or federal healthcare reform measures or other social or political pressure to lower the cost of pharmaceutical products could have
a material adverse impact on our business, results of operations and financial condition.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The Biden administration also
introduced various measures in 2021 focusing on healthcare and drug pricing, in particular. For example, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace, which began on February 15, 2021, and remained open through August 15, 2021. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that
create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. On the legislative
front, the American Rescue Plan Act of 2021 was signed into law on March 11, 2021, which, in relevant part, eliminates the statutory Medicaid
drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source drugs and innovator multiple source
drugs, beginning January 1, 2024. And, in July 2021, the Biden administration released an executive order entitled, &#8220;Promoting Competition
in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response, on September 9, 2021, HHS released
a &#8220;Comprehensive Plan for Addressing High Drug Prices&#8221; that outlines principles for drug pricing reform and sets out a variety
of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these
principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Most recently, on August 16,
2022, President Biden signed into law the&#160;Inflation&#160;Reduction&#160;Act&#160;of 2022 (the &#8220;IRA&#8221;), which, among other
provisions, included several measures intended to lower the cost of prescription drugs and related healthcare reforms. Specifically, the
IRA authorizes and directs the Department of Health and Human Services (the &#8220;DHHS&#8221;) to set drug price caps for certain high-cost
Medicare Part B and Part D qualified drugs, with the initial list of drugs to be selected by September 1, 2023, and the first year of
maximum price applicability to begin in 2026. The IRA further authorizes the DHHS to penalize pharmaceutical manufacturers that increase
the price of certain Medicare Part B and Part D drugs faster than the rate of inflation. Finally, the IRA creates significant changes
to the Medicare Part D benefit design by capping Part D beneficiaries&#8217; annual out-of-pocket spending at $2,000 beginning in 2025.
We cannot be sure whether additional or related legislation or rulemaking will be issued or enacted, or what impact, if any, such changes
will have on the profitability of any of our drug candidates, if approved for commercial use, in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with customers, health
care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including
administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs
such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and
earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Healthcare professionals and
third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing
approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we conduct research, market, sell and distribute any products for which we obtain marketing approval. Federal and state
healthcare laws and regulations that may affect our operations, directly or indirectly, include the following, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false claims laws, including civil whistleblower or qui tam actions under the federal False Claims Act, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of the covered entity as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians and any ownership and investment interests held by physicians or their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state laws and regulations, including (among others) state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the United States federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information and that require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Efforts to comply with applicable
healthcare laws and regulations will involve substantial costs. Interpretations of standards of compliance under these laws and regulations
are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may
be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight (if we become subject to
a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws), and the curtailment or restructuring
of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities
with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party payors may not adequately reimburse
customers for any product candidates that we may commercialize or promote, and may impose coverage restrictions or limitations such as
prior authorizations and step edits that affect their use.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to commercialize
any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products
and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other
third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend
in the United States healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring
that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage
and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement
may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate
for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may
not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Obtaining reimbursement approval
for any product candidate for which we obtain marketing approval from any government or other third-party payor is a time-consuming and
costly process. There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products. Moreover,
eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our
costs, including research, development, manufacture, sale and distribution. Even when a payor determines that a product that we may commercialize
or promote is eligible for reimbursement under its criteria, the payor may impose coverage limitations that preclude payment for some
uses that are approved by the FDA, or may impose restrictions, such as prior authorization requirements, or may simply deny coverage altogether.
Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.
Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be
based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other
services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices
than in the United States. Furthermore, the Centers for Medicare and Medicaid Services frequently change product descriptors, coverage
policies, product and service codes, payment methodologies and reimbursement values. Commercial third-party payors often rely upon Medicare
coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain and maintain coverage
and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have
a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our
overall financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Third Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on third parties to conduct our
clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with
regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We do not have the ability
to independently conduct our clinical trials for our product candidates and we must rely on third parties, such as contract research organizations,
medical institutions, clinical investigators and contract laboratories to conduct such trials. Our reliance on these third parties for
clinical development activities results in reduced control over these activities. Moreover, the FDA requires us to comply with regulations
and standards, commonly referred to as GCPs (good clinical practices), for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our
reliance on third parties does not relieve us of these responsibilities and requirements. If we or any of our third-party contractors
fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable
foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing
practice, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay
the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If our consultants, contract
research organizations and other similar entities with which we are working do not successfully carry out their contractual duties, meet
expected deadlines, or comply with applicable regulations, we may be required to replace them. Although we believe that there are a number
of other third-party contractors we could engage to continue these activities, we may not be able to enter into arrangements with alternative
third-party contractors or to do so on commercially reasonable terms, which may result in a delay of our planned clinical trials and delayed
development of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors, we
cannot control whether or not they devote sufficient time and resources to our programs. If these third parties do not successfully carry
out their contractual duties or regulatory obligations or meet expected deadlines, or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory
approval for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results
and prospects would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The antibodies we use in our targeted radiotherapy
product candidates may be subject to generic competition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are not aware of any existing
or pending regulations or legislation that pertains to generic radiopharmaceutical products such as our targeted radiotherapy product
candidates. Our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these products pursuant
to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval
of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review
and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity
to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after
the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As
a result, its ultimate impact, implementation, and meaning are subject to uncertainty. Even if a biosimilar gets approved for one of the
antibodies that we use, the final constructs of our drug candidates consist of an antibody, radioisotope and in some cases a linker. Therefore,
we do not believe that the final drug product of our candidates can be subject to competition from a biosimilar as outlined in BPCIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may never achieve
market acceptance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Iomab-B, Actimab-A and future
product candidates that we may develop may never gain market acceptance among physicians, patients and the medical community. The degree
of market acceptance of any of our products will depend on a number of factors, including the actual and perceived effectiveness and reliability
of the product; the results of any long-term clinical trials relating to use of the product; the availability, relative cost and perceived
advantages and disadvantages of alternative technologies; the degree to which treatments using the product are approved for reimbursement
by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education and awareness
among physicians and hospitals concerning the product.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and published
peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means of treating specific
cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does not provide patients with
sufficient benefits in extension of life or quality of life. We believe that recommendations and support for the use of each product candidate
from influential physicians will be essential for widespread market acceptance. Our product candidates are still in the development stage
and it is premature to attempt to gain support from physicians at this time. We can provide no assurance that such support will ever be
obtained. If our product candidates do not receive such support from these physicians and from long-term data, physicians may not use
or continue to use, and hospitals may not purchase or continue to purchase, them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Failure of Iomab-B, Actimab-A
or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business financial
condition and results of operations.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our third-party
service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have received confidential
and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology
or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently
or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may
be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial
cost and be a distraction to our management and employees.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently depend on single third-party
manufacturers to produce our pre-clinical and clinical trial drug supplies. Any disruption in the operations of our current third-party
manufacturers, or other third-party manufacturers we may engage in the future, could adversely affect our business and results of operations.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We do not currently operate
manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We rely on third-party manufacturers
to supply, store, and distribute pre-clinical and clinical supply of the components of our drug product candidates including monoclonal
antibodies, linkers and radioisotopes, as well as the final construct which comprises our drug product candidates. We expect to continue
to depend on third-party manufacturers for the foreseeable future. Any performance failure on the part of our existing or future manufacturers
could delay clinical development, cause us to suspend or terminate development or delay or prohibit regulatory approval of our product
candidates or commercialization of any approved products. Further avenues of disruption to our clinical or eventual commercial supply
may also occur due to the sale, acquisition, business reprioritization, bankruptcy or other unforeseen circumstances that might occur
at any of our suppliers or contract manufacturing partners including an inability to come to terms on renewal of existing contracts or
new contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We currently rely on single
manufacturers to manufacture our pre-clinical and clinical trial drug supplies. With a view to maintaining business continuity we are
evaluating alternatives and second and even third sources of supply or manufacturing for our core suppliers and manufacturing partners,
however there can be no assurances that we will be able to identify such suppliers or partners and assuming we did, that we would be able
to enter into contracts that are on favorable terms or on terms that will enable sufficient supply to ensure business continuity and support
our growth plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our product candidates require
precise, high-quality manufacturing. Failure by our current contract manufacturer or other third-party manufacturers we may engage in
the future to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals,
delays or failures in testing or delivery, cost overruns, or other problems that could seriously hurt our business. Contract manufacturers
may encounter difficulties involving production yields, quality control, and quality assurance. These manufacturers are subject to ongoing
periodic and unannounced inspections by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and
other applicable government regulations and corresponding foreign standards; we do not have control over third-party manufacturers&#8217;
compliance with these regulations and standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may elect to build or purchase
a manufacturing facility or facilities in the future to operate for the purposes of manufacturing our own products. We have never built,
owned or operated a manufacturing facility. There can be no assurances that we will be able to successfully accomplish this and in doing
so we may experience delays, cost overruns, or other problems that could seriously hurt our business. Even if we successfully build or
purchase a manufacturing facility, we may not realize the expected benefits of these efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We depend on vendors with specialized
operations, equipment and know-how to manufacture the respective components of our drug candidates. We have entered into manufacturing
and supply agreements with these third-parties, and in some instances, we have agreed that such vendor be the exclusive manufacturer and
supplier. If any of the third-parties we depend on encounter difficulties in their operations, fail to comply with required regulations
or breach their contractual obligations it may be difficult, or we may be unable to identify suitable alternative third-party manufacturers.
While we identify and evaluate third-party manufacturers from time to time, even if we do identify suitable alternative third-parties,
we may fail to reach agreement on contractual terms, it may be prohibitively expensive and there can be no assurance that we can successfully
complete technology transfer and development work necessary or complete the necessary work in a timely manner. Any of which could prevent
us from commencing manufacturing with third-parties which could cause delays or suspension of our clinical trials and pre-clinical work
that may have a negative impact on our business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Furthermore, these third-party
contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shutdowns, employee strikes, or
any other unforeseeable acts that may delay or limit production. Our inability to adequately establish, supervise and conduct (either
ourselves or through third parties) all aspects of the formulation and manufacturing processes, and the inability of third-party manufacturers
to consistently supply quality product when required would have a material adverse effect on our ability to develop or commercialize our
products. We have faced delays and risks associated with reliance on key third party manufacturers in the past and may be faced with such
delays and risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company,
including delays in clinical trials.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are successful in obtaining marketing
approval from the FDA and/or other regulatory agencies for any of our product candidates, we anticipate continued reliance on third-party
manufacturers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">To date, our product candidates
have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the FDA or other regulatory
agencies approve any of our product candidates for commercial sale, we expect that we would continue to rely, at least initially, on third-party
specialized manufacturers to produce commercial quantities of approved products. These manufacturers may not be able to successfully increase
the manufacturing capacity for any approved product in a timely or economic manner, or at all. Significant scale-up of manufacturing may
require additional validation studies, which the FDA must review and approve. Scale-up for commercial product may require financial commitment
or investment by us, which we may not have sufficient capital for or may elect not to undertake. If third party manufacturers are unable
to successfully increase the manufacturing capacity for a product candidate, or we are unable to establish our own manufacturing capabilities,
the commercial launch of any approved products may be delayed or there may be a shortage in supply, which in turn could have a material
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will
be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract
manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure
and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not
approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for
or market our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We may have conflicts with
our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation
of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during
our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests.
Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization
of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us milestone
payments or royalties we believe are due under a collaboration; uncertainty regarding ownership of intellectual property rights arising
from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the partner to
cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the
part of a partner to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure
of the results of those activities; initiating litigation or alternative dispute resolution options by either party to resolve the dispute;
or attempts by either party to terminate the agreement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we are unable to establish
U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates,
we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that may receive regulatory approval.
In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis marketing, sales, distribution,
managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales or marketing team with
technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming
and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">With respect to the commercialization
of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with
third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution
systems or in lieu of our own sales force and distribution systems. In particular, we have and expect to continue to partner with third
parties to commercialize Iomab-B outside the United States. In April&#160;2022, we entered into a licensing agreement with Immedica, in
which Immedica acquired the product rights for commercialization of Iomab-B for certain territories outside the U.S. If we are unable
to enter into or maintain such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize
any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If
we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties,
our future product revenue will suffer and we may incur significant additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face significant competition from other
biotechnology and pharmaceutical companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our product candidates face,
and will continue to face, intense competition from large pharmaceutical and biotechnology companies, as well as academic and research
institutions. We compete in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii)
emerging competition and (iv) new product introductions. Our competitors have existing products and technologies that will compete with
our product candidates and technologies and may develop and commercialize additional products and technologies that will compete with
our product candidates and technologies. Because several competing companies and institutions have greater financial resources than us,
they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development, or R&amp;D,
and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we do and have substantially
greater experience in undertaking preclinical and clinical testing of product candidates, obtaining regulatory approvals, and manufacturing
and marketing pharmaceutical products. They also have greater name recognition and better access to customers than us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial
potential, or result in significant negative consequences. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Undesirable side effects caused
by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The drug-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Even if any of our product candidates
receives marketing approval, as greater numbers of patients use a product following its approval, an increase in the incidence of side
effects or the incidence of other post-approval problems that were not seen or anticipated during pre-approval clinical trials could result
in a number of potentially significant negative consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may withdraw their approval of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may elect, or we may be required, to recall or withdraw product from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for harm caused to patients; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any of these events could substantially
increase the costs and expenses of developing, commercializing and marketing any such product candidates or could harm or prevent sales
of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon securing and protecting critical
intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are dependent on obtaining
and maintaining patents, trade secrets, copyright and trademark protection of our technologies in the United States and other jurisdictions,
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
The degree of future protection of our proprietary rights is uncertain for product candidates that are currently in the early stages of
development because we cannot predict which of these product candidates will ultimately reach the commercial market or whether the commercial
versions of these product candidates will incorporate proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our patent position is highly uncertain
and involves complex legal and factual questions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Accordingly, we cannot predict
the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or our licensors might
not have been the first to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors
might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative
technologies or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis for commercially
viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and,
we may not develop additional proprietary technologies that are patentable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As a result, our owned and
licensed patents may not be valid, and we may not be able to obtain and enforce patents and to maintain trade secret protection for the
full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We or our licensors have applied
for and will continue to apply for patents for certain products and methods. Such applications may not result in the issuance of any patents,
and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible
that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because
of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we
could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our
patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that we license from third parties, or subsequent
related filings, would adversely affect our business and operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement
is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further, such litigation
can go on for years and the time demands could interfere with our normal operations. There has been substantial litigation and other proceedings
regarding patent and other intellectual property rights in the pharmaceutical industry. We may become a party to patent litigation and
other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Some of our competitors
may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources.
Litigation may also absorb significant management time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Unpatented trade secrets, improvements,
confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although we attempt
to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of confidentiality
agreements with our partners, collaborators, employees and consultants and other appropriate means, these measures may not effectively
prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access to, the same
or similar information. In addition, we cannot guarantee that we have executed these agreements with each party that may have or have
had access to our trade secrets. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the
terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through
such breaches or violations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Certain of our patent rights
are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those patents may
be terminated, and we may be unable to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are found to be infringing on patents
or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the
development or sale of our products, and/or pay damages.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others,
or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases
that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other
persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the
affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected process.
Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved
in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition to infringement
or other intellectual property claims against us, we may become a party to other patent litigation or proceedings before regulatory agencies,
including post-grant review, inter parties review, interference or re-examination proceedings filed with the U.S. Patent and Trademark
Office (or similar proceedings before corresponding tribunals in other jurisdictions) that challenge our patent rights or the patent rights
of our licensors. The costs and efforts of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings
can be substantial and the outcome can be uncertain. An adverse determination in these proceedings could weaken or invalidate the patent
claims that cover our technology, which adverse determination could harm our business significantly and dissuade companies from collaborating
with us or permit third parties to directly compete with the same technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to protect and enforce our patents
does not guarantee that we will secure the right to commercialize our patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">A patent is a limited monopoly
right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious invention.
This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using its invention.
While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention where other permissions
may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate authorization from the
FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented itself, cannot be commercialized
if it infringes the valid patent rights of another party.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely on confidentiality agreements to
protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our
competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We rely on trade secrets that
we seek to protect through numerous measures, including non-compete and confidentiality agreements with our employees and other parties.
If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. Any remedies
that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we
may have to expend resources to protect our interests from possible infringement by others. For instance, we learned that a former employee,
Qing Liang, Ph.D., who was employed by Actinium in the position of Vice President, Head of Radiation Sciences, violated the non-compete
provision of her employment agreement by working for a direct competitor. Additionally, while working for the direct competitor, Dr. Liang
continued to provide consulting services to Actinium. We also learned that Dr. Liang was providing consulting services to another company,
which was in violation of certain provisions of her post-employment consulting agreement with Actinium. Dr. Liang, who had access to materials
containing proprietary information and trade secrets, pursuant to actions taken by Actinium, is no longer employed by the direct competitor.
With the assistance of outside counsel and a forensic investigator, we identified that Dr. Liang downloaded confidential information prior
to her employment at Actinium ending. To aid in arbitration proceedings, we petitioned and were granted a Stipulated Preliminary Injunction
by the Supreme Court of the State of New York, New York County (Index No. 656841/2022) on June 28, 2022 that ordered that Dr. Liang is
enjoined from destroying or deleting any Actinium documents or information, is enjoined from using, transmitting or transferring any Actinium
Information other than to her counsel or Actinium&#8217;s counsel, ordered to return Actinium information within 5 days of Stipulated
Preliminary Injunction, ordered to disclose to Actinium under oath, all persons and devices she transferred or disclosed Actinium Information,
and ordered to allow a qualified forensic examiner selected by Actinium to remove and permanently delete all Actinium Information from
any electronic devices, systems, email accounts, or other electronic or physical storage sites belonging to Dr. Liang. We are currently
in arbitration with Dr. Liang and intend to enforce the terms of her employment agreement, especially the non-compete and confidentiality
provisions, to the fullest extent of our ability. On April 25, 2023, a Final Award and Permanent Injunction was granted by the Supreme
Court of the State of New York, New York County (Case No. 01-22-0003-2375_ that ordered that Ms. Liang is permanently enjoined from using,
possessing, transmitting or transferring any Actinium property, documents of business information. Further, until April 1, 2024, Dr. Liang
shall not, either directly or indirectly, engage in any business that directly or indirectly is developing, or plans to develop, radioimmunotherapies
for cancer or any targeted conditioning therapy or agent for adoptive cell therapy including bone marrow transplant and CAR-T.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to expand our development and
regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and, as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We expect to experience significant
growth in the number of our employees and the scope of our operations, particularly in the areas of product candidate development, regulatory
affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We currently do not have a
marketing or sales team for the marketing, sales and distribution of any of our product candidates that are potentially able to obtain
regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales,
distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we
may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be
expensive and time consuming and will require significant attention of our executive officers to manage. We will also have to compete
with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of
any of our product candidates that we obtain approval to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">To manage our anticipated future
growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue
to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management
team in managing a public company with such anticipated growth, we may not be able to effectively manage the expansion of our operations
or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our
management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject us
to liability for claims arising from the use or misuse of these materials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our research, development and
manufacturing activities involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials,
such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations governing, among
other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot completely eliminate the
risk of contamination or injury from these materials and we could be held liable for any damages that result, which could exceed our financial
resources. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future claims
may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs
of complying with such federal, state, local and foreign environmental regulations are not significant, and consist primarily of waste
disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our research,
development, production and commercialization efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Although we do not have any
international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries involves
inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected changes in
regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">If we were to experience any
of the difficulties listed above, or any other difficulties, any international development activities and our overall financial condition
may suffer and cause us to reduce or discontinue our international development and registration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on our key personnel,
and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our future operations and successes
depend in large part upon the continued service of key members of our senior management team whom we are highly dependent upon to manage
our business. If any member of our current senior management terminates his or her employment with us and we are unable to find a suitable
replacement quickly, the departure could have a material adverse effect on our business. An overall tightening and increasingly competitive
labor market has been observed in the U.S. employment market generally, especially in response to the COVID-19 pandemic. Specific to the
biotechnology industry in which we operate, there is significant demand and competition for highly specialized talent that we require.
A sustained labor shortage or increased turnover rates within our employee base, caused by the COVID-19 pandemic, as a result of general
macroeconomic factors, or due to dynamics within our industry, could lead to increased costs, such as increased wage rates to attract
and retain employees, and could negatively affect our ability to efficiently conduct our clinical development, R&amp;D, business development
and potential regulatory and commercial activities. If we are unable to hire and retain employees capable of performing at a high-level,
or if mitigation measures we may take to respond to a decrease in labor availability, have unintended negative effects, our business could
be adversely affected. An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, caused by the COVID-19
pandemic, general macroeconomic factors or as a result of biotechnology industry dynamics could have a material adverse impact on our
operations, results of operations, liquidity or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our future success also depends
on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory
personnel. This activity is likely to create additional demands on the time and attention of our senior management personnel as they identify,
hire, and train external and internal candidates to fill the sizable number of positions required to execute our business plans, including
submitting a BLA and building a commercial organization. The market for talent in our industry is very competitive. Many of the other
biopharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk
profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities
and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have
to offer. There can be no assurance that such professionals will be available in the market, or that we will be able to retain existing
professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us. Failure to establish
and maintain an effective management team and workforce could adversely affect our ability to operate, grow and manage our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Managing our growth as we expand operations
may strain our resources.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We expect to need to grow rapidly
in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates as well as potential
commercial operations, which will place a significant strain on our financial, managerial and operational resources. In order to achieve
and manage growth effectively, we must continue to improve and expand our operational and financial management capabilities. Moreover,
we will need to increase staffing and to train, motivate and manage our employees. All of these activities will increase our expenses
and may require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm our business,
financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expand our business through the acquisition
of rights to new product candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&#8217;
ownership interests in our company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our business strategy includes
expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies to do so. Acquisitions
involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt
and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
acquired technologies or the operations of the acquired companies; diverting our management&#8217;s attention away from other business
concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key employees or key
employees of the acquired companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We can make no assurances that
any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired product,
company or business. In addition, our future success would depend in part on our ability to manage the rapid growth associated with some
of these acquisitions. We cannot assure that we will be able to make the combination of our business with that of acquired products, businesses
or companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business or companies
may require a substantial capital investment by us. We may not have these necessary funds, or they might not be available to us on acceptable
terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute each current stockholder&#8217;s
ownership interest in the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Ownership of Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The sale of securities by us in any equity
or debt financing could result in dilution to our existing stockholders and have a material adverse effect on our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have financed our operations
primarily through sales of stock and warrants. It is likely that during the next twelve months we will seek to raise additional capital
through the sales of stock and warrants in order to expand our level of operations to continue our research and development efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any sale of common stock by
us in a future offering could result in dilution to our existing stockholders as a direct result of our issuance of additional shares
of our capital stock. In addition, our business strategy may include expansion through internal growth or by establishing strategic relationships
with targeted customers and vendors. In order to do so, or to finance the cost of our other activities, we may issue additional equity
securities that could dilute our stockholders&#8217; stock ownership. We may also assume additional debt and incur impairment losses related
to goodwill and other tangible assets if we acquire another company and this could negatively impact our earnings and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>Our common stock is subject to price volatility which could
lead to losses by stockholders and potential costly security litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The trading volume of our common
stock has been and may continue to be extremely limited and sporadic. We expect the market price of our common stock to fluctuate substantially
due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of
other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial
markets or other developments affecting our competitors or us. This volatility has had a significant effect on the market price of securities
issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The trading price of our common
stock may be highly volatile and could fluctuate in response to factors such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our operating results;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of developments by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory actions regarding our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adoption of new accounting standards affecting our industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock or other securities in the open market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inaccurate or unfavorable reports from securities or industry analysts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our control.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The stock market is subject
to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities,
securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful,
could result in substantial costs and diversion of our management&#8217;s attention and our resources, which could harm our business and
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not intend to pay dividends on our
common stock, so any returns will be determined by the value of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We have never declared or paid
any cash dividends on our common stock. For the foreseeable future, it is expected that earnings, if any, generated from our operations
will be used to finance the growth of our business, and that no dividends will be paid to holders of our common stock. As a result, the
success of an investment in our common stock will depend upon any future appreciation in its value. There is no guarantee that our common
stock will appreciate in value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>Certain provisions of our Certificate
of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult
to complete, even if such a transaction were in our stockholders&#8217; interest.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Provisions of our certificate
of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our
stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock.
Among other things, the certificate of incorporation and bylaws:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that the authorized number of directors may be changed by resolution of the board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divide the board of directors into three classes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and meet specific requirements as to the form and content of a stockholder&#8217;s notice;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, we are governed
by Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging
in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
A &#8220;business combination&#8221; includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder.
An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years, did own,
15% or more of the corporation&#8217;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compliance with the reporting requirements
of federal securities laws can be expensive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">We are subject to the information
and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley
Act. The costs of preparing and filing annual and quarterly reports and other information with the Securities and Exchange Commission
and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the
preparation of registration statements and related documents with respect any offerings of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our ability to utilize our
federal net operating loss and tax credit carryforwards may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code.&#160;The limitations apply if we experience an &#8220;ownership change&#8221;, generally defined as a greater
than 50 percentage point change in the ownership of our equity by certain stockholders over a rolling three-year period.&#160;Similar
provisions of state tax law may also apply. We have not assessed whether such an ownership change has previously occurred.&#160;If we
have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize
our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership,
which may be outside of our control, may trigger an ownership change and, consequently, the limitations under Sections 382 and 383 of
the Code.&#160;As a result, if or when we earn net taxable income, our ability to use our pre-change net operating loss carryforwards
and other tax attributes to offset such taxable income may be subject to limitations, which could adversely affect our future cash flows.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to establish and maintain adequate
finance infrastructure and accounting systems and controls could impair our ability to comply with the financial reporting and internal
controls requirements for publicly traded companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">As a public company, we operate
in an increasingly demanding regulatory environment, including with respect to more complex accounting rules. Company responsibilities
required by the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, include establishing and maintaining corporate oversight
and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary
for us to produce reliable financial reports and are important to help prevent financial fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our compliance with Section
404 of the Sarbanes-Oxley Act requires that we incur substantial accounting expense and expend significant management efforts. We complied
with Section 404 at December 31, 2022 and 2021 and while our testing did not reveal any material weaknesses in our internal controls,
any material weaknesses in our internal controls in the future would be required us to remediate in a timely manner so as to be able to
comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner
each year, we could be subject to sanctions or investigations by the SEC, NYSE American or other regulatory authorities which would require
additional financial and management resources and could adversely affect the market price of our common stock. Furthermore, if we cannot
provide reliable financial reports or prevent fraud, our business and results of operations could be harmed, and investors could lose
confidence in our reported financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Multiple
securities and industry analysts currently cover us. If one or more of the analysts downgrade our common stock or publish inaccurate or
unfavorable research about our business, the price of our common stock would likely decline. If one or more of these analysts cease coverage
of us or fail to publish reports on us regularly, demand for our common stock could decrease, which could cause the price of our common
stock and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated&#160;bylaws, as
amended,&#160;designate the U.S.&#160;federal&#160;district courts as the&#160;exclusive forum&#160;for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Our amended and restated&#160;bylaws,
as amended,&#160;provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities
Act of 1933, as amended. In addition, our amended and restated bylaws, as amended, state that any person purchasing or otherwise acquiring
any interest in our security shall be deemed to have notice of and to have consented to such provision. Such choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits, if successful, might benefit our stockholders. Stockholders who do bring
a claim in the federal district courts of the United States of America could face additional litigation costs in pursuing any such claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. EXHIBITS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Copies of the following documents
are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed with the SEC on April 17, 2013).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0623ex31-1_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0623ex31-2_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0623ex32-1_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10q0623ex32-2_actiniumphar.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Label Linkbase Document </span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
herewith.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
a management contract or compensatory plan or arrangement.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ACTINIUM PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 14, 2023</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sandesh Seth</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer<br/>
(Duly Authorized Officer and<br/>
Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Steve O&#8217;Loughlin</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve O&#8217;Loughlin</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Duly Authorized Officer and<br/>
Principal Financial and Accounting Officer)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">75</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-7" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-8" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:SubleaseIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-10" name="us-gaap:SubleaseIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-11" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-12" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="2" id="hidden-fact-13" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.33</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-14" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.56</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-15" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.58</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-16" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">1.01</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-17" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">22942317</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="0" id="hidden-fact-18" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">23731886</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-19" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">25958706</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-20" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">26217910</ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-22" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-28" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-37" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-39" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-40" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-41" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-43" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-44" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-45" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-47" name="atnm:IncreaseDecreaseInLongtermLicenseRevenuesDeferred" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-48" name="atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-49" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-50" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-51" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-54" name="us-gaap:RestrictedCashCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-55" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-57" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-58" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-59" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-60" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-61" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-62" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-63" name="atnm:PaymentWithImputedInterestPremium" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-64" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-66" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-67" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001388320</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="atnm-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cai7eOb3yJcUMi1RySwrMYUM7gHRFDCgY8O3w4R4W8jAgTqmrArcxHx7XqiBoFhPlendAbytLxtxkC79CLaYQBr5C0E1635qjCOsDefpXTBZUiZk1WFP19q1EVUMjBIbUvKYtU6pOwH0Fg==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2012-05-16</xbrli:startDate>
    <xbrli:endDate>2012-06-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2012-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-01</xbrli:startDate>
    <xbrli:endDate>2022-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-03</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0623ex31-1_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION
302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sandesh Seth, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this Form
10-Q of Actinium Pharmaceuticals, Inc.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. I am responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. I have disclosed, based
on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Dated August 14, 2023</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%"></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0623ex31-2_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO SECTION 302 OF</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Steve O&rsquo;Loughlin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. I have reviewed this Form
10-Q of Actinium Pharmaceuticals, Inc.;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Based on my knowledge,
this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. Based on my knowledge,
the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. I am responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. I have disclosed, based
on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee
of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b) Any fraud, whether or not
material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Dated: August 14, 2023</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%"></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0623ex32-1_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Sandesh Seth, Chairman &amp; CEO of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. The information contained
in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Dated: August 14, 2023</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%"></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Sandesh Seth</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer)&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10q0623ex32-2_actiniumphar.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">18 U.S.C. SECTION 1350,</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AS ADOPTED PURSUANT TO</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Quarterly Report of Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Steve O&rsquo;Loughlin, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. The information contained
in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Dated: August 14, 2023</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%"></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Steve O&rsquo;Loughlin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Duly Authorized Officer,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Principal Financial and Accounting Officer)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>atnm-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sun Aug 13 17:17:31 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" targetNamespace="http://actiniumpharmaceuticals.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:atnm="http://actiniumpharmaceuticals.com/20230630" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="atnm-20230630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet" id="atnm_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals" id="atnm_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement" id="atnm_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals" id="atnm_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3" id="atnm_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow" id="atnm_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies" id="atnm_r_CommitmentsandContingencies">
        <link:definition>008 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Leases" id="atnm_r_Leases">
        <link:definition>009 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue" id="atnm_r_OtherRevenue">
        <link:definition>010 - Disclosure - Other Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/Equity" id="atnm_r_Equity">
        <link:definition>011 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy" id="atnm_r_AccountingPoliciesByPolicy">
        <link:definition>012 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>013 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables" id="atnm_r_LeasesTables">
        <link:definition>014 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityTables" id="atnm_r_EquityTables">
        <link:definition>015 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable" id="atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable">
        <link:definition>016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable" id="atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable">
        <link:definition>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails" id="atnm_r_CommitmentsandContingenciesDetails">
        <link:definition>018 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails" id="atnm_r_LeasesDetails">
        <link:definition>019 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable" id="atnm_r_ScheduleofcomponentsofleaseexpenseTable">
        <link:definition>020 - Disclosure - Leases (Details) - Schedule of components of lease expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" id="atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
        <link:definition>021 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable" id="atnm_r_ScheduleofweightedaverageremainingleasetermsTable">
        <link:definition>022 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cai7eOb3yJcUMi1RySwrMYUM7gHRFDCgY8O3w4R4W8jAgTqmrArcxHx7XqiBoFhPlendAbytLxtxkC79CLaYQBr5C0E1635qjCOsDefpXTBZUpwRSh2/0DFOGQJiASSXbLvvtIBCZTU/sg==] CSR-->
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable" id="atnm_r_ScheduleofweightedaveragediscountratesTable">
        <link:definition>023 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>024 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails" id="atnm_r_OtherRevenueDetails">
        <link:definition>025 - Disclosure - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails" id="atnm_r_EquityDetails">
        <link:definition>026 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable" id="atnm_r_ScheduleofsummaryofstockoptionactivityTable">
        <link:definition>027 - Disclosure - Equity  (Details) - Schedule of summary of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable" id="atnm_r_ScheduleofsummaryofrestrictedstockunitactivityTable">
        <link:definition>028 - Disclosure - Equity  (Details) - Schedule of summary of restricted stock unit activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable" id="atnm_r_ScheduleofwarrantactivitiesTable">
        <link:definition>029 - Disclosure - Equity  (Details) - Schedule of warrant activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xs:element name="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
  <xs:element name="ScheduleOfComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfSummaryOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfWarrantActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWarrantActivitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract7"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract8"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract9"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract10"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract11"/>
  <xs:element name="UnlabeledAbstract12" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract12"/>
  <xs:element name="UnlabeledAbstract13" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract13"/>
  <xs:element name="UnlabeledAbstract14" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract14"/>
  <xs:element name="UnlabeledAbstract15" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract15"/>
  <xs:element name="UnlabeledAbstract16" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract16"/>
  <xs:element name="UnlabeledAbstract17" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract17"/>
  <xs:element name="UnlabeledAbstract18" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract18"/>
  <xs:element name="UnlabeledAbstract19" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract19"/>
  <xs:element name="FinanceLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseCostAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract20" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract20"/>
  <xs:element name="NonCashActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_NonCashActivityAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageDiscountRatesAbstract"/>
  <xs:element name="UnlabeledAbstract21" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract21"/>
  <xs:element name="UnlabeledAbstract22" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnlabeledAbstract22"/>
  <xs:element name="LongtermOperatingLeaseObligationsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
  <xs:element name="IncreaseDecreaseInLongtermLicenseRevenuesDeferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred"/>
  <xs:element name="IncreaseDecreaseInOperatingLeaseRightofuseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
  <xs:element name="SalesOfSharesOfCommonStockNetOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
  <xs:element name="OtherRevenueTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OtherRevenueTextBlock"/>
  <xs:element name="GrantRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantRevenuePolicyTextBlock"/>
  <xs:element name="LicenseRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LicenseRevenuePolicyTextBlock"/>
  <xs:element name="ScheduleOrDescriptionOfWeightedAverageTerm" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
  <xs:element name="ScheduleOfWeightedAverageDiscountRate" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ScheduleOfWeightedAverageDiscountRate"/>
  <xs:element name="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
  <xs:element name="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
  <xs:element name="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
  <xs:element name="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <xs:element name="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
  <xs:element name="LeaseDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeaseDomainDomain"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
  <xs:element name="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
  <xs:element name="PaymentWithImputedInterestPremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_PaymentWithImputedInterestPremium"/>
  <xs:element name="MaturitiesOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MaturitiesOfLeaseLiabilities"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
  <xs:element name="RSUsOutstandingBeginningBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_RSUsOutstandingBeginningBalance"/>
  <xs:element name="NumberOfWarrantsOutstandings" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="atnm_NumberOfWarrantsOutstandings"/>
  <xs:element name="WeightedAverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageRemainingContractualTermGranted"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_MilestonePayment"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_LeasesDetailsTable"/>
  <xs:element name="LeasesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_LeasesDetailsLineItems"/>
  <xs:element name="RevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_RevenueRecognized"/>
  <xs:element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UpfrontPayment"/>
  <xs:element name="LongtermLicenseRevenueDeferred" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_LongtermLicenseRevenueDeferred"/>
  <xs:element name="AgreementDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_AgreementDomainDomain"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="atnm_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_EquityDetailsLineItems"/>
  <xs:element name="GrantOfStockOptionsToEmployees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_GrantOfStockOptionsToEmployees"/>
  <xs:element name="DescriptionOfExercisePriceRange" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DescriptionOfExercisePriceRange"/>
  <xs:element name="StockOptionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_StockOptionTerm"/>
  <xs:element name="VestingPeriodOfStockOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_VestingPeriodOfStockOption"/>
  <xs:element name="AggregateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="atnm_AggregateFairValue"/>
  <xs:element name="UnrecognizedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_UnrecognizedCompensationExpense"/>
  <xs:element name="WeightedAverageTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_WeightedAverageTerm"/>
  <xs:element name="CompensationExpenseRelatedToStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="atnm_CompensationExpenseRelatedToStockOptions"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_AgreementAxis"/>
  <xs:element name="LeaseAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="atnm_LeaseAxis"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="FinanceLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_FinanceLeaseLiabilitiesMember"/>
  <xs:element name="OperatingLeaseLiabilitiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_OperatingLeaseLiabilitiesMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="atnm_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>atnm-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sun Aug 13 17:17:31 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cai7eOb3yJcUMi1RySwrMYUM7gHRFDCgY8O3w4R4W8jAgTqmrArcxHx7XqiBoFhPlendAbytLxtxkC79CLaYQBr5C0E1635qjCOsDefpXTBZUka4/9w5pd1H3DzJdYz7xIyI7Lbs1u3iPQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_SubleaseIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>atnm-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sun Aug 13 17:17:31 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofsummaryofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofsummaryofrestrictedstockunitactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenue" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_Liabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20230630.xsd#atnm_OtherRevenueTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_OtherRevenueTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20230630.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_GrantRevenuePolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20230630.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="atnm_LicenseRevenuePolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20230630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20230630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cai7eOb3yJcUMi1RySwrMYUM7gHRFDCgY8O3w4R4W8jAgTqmrArcxHx7XqiBoFhPlendAbytLxtxkC79CLaYQBr5C0E1635qjCOsDefpXTBZUuhcbkD9f6qhGScThf+n7DuQzC4v2ns58Q==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseCostAbstract" xlink:href="atnm-20230630.xsd#atnm_FinanceLeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_FinanceLeaseCostAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_LeaseCostAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20230630.xsd#atnm_LeaseAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeaseAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomainDomain" xlink:href="atnm-20230630.xsd#atnm_LeaseDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomainDomain_0" xlink:href="atnm-20230630.xsd#atnm_LeaseDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20230630.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomainDomain" xlink:to="atnm_OperatingLeaseLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20230630.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeaseDomainDomain" xlink:to="atnm_FinanceLeaseLiabilitiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20230630.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="atnm_PaymentWithImputedInterestPremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20230630.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_MaturitiesOfLeaseLiabilities" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingBeginningBalance" xlink:href="atnm-20230630.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_RSUsOutstandingBeginningBalance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20230630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_NumberOfWarrantsOutstandings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="atnm_WeightedAverageRemainingContractualTermGranted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20230630.xsd#atnm_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="atnm_MilestonePayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DerivativeNetAssetsPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="atnm_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_LeasesDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateAndOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_CorporateAndOtherMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="us-gaap_LandImprovements" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20230630.xsd#atnm_RevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_RevenueRecognized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20230630.xsd#atnm_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_UpfrontPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20230630.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="atnm_LongtermLicenseRevenueDeferred" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20230630.xsd#atnm_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20230630.xsd#atnm_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20230630.xsd#atnm_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_AgreementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomainDomain" xlink:href="atnm-20230630.xsd#atnm_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomainDomain_0" xlink:href="atnm-20230630.xsd#atnm_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="atnm_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20230630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_AgreementDomainDomain" xlink:to="atnm_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantOfStockOptionsToEmployees" xlink:href="atnm-20230630.xsd#atnm_GrantOfStockOptionsToEmployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_GrantOfStockOptionsToEmployees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfExercisePriceRange" xlink:href="atnm-20230630.xsd#atnm_DescriptionOfExercisePriceRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_DescriptionOfExercisePriceRange" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20230630.xsd#atnm_StockOptionTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_StockOptionTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20230630.xsd#atnm_VestingPeriodOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_VestingPeriodOfStockOption" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20230630.xsd#atnm_AggregateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_AggregateFairValue" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20230630.xsd#atnm_UnrecognizedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_UnrecognizedCompensationExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_WeightedAverageTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20230630.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_CompensationExpenseRelatedToStockOptions" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" xlink:href="atnm-20230630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" xlink:href="atnm-20230630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="29" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>atnm-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sun Aug 13 17:17:31 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In/Provided By Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseAxis" xlink:href="atnm-20230630.xsd#atnm_LeaseAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeaseAxis_lbl" xml:lang="en-US">Lease [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Other revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of Summary of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="atnm_ScheduleOfSummaryOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule of Summary of Restricted Stock Unit Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RSUsOutstandingBeginningBalance" xlink:href="atnm-20230630.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl" xml:lang="en-US">RSUs Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl0" xml:lang="en-US">RSUs Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share Outstanding, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US">Weighted Average Exercise Price,Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2"/>
    <loc xlink:type="locator" xlink:label="atnm_NumberOfWarrantsOutstandings" xlink:href="atnm-20230630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl" xml:lang="en-US">Number of Shares, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl0" xml:lang="en-US">Number of Shares, Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $590 and $487</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance leases right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract0" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract1" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract1" xlink:to="atnm_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance leases current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract2" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract2" xlink:to="atnm_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term operating lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract3" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract3" xlink:to="atnm_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract4" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract4" xlink:to="atnm_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 26,984,443 and 25,674,823 shares issued and outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract5" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract5" xlink:to="atnm_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract6" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract6" xlink:to="atnm_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract7" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract7" xlink:to="atnm_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract8" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract8" xlink:to="atnm_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income - net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract9" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract9" xlink:to="atnm_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract10" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract10" xlink:to="atnm_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per common share &#8211; basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract11" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract11" xlink:to="atnm_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock from exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract12" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract12"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract12_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract12" xlink:to="atnm_UnlabeledAbstract12_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract13" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract13"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract13_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract13" xlink:to="atnm_UnlabeledAbstract13_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract14" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract14"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract14_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract14" xlink:to="atnm_UnlabeledAbstract14_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation &amp; amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Payment of security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Other revenue deferred &#8211; current liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:to="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract15" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract15"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract15_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract15" xlink:to="atnm_UnlabeledAbstract15_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Used In Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract16" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract16"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract16_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract16" xlink:to="atnm_UnlabeledAbstract16_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows Provided By Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl" xml:lang="en-US">Sales of shares of common stock, net of costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract17" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract17"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract17_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract17" xlink:to="atnm_UnlabeledAbstract17_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract18" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract18"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract18_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract18" xlink:to="atnm_UnlabeledAbstract18_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Financing cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl" xml:lang="en-US">Restricted cash &#8211; long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of diluted net loss per share anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract19" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract19"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract19_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract19" xlink:to="atnm_UnlabeledAbstract19_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseCostAbstract" xlink:href="atnm-20230630.xsd#atnm_FinanceLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-to-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Total finance lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow use from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flow use from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract20" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract20"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract20_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract20" xlink:to="atnm_UnlabeledAbstract20_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_NonCashActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_NonCashActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_NonCashActivityAbstract_lbl" xml:lang="en-US">Non-cash activity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20230630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl" xml:lang="en-US">Schedule of weighted average discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Weighted average discount rates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20230630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023 (excluding six months ended June 30, 2023)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MaturitiesOfLeaseLiabilities" xlink:href="atnm-20230630.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_OtherRevenueTextBlock" xlink:href="atnm-20230630.xsd#atnm_OtherRevenueTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OtherRevenueTextBlock_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summary of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted average remaining contractual term (in years), Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Cancelled/Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term (in years), Outstanding Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract21" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract21"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract21_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract21" xlink:to="atnm_UnlabeledAbstract21_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of Shares, Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summary of restricted stock unit activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant date Fair Value Per Share, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted average remaining contractual term, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingContractualTermGranted" xlink:to="atnm_WeightedAverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled/Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Shares, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_UnlabeledAbstract22" xlink:href="atnm-20230630.xsd#atnm_UnlabeledAbstract22"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnlabeledAbstract22_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract22" xlink:to="atnm_UnlabeledAbstract22_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Exercisable Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_PaymentWithImputedInterestPremium" xlink:href="atnm-20230630.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_OperatingLeaseLiabilitiesMember" xlink:href="atnm-20230630.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl" xml:lang="en-US">Operating Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_FinanceLeaseLiabilitiesMember" xlink:href="atnm-20230630.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl" xml:lang="en-US">Finance Leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementAxis" xlink:href="atnm-20230630.xsd#atnm_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_MilestonePayment" xlink:href="atnm-20230630.xsd#atnm_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeNetAssetsPercentage_lbl" xml:lang="en-US">Net sales percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNetAssetsPercentage" xlink:to="us-gaap_DerivativeNetAssetsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Current annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandImprovements_lbl" xml:lang="en-US">Landlord assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovements" xlink:to="us-gaap_LandImprovements_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_RevenueRecognized" xlink:href="atnm-20230630.xsd#atnm_RevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_RevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Other revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UpfrontPayment" xlink:href="atnm-20230630.xsd#atnm_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LongtermLicenseRevenueDeferred" xlink:href="atnm-20230630.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl" xml:lang="en-US">Long-term license revenue deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of common stock, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantOfStockOptionsToEmployees" xlink:href="atnm-20230630.xsd#atnm_GrantOfStockOptionsToEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantOfStockOptionsToEmployees_lbl" xml:lang="en-US">Grant of stock options to employees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsToEmployees" xlink:to="atnm_GrantOfStockOptionsToEmployees_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_DescriptionOfExercisePriceRange" xlink:href="atnm-20230630.xsd#atnm_DescriptionOfExercisePriceRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_DescriptionOfExercisePriceRange_lbl" xml:lang="en-US">Exercise price ranging, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfExercisePriceRange" xlink:to="atnm_DescriptionOfExercisePriceRange_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_StockOptionTerm" xlink:href="atnm-20230630.xsd#atnm_StockOptionTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_StockOptionTerm_lbl" xml:lang="en-US">Stock option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cai7eOb3yJcUMi1RySwrMYUM7gHRFDCgY8O3w4R4W8jAgTqmrArcxHx7XqiBoFhPlendAbytLxtxkC79CLaYQBr5C0E1635qjCOsDefpXTBZUuABTkpWfSr9cwZjP+v/FwzwMjgV8gSVnQ==] CSR-->
    <loc xlink:type="locator" xlink:label="atnm_VestingPeriodOfStockOption" xlink:href="atnm-20230630.xsd#atnm_VestingPeriodOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_VestingPeriodOfStockOption_lbl" xml:lang="en-US">Vesting period of stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AggregateFairValue" xlink:href="atnm-20230630.xsd#atnm_AggregateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_AggregateFairValue_lbl" xml:lang="en-US">Aggregate fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_UnrecognizedCompensationExpense" xlink:href="atnm-20230630.xsd#atnm_UnrecognizedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_UnrecognizedCompensationExpense_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_WeightedAverageTerm" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_WeightedAverageTerm_lbl" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20230630.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl" xml:lang="en-US">Compensation expense related to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Expected term year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" xlink:href="atnm-20230630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription_lbl" xml:lang="en-US">Discount rate, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" xlink:href="atnm-20230630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription_lbl" xml:lang="en-US">Expected volatility rate, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xml:lang="en-US">Collaborative Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_GrantRevenuePolicyTextBlock" xlink:href="atnm-20230630.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl" xml:lang="en-US">Grant Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LicenseRevenuePolicyTextBlock" xlink:href="atnm-20230630.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl" xml:lang="en-US">License Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateAndOtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateAndOtherMember_lbl" xml:lang="en-US">Corporate Office Space [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20230630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Capital on Demand Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeaseDomainDomain" xlink:href="atnm-20230630.xsd#atnm_LeaseDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseDomainDomain_lbl" xml:lang="en-US">LeaseDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseDomainDomain" xlink:to="atnm_LeaseDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl" xml:lang="en-US">Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsTable" xlink:to="atnm_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_LeasesDetailsLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsLineItems_lbl" xml:lang="en-US">Leases (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsLineItems" xlink:to="atnm_LeasesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_AgreementDomainDomain" xlink:href="atnm-20230630.xsd#atnm_AgreementDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementDomainDomain_lbl" xml:lang="en-US">AgreementDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementDomainDomain" xlink:to="atnm_AgreementDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsTable" xlink:href="atnm-20230630.xsd#atnm_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsTable" xlink:to="atnm_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_EquityDetailsLineItems" xlink:href="atnm-20230630.xsd#atnm_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_EquityDetailsLineItems" xlink:to="atnm_EquityDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AggregateFairValue_lbl0" xml:lang="en-US">The amount of aggregate fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl0" xml:lang="en-US">The amount of compensation expense related to stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_DescriptionOfExercisePriceRange_lbl0" xml:lang="en-US">Description of exercise price range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfExercisePriceRange" xlink:to="atnm_DescriptionOfExercisePriceRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GrantOfStockOptionsToEmployees_lbl0" xml:lang="en-US">Grant of stock options to employees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsToEmployees" xlink:to="atnm_GrantOfStockOptionsToEmployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for grant revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred_lbl0" xml:lang="en-US">Amount of long-term license revenue deferred.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:to="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl0" xml:lang="en-US">Amount of lessee&apos;s right to use underlying asset under operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for license revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl0" xml:lang="en-US">The amount of long-term license revenue deferred.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl0" xml:lang="en-US">Long-term operating lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl0" xml:lang="en-US">The amount of present value of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl1" xml:lang="en-US">The number of shares, outstanding beginning.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of maturities of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_OtherRevenueTextBlock_lbl0" xml:lang="en-US">The entire disclosure for other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl0" xml:lang="en-US">The amount of payment with imputed interest premium.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl1" xml:lang="en-US">RSUs Outstanding, Beginning balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_RevenueRecognized_lbl0" xml:lang="en-US">The amount of revenue recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0" xml:lang="en-US">The amount of sales of shares of common stock, net of costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0" xml:lang="en-US">Tabular disclosure of Weighted average discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0" xml:lang="en-US">Tabular disclosure of Weighted average remaining lease terms.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription_lbl0" xml:lang="en-US">Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award&apos;s fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription_lbl0" xml:lang="en-US">The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_StockOptionTerm_lbl0" xml:lang="en-US">Stock option term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UnrecognizedCompensationExpense_lbl0" xml:lang="en-US">Unrecognized compensation expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_UpfrontPayment_lbl0" xml:lang="en-US">Upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_VestingPeriodOfStockOption_lbl0" xml:lang="en-US">Vesting period of stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WeightedAverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">Weighted average remaining contractual term, granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingContractualTermGranted" xlink:to="atnm_WeightedAverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_WeightedAverageTerm_lbl0" xml:lang="en-US">Weighted average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_AgreementAxis_lbl0" xml:lang="en-US">Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="atnm_LeaseAxis_lbl0" xml:lang="en-US">Lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Anti Dilutive Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnrecognizedCompensationExpense_lbl1" xml:lang="en-US">Unrecognized Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnrecognizedCompensationExpense" xlink:to="atnm_UnrecognizedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RSUsOutstandingBeginningBalance_lbl2" xml:lang="en-US">RSUs Outstanding Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RSUsOutstandingBeginningBalance" xlink:to="atnm_RSUsOutstandingBeginningBalance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_PaymentWithImputedInterestPremium_lbl1" xml:lang="en-US">Payment With Imputed Interest Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_PaymentWithImputedInterestPremium" xlink:to="atnm_PaymentWithImputedInterestPremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AggregateFairValue_lbl1" xml:lang="en-US">Aggregate Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AggregateFairValue" xlink:to="atnm_AggregateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LicenseRevenuePolicyTextBlock_lbl1" xml:lang="en-US">License Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LicenseRevenuePolicyTextBlock" xlink:to="atnm_LicenseRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NumberOfWarrantsOutstandings_lbl2" xml:lang="en-US">Number Of Warrants Outstandings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NumberOfWarrantsOutstandings" xlink:to="atnm_NumberOfWarrantsOutstandings_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandImprovements_lbl0" xml:lang="en-US">Land Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovements" xlink:to="us-gaap_LandImprovements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeaseAxis_lbl1" xml:lang="en-US">Lease Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeaseAxis" xlink:to="atnm_LeaseAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MilestonePayment" xlink:to="atnm_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantRevenuePolicyTextBlock_lbl1" xml:lang="en-US">Grant Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantRevenuePolicyTextBlock" xlink:to="atnm_GrantRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateAndOtherMember_lbl0" xml:lang="en-US">Corporate and Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateAndOtherMember" xlink:to="us-gaap_CorporateAndOtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract18_lbl0" xml:lang="en-US">Unlabeled Abstract18</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract18" xlink:to="atnm_UnlabeledAbstract18_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract19_lbl0" xml:lang="en-US">Unlabeled Abstract19</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract19" xlink:to="atnm_UnlabeledAbstract19_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract16_lbl0" xml:lang="en-US">Unlabeled Abstract16</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract16" xlink:to="atnm_UnlabeledAbstract16_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract17_lbl0" xml:lang="en-US">Unlabeled Abstract17</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract17" xlink:to="atnm_UnlabeledAbstract17_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl0" xml:lang="en-US">Lease Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseLiabilitiesMember_lbl0" xml:lang="en-US">Finance Lease Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseLiabilitiesMember" xlink:to="atnm_FinanceLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract21_lbl0" xml:lang="en-US">Unlabeled Abstract21</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract21" xlink:to="atnm_UnlabeledAbstract21_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract22_lbl0" xml:lang="en-US">Unlabeled Abstract22</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract22" xlink:to="atnm_UnlabeledAbstract22_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract20_lbl0" xml:lang="en-US">Unlabeled Abstract20</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract20" xlink:to="atnm_UnlabeledAbstract20_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_GrantOfStockOptionsToEmployees_lbl1" xml:lang="en-US">Grant Of Stock Options To Employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_GrantOfStockOptionsToEmployees" xlink:to="atnm_GrantOfStockOptionsToEmployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsCurrent_lbl0" xml:lang="en-US">Other Restricted Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsCurrent" xlink:to="us-gaap_OtherRestrictedAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred_lbl1" xml:lang="en-US">Increase Decrease In Longterm License Revenues Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:to="atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_NonCashActivityAbstract_lbl0" xml:lang="en-US">Non Cash Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_NonCashActivityAbstract" xlink:to="atnm_NonCashActivityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CapitalOnDemandSalesAgreementMember" xlink:to="atnm_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWarrantActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Warrant Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWarrantActivitiesAbstract" xlink:to="atnm_ScheduleOfWarrantActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Terms Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageTerm_lbl1" xml:lang="en-US">Weighted Average Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageTerm" xlink:to="atnm_WeightedAverageTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingContractualTermGranted_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Term Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingContractualTermGranted" xlink:to="atnm_WeightedAverageRemainingContractualTermGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CompensationExpenseRelatedToStockOptions_lbl1" xml:lang="en-US">Compensation Expense Related To Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CompensationExpenseRelatedToStockOptions" xlink:to="atnm_CompensationExpenseRelatedToStockOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract10" xlink:to="atnm_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract11" xlink:to="atnm_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract14_lbl0" xml:lang="en-US">Unlabeled Abstract14</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract14" xlink:to="atnm_UnlabeledAbstract14_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract15_lbl0" xml:lang="en-US">Unlabeled Abstract15</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract15" xlink:to="atnm_UnlabeledAbstract15_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract12_lbl0" xml:lang="en-US">Unlabeled Abstract12</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract12" xlink:to="atnm_UnlabeledAbstract12_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract13_lbl0" xml:lang="en-US">Unlabeled Abstract13</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract13" xlink:to="atnm_UnlabeledAbstract13_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_RevenueRecognized_lbl1" xml:lang="en-US">Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_RevenueRecognized" xlink:to="atnm_RevenueRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRate_lbl1" xml:lang="en-US">Schedule Of Weighted Average Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRate" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract2" xlink:to="atnm_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract1" xlink:to="atnm_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract4" xlink:to="atnm_UnlabeledAbstract4_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract3" xlink:to="atnm_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract0" xlink:to="atnm_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_VestingPeriodOfStockOption_lbl1" xml:lang="en-US">Vesting Period Of Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_VestingPeriodOfStockOption" xlink:to="atnm_VestingPeriodOfStockOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract9" xlink:to="atnm_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract6" xlink:to="atnm_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="atnm_ScheduleOfWeightedAverageDiscountRatesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract5" xlink:to="atnm_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract8" xlink:to="atnm_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract7" xlink:to="atnm_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OtherRevenueTextBlock_lbl1" xml:lang="en-US">Other Revenue Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OtherRevenueTextBlock" xlink:to="atnm_OtherRevenueTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl3" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UnlabeledAbstract" xlink:to="atnm_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_StockOptionTerm_lbl1" xml:lang="en-US">Stock Option Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_StockOptionTerm" xlink:to="atnm_StockOptionTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_MaturitiesOfLeaseLiabilities_lbl1" xml:lang="en-US">Maturities Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_MaturitiesOfLeaseLiabilities" xlink:to="atnm_MaturitiesOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_FinanceLeaseCostAbstract_lbl0" xml:lang="en-US">Finance Lease Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_FinanceLeaseCostAbstract" xlink:to="atnm_FinanceLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeNetAssetsPercentage_lbl0" xml:lang="en-US">Derivative, Net Assets, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNetAssetsPercentage" xlink:to="us-gaap_DerivativeNetAssetsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" xlink:to="atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Restricted Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="atnm_ScheduleOfComponentsOfLeaseExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_DescriptionOfExercisePriceRange_lbl1" xml:lang="en-US">Description Of Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_DescriptionOfExercisePriceRange" xlink:to="atnm_DescriptionOfExercisePriceRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl0" xml:lang="en-US">Restricted Investments, at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl1" xml:lang="en-US">Sales Of Shares Of Common Stock Net Of Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SalesOfSharesOfCommonStockNetOfCosts" xlink:to="atnm_SalesOfSharesOfCommonStockNetOfCosts_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl1" xml:lang="en-US">Schedule Or Description Of Weighted Average Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOrDescriptionOfWeightedAverageTerm" xlink:to="atnm_ScheduleOrDescriptionOfWeightedAverageTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl0" xml:lang="en-US">Leases Details Scheduleofsupplementalcashflowinformationrelatedtoleases Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl1" xml:lang="en-US">Longterm Operating Lease Obligations Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermOperatingLeaseObligationsNoncurrent" xlink:to="atnm_LongtermOperatingLeaseObligationsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_AgreementAxis_lbl1" xml:lang="en-US">Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_AgreementAxis" xlink:to="atnm_AgreementAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_UpfrontPayment_lbl1" xml:lang="en-US">Upfront Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_UpfrontPayment" xlink:to="atnm_UpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl0" xml:lang="en-US">Leases Details Scheduleofcomponentsofleaseexpense Line Items</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0" xml:lang="en-US">Finance Lease, Interest Payment on Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingLeaseLiabilitiesMember_lbl0" xml:lang="en-US">Operating Lease Liabilities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingLeaseLiabilitiesMember" xlink:to="atnm_OperatingLeaseLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageRemainingLeaseTermAbstract" xlink:to="atnm_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl0" xml:lang="en-US">Sublease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_LongtermLicenseRevenueDeferred_lbl1" xml:lang="en-US">Longterm License Revenue Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_LongtermLicenseRevenueDeferred" xlink:to="atnm_LongtermLicenseRevenueDeferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturities Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl2" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl1" xml:lang="en-US">Increase Decrease In Operating Lease Rightofuse Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:to="atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_WeightedAverageDiscountRatesAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rates Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_WeightedAverageDiscountRatesAbstract" xlink:to="atnm_WeightedAverageDiscountRatesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US">Operating And Finance Lease Liability Maturity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>atnm-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Sun Aug 13 17:17:31 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedBalanceSheet" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedIncomeStatement" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ShareholdersEquityType2or3" roleURI="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ConsolidatedCashFlow" roleURI="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPolicies" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_CommitmentsandContingencies" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_Leases" roleURI="http://actiniumpharmaceuticals.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_OtherRevenue" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenue"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_Equity" roleURI="http://actiniumpharmaceuticals.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_AccountingPoliciesByPolicy" roleURI="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_LeasesTables" roleURI="http://actiniumpharmaceuticals.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_EquityTables" roleURI="http://actiniumpharmaceuticals.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofdilutednetlosspershareantidilutiveTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofcomponentsofleaseexpenseTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofsupplementalcashflowinformationrelatedtoleasesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofweightedaverageremainingleasetermsTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofweightedaveragediscountratesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofsummaryofstockoptionactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofsummaryofrestrictedstockunitactivityTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_ScheduleofwarrantactivitiesTable" roleURI="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_CommitmentsandContingenciesDetails" roleURI="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_LeasesDetails" roleURI="http://actiniumpharmaceuticals.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_OtherRevenueDetails" roleURI="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#atnm_r_EquityDetails" roleURI="http://actiniumpharmaceuticals.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="atnm-20230630.xsd#DocumentAndEntityInformation" roleURI="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_RestrictedCashNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermOperatingLeaseObligationsNoncurrent" xlink:href="atnm-20230630.xsd#atnm_LongtermOperatingLeaseObligationsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenue" xlink:to="LongtermOperatingLeaseObligationsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_Liabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInLongtermLicenseRevenuesDeferred" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInLongtermLicenseRevenuesDeferred" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInOperatingLeaseRightofuseAssets" xlink:href="atnm-20230630.xsd#atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseRightofuseAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SalesOfSharesOfCommonStockNetOfCosts" xlink:href="atnm-20230630.xsd#atnm_SalesOfSharesOfCommonStockNetOfCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="SalesOfSharesOfCommonStockNetOfCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenue">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherRevenueTextBlock" xlink:href="atnm-20230630.xsd#atnm_OtherRevenueTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="OtherRevenueTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantRevenuePolicyTextBlock" xlink:href="atnm-20230630.xsd#atnm_GrantRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GrantRevenuePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicenseRevenuePolicyTextBlock" xlink:href="atnm-20230630.xsd#atnm_LicenseRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicenseRevenuePolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOrDescriptionOfWeightedAverageTerm" xlink:href="atnm-20230630.xsd#atnm_ScheduleOrDescriptionOfWeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOrDescriptionOfWeightedAverageTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRate" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfWeightedAverageDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="atnm-20230630.xsd#atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_OtherRestrictedAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb5nsTZF1hxsII3StF2nMaFie2WjubTneMhItBwoNuKpVkBjepuDGZJv0uAY/2011DiRxFwSK8IV5mRgvGfHwlBphcd0S/9cai7eOb3yJcUMi1RySwrMYUM7gHRFDCgY8O3w4R4W8jAgTqmrArcxHx7XqiBoFhPlendAbytLxtxkC79CLaYQBr5C0E1635qjCOsDefpXTBZUvjtGSerqczOIErbivGa5il0MMPDn1vXuQ==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfComponentsOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfLeaseExpenseAbstract" xlink:to="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseTable" xlink:to="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseCostAbstract" xlink:href="atnm-20230630.xsd#atnm_FinanceLeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="FinanceLeaseCostAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable" xlink:to="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems" xlink:to="us-gaap_LeaseCostAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageRemainingLeaseTermsAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWeightedAverageDiscountRatesAbstract"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRatesAbstract" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageDiscountRatesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDiscountRatesAbstract" xlink:to="WeightedAverageDiscountRatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRatesAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LeaseAxis" xlink:href="atnm-20230630.xsd#atnm_LeaseAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeaseAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitiesMember" xlink:href="atnm-20230630.xsd#atnm_OperatingLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="OperatingLeaseLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceLeaseLiabilitiesMember" xlink:href="atnm-20230630.xsd#atnm_FinanceLeaseLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAxis" xlink:to="FinanceLeaseLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable" xlink:to="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentWithImputedInterestPremium" xlink:href="atnm-20230630.xsd#atnm_PaymentWithImputedInterestPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="PaymentWithImputedInterestPremium" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="MaturitiesOfLeaseLiabilities" xlink:href="atnm-20230630.xsd#atnm_MaturitiesOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentWithImputedInterestPremium" xlink:to="MaturitiesOfLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSummaryOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="RSUsOutstandingBeginningBalance" xlink:href="atnm-20230630.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="RSUsOutstandingBeginningBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="RSUsOutstandingBeginningBalance_0" xlink:href="atnm-20230630.xsd#atnm_RSUsOutstandingBeginningBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="RSUsOutstandingBeginningBalance_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivitiesAbstract" xlink:href="atnm-20230630.xsd#atnm_ScheduleOfWarrantActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivitiesAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings" xlink:href="atnm-20230630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWarrantsOutstandings_0" xlink:href="atnm-20230630.xsd#atnm_NumberOfWarrantsOutstandings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfWarrantsOutstandings_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="atnm-20230630.xsd#atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualTermGranted" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="WeightedAverageRemainingContractualTermGranted" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="atnm-20230630.xsd#atnm_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="MilestonePayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeNetAssetsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNetAssetsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DerivativeNetAssetsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsLineItems" xlink:href="atnm-20230630.xsd#atnm_LeasesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateAndOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateAndOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_CorporateAndOtherMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="LeasesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandImprovements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsLineItems" xlink:to="us-gaap_LandImprovements" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/OtherRevenueDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueRecognized" xlink:href="atnm-20230630.xsd#atnm_RevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="RevenueRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayment" xlink:href="atnm-20230630.xsd#atnm_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="UpfrontPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermLicenseRevenueDeferred" xlink:href="atnm-20230630.xsd#atnm_LongtermLicenseRevenueDeferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="LongtermLicenseRevenueDeferred" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="atnm-20230630.xsd#atnm_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="atnm-20230630.xsd#atnm_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="atnm-20230630.xsd#atnm_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="AgreementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomainDomain" xlink:href="atnm-20230630.xsd#atnm_AgreementDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="atnm-20230630.xsd#atnm_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantOfStockOptionsToEmployees" xlink:href="atnm-20230630.xsd#atnm_GrantOfStockOptionsToEmployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="GrantOfStockOptionsToEmployees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfExercisePriceRange" xlink:href="atnm-20230630.xsd#atnm_DescriptionOfExercisePriceRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfExercisePriceRange" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionTerm" xlink:href="atnm-20230630.xsd#atnm_StockOptionTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockOptionTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriodOfStockOption" xlink:href="atnm-20230630.xsd#atnm_VestingPeriodOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="VestingPeriodOfStockOption" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateFairValue" xlink:href="atnm-20230630.xsd#atnm_AggregateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrecognizedCompensationExpense" xlink:href="atnm-20230630.xsd#atnm_UnrecognizedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnrecognizedCompensationExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageTerm" xlink:href="atnm-20230630.xsd#atnm_WeightedAverageTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WeightedAverageTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationExpenseRelatedToStockOptions" xlink:href="atnm-20230630.xsd#atnm_CompensationExpenseRelatedToStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CompensationExpenseRelatedToStockOptions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" xlink:href="atnm-20230630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" xlink:href="atnm-20230630.xsd#atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="atnm-20230630.xsd#atnm_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #J E(# 2(  A$! Q$!_\0
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M;>=-C0/"AC+Y*N>O!P02"!51E4DKJ3^]_P"8G2HK[*^Y?Y'4?V)I7_0-M/\
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MMI_WY7_"L:'Q7<W.L65@FF-&9+F:WN?,D4F,H@?(P<'(8']*ZBI<ZBW;^_\
MX)2HT7]E?<O\BA_8FE?] VT_[\K_ (4?V)I7_0-M/^_*_P"%7Z*7M9_S/[W_
M )A["E_*ON7^10_L32O^@;:?]^5_PH_L32O^@;:?]^5_PJ_11[6?\S^]_P"8
M>PI?RK[E_D4/[$TK_H&VG_?E?\*/[$TK_H&VG_?E?\*OT4>UG_,_O?\ F'L*
M7\J^Y?Y%#^Q-*_Z!MI_WY7_"C^Q-*_Z!MI_WY7_"K]%'M9_S/[W_ )A["E_*
MON7^1FMHNE^:@_LZUZ'_ )9+_A3_ .Q-*_Z!MI_WY7_"KC?ZY/H?Z50UV[NK
M+2WN+22TB=2-TEUNV(O<X7ECZ#N3352;TYG][#V-+^5?<O\ (?\ V)I7_0-M
M/^_*_P"%']B:5_T#;3_ORO\ A7+P>+=:>_MHI]/MH<F&">%BPD$TJ,ZD>BC:
M,@C/)]*;)XF\11Z+>72P:;,]M(2)(]^R9%7+B,$Y;:W!;I@$]JO][_-^)/LZ
M/\B^Y?Y'5?V)I7_0-M/^_*_X4?V)I7_0-M/^_*_X5B^)/%,NC+HUQ"L+VMW)
MNN'))VQ!0Q93[#FL2+Q]J$EG?3FW@5D>X-N I(*)&KH6.>I##I^E"]JU=-_>
MP=.BM.5?<O\ ([7^Q-*_Z!MI_P!^5_PH_L32O^@;:?\ ?E?\*P?^$\MO-O8T
MT^\F-JK9:),AV4@,/;D]3V!J,^.U$D$_V(FP:SDN'=)59PZR*@4 '')8#\1T
MP:7[[N_O_P""'LJ/\J^Y?Y'1?V)I7_0-M/\ ORO^%']B:5_T#;3_ +\K_A6'
M<>-A;,T#:1<F]B\WSH!(G[L(BR9W9P0588Q]*0>/+)[N>&"QO9UBB+[HH]Q+
M",/MQVX/7UHO6[O[_P#@C]E1_E7W+_(W?[$TK_H&VG_?E?\ "F?V+I7G8_LZ
MU^[_ ,\E_P *30M9BUW31>11^6-[(R%PQ!'T_KS6A_RW/^[_ %J74J)V;?WO
M_,?L:7\J^Y?Y%/\ L32O^@;:?]^5_P *S=7&AZ,MMYNC+/)<R>5%';6JNS-M
M+=/HIKH:Q]=\/6WB!K!;S:\%K.9FB9<B3Y&7'7C[V?PHC4E?63^]_P"8.A3M
MI%?<O\BG8W/A/4(;:2&/3U:Y0O'%)&J2$#(/RGG@@_D:C74?!CW7V=7TMCY)
MF+A4V!00,[NG>FWW@T7.HVTMO>K;V=MY9BM%@&U-H8<$$==W<'I45QX&$UA;
MVB7X1(]/%@Y\@'< RMN'/'*].>M:<_\ >?WLCV,/Y%]R_P C1!\*F&.8?V5Y
M4KF-'^3#,.H!]:0_\(T;E;:*WL9IC/\ 9RD4:L4?!)#8Z8"FLV^\!0WE[+<F
M['[VXED:)HB4V.$!7 8<_)U]^E:>G>&DT^[CF%P75+BXN NS&6E/&3G^$9'O
MFDYZ?$_Q'[&'\B^Y?Y%_^Q-*_P"@;:?]^5_PH_L33/X;&!#_ 'HUVD?B.:OT
M5G[6?\S^]E>PI?RK[E_D9;--I,BM)*\UBQ"EI#EX2>ASW7Z\BM2HYXDGMY(9
M!E'4JP]B*KZ3(TVD6DCG+&)<D]^.M$O>CS=107)/DZ;KR+E%%%9FX4444 %4
M=3CDV0W4"%Y;9]^P=77&& ]\'CW J]151ERNY$X\\;$<$\5S DT+AXW&584V
MZM8+VUEM;F,202J4=&Z,#U%5Y-,43/-:3R6LKG+[,%6/J5/&?<8-)]FU+_H(
MQ_\ @,/_ (JJY8[ID<\UI*-_2WZD\EC;326TDD*L]JQ:$G^ [2N1^!(_&LJZ
M\):5+974%M;16KW.-TBH&QAMV #T&><#'K5[[-J7_01C_P# ;_[*C[-J7_01
MC_\  ;_[*FE;:7Y_Y"YW_(_P_P RCIGA/3+"P:VDB6Y,B21RO(N-ZR-N9<=
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MGAU;3[)_9<)@WB0(Q8@,!CC)XX.,=#5[[-J7_01C_P# ;_[*C[-J7_01C_\
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MXF2%Y$E,!W; F"6/L0P-4QX9UPRQ1_V5<[YD,D8VCE1C)SG QD=?44E0HO\
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M\ZUI249J3(FKJQ\KT5Z\WP,EW';KJ;<\9MCG_P!"I/\ A1D__0=C_P# 8_\
MQ5>G]8I=SE]E/L>145Z[_P *,G_Z#L?_ (#'_P"*H_X49/\ ]!V/_P !C_\
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M<4:-D./4 ]>M>3^([73%T:!;&XM9)].D%O+Y7#.&498G^+YPW(R,$58^%_\
MR."_]>[_ -*'1CR.2''$U/:*#MJ>RQ>9Y8P4ZGL?6GXE]4_(T0_ZL?4_SI]<
MC/10S$OJGY&C$OJGY&J<FMZ7%?/92:A;+=(NYH3*-ZC&<D=>G-7(Y8YE+12(
MZ@E258'!'!'UI##$OJGY&C$OJGY&B.:.4N(Y%8QML?:<[3C.#[\BJK:SIBJ[
M-J%J DXMF)E7Y93_ ,LSS][GIUH M8E]4_(T8E]4_(U7AU2PN;AK>"]MY9D=
MD:-) 6#+C<"/49&?3(JW0 S$OJGY&LW4M:M-"TY+K4+A8HB0JX0L6/H *U>U
M>=?%7G0--'_3?_V4UI3BI229C6FX0<ET-3_A97A[_GZE_P# =O\ &C_A97A[
M_GZE_P# =O\ &O*Y_"NM6[JCV8))*_)*C;6"EB#@\' )P?2LGR9?F_=2?(,M
M\A^7Z^E=BH4WLSS7BZRW7X'M7_"RO#W_ #]2_P#@.W^-'_"RO#W_ #]2_P#@
M.W^->*^3+E!Y4F7^Y\I^;Z>M26MG<WMVEI;0/+<.VU8U'.?Z4?5X"^NU3V;_
M (65X>_Y^I?_  ';_&C_ (65X>_Y^I?_  ';_&O')]-O+: 3RP,(C(\>X<@,
MAPP..F"14UAH>I:I \UG:F2-6VY+*NYL9VKD_,<=A1["GO<?UNLW:WX'KO\
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MG;=,?\?'_P!C2TM:Q5GS7N<NGB74O*A=+NWFC:1C%((@#<8*#9M!^4G<Q'?
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M&PJ5(Q_NDCZ4 1:%XQLM>U6YTZ&UNXI[<'>TB#864A74,">5)QSC/49%;_\
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M<>8HRI&.AKC-2\2W6JVL]M<0P^7).LT6U<&' V[1CJ,8'/H*VOA?_P C@O\
MU[O_ $J9Q7LW=%4ZC]M%1;L>S1(OECY1U/;WI^Q/[J_E20_ZL?4_SK,\1ZN^
MB:2+V.-'/VB"(AS@ 22JA.?8,37GL]I&IL3^ZOY4;$_NK^5<4WQ"6WO)+>?3
MI)56[FA,L#KM2-)TA#')R26D7@>]5-,^(6H7=YIMM-I40DO;E8R%E $<;-,
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MDYN;NSTJ5*-*-HCZ*9F3^ZO_ 'U_]:C,G]U?^^O_ *U9FH^BF9D_NK_WU_\
M6HS)_=7_ +Z_^M0 ^BF9D_NK_P!]?_6HS)_=7_OK_P"M0 ^BF9D_NK_WU_\
M6HS)_=7_ +Z_^M0 ^BF9D_NK_P!]?_6HS)_=7_OK_P"M0 ^BF9D_NK_WU_\
M6HS)_=7_ +Z_^M0 ^BF9D_NK_P!]?_6HS)_=7_OK_P"M0 ^BF9D_NK_WU_\
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M?^^O_K4 R9Y5?^^J 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#(?]6/J?YT^F0_ZL?4_SI]-@@HHHI %%%% !1110 =J9%_J4^@I],B_U*?04
M /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!C?ZY/H?Z4^F-_KD^A_I3Z "BBB@ HHHH ****
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M]W]:H:9JPU*\U2W$)C^P77V<L6SO_=H^?;[^/PK2HN!'Y,?]W]:9''&(59@
M-N22:G[5YM\7]2NK+P?:6]O(T:W4P24J<%E"DX^F<?E5PBYR429.RN=B^O\
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M\.?]!G3O_ I/\:/^$B\.?]!G3O\ P*3_ !KY6S11]37\P>V?8^J?^$B\.?\
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MX0GQ/_T =0_\!V_PH_X0GQ/_ - '4/\ P';_  HYX]PY7V,&BM[_ (0GQ/\
M] '4/_ =O\*/^$)\3_\ 0!U#_P !V_PHYX]PY7V,&BM[_A"?$_\ T =0_P#
M=O\ "C_A"?$__0!U#_P';_"CGCW#E?8UO#_C"/PYX5BBA1I[W[=+)Y/GO&@4
MQJ 74<.N<_*?2K;ZMX>U(6L5]+9(8(;$).UN6;*J1*K>JC@8Z5SW_"$^)_\
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MUO\ Y];'_OEO\:/^%JZW_P ^MC_WRW^-/ZO,7M$>O><GJ?R-'G)ZG\C7D/\
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M%(8SSD]3^1H\Y/4_D:?10 SSD]3^1H\Y/4_D:?10 SSD]3^1H\Y/4_D:?10
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M-P4DJ3N!R1DX/6AJ8:$\.EZ0VE:A=/>7Q>S<)A(%"ON)"'DY'3G/2M/X8_\
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MW#D78XK_ (5CX;_YZW?_ '_'^%:NA>$-%\/7;W5EYC3,NS?++NP.^*Z#8O\
M='Y4;%_NC\J3J2:LV-12Z#(I$\L?.O4]_>G^8G]]?SHV+_='Y4;%_NC\J@8>
M8G]]?SH\Q/[Z_G1L7^Z/RHV+_='Y4##S$_OK^='F)_?7\Z-B_P!T?E1L7^Z/
MRH /,3^^OYT>8G]]?SHV+_='Y4;%_NC\J #S$_OK^=4[FTLM2TXVEXD<L+J
MRL?\X-7-B_W1^5&Q?[H_*B]A'&'X:>&R20]R/83#C]*3_A6GAS_GI<_]_E_P
MKM-B_P!T?E1L7^Z/RK3VL^Y/(NQQ?_"M/#G_ #TN?^_R_P"%'_"M/#G_ #TN
M?^_R_P"%=IL7^Z/RHV+_ '1^5'M9]PY%V.+_ .%:>'/^>ES_ -_E_P */^%:
M>'/^>ES_ -_E_P *[38O]T?E1L7^Z/RH]K/N'(NQQ?\ PK3PY_STN?\ O\O^
M%'_"M/#G_/2Y_P"_R_X5VFQ?[H_*C8O]T?E1[6?<.1=CB_\ A6GAS_GI<_\
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M_?7\Z-Z$_>7/UHV+_='Y4NQ?[H_*D N .U%%% !1110 4444 %%%% !1110
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M R1E<G/O7I]%%8SGSRN=-*FJ<.5!1114&H4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $\ C,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y?3_ !I9ZA<76VTO8+&V>6-]1G$:VQ,;;6PV_/7(&172/N>-
M@C;6((!QG!KAX?AGIMIH-I:VOD1ZG!+%/)?FV!:YD1M_[Q<Y92W.,^GI0!UB
MZWIC-;!=2M&-V,VV)5_>\X^7GYOPK"N?B#I%OJ5W8F*\>:UD\MO+C!#-NC3
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M\2QX' Y[7P=<ZQ=:))-K)+3&=_*9HC&S1?PE@57GKV'&*Z2B@ HHHH ****
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MPN1#%(+%[B,PJ01CGYB,\@5/=6?V:XU2*WAV1-;*0JYQGI0J*ON-XN=KJ/\
M6O\ D=4LR-&KDA,KDACR/K3BR*NXL OJ:Y9+-;K68!<PAXOL*G#9QG=52%'%
MAI7VR*1[56D$BE3P<G;D>E)44^HWBY+=?UH=MO4YP<XZ^].(SGIU_.N=\+;?
M*U (K*OVDE5;J!@8S71CGZ5C./+)HZZ-7VD%(=11VHJ#8**** "BBB@ HHHH
M **** &X '0"D&"1BE/0=*H:S?\ ]F:1=7GEEVBC+*HY+-V'YXII7=AI7,ZS
M\66%[XGN=#BWBY@#?.<;7*[=P'N,_H?2FVWBVRN/%5QX>$4J7,()\PXVM@ X
M'.>A_2N"BTOQ'HUAI>M2V4#?99_M$K1LQGD64C<K+MZX('M3]:6\@U75];L(
M)&N+:]B:,[#DQR0E3M[]Q79[&FW:_3\3?DCT.PL/'6G:C;ZO/#!<>5I:EY"0
M/G S]WG_ &>]=#I]['J6F6U[&KI'<1+(H;J 1D9KS2QTF33++Q59B"3*:5"N
M54_,YB8MCUY/Z5T?A3Q1IQT[2=(/V@72P1Q$-;N '"@'YL8J*E*-FX?UH3.*
MM=%S7_%@\/SE)M(U"6%2H%Q$@\LD] "3USQ4D/BN-[G3[>YTR]M);V61(UG4
M C:H8L>>G/Z55^(432>'$"1EV^U1<* >]0>+M/34/$7AF&> R6YEF\P#.,;!
MP2.QJ81@TKKN))-(Z\2(R^9O4QD9!W<?G2^<A D\Q?+(^]GC%>3WEG=6NC:G
M:VT3QZ?#KO[V/RV9$M\9^Z.63.W(%,ELFF\,7ZVSM)9SWT/DI!;O%&C9PQCW
M$DCI^--4%:]Q^S\SUIKB%$W-+&$SC)88!]*7S8T(W2+R,C/\_P!:\Z\46.FZ
M??6&EQ:9#%;""1XY98Y9DWL>55%/+GKD^U8L)A6U\'?VO#,\"172W$>PDJH;
MC<!_".,^U"H)QYKB5.ZN>O[TV>8'781D-GC'UH\Q,"3S%VMT.>#7DDEM=C0
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MK\)F22)D/RM&VTBKQ&32;<<4TVG="E",E9HIV%A!IT3+"6)9B[,YR68]R:N
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M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI-P]11D>M
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M&T@$5O#'!$O1(D"@?@*TM3CY_@.T5YG*^=X[U;HNGZ+"W/S'S91^'(_E2?\
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M<@CV-2YK$@**3(]12T %%%% !1110 4444 %%%% !1110 AH.*-PHR/6@!F
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M<MG^E6E18D"( J*#\H&%'^>*?_%T_P _Y'Z5OS65HZ(QC2][FJ.[_!"=._\
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M17[O;K_78ZZ=7DM3;N^_<U*!1VHS7&;A1110 4444 %%%% !1110 444?UH
M**** "BBB@ HHHH .U%%% !1110 4444 %&*** (YHHKB%X9462*0%75AD,/
M0BN+FM;[P'<R7NF*]UH#MON+3.6M\]67V_R?6NWY/7\Z" 001D$8(]151ERZ
M/8I/[@L-1MM5LHKRSE62&095A_7T^E6^#P3S]*\]NH)O .J-JEC&TF@7#C[7
M;H,_9V/\:^W_ .KTKN[>>&\MDN+=U>)U#*ZG(8'O4SA;5;":MJMBR.E+2#@
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MRCZ_UKSZPCN;JXFU?4F+7UUSM(_U2=E'IQ5OQ#>?\)!XF-H/FT[3.']))?\
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MI5R460#*D9!'3/\ ^O\ D*<(WX^4C\/Z?B/RH-A@]_S_ "_^O_DT?Y_S^?\
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M*L-F]KN3.,8&-O\ 6KIQYIKL:4XIRUV,G2+/[%IT:O@R2?O96[LQY-7N_O\
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MTDN(5MPA6:2%E*1.C%)%&5/S^A!&013U Z5/%&D-J\FFO>0QS 1&(O*NV?S
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MW>[#M'YBLH*CY<$ YQ@^PK,G\;ZA>0O%96D<=R)+.2%DD8I-').(RFYT'O\
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MT%)4/SQ/]Y3_ (5H 8P*S<7%V9K"<9I2B[H#1UI.WT'I2]Z184=>N:3I2XH
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M6:T8^G=?4?R_6M\1.T?<[:A1I*M^\Z7V.@Z44AX%+_C7FG<%%&?>B@ HHHH
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MD3O[']:JVFMR6\PL]706]QT63^"3WSVKH=Q! ).?2J]Y8V]] T4\2R*1T/\
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MH9TB_&JV(Y%I=G$@'HK?_7'TKO!D=>E&,]#BM(U9)6W1:DUIT.)M?'FGK/\
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MHR"5^7@BDBM]8O/!,-MJ2ZCYDNH@.4W"9+<39&>=W*KWR<'F@"W<>"'N8KB
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L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &; D,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(I<T %
M%)N%+F@ HHHH **** "BBB@ HHHH ****  TF:1NW/ZUF:_J+Z3HES?11J\D
M2@A7. >1U_.FE=V1,I**NS4!S2U2TJ[>_P!+M+MU"M-"DA49P-P!J[FD]!IW
M5T%%%% PHHHH **** "BBB@ HHHH ***3(H 6BDS1D9Q0 M%&:,T %%)D?UH
MR* %HI <TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:3@#K2FDSB@#DKKQ!
MK,GB6^TG3K.TE^S*K RN5)!52?U:M*PNM?8W!U*TLX42,F)HY2=S>^>@KFS;
M:A=_$/64TZ_^Q2B.,LYB63(V1\8/2NCBM=2M='OUU/45OG:-BC")8MHVGCC^
M==,HQ225NAR0E)MO4JS^)I+#PRNHWR6TMTV=L-O."K_-C@\Y R,XS6]8W27M
MK'-')&Y(&[RVR W<5YI+:P/\+K>Z:%6GAD?RF(Y4-)SCZ@"O1-'LK:QTR**U
MA6)& =E0=6.,FE5A&,?.XZ4Y2EY6+_?D4ZD'6CM7.=0M%%% !1110 4444 %
M%%% "&L_6M..K:5<6(F\KS0,2;=V.0>F1Z>M:!XK#\72R0^%[V2&5XI HVR(
M^TCY@.#VJHWYE8SJ6Y'<T-,LAI^FVMEO\S[/"D6_;C=M &<5=K+\//)-X=TV
M25WD=[6)F9R26.T9))ZFM/'6D]V.%N56%HHHI%A1110 4444 %%%% !1110
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M8:>%;%?#AT,O,UL22'8C>#NW9SC'7VJ[I.EII%G]G2XN+@;BQDN'WN3QQGZ
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M@NG64=JDLTRIN_>3/N=B3DDGZFK=)BEQFI*2LK!1110,**** "BBB@ HHHH
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M=3MU2-9'?9%Y@9Q&'949@/NE@N<=NG:M:'4;*YGDMX+NWEGCSOC2169<'!R
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MR"X",2=WE@;-^6/.X^^3S5SPOX%O](O?"[7ALC!HNF31'RG9BUU*PWNH*C'
M;+9R=Q&!UKT&B@# \::-?>(?".H:/I\Z6\]Z@A,KL5"(6&_H"3\N1COG&17+
MS>#O%6MZ=:>&M<O-*'AVW,:S26@D%Q>QQD;$8'"QYP"Q4GD<8%>CT4 <5K6@
M>)(/&O\ PDOAV;3)VFLELI[74=ZA%5BP:-U!(R3RN,<9YXQE6_P^UO5KSQ)<
M^++^PN)M7TY+*&2S1Q]D +$J@;G;G8W7D@Y]3Z510!P+:'X[UA;32]:O=&@T
MJ-T-W/8-,+B[1""$QA1&&Q\V">N!Q6GHGA,P>)?$NMZK!:2SZI((8<$RE;54
M50A+ 8W$%BH&.F2V!CJZ3<* /+&^'WBG^Q] TR/4[!$T&^FN;25V>02(O_'L
MKH1VW,IPWRJ!@DGCH-,\.>(-1\5V>O\ BF;3T.FQR)I]GIK2,BM(NUY'9P-Q
MQD 8P ?6NS#9I: ."C\/^,?#UYJ</AN?1IM-O[N6\4WYE66VDDY8#:"'4'Y@
M#@\D$U#_ ,*XNH-%TS3(]3%T6UQ-7UBZN 0;PJ=Q7RQD8)5!C.!MSR:]#HH
MYOQ%X>N-<U_PW.6B^P:;=O>3H[L&:0(5BV@#G#,3DD8QT.:QT\/^+_#VJ:K_
M ,(S/HT^G:E=27I74?-62WFDQOQL!#KD;L''7&>]=Y10!B^%]%O="TG[/J.L
MW6KWDDKS2W5QQEF/1%R=B@=%!QU^E9=UH.LI\3X/$5G]@?3WTU;"Y6:1UF7$
MK2;D 4@]0.2.]==10!S?A'0+S16URYU&:*6[U/4Y;O*$MLB.%CCW$ G:J^@
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M<?\ Q%'_  LWPG_T$)__  !N/_B*Z[:*-HHO#LPM/N<C_P +-\)_]!"?_P
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M\&-N2&TR(]N1_GTKICS."W,7:YZY$ZR1*Z'*,H8'&/TJ2HH'1X(WC7$;("@
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MCC2,L6*J!ENIJ6L#4**** "BBB@ HHSS2<$=./I0 9]*.F>*,YZ4A/')_.@
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M'*"6QUV_WO7C/'/0&MH=NQXJ;HTLUN.'0#G\?\_YQ2CIG'7!IHZ X/\ G_\
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M-J4C??\ FQD*<@#'(Z'D'H!D^D64EM=6D-W;*ICFC$D;!,$JPR."!C(KS/\
MX5]XD_X1K4[9M2LQJNN7WF:A*%+1I!\Q(4D YR<XQW"C;RU>GV=M'964%I"#
MY4$:Q*"<D!1@?RK2IRVLB8WOJ<!\78[6;2]&&H70BTX:BAN45P)&3!!* Y+$
M9S@ GG/09K'^P_!EHLM+:;6'(:[N <'J"-V<^U;&NZ]>:AI EO?AY-J;0W\M
MO';2JSD(J\3#,9X;..GXFN:;4OE.?@L#P>/(//\ Y K2/PV_5$O>Y[-;B,6\
M8AP(P@VX],<5-4-N<V\1\OROD'[L?P\=/PJ:N8U04444#"BBB@!K=/KQ6)JU
MS/YODE62+N1_%ZUN?Y-13P+<QF.09![CJ#5TY*,KM&-:$IPM%G*] >OO3O7Z
MU/>63VCX/S(QX;_/>H/6O24E)71X4H.+LQ1_G_/^?QIV3P<^_P#.D'7'X4H/
M(/X\]NE #E&XJH[\#-<OX$)N=.U75LDIJ6K7-S$&X(C5O+4$=C^[.>M=)(LC
M02+$XCD*$(S*656P<$@$9 /49!/KW'(:7X0\3:-I5OIMEXTB2VMTV1JVBQL0
M,D\DOSU-9RO='1"W*U<FNM6OFU?QBL=]]D@T?3XO+?[.CE',;3,^""6P   3
MCK\IZUR%CJ=]X0T/0K!]<>.ZUN/[?-='3A.UG&P+L5V F1W9@,MD*!T'6NXF
M\(M+H&OZ8-29)-9NI+B6=82"@?8"H&[GY5QUQ\QXQ\M6-:\-S7U]8:AH^J2:
M/?V436\<B0+*CPMCY&C) P,#&. >W3&+C)ZG1&<%H9_@/7KS5Y=8M+F^?4H;
M*2(V^H269M6F60-E3'@#Y2F,CKFI?%4*ZSXC\.^';AV.GW+3W=W$&($XA *1
MM_LEF!(/H.G&-O1=,ETNSD2XU*ZU&[FE,TUS.<%F/&%4<(HQ@*.GK5?Q#X=3
M78[2>&\DT_4[)F>ROHT#-$6&U@5/#*1P5..GU%59\I/-'GNA=8T;0+FUL;>^
MCM+-8YXA8NFR%XY0P*)$>Q.P#:O4 XK(N_%-[I \50S;KJ[M;R*/2HS&JF5K
MB-3%"JC&X*^[G))7/I5RT\-W46IQ:QXB\02:I+8J[VR_9EMX("1AG**3N;&0
M"3QGIG&,71-/LO%?Q"F\8V;W$FD0PQQ0&92J7%RH9/,12!E$5BN3SO+8Z5#O
MT-8VMJ[ERV?Q+J^J7&BVWB$69T>&".^U!;"*5KJY<;B$4@*L:C'0 \]ZK//?
MQ>)_#:>(IH?M6B:=?:G?2VZD*\8 A5P /O$$DJ,#GCTK3U+P??SZMJ-_HWB:
MYTI-45/ML*VRS[F50H>-B08VV\9&?7L,6].\&V5A>W;!]]C+ID6E16BIM*PH
M&W;GSEF8L3D!?Q/-39E*43@(?B+JDUM#K::T\DTDR/\ \(_'H[E#$7"[1<%<
M[PAW;LXSP :]F(VNRCG!KC]'\':EIS:=:W7BJ]O-*TU@;6R$ A)V\(LLBG,B
MJ!PN #@9R!BNO'7T'I3BFMPFT]A5Z"E^M(.F*6F(7';O3CS^--^M./2I92'#
MN>>E X;G\:!UZ<TH/(Z]/6I+0[N/P_E2CMFDZ;1^5*"/\]^*1:)5[U8C^X*K
MCJ:L1_<%9LUB.HHHI% 3BL[7M430_#VI:JZ[ELK:2XVYQNVJ3C\<8_&M ]*X
M7XMM--X&;2;6(RW6K7EO8PIC@LT@8[C_  C:C<]OU !G_P#"P_$=KH6G^(]4
M\+0VFA3>2+F0WA,T*N0#,8]GW 2,#.[!!XSQIWOC/5IO&&J^&M"T5;VYL(87
M>6>;RHD+@L=S8/&W:  ,DL>,*2,?Q!K;_$>RB\*Z5I&JPI=2PMJDU]:/ MI
MK!G0ENLI*@ +D')YXS6U\/8)99O$VLSVK0OJ.L3>4S1%#)!'B.-L'YA]T\'O
MG &: *__  F?B'5-3OM,\-Z#;7S:8%BOKZ>Y,-N;C'SPQ?*2Q7/4XQCG&5)<
MWQ"F/A0ZRVE&WFL]433M4M)9=S6Q,BHVQ@,2$;T(QP0:Q_#?B67P3I=[X=U7
M1-6FUBWNKB2$VUH\JZEYDC2*ZR $<A@#N.1CGD$!;KPMJ3_!WQ6-6B6/5=6-
MSJLULBB41/PR1#'4@1H,]CZXY .RU_Q#-I>IZ/I5A:I=:CJ<[*L<CE5CA0;I
M)&(!Z#  XR6%8T?B_P 1:YYUWX7\-PWFDQ,RQW5[>" WA4D'R0%;Y?EX9L [
MAZ&J7@ZVU7Q3:ZMXLU2)]/U#4;9K#3H6!1K.!<@GLV6DRQSSA5QQ@5P&G^&_
M",'AZ+3[SX=:M<>+X$%O):'[0$FE& 9?-5O+$9/S9!P,\<8) /2]2^(\-KX+
MTCQ%:V$\XU"]CL_L80F8,699$50/F<%' '0XI;/QAXAB\6Z1I&O^'H-/BU=9
M_LS0WHF>-HTWD2 #'3^Z2.169:>'A9>(O VA1:?';VVEV]SJ5S;1&22&*5AM
M7#.3NP\CD')(QG %:]S#<:G\8K$M"39:/I4DHE*DJ)YGV;0>QV+G([$CO0!V
M%U<+:VLUPR2.(4,A2*,N[8&<*HY8GL!R:X*Y\9>,[71Y-?G\&0PZ5%$9Y;>7
M4 MVD(&2Y4KM! &[83GMUK<^(!U<>"-2_L2.YDO2BC;:D>=Y98>9Y?\ M[-V
M,9.>@S7CWBO2_#&OZ79P:)X>\27EW--#%+JE^+HBRC:1=P_>-AG^8#: 1@DY
MXY .W\1:O=ZE\3O#Z:+IGV^XL])EOX$>81(AG98]TI/153<?E#,2<8QR.DT;
MQA)<Z=KIUFSAT[4=")-["LWFIL\OS%D# #Y67GU&#D5R6G>(QX?\?>,-6U'2
MM4;3[F2*SL);:S>5=ULF'B  RNXOE3@(VUN>*AU/3]8D\"^*]8FL)[?6/%=S
M#;P6A4^;';DK#&L@!PK^669@3CG![B@"Q?&VUC0/ .F1V,5@=<U&/4;BR3+"
M2-%,\F[.-P)V9+>HZXJIXHUZ^O/"/B.YT73+.TOM4UHZ*+L38ENT4B)67(RY
M^^NT?= 9ATS6]?0K9_$&.>*Q/]E^&/#TCP%8CM25SC8H Z^7'_",X./05SJV
M/_".^!/AX=3M;N6VAU!=1OV%N\DB2LDDBE@@W9#N!SUP,T =O;:SJ.BWGA;1
M;_3+.V^WK/ 1;SM(L!B0-&JD@%LH#DD#&.OK?@\0S7WC2\T2SMHWM=/@1[VZ
M9R"DLG*1J,8)VC<3GC(KG?BQ<WFDZ=H/B#3[5[F[TW58V$<?+.DB/&4 [[BR
M+P">>*W_  /X?F\.^&H8+V4SZI<LUUJ$Q.3)</RW/?& H]E% '/?%.YU:9="
MT'2[>VG&JWRK+%)<&-YDC_>,F "P0A?F<=. ?O5?U+QAJT&IV?A[3=%@U#Q
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M+RXD&V&'?]U2YXW$$''N.]9^F_$30M2U&VM%74+7[8VVSGO+&6&*Z."1L=@
M<@9&<9R,<T =9S0/KQ02.#ZUYQI6GZMXPU/7[]_%&L:;!;ZK-96]O9-&J;(@
MJ$X96.2P;O\ @* /1\T=.O\ *N$\%^(K\^$-<N=5O$U%M$N[JW2^8");J.(!
M@Y(&T=2N1G[N3DYK/^$&K:[>V6I6?B'4I;R\B6VND\Q0&2*>$.H.!ZAAC.>#
MP,B@#TO/'7\J._6O*KWQ%K6M?%C2['3=3FM-%@O)+62.*,,+EX8S).6/4*&,
M47U+'ZW/B)INJ:-H6J^(++Q9KD4V]!!:1M&8E=W5%7&S=MRWKGZT >DY]Z.G
M0?6N9T;PK?:;J$-W<^*];U!8U(-M<O'Y;$C&2 @/&<CGKBM#7O$FE>&;)+K5
M+DQ)+((HE5&D>1ST554$DT 9DWA*[U#Q=#J^K:VUYIUG*9[#3/LRHD$NW:'9
M@<R$?,1D#!/%=37-:)XYT?6]5.EJE]9:CL,J6FH6CV\DD8QEEW#YA].>#Q@5
M4U+XE>'--O+NVWWMT+%]E_-96<DT-F>_F.HP,<YQDC:0>1B@#L,_G1T%<YJO
MCC0-*M+&:2[>=]1C$EE;VL+S2W*E=P*HHS@CN<#WJ31O&>B:W87UY#<O;KI[
M%;V.\C,#VQ S\ZMC QSGIP>X- &_WI:X^T^)/AV[O+>)#?1VUU((;6_FL94M
M;B0]%20C!)PV.QVGVS>USQEI>A7T=A)'?7M^Z>=]DT^U>XD2/./,8*.%S@9/
M4GB@#H<@T=.3U^E<W!X\\.3^%SXA%_MT]9/*<M&PD67('EF/&[?D] /<<<TW
M0_'6DZUJYTA8;^PU'R3.EKJ%F\#O&#@LNX8(!R/P/H: .GHHS_\ KHH ****
M "BBB@ HHHH 0UR?C[1=1U?1[*;2$CEO]-U"&_AAD("RE,C:22,?>S^&..M=
M63Q7&?$O3]6U'P]:)H<-W)?17R2*;:<1% %<$MR"RX., @Y8'H"#4/B1,MCE
M?&5IK\4FM6D'AN>^C\30VQ)B8RI:SHJHP;C   0ACM&1G/!V^IZ9!-::59V]
MS)YL\,")+)N+;F"@$Y/)R<\FN 7Q5\2!$N_P1"SA1N(N0H)QR<9..>V3]:]"
MLI)YK&WENH?)G>)6EBW9V,0,KGO@Y%7.]DF3'<X+XLQ(+#0KN[MIKC2[744E
MO5CR0$P>3@^F1GWQD9KSV]6+4_"FO:W/83S7_B'5A!I+_9]S*%?<-K]1E<I@
M<G9T.#CUGQYKNIZ39Z;9Z.8TU#4[Q+2.65=RQ@]6QZ].H/>N,FU+Q)X>\*Z_
M=MK/V^\T35XMTUS'D21F.,,BKGY03*?PSC!P1I!OE)E\1ZY;JZ6\:2-N=4 ;
MG.3BINU16\GG6\4N,;T#;<YQGMFI.]<QJA:***!A1110 4444 %%%% #2 1V
MK(O=-V@RPCC^)!_2M@]J3'J*N$W%W1E4I1J*S.7';_/^?_U_BX>O^?\ /^%:
ME[IWF'S(0 Q^\O3/O67R"<C!Z$'J#7=":FM#R:E)TW9ERQLTNE?<SC;QQCTJ
MY_947_/23\Q_A[TS2!\LOU%:6*Y:DY*329Z%&E!P3:*/]E1?\])/S'^%']EQ
M?WW_ $_PJ_16?M)=S;V4.Q1&F1@_??CW'^% TR,?QO\ F/\ "KU%'/+N/V4.
MQ2_LV+^^Y_$?X?YQ2_V='D_,_/O5SFBESR[A[./8I_V?&>KL?RI?L$?]]S^5
M6J.?>CFEW#V<>Q5%C'_??\Q2_84_OO\ I_A5FC'TI<S'R1[%;["G]]_T_P *
M7[''_>;\ZL&C\Z.9AR1[$'V1#_&_/O6;K]P^D:)<WT&TR1 %1)RO4#MC^=;!
M) SBJ.KZ>NK:9<6#RO$LH WKU'(/'Y4XO74F<?=?+N1:0QU#1[*[E&V2>!)&
M"_=!903C-7_LZY^\W7UJ+3[-;#3[:S1BZP0K$&/?  S^E6Z&]1PC[JN1B(#U
MIP7 QBG4G:I+L<5K@.H_%/PMIZ,=NGVUUJ4RMC!X6%,<')!=O3L<UF^"GMK/
M1?%?C>:!-UY>WEPLH0&3[-"2JJ1P?^69.,\GFN^6PM%U%M0%O%]L:(0M/M&\
MQ@DA<^F23CWJ%-#TN/1?['33X%TWRS']E"#R]IZKCTH&>8);#P[^S=-)%&AN
M=2L \C!1F1[M@.>G:4#/8 =<<W-*_LG3_BW;Z==7,<?]BZ%#8Z?]J=?FDP&D
M93P!)Y;)D 9*G/ Z^D7&FV5W%!%<6L4D=O(DL*LN1&Z'*,!V([5RFC>$5U >
M(9/%>D6=T;_6)+B!9TCD80*B1Q9(X!"J<#.0&YY)H X[Q%KEM.WC[Q;IA!T^
M#28M)BNH-CI=SL6RX;."$\Q%/7(Z=,5N>-M*A\.?!^VT=0T.F6[6EO?O!G<(
M/,3SF^49YYS@'.X\<UW9T+23ID6F?V=:BPA*M';"("-"IW A>@P>:NR1)-"\
M4T:R1R*5=& (8$8(([B@#SKXAZKHUSX&7PSHYL[ZYUA([33;.U*,NW*X<!?E
M5$7# \ 8'(ZU3\;:Y;^!/'VEZ]/'+-]HT6>Q2-<?Z1+&RO&G<KDL1G!ZCK7>
MZ3X7T'0II)M)T:QLI9!M=X(%0L.N,@=/:K%]HFF:I<V=S?V%O<SV3^9;22QA
MFA;(.5)Z'*K^0H \E\3Z%<Z/X/\ #5KJ^IC3Y=0UQ;W6+\HLD:7+*S*'!.PH
M&"+\WRX0$]*N:E9WE_XCT?P_?^/[G6)I+F.\^RVVEV^(UB8-OD=<%%R,9SDY
MZ'I7JMY96NH6DMI>V\5S;2C;)%,@=&'H0>M5-)\/:/H*2QZ1I=I8K*09/L\(
M3?CID@<]_P Z )M6OX]*T>]U&7/E6L$D[[1D[54L<#OTKR?PCX \!3^"=-U+
M7C ][<VPO+J9]3EC +C><@.H& 0#QVY)ZUZ]=VEOJ%G+:7D"3V\R[9(I%!5E
M/8CN*Y\?#GP6/^96TGC_ *=5_P * /.;6:>T^"/B"QT]V_L^?4)=-T65T0&2
MVED6,'@?,"6D^;&XCGTK2\07S>"O&]_::'&J7FKZ-:6VGV[-O\RY61HD;YLX
M"(P)S@$ YR<FO3KG2=.NH;6*XL;>2*SD2:W1D&(73[C*.Q';'2DFTC3KG5+?
M5)K&WDO[92D-PZ O&#U"GJ."?SH X#PCI%M8_$6?2K8RRP^&M'AM=\G0SW#&
M627!)^9@H)(QU(.>*U_'1%YK?@W1U)$EQK*W>>VRW1I#S@X.0O&.>>1UKK;>
MPM+2:YFM[:.*6Y<23NB@&1L 9)[G  HDT^TEOX;Z2WC:[@5DBF*Y9%;&X ]L
MX&?I0!/UYS7 >*M7N)_B#IF@6=]I.E7<-B]]'?7]J)I#N?RS'%EEP<*Q;!R1
MCL#7H&/PK-U?P_H_B"../6-+M+Y8B3']HB5]F>N,],X'Z4 >5Z==:CJGQ#U
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MH, *!@ 8P.@I_>H;9'CMHED8LZH QSG)[U-7.:A1110 4444 %%%% !1110
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MS_A6-H?B*'7;W68;6%A;Z9=FR:8M_K)54%P%Z@+N SWYKF=9-GJGQ>TNWN&
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MB\JRY'XT_O3(3&8D,0 CVC;@8 ';BI*Q- HHHH&%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "'W''YU6OK*#4;22UNDWPR8WKN*YP<]00>HJPYPI(ZTZ@32>C(+
M6UBLK:*V@79#"@C1<DX4# Y//:IZ:3C./0TZ@$K;!1110,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #R F@# 2(  A$! Q$!_\0
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MXMHUD6T#.DJ@N%YW !AR#N4D5MW/C33[*[N+:[M[J%X86EY56W[=N0,,3G+
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M'I7_ $#;3_ORO^%']AZ5_P! VT_[\K_A6+KOBJXTSPOIVKVUK',]T\0,6_(
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M=FW][_S'[&BUI%?<O\BG_8>E?] VT_[\K_A1_8>E?] VT_[\K_A5^BE[6?\
M,_O?^8_84OY5]R_R.0T[5O">HS"-;".W#1O+')<V@C21$.&*L1@@5H3'PG;V
MPN)3I*Q,A=6^3YP.I7U_"LVS\"0Z?H,D%J\*ZM)&4-XZ%Q@ON("L2 ".#C'K
M3=.\#O:N[7%S!)N@N8AMB/RF9PV1DGIR/>MG/M)_>R/8P_D7W+_(T[4^%;Q+
M=H5TLFX56B0A S C(^7K4K0^&$25V72E6%MDA)C 1O0^A]JQ8/ \RQ#SKFV,
MP%B%=(B-HMVR<<Y&X5'9?#[[*JH]S%($N89 [*Y+QI(7VL"Q&3GL/7UI<_\
M??XA[&'\B^Y?Y'0VECH5ZTX@L+5Q!)Y;-Y*X+;0W![\,*L_V'I7_ $#;3_OR
MO^%+I5@VGVLB.XDEEGDF=E& 2S$_H,#\*O5FZL[Z2?WO_,M4*7\B^Y?Y&<=%
MLU&;56M).SV[;/TZ'\13K.ZF6X:RO-IG5=R2*,"5?7'8CN*OUG:J-ALIQP\=
MRB@^S':1^1_2G&3G[LM2)P5)<\-+;]FC1HHHK$Z0HHHH *IZG!)/9$P@&:)E
MEC![LISC\>GXU<HIQ?*[HF<5*+B^I#:745Y;)/$<JPZ'J#W!]"*FJA-IQ%PU
MS93FVF<Y<;=R2>[+Z^XP:3.L#^&Q/OEQ_2M'&+UB_O,E4E'2<7?R_K0;_86G
MG1)M(\IOL4P<.F\Y.\DMSUZDTR?PYIESJ O98&,N49E\Q@CLGW&9<X8CL2/2
MI<ZQ_<L?^^G_ ,*,ZQ_<L?\ OI_\*?*_YE]X>T7\K^[_ ()S^G>!(8+N62]N
M!/#Y8BBACWJ$42>8.K'&"!P,#K6E<>#=%NKJYN)8)2]SYGF 3.%_>*%<@9P,
M@#\JO9UC^Y8_]]/_ (49UC^Y8_\ ?3_X4WS-WYE]XN=?RO[O^",70-/2]6\$
M3><LYN V\_?,?EYQG^[QBM.L_.L?W+'_ +Z?_"C.L?W+'_OI_P#"I<&]VOO*
M]JOY7]W_  2XW^NC^AJ2LQCJ_FIE+'.#CYG_ ,*?G6/[EC_WT_\ A2]GYK[P
M]K_=?W?\$;J6@Z?JTGF7D3.WE&'AROREE8CCW457NO"FDWCRR2PRB261Y'>.
M9T8EE"L,@_=(49'3BK6=8_N6/_?3_P"%&=8_N6/_ 'T_^%4E)?:7WB]HOY7]
MW_!*1\(:/L 2&:-EV;9(YW5UVIY8PP.1\O!]:!X0T87K7?D2&1MV09W*DLGE
ML<9QDKP3[5=SK']RQ_[Z?_"C.L?W+'_OI_\ "BTOYE]X>T7\K^[_ ()27PAI
M"1!%CG#+Y>R43OYB;%*KALY'!(]Q3QX4T<0/ MJ5C>*.)E61AE4<NO?KN))/
M4]ZM9UC^Y8_]]/\ X49UC^Y8_P#?3_X46E_,OO#VB_E?W?\ !-"F3?ZL_4?S
MJEG6/[EC_P!]/_A3)#J^SE+'&1_$_K]*GV?FOO'[7^Z_N_X)IT5GYUC^Y8_]
M]/\ X49UC^Y8_P#?3_X4>S\U]X>U_NO[O^":%%9^=8_N6/\ WT_^%&=8_N6/
M_?3_ .%'L_-?>'M?[K^[_@FA16?G6/[EC_WT_P#A1G6/[EC_ -]/_A1[/S7W
MA[7^Z_N_X)H45GYUC^Y8_P#?3_X49UC^Y8_]]/\ X4>S\U]X>U_NO[O^":%(
MRAE*L 5(P0>]4,ZQ_<L?^^G_ ,*,ZQ_<L?\ OI_\*/9^:^\/:_W7]W_!,]/!
M>B1PSQ"WF9)HO)P]P[>6F<[4R?D&0#QCH*CN?!.E2QW30HRSSI(N^61Y%!?&
MX[=W<J">AR,UJ9UC^Y8_]]/_ (49UC^Y8_\ ?3_X5?O?S+[Q>T7\K^[_ ()B
MZ=X)MH8)3?W$EQ=/<&X$T<CHR$H$(#;BQR%YR:V=1T.QU1(!<I(&@!$<D4K(
MZ@C!&X$'!'44N=8_N6/_ 'T_^%&=8_N6/_?3_P"%)J3=^9?>'M%_*_N_X(ZR
MT>QTZ25[2 1>;''&RJ3C:@PH [8!K,M?!.A6B,@MI9D,+0*D\[R!$;J%#$[<
M^U:.=8_N6/\ WT_^%&=8_N6/_?3_ .%%I?S+[P]HOY7]W_!*[^&-+FL8+.XB
MDGB@N%N(_.E9V#KT.2<X]NE$WAC2YY;UWBE O599T69@C[@ 6V@X#$ <U8SK
M']RQ_P"^G_PHSK']RQ_[Z?\ PHM+^9?>'M%_*_N_X)1NO"6FS?:9(HVCGF1]
MI+LT:2,FPR!,XW8[TFG>$-,L(K0LLDMS;F)A,TC$[D4J,9)POS-\O3FK^=8_
MN6/_ 'T_^%&=8_N6/_?3_P"%%I6MS+[P]HOY7]W_  2G_P (AHWD+#]G<*L2
M1(1*V5".74@YR"&8G-2/X9TR1)%DBD?S(XHG9I6)98WWKDYZ[CG/>K&=8_N6
M/_?3_P"%&=8_N6/_ 'T_^%%I?S+[P]HOY7]W_!);'3;;3C<_9E=1<3-.X+DC
M>W4@'IGT%6ZS\ZQ_<L?^^G_PHSK']RQ_[Z?_  J7"_5?>/VO]U_=_P $T**S
M\ZQ_<L?^^G_PHSK']RQ_[Z?_  H]GYK[P]K_ '7]W_!-"BL_.L?W+'_OI_\
M"C.L?W+'_OI_\*/9^:^\/:_W7]W_  30HK/SK']RQ_[Z?_"C.L?W+'_OI_\
M"CV?FOO#VO\ =?W?\$T**S\ZQ_<L?^^G_P *,ZQ_<L?^^G_PH]GYK[P]K_=?
MW?\ !+I_UX_W3_,53U?1[37+(6EZ)3"'$F(Y6C.1TY4@^]1DZOYH^2QSM/\
M$_M[4_.L?W+'_OI_\*?(UJFOO%[7^Z_N_P""5!X4TH7=O=M'.]Q H59'N'8G
M&<,V3\S#<<$\C-01>"-&AL6LU%YY.\.H-Y+F-AGE#NRN=QSCKFM+.L?W+'_O
MI_\ "C.L?W+'_OI_\*=I?S+[P]HOY7]W_!"70].FLK.S:W M[-U>"-20%*@@
M?48)ZU1MO!VB6BPB"U9!#Y>S]ZW'EEBO?_;;ZYJ]G6/[EC_WT_\ A1G6/[EC
M_P!]/_A1:7\R^\/:+^5_=_P2K:^%M*LIH9;:*6)HHUBPLS@.J@A=PS\Q&3R:
M9%X1TB)2%BFWF:.;S&G<ON3[GS$YP,GCW-7<ZQ_<L?\ OI_\*,ZQ_<L?^^G_
M ,*+2_F7WA[1?RO[O^"4E\'Z*JR(+9]K !5,K$1J'#[4&?E&X X'I4DOA;2I
M9S/Y4J3&9YC)',RME\;AD'H=HXZ<59SK']RQ_P"^G_PHSK']RQ_[Z?\ PHM+
M^9?>'M%_*_N_X(RWT#3[;5FU-(Y&NF# ,\K,$#8W;03QG K0E_U?XC^=4LZQ
M_<L?^^G_ ,*;(=7V<I8XR/XG]?I2Y&]VOO#VJ_E?W?\ !*GB^:[@\/N]H\\8
M\V,3R6XS(D)<>8RXYR%STKGX]96RM(ETG4;T:;+=.CZA?QO,L.(]P"%L%E+<
M9)ZY [5UN=8_N6/_ 'T_^%&=8_N6/_?3_P"%7%65KK[_ /@"=2[V?W?\$X6/
M6-7N-2M[JY%U SRVCR0)OV@&.4L OH< X^F:@'BK4[X6SR7Y@BCOHC]I$!4"
M-XG)#J#@@$8Y/!Z]*]!SK']RP_[Z?_"C.L?W+#_OI_\ "JNO+[_^ +G?9_=_
MP3C8_%NNO';M)''',8XFAM_L[9ORTA5BI_@PH#8[;LGBFZAXJUNRT07AG7[1
M++<F&+[)\NV)B%0G/5N/<]NE=IG6/[EC_P!]/_A1G6/[EA_WT_\ A2]WR^__
M ( <[[/[O^"<<->U2VU"_CEU+RH9+X!IY;?>MI$80RX'HS?*">.#W-:WAK5]
M8U?4F^W*MM#%9PR-#Y)!=WWY.3R!\H..O-;>=8_N6'_?3_X49UC^Y8_]]/\
MX4FDUT^__@#53R?W?\$T*S;IOMNIP6D?*6[">=AV(^XOU)Y^@]Z4PZI/\LMS
M!;H>I@4LY^A;@?E5NUM(;.'RH5P,Y))R6/<D]S4*T-;W8/FJ:6LO/\B:BBBL
MCH"BBB@ HHHH HZGK.FZ+ LVI7L-K&QPID;&X^PZFL;_ (6'X2_Z#=O^3?X5
MXU\5KV>Z\?7L,KDQVRI'$N>%&P,?U)KBT1I'5$4L['"JHR2?05Z%/"Q<4VSG
ME6:=D?3/_"P_"7_0;M_R;_"C_A8?A+_H-V_Y-_A7S*ZF.1HW!5U)#*>"#[TW
M<#W%7]3AW9/MI'TY_P +#\)?]!NW_)O\*/\ A8?A+_H-V_Y-_A7S-''),6$2
M,^Q2S;1G:HZD^U+#%)<2I%!&TLCG"H@R6/L!UH^J0[A[:78^F/\ A8?A+_H-
MV_Y-_A5O3O&/AW5;I;:RU>VEG;[L>[:6^@.,U\P75E=V,@CO+6>W<C(6:,H2
M/7FHHW:.19$8JZD%6!P0?6E]3@UHP]L^Q]>-_KH_H:DK-T:YDO-'TNYF.99;
M9'<^I*@FM*O.:MH=*"BF1317$8DAE21"2 R,",@X/(]Z/-C\P1^8N\@D+GGC
MKQ^(_.D,?1136=$ +L%!( R<9)Z"@!U%,EFB@4--*D:E@H+L "3P!SWJ-KZT
M3S-]U OEL%DS(!L)Z ^A- $],F_U9^H_G2QR)*NZ-U=<D94Y&1P:2;_5GZC^
M="!E+5];TW0;/[7J=VEO#G +<ECZ #DFN8_X6SX0_P"?^;_P'?\ PK@OC;/(
MWB6Q@+GRDM=RKG@$L<G]!^5>8UWTL-&4%)]3GG5:=D?1?_"VO"'_ #_3?^ [
M_P"%'_"VO"'_ #_3?^ [_P"%?.E%:_5*?F1[:1]%_P#"VO"'_/\ 3?\ @._^
M%'_"VO"'_/\ 3?\ @._^%?.E%'U2GYA[:1]%_P#"VO"'_/\ 3?\ @._^%'_"
MVO"'_/\ 3?\ @._^%?.E%'U2GYA[:1]%_P#"VO"'_/\ 3?\ @._^%'_"VO"'
M_/\ 3?\ @._^%?.E%'U2GYA[:1]%_P#"VO"'_/\ 3?\ @._^%'_"VO"'_/\
M3?\ @._^%?.E%'U2GYA[:1]%_P#"VO"'_/\ 3?\ @._^%'_"VO"'_/\ 3?\
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MFM-?#FM-IBZDNF7#63*&$P7*D$XS],\9I/"TUNQ^VD>\?\+:\(?\_P!-_P"
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M_P#Z LO_ '\3_&C_ (5MXO\ ^@++_P!_$_QH]I#N@Y9=CE**ZO\ X5MXO_Z
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M"",TR;QSH:3R00W7VB:*XCMY40$;"[[-V6P"H;@D9QC'6@#H?,_V'_*CS/\
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MMH;411-*&7RU$HSY@//&1TKU*D95<8901G/(SS6D)\M]"6KBT445F4>#>/\
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M/?/2G7&G:-KUV^GB&:W:$"1ML042H0%X)!.,*!VZ4G]B:4(!"FM$*'0X,L;
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MP?.5.3_=KO5.*@F>1*O-U''3[CH_^$^\*?\ 0!/_ ("Q?XT?\)]X4_Z )_\
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M:D=B3;)_?'_?-&V3^^/^^:2&XAN QAE20*<'8P.#@'G\"#^-*LT;3/$LBF1
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MA_\ A>5IG_D!3?\ @0/_ (FM8T9R5TB7.*T;/5_-_P!A_P J/-_V'_*O*/\
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M9T?:T6'#9'KG&/QJ97MH-6OJ6K_P5KFGPSRM;"=8)7CD\@E]H55;=_ND,#5
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MI!_X$+_C7T,6<'A,CUS1OD_YY_\ CPKJCB9Q5C)THMW/GG_A4?BW_GT@_P#
MA?\ &C_A4?BW_GT@_P# A?\ &OH;?)_SS_\ 'A1OD_YY_P#CPJOK=3R)]C$^
M>?\ A4?BW_GT@_\  A?\:/\ A4?BW_GT@_\  A?\:^AM\G_//_QX4;Y/^>?_
M (\*/K=3R#V,3YY_X5'XM_Y](/\ P(7_ !J>T^#_ (GFNHTN$M[>$GYY3,&V
MCZ#DU[_OD_YY_P#CPHWR?\\__'A2^M5/(?L8E>TM4L;:SM(LF."(1KGK@ #^
ME6Z@9G\U/W?8_P 52;Y/^>?_ (\*Y6:E=]+L))7E>SA:1Y5F9B@R9%&%8^X
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M7N&^3_GG_P"/"C?)_P \_P#QX5M"O4@K)D2IQ;NSP_\ X4CK?_03T_\ -_\
MXFC_ (4CK?\ T$]/_-__ (FO<-\G_//_ ,>%&^3_ )Y_^/"K^LU>Y/LH'A__
M  I'6_\ H)Z?^;__ !-'_"D=;_Z">G_F_P#\37N&^3_GG_X\*-\G_//_ ,>%
M'UFKW#V4#P__ (4CK?\ T$]/_-__ (FC_A2.M_\ 03T_\W_^)KW#?)_SS_\
M'A1OD_YY_P#CPH^LU>X>R@>'_P#"D=;_ .@GI_YO_P#$T?\ "D=;_P"@GI_Y
MO_\ $U[AOD_YY_\ CPHWR?\ //\ \>%'UFKW#V4#P_\ X4CK?_03T_\ -_\
MXFC_ (4CK?\ T$]/_-__ (FO<-\G_//_ ,>%&^3_ )Y_^/"CZS5[A[*!X?\
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M^3_GG_X\*5ACZ*9OD_YY_P#CPHWR?\\__'A18!]%,WR?\\__ !X4;Y/^>?\
MX\*+ /HIF^3_ )Y_^/"C?)_SS_\ 'A18!]%,WR?\\_\ QX4;Y/\ GG_X\*+
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M!\$9]>:B%E; 8&GP 9SC8O7UZ5:FR>5'-ZC9Z)K+WE\-UU)=QQVR8A&8R-S
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M2!UH *9-_JS]1_.G@YZ4R;_5GZC^="!G#?$+Q;>Z(\%AIS"*:5/,>7 )49P
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MQ!75;G1;.ZL/)N=2A#GRIA(L3%#(%..F57////3O7;4 %,E_U?XC^=/IDO\
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M-O?113Q$YVOV/J/2L7_A"/"G_0/3_O\ /_\ %5UTZZC%)HQE"[NCPRBO<_\
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MW^@6R6EM+.R7(9EC4L0-K#.!7&HQ]IR]+EU92C2<EN5H_BI9S9\K1[^3'78
MV/RIC?%G3T8J^F7:L.H8J"*X33+#7M-:Y,>G:DOG6[Q?NXW7DC )X[5MR3W<
M\LDMQX5NII60H'>WR<87 /'/0\]>:Z72II[?B>>L16:U=OD;_P#PMS3/^@==
M?]]+_C1_PMS3?^@==?\ ?2_XU@6N\R.EQX7N@DDD>&^R9$:+MSQMSV;Z[J8W
MF@2JOA*XD)9#YCVV"X4CD@# Z=OQI>SI]OQ'[:M_-^!T8^+6G-G;IEV<#)P5
M.!2?\+;TT_\ ,-NO^^EKG@T\<#01^%[XP\'8UOC><,#N('N.GI6)JFD:I>WS
M30:-?1H0!@VVW]% 'M^%-4J;W7XDRQ%9+1W^1[EI&I1:QI5OJ$*,D<R[@K]1
MSC^E7:P_!UO-:^$M.AGB>*58SN1Q@CYCVK<KCDDFTCU(-N*;"BBBI+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "_ G # 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHKD_B1KU_X:\#7NJ::Z)=1-$$9T#
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MAJOQ0T;2+W5+66QU:<Z4RK>RP6P9(0P!5B=PX.?KUXH [:BN2U'XAZ1I]_\
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M G25/OJP+ #''?N,9H [6BLW0]9AU[3%OH;:[M@69&ANX3'(I!P<C^H)%:5
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M.-1DCEADCFC^;:SDL-H3KP>>_2I;7XF>&KNVO)S/<P):VPO"+BU>-I(,X$J
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M<WX'T?6-#\-16>MWYO+M9&8$R-)Y2$_+'O89; [FNDH **** "BBB@ HHHH
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M\LU_K6\RAT*NH96R"",@BN)^'$K6%CJ'A.X+"YT*Y:% QY>V<EH7_%3CZJ:
M.XKE]>\#Z?XE\2:?JFK/]JM+*%XTT^6,-$SOU<^IQ@8]JZBB@#A)OA7HYDUJ
M.SFEL+'5;>.)[6T 01R1G*RJ1T/MT-1K\.+^XO8K[5O%M[J%W:6DMM82-;1I
M]F,B[3)Q]]\=S7?T4 >?3_!_PRWA:+2K:WCMKZ%(PFJ1Q#SPZ$'?GU.#GZUT
M.D>%UTKQ/K6N_;))YM56W62-D 5#$FS(^O7%=!10 ?C1110 5G:[J\.@Z)>:
MI,CR);1F3RT^\YZ*H]R< 5HUC>*])EUWPO?Z?;,$N)(PT#/T$BD.F?;<HS0!
M2\.>')()?[;ULI=:]<+EY,?):*1_J8@?NJ.A/5CDGT'2\$=.O6L?PYX@@\0Z
M;YRJ\%Y"?*O+208DMYA]Y6'\CT(P16S0!P_BGP;?:[XB2]C:V-MLLT=)2<L(
MKDR.,8Z%3@>]<Z/A=JXL7MX[FS@D:TOK6.>-FW0+),)(PO'W=H*$#& QQGI7
M4^./$]]X?FTV&UEM+.*Z$QEO[U&>&+RTW*I"D'+?T. 37+-XUU[2-6U.9"FH
MVDFH30Q6C*^\%;,3 (W921C;C/S?A0 UOA=J4\#!TLT_T*]BCADN&E$4TNW8
MRG8H !4G@#';-6]4^'>N7^K:A/;7EO:"]M##+<&5I')\I4&T%0T9R#G#8([9
MJC:?$;Q->PV21G20]PMRYG1?-7$=NDP&U7^4Y8KR?0\'BK<'Q!\0,B17 TZ$
MW*V,WVPQ.(;-+A';YP6YP4"@D@989H ZSP-X=N?#FE7,%RJQM-<F81I<&55X
M X.Q0,XS@#%=/P!P./:L3PEK-SK_ (8M-2O+?R)I@V0H(5@&(#KGG:P 89[&
MMPG% ''>)-+?0FN/%>APA+N!#)?6BC"7T0Y;([2 9(8<]CD'C3U[7VL/#L5_
MIZ"XN;QHXK)"#M=Y2 A;O@9W'V!JOXPU@V]A_8]AB;6M41H+2$#.T$8:5_1%
M!R3]!WJ+Q#HES#X6T]=,B-Q>:*\-Q;Q=#-Y8PR#T++N'U- %_P /^&;;1!)<
MR2->:M<<W>H3#]Y,?0?W4'0*.  /K6Y7+:MXFGN? 5WKOAB/[;<"+,490ED;
M< VY.NY!N)7KE<5RNH>)_$-MIUK]DU>6XMF%R1JAT@AI94"F*'R\8PV6&X 9
MQQ@T =-K7AG6)==GUCP_JMO8W-Y9K:7!N+<R[0K$HZ<C##<W!R#QZ5EWOPWF
MO=2N[N34D,EQ?17)G,(\W:MJ8&&1C!).[CBLEO%/CB.=[I;=I'%X]JNF&TX_
MX]?-!\SKQ(-H[')!YQ69IFI:_>:]%*U]>7OGS62-<&R>-$;R9R^U"-H*MM!.
M/0'GF@#;TCX4/I\FFM+<63_9)@\@$;N)@(&B4D.Q /(/'3%+;_"J>T.F2P7M
MGYNGVMK&(FMSY4\D+2$F0 \@B3([@J#S6'HFM>)++1]-<37;N^FVRWE[/:M)
M):[IW65BI'SLH"]0>N3D"K<OBSQNPDEBD<16MH+A#_9W_'X!<F-3@\H6C.X@
M<C (QF@#T;PMH0\-^'[?3/.\YHV=V8+M4%V+$*/X5&< =@!6P0""",@]0:\8
MNO$7B^TOM:CT]I+:."74+A?]!,GF>4T?EJ-W]X%AD=><<\ULR^+/$">.;*QF
MN/LUM<:H+06AL\!X!!O$HE(ZLQQ@=-O;G(!LZE9+X)ODUK2U$.CW%PB:I9 X
MC3>0HN(Q_"02-P'##)ZC-=J/RKD/&%TNLRQ>$++][=W;QO>,O2UM@P9F8]BV
MW:H[DYZ"NOXX- "T444 %!Z<44A.* .+\<[3KG@M /WIUH%<?W1%)N-=K7$/
M(=?^*T*1?/9^';9FE<'(^TS# 7ZA 3[;A7;<9]30 M%%% !5;459],NT12S-
M"X '4G::LT4 >"ZUX+UZ'P=H%WIEA.\UY;V=KJ]D(SO!B=6CEQ_>7!4^Q%:/
MB/P_J<5_XUL[CPM/K-SKY!TZ_C1&6(; %5V)S'L/.>^*]IHH \47P7J 'C=-
M1TM[^\.A6]O;7;P[C/*L!#>63WW =/05V&F:'X@'A;1MFKS6<$&E11W&EFS1
MFD<1X8%S\RDGC ]*[L=.N:* /%/"?A.]-]\/!JFB2F&RT^[6X$\'RQ.6)7<"
M.#Z9JKI?@Z\'_".1S>'Y/)@\373NKVV5CMC]TX/1...W%>ZXH/2@#PP^$M77
MQ)>6%[INK7$\^N"^AO[>*$1>7D%7,[*77:!C9W[=:EN/!]TW@CXB2_V&[:M>
M:K/]E<PYEEAW(04/7:?F/'6O;J* /(=5T>\T_P 4:G?ZAX7N-=M=3TF&TLA%
M&LAMG5,-$P8_(&/):H_!O@B_L?&FCC7].^UK9>'UC\^:,21Q3>:2$5CP653B
MO8J* /"&\,ZI%X9T^ZN/#US=&R\537DT A#2/;L3RJG[P/R_D/2M Z),_P 5
MAX9C@4:-+>)XDD0'[A"%?+91TS* V*]GK-T_0-*TN^O+ZQL(8+N^?S+F91\\
MK9SR3VY/% &CT/4TM)CW-+0 4444 %%%%  **** #%)M7!&T8/48ZTM% "!0
M%V@ #T%+110 4#ITHHH **** "BBB@ HHHH **** "BBB@ (R,&N/\7:%J*:
MA;>*O#L:R:S9H8I;5CM6^M\Y,1/9@>5/K]:["CO0!B>&_%&F^)[)I[&0K/$=
MES:396:WD[HZGD8/?H>U;8(/0US6O>"=+UR]&I(UQIVKH-J:C8OY<V/1NS#V
M8'I6<NG?$33FV6^M:+JT Z&_M7AE/U,9Q^./RH [:BN-\SXD_P#/OX6_[^3_
M .%'F?$G_GAX6_[^3_X4 =E17&^9\2?^>'A;_OY/_A1YGQ)_Y]_"W_?R?_"@
M#LJ*XWS/B3_SP\+?]_)_\*/,^)/_ #P\+?\ ?R?_  H [*BN-\SXD_\ /OX6
M_P"_D_\ A1YGQ)_YX>%O^_D_^% &IK/A:#4KT:G97,VF:PJ;%O;;&67^[(I^
M61?8].Q%4#JWBK15"ZIH@U:%1_Q]:0P#D<?>A<CG_=8U%YGQ)_Y]_"W_ '\G
M_P */,^)'_/OX6_[^3_X4 61X^\+G$5[>_8'SCRM1MWMR"/]\ ''M6S;ZSI%
MW\]MJ-E/SUCG1N<>QZXKFY!\1)D,<MIX4=#P59YR#^&*R9O"WB6X;=-X9\".
MWJ89._7^&@#T(2V:C D@&,G[PX]:IW6NZ#9(?M6J:="I7I).BY ^IYK@!X&U
MM6##PKX&W Y!VS=?RJW;^&?$]H2;?PWX%C.<Y6*3/_H- &\_C_0'#+ILEUJL
M@R!'IMJ\^<=@P&T=>Y%->Y\8:TNRTLH- MVZSWC+<7&/58U.Q3_O,<>E0JWQ
M'486V\+ >@DG_P */,^)/_/OX6_[^S_X4 ;&A^&;'0FGN4>:ZO[C'VF^NGWS
M2X[$]E'91@#TK:KC?,^)/_/OX6_[^3_X4>9\2?\ GW\+?]_)_P#"@"]J/A3=
MJ$NJZ)>OI.J2\S/&N^&YQT\V,\,?]H8;WJNOB#Q'I6$UOPW)<H" ;O1V\Y3[
MF)L./4XW5#YGQ)_Y]_"W_?R?_"CS/B3_ ,^_A;_OY<?X4 78_'_A=Y/*EU>*
MTFQGRKQ6MW_*0"MB#5]-NE5K;4+296SM,<ZMGZ8-<M-%\0;F,I<6/A*5#U61
MIV'ZBLF;PEXCN#F7PQX%8D;<^5(./^^: /1C=VZC)GB '))<50N_$^@6(/VK
M6M/A(&</<H#CZ9K@4\#ZW&VY/"O@8,.F4F/;'I5ZU\/^*[':;7P_X(A93D-'
M'*"/QVYH VF^(.CSK_Q*8=0UE^RZ?:.Z_P#?9PG_ (]66WAS6M=UA=4-A8^'
M7)),X87-WTVDK_RRC8CC=\QQ5T/\2!Q]G\+ ?]=)_P#"CS/B3_S[^%O^_D_^
M% &]HF@:?X>M7AL8F!E;S)YY7+RS/_>=SRQ^M:E<;YGQ)_YX>%O^_D_^%'F?
M$G_GW\+?]_)_\* .RHKC?,^)/_/#PM_W\G_PH,GQ)[6_A;_OY/\ X4 =B<8_
M^M7(>*/&$EM=_P#"/^'(EU#Q'.N%B7F.T!_Y:SM_"HZXZG\:KGPUXRUE6CUS
MQ3%96Q/,&B0&)F'<&5R6'X 5T6@^&M)\-6;6NE6:0*YW2R9+22M_>=CRQ]R:
M (O"WAR'PSHZV<<K7%Q(YGN[IQ\]Q,W+N?J?R&!6W110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 G4=B#2TA^G_ ->FD@Y'K^= #NO4#%'/J/RJ,RH#RR@GL3BD\Z/LZ_BW
M^?;\Z+,GFCW)OK14/G(3]]?S'^?2@31\8=>GJ.*=F'-'N2T<^WYU$)D[.OTS
M_GVH\Y,?ZQ?S'^?3\Z+,.>/<ER?;\Z6H?/CP?WJ=/[PH,\8S^\7W^8468<R[
MDO/M^=&3[?G47G1CK*OOR*#.G.9%]^119AS+N34G/M^=1&>,9_>+[_,*/.C'
M65??D468<R[DN3[?G2U"9TYS(OOR*#/&,_O%]_F%%F',NY+S[?G1D^WYU%YT
M8ZRK[\B@SISF1??D468<R[DU)S[?G41GC&?WB^_S"CSHQUE7WY%%F',NY+D^
MWYTM0F=.<R+[\B@SQC/[Q??YA19AS+N2\^WYT9/M^=1>=&.LJ^_(H,Z<YD7W
MY%%F',NY-2<^WYU$9XQG]XOO\PH\Z,=95]^119AS+N2Y/M^=+4)G3G,B^_(H
M,\8S^\7_ +Z%%F',NY+D^WYT<^E1><G/[Q>.O(H\Z,<[UR.O/^?2BS#GCW)?
MIQ^%'-1F:/NZ\'U%)YT>!\Z_]]?Y]:5F'-'N2YI:8&R3@_E2@KGH/\\T#N.H
MIHZ =.. *=GICG- PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *0^GKQ2TG/I0!D#Q3HC:%/K:ZG!_9D!99+GG:I#;3^O%:J.LJ*
MZG<CKD''4&O 1JEA!\!/$.DRWD":E]NGA^R,X$N\S@A=G7.*WM9DU6^U[Q?:
M?V[J=E;Z1H\%U;P6TOEA9?*)R>^,KRN><T >EZKXIT/0[RVM-2U2WM;BY_U4
M4C?,_;IVJ>SUS2]1M+*ZM;Z&2&]S]E8/CSB,Y"@\G&#^5>,:,UWJ7CS2-:N=
M5NVO)O"0O7(9=I;H5QCA"?F('>H;+S-1O?A/J-_K%S ]Q#=!G614567!XXP"
MV0I]1B@#VC7/$VC>&H(9=8U&&RCF.R)IB?F('2GZ+XATCQ%:M=Z/J$%["K;7
M:%L[3Z$=17$?%2.\FUCP9'8):/=MJ;B-;P%HB?+/W@.<5E:CI=[X#\,^)O$F
MKWJQ:CJ[P1;-$00)!@[5VL_0G/+'IUH ]9N+F"TMY)[F9(8$!+R2-M51[DU5
MMM:TV\U2ZTV"\CDO;1$>>%2<HKC*D]N1S7SYJM]J&H^#_'>F76K3R6>F_8IX
M8DO_ +5MWMAD:7'S#H2!QD5O7GB+6-&'CDZ3J<UV-/TO3_LMPVV1@&5=\F0.
M2 6.?;VH ]TSQ[_2D=U16=V"JO))X 'O7@LWB#7-*\->*39Z\[Q6]A;SQ%M2
M6\GAE9U&X2*H&UU.<<U<UQ-1AOO$6BOKVIW5M=>%6U"032AF$P89V\?*I&05
M'8F@#VN">&Z@2:"5989!N21#E2#W!'6I!R <_E7S]+<W]OX:\(VNE^)?M-N=
M-:5[3^U!:2[\#.V7&TA.@0G(QSG->N^ =7_MWP/I>HB2[D,D6TO=@"1RI*Y.
M!@YQU'6@#I:*** "BBB@ HHHH *2C(/;/O44TT<,+RR,%C12S,3P .M F[*[
M*FJ:K;:5;B2<LSR$)'$@R\C>@'>LL6.LZP#)?W;Z?;L,K;6I^?'^T_\ 0?G3
MM"MWU*X.OWB-YDPQ:HP_U478CW;J3[XKH/K^HK5ODT6YRJ+K>]+;HO\ ,Q$\
M)Z*I)>S$S_WYY&<_F33_ /A%="/_ #"X/P&#6SD#KQ1QC&.M1[2?<U]A37V4
M8W_"*Z'S_P 2R#GVQ2?\(KH1_P"89!G_ '<&MK(ZBCC &.OK1SR[A["G_*C&
M_P"$5T+/_(,M_P#OCK0/"NA\?\2RW_[YS6SD<X_E1D'MG-'M)=P]A3_E7W&,
M/"NA8_Y!D'_?-'_"*Z'S_P 2R#IZ5M8HX],]Z.>7</84_P"5&+_PBNA_] RW
MSCTH_P"$5T/_ *!<'_?)K9.,=./3M1D?RH]I+N'L*?\ *C&_X170QC_B66__
M 'S1_P (MH?_ $#+?V^6MO%)QSG\:.>7</84_P"5?<8G_"*Z%_T#(/RI3X5T
M,?\ ,,@]/NULY'3I1D<X!_6CGEW#V%/^5&-_PBNA]/[+@_[YYH_X1;0O^@9;
M^G3\*V?PSZ8HS[DT<\NX>PI_RHQO^$5T/MID'_?-)_PBVA<?\2RWZ>E;7&<8
MY^E+G/3K1SR[A["G_*ON,4^%=# _Y!D 'TH_X170\\:9!GZ9K:_"CCO1SR[A
M["G_ "K[C%_X1;0^VF6^1TRM'_"*Z'G_ )!D'_?-;/U_+%*,'D?G1SS[A["G
M_*ON,4>%M"X/]F0=NU'_  BVA@?\@R#C_9)__76UGCN:3CM^='/+N'L*?\J^
MXQO^$6T,?\PR#\1_]>C_ (170_\ H%P>GW:V<\_3UI>W(HYY]P]A3_E7W&+_
M ,(KH7_0,M_^^:!X5T+&?[+M^Q^[D5M=.W%+BCGGW#V%/^5&)_PBNA_] R#\
MJ3_A%-"_Z!<'/^S6W@$T  __ %J.>?</84_Y4<\?"\5OA]*OKNQ?J KET/U5
MLCO2V^LW-E>1V.M1I&\AVPW47^JE/H?[K>WY5T'')[=<U6OK*'4+22UN8P\4
M@P0?KQ5*=])Z_F0Z/+[U/1_@6%(P!2]1G]*P= N9XI)]&OI-]S:8V2-R98C]
MUC[]C[BMT'CN"<=JF4>5V-:<^>-QU%%%2:!1110 4444 %% .>V** "BBB@
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MI%AJB@7EJDI7HW1E^A'(J^<8.>E+CFFFUJB914E:2, >&43B#5-3A7/W1<9
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M3G5/^_W_ -:MW'2C'L*/:2#V$.Q@_P#".O\ ]!O4S_VV'^%*?#K_ /0:U/\
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K0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 G # 2(  A$! Q$!_\0
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MS]2:K_\ "Q=+_P"?:[_[X7_&O-".2>N2:#7TT<JH65VSX:>?XKF=K?<>E_\
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M?!((0XY]JY_2=)^VZ5:74NHZEYDT8=L7+ 9/\JWKG'V608'W#QCIQ5+P^?\
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M/TQ1U/?B@!:*3MM)/3K1G(XZX[B@!:*,T4 %%("#T(/&:,C .1@]Z %HHHH
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ML2!G!Z8R.#P1W%-0HO1) ZN(2NY,Z ^/M=!^]:^Q\D\_K0/'VO>MJ3QTB/\
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MQ7 (F,'F%1L+@9QUST[XH7,]@ERQW8_^SM7_ .@[)_X#1T?V=J__ $'7_P#
M:.H8_%-C-%:O'%<.UPTBI&%^8%.2",\9P,?6KFEZLFJK*T=M<Q)&Q0F50,L"
M00,$]"#3?,MR4X-V3(?[-U?/_(>?_P !HZAFDU/1WBGN+Q;VU:18Y0T01H]Q
MP&!'49(R#6Z.1R._KFLKQ%_R"6X_Y;1=/]]:2=W8J2LKHU5 QZ]\XZTO';OS
M2"G5)J0RQK-$\3A61U*D'N#Q5'1W:.S%G*,2VW[LXC**P'0J"2=N.,]\5I]#
M5"YT^*YG2X1VAN$P/-CQN91SL)Q]TYZ4T^C,Y)WYD7AZ9Z4OK_.LE9=9BC"M
M;VUQ(%3+(Y0$EOF(!S@ <]>:5KG5 &VZ;$3M<J#,.2" HZ=QS[4^47M%V-7\
M:/J>O:LPW&I[V L(RN]@"9NJ[<@].[<8_&A;G5"R;M.0 F/<1.. 1ECT['CW
MHY6/VB-/IWXHX]S62+G5S&2VF1;]@.WSP?FW8(Z?W><_A3GN=54-LT^-O]9C
M,P&<8V9X_BYSZ8HY6'M$:G;U(HXS68;C4C(5.GILWXW&89*[<YZ?WN,?C2+=
M:J=I.G1@D1D_OQQDG>.G.T<^]'*P]HC4S1GD5E&YU8(2-.CW;20//_B#8 Z=
M"O-.:YU0,VW3T(W28_?=0!\I_$\>U'*P]HC3&.@HZ9S68+C4RZAM/C"[E!/G
M#A2N6/3L<"FI<ZOY:EM-C#X0E1<="6(;MV7GWHY6'M%YFKGK@\TO>LE[G5E1
MMNG1L0CD#S^I!PHZ=QS[4XW&I>80-/3:&8!O/'3;P<8[MQ1RA[1&GS]*JW=R
MEG:/.X8[5R%098\= !U/M559]6<(#80)GR]V9\[<@[\<=N/KFBWTZ226.XU*
M59YEP5C5/W<;C/S(#R#@\\T62W$YMZ11+I5L;:Q176,2N3)(44@%F.3P22*T
M*3&1SS^%*,=1WJ7J[EQ5E8****"@HHHH **** "BBB@ HHHH **** "BBB@
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M(I))YV&W?)CY1[ =*W^/0 ]_KBG"FX/'-8RG*3O)FL8J*M$RM/XU_6#[Q?\
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M7'6JP\%^'N/^):@]/G;_ !KUXX^"233/*E@IMZ,\@_'/K2;0"3M )_"O8/\
MA"_#V!_Q+4Z?WV_Q]Z7_ (0OP]G/]F)_WVW^-/\ M"'9D_4JG='CV!D' _*@
M=.H_S_\ KKV#_A"_#W;3D_[[;_'VI?\ A"O#P_YAJ?\ ?Q_\:/[0AV8?4JG<
M\?[^OIFNM\!1WS7E\UBT"XC4,9D+ \G X(]Z[+_A#/#_ /T#$ZY^^W^-:ECI
MUIID @LK9(8LY(0=3ZGUK&OC8S@XI&M'"2C--LI^7K^?^/C3O^_3_P#Q5-\,
M[_[(*R;"ZW$H8IP"1(>?;Z5LUC^'/^0=-T/^ES]O^FC5Y]]&=O+:2-C.*3.>
MG(JOJ%Y'8V4EQ*&(7@*G+,2< #W.:H++KTH$GV2QCSR$>9B5^I"XS]*213DE
MH:^:#63G7_\ GCIW_?U__B:-VO9_U.F_]_'_ /B:=A<_D:V>:,\=.<5D[M?S
M_J-._P"_K_\ Q- ;7Q_RQT[_ +^/_P#$T6#G\C6SZ49]JR<Z]_SQT[_OX_\
M\34<VH:GIR^??VENUJ#^\DMY"3&/[Q4CD?2CE#G78VQ[=*6FJ01G/'7-.J30
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ Q0!Q110 4F*6B@!,>]+BBB@!!
MT%+BBB@!*Q_#O_(/FZ_\?4W;_IHU;&*Q_P#A';4.YCN+V+>YD,<=RP4%B2<#
M/&3FFMM2))W30OB!E;3DVE3BYBS@]/WBUK#K7&7OAB/3+B745O;F0RW,)$3.
M2OWU'S9^\?<^WI79'Z#\:J222LR*;DY/F5ADS.L+%%W/M)5?4^E<*=6OUM&D
MM=3FGNS:RR7<<D>1;.!D8&/E.> #G/6MR_\ $YLI]2B6S+O:A/+P^/-+8R/;
M&15D^)],0MYDK+M4G=L;:Q'55;'S$9' YJHIQZ$3E&;LI6,,:_J5HUW*ICO8
MS(RQ* <\0JXVX[9R<=>:O:;KNH7]U8PXM-LQD+R)\V57;P,' )R1WZ58A\56
MACDDN8Y($%R;=24/;'+>G)Q4)\6(DH1[-B3<>1MC)+ ^:4W=.G'US3=W]DS3
M2^V=*,G//>LOQ%_R+VH_]<'_ )5+9:Q:7\WDV[.TBQER"A&T;BN#Z'*G\C47
MB(_\4[J.?^?=^#]*S2:DCIDTX.QI0\0)V 45)4<(Q"G SM%25+W+CL%%%% P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HZTA.!2=3T![
M4 .HIO7L,GFC'L* '44W'^R*._0=: '44W'^R.U&/]D4 .HIO?H.M&/]D=J+
M@.HIN!_=%'?H/6@!U%-Q_LCM1C_9% #J*;WZ#K1C_9':BX#J*;C_ &11]0.V
M?K0 ZBF\>F<'/-' ' X' !X H =13>_09HX[ =./Z4 .HIO![#G^5 (..!SS
M0 ZBF\<8 Z<?THX/8<_RH =13<CK@>M' [+Q_D4 .HIN!G.WOF@ <?)Z4 .H
MIN!C[G^3UHXZ[>>M #J*;A>RC'L/2C _NC\OSH =13>,YV\]:, #[G\NW2@!
MU%-('/R@]:.,^YH =13>/0=R*"!C&TG QSWH =13<#/W>]  _N^GI2 =13<#
M'W/7THP,_=[T .HIN!_=':C Z;1WI@.I.V.M)QU(]\T=@,<4 9NO033:4WD1
MF62.1)1&IY8*P) ]\"FQ^(=)D0-]LC3/57RK#V(/(-:G7\^M)M&<@+GOBG=6
MLR&G>Z.<N!X<NIY)I;R,NY9B1+C!*;#C\*B-OX78ONNHV1@<(93M1CC++Z$X
MZUU&WV.?>C;STJN8S]EZ')/8>%G.Y[\NQ8LS&<Y<DJ>?7E0:D>W\,.[/]M57
M,GFAA,<AMYDR/^!$_A74[0.W;L*-H_QXHYP]EY(YS2[K2["6^G?4+4SW4N]M
MAP% X Y_$_4FI-8U6UO].FL+&7[5=7*F.-(LG&>-Q/8#N:W]O';CTH  /'7T
MI75[CY';E"-=J!<] !BG]Z;T'?%&3G&![9]:DU6@ZBD&,<"EH&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 =*;N (R<'IBAF &>.>],9E^3*GG
MD9[4Q-DA_4]ZAEA:1@4N'C [*!C]14QZ&L?7_$=KX>C@DO+>[ECF?9O@AW"/
MD#+<^K  =3V%):[ R_\ 9I>@O)N/9?\ "D-K)@_Z7,/H%X_3WJAJ7B:PTK5K
M73KGSA-<PRS1E4^7"#)!.>#CH._-+:^)M(N([8B]ABDGMUN5AD8*XC*[AD9X
M.W)_"GJ*R+YM9.?]+E]\A?\ "C[+(/\ E[F//HO^'UJF_B/1HU4OJ=H P1AF
M0='&Y3^(Y^E3Z7JL&K1W$EL) (+B2W;S!C+H<$CV]*-0LB3[+)_S^3?DO^%+
M]EDX_P!+F_)?\/\ /YU9_#WH_.E<.4K?99/^?R;\E_PI/LTG_/Y+_P"._P"'
M^?SJW10%BI]FD_Y_)O\ QW_"E^RR?\_<W_CO^'^?SJU2?YS0%BK]ED_Y^YOR
M7^>*/LTAR/MDO'LI_#I27EX;.-7-N[IT)7^'Z]\5AV&MDW$NZ)Y/-<%%49QQ
MC\/TK@KYA1HU8TIO5FT*$I1<ET-[[+)_S]S?DO\ A]*/LLG_ #]S?DO^%5-5
MUA=*T@ZB\#2 /$A16&<NZIUZ<;NWI6=)XZT*),F><_,0 MNY9EVLV\#&2N$?
MYNGRUWJ[5T8V1N?99?\ G\FS]%_PI/LTG'^F3?CM_P *P9?'FC+$S(TS2;9-
ML;P,FYT4MM)(PN0"1GBFW'CO3H="EU%03/%Y>ZSE/E2Y;:>C=@'4[AD8JK2%
MH=!]FFX*WDA'NJG^E+]GGS_Q]-_WP*IZ!K2Z]I:WJPM"?,>)DW!L,I(//<<<
M=.M:N*5V/E16$$__ #]-_P!\"CR)_P#G[/\ WP*L\^U'!_G1<.5%;R)_^?MO
M^_8H\B?_ )^V_P"_8JSCZ_G1BBX<J*WD3_\ /VW_ '[%'D3_ //VW_?L59Q2
MT7#E15\B?_G[/_? H%O/C_CZ/_? JS4-Q,\4+2)$TK+_  *0"?SJ92Y5=ARH
M9Y,W7[6?^^!1]GG/6Z/XH*P#KO\ Q-?/"/Y>W9MP0WY5NQ7R&V:XE!C5 6;)
M!P!SG\A7'A<?2Q+E&F]F:U*$J:3DMQWV><_\O1_[X%'V>?'_ !]-_P!\"L*U
M\90-:_:[^PN[&UD5'M9)%$AN58$@JJ$G. 21C@<^M%WX[T2WBF,<TMT\94;(
M(F.[<4&5;&"!YBGCL:[[,QLC>\B?_GZ;_O@4GD3\_P"E-_WP*R_^$OT4E0+E
M\N[("T3J,AMG)(PH+#:"< GBM#2M075=*M;](WC6X0.$<C(SV/N*6J"R)/(N
M/^?L_P#? H^SS_\ /VW_ 'P*LT?A1=CY45O(G_Y^F_[X%'V>?_GZ/_? JS1S
M_C2NPY2#R9NUQC_@ H\F?_GY_P#'!4_N>**+CL0>1/\ \_/_ (X*3R9O^?G'
M_ !5C%!XZFBXK%?R)O\ GX_\<%'DS=?M'/\ N"K'XU7N[HVL1D$+R 9SM[=>
M?_U>M3.HH1<GT&HW=D BF[7/3CA!2^3/VN/_ !P5S]MKA_M*9RA=),!5!Z8X
MY_QK6O=8M].T:?4[M72&",R.JX9OI@=^GYURX3'4\4FZ;O9FE2C*G\19\F;_
M )^?7^ 4&&8];C_QP5CQ>*X80BZQ9W&ESN7(CF <;%4,S[D) 4 \DXYIT?C#
M19)8H5NV$LBN=C0.&39]XL,97MUQ7=J9:&OY,Y&/M)_[X%!AG/\ R\G_ +X%
M9,?C'1)8;687;".ZSY1:%QP"!N/'RKD@;C@9-,'C70&>%/[04--MVAHW'WNF
M3CCD@'/0G%%I=@T-GR9\_P#'R?\ O@4>3-_S\?AL%1:;J=MJ]FMY9L[P,2%=
MXV3=@X) (!Q[]ZN=>^:FX6(/)F_Y^3_WP*/)G[W)/_ !5C%&*=V.Q7\F?_GY
M/_? H\F?'_'R?^^!4^**5Q6(/)G_ .?D_P#? I/*N,C%P"/0QU8[48/MGZ47
M8[!T&2W '>E  & ,"BB@84444 %%%% !1110 4444 %%%% !1110 444A"DX
M('(_,4 +3221D $XX^M+W]JC ?#9(W?P_6@0I9MA.WDGM2%G 4A.3C(ZXH(?
M8>1NR0">PI"),)M(S_%CI_GK3$2GI[5@^)]$&MV:12:M+80*=LVS;B13C(RW
MW6XX8<BMX],^E<IXNTR>\OM*NFTUM6T^V,PGL 5RS,N$?#$*VW!'/3=D=*([
MC99UWPK;Z](99+J6%A:-;QL@!*,65A(">X*_CS5*R\"6]G>6LGV^:2WA>*X:
M!HU_>31Q"(-NZ@;0,KTS6;+I_BB%K"*P@GLX8[>!;>WAN0\-NP<^:LI;YG^3
M 7Z<<\U5T_2_&,3V,TUUJ;$+9R3+)<J5WF1A."/3R]O'3/(YYK2SMN3IV-&3
MX9V1AA5+^3S8I)=K2PJZF%P%\HJ>#M55 /MSG-=-H>C1Z):W$$<K2)-<R7&"
MH&W><[0!V%>>Z/\ \);J>CP74-SJ4EE,L37):=?-D'F-O\D_P_(%!Z>W/-78
M+#QN+M9Y;F[WQ_9/+4S+L(+2"7>O0D(8\^_(YI-/9L$UV/2"?Z]J3<"2N5SQ
MD?Y_&O.+#2_&,MG!#?W6HAY+M/M)254*+Y;^84;<?D+;.!C';%4;;2/&$=A=
M74W]H+J5U!9-,T<H/F,D9$B'# I\V,E>?3J:7)YCYCU;.?Q]13/-0N8O,4OM
MSLS\V/7UKEM6@UZ?1-'$2W<; C^T(K6X7[1]P@!9" " ^">F?IFHO".C:K:Z
MYJ>IZTA-Y<6MHAEW!E9EC/F  =/F].,DXJ;:7'?4[+OT%+30<=2/SI3@\<9I
M#*]U&\UL\:,%=QC<1T'?M6(-#:&17@+$)P<GYF''Y=/\]*Z+'/IG]:,#GU]J
MY:N%I59J<U=K;R-(U)15D]S+U5=/BT=A?V_F6^^(&)1DE_,4(..OSXK%%MX/
MC@ED>UB@V-(SQON#+\K*P SP-K-@#CDX%='J=G;W]@T%V0EN'21B< ?(X<9S
MQCY16)+H>D:G<Q3P7ABB *111A0NX @[,C_:.<=<"NM&3(SH_@]KAKI[:U65
MU9F9Y&&1RI)Y],C\321V7@U[632UBM/*?:Y7<V3DX7#]1CRP, \;1TI__",:
M3-=B<WXDDER3DH=[ D[EXXQN((%27'AO3;Z3*W[?OY&E4(R$DEF)*G&1C<1D
M=*=_,5C0L5TC1K9[:T,4"AWD=3)EBQ(W$DG).2.<GJ*6U\0:9=W*VT-TGFMG
M"L,9.2./4Y%5KW1M)N=1:]GN-LJL@<>< NX X!'KT//7:*2VT*PC$J+=-)L*
M!AN4^6%?> ?Q]:6@]31DU>PB:827D*&$_O 6^[4=OKFGW32K'=)^Z+AF)P/E
M.&QZ_6LP:!8R:C/?0:HPNIR7C9"C;.3R./FQDCG.*E7PE8^:7DDGD_>"0 D>
MN2IXY![CO1H&IL6]W!=>9Y$Z2;&PVTYP:G'X5EZ/H5KH_P!H\@[_ #FY+*N0
MO.%) YZGKZUJ]J0PHHHH .],.=N ,^QI])@$4FK@<[+H,C$MO9KAB6+DX4'T
M'^<UKVD2Q6_[P*#CYL\Y'?\ "K9 '7 YIDIC2&1I2HB"DOD<8QSFN>CAJ5!M
MTU:^YI.I*:M)G&_V9X.@C_<Q/)%*5)GAED98%!PH#@_(OSD8'9CVJ>'2O"MQ
M9SN;-K>)&!82%H]H8)M*C/0B-,8]/K5V73=+N/*DM+R""S ,LD$83RY=P #-
M[XX!]_6E;1[-[*:!M29V>1%\QF0D;.%0CH>_7DFNNYC8KMIWA/? K/ 3"GFJ
MOG$[U+^8-PS\XW-N .<$YJ_%J6B:/90VD5U$D,"HL<:MN(!P%_F*PH?#5I<)
M%;PZI'_9<,>^ *RLY9 J[VR,$ ISV]JN-8:%!:6Z+J(B02F2)EVC+( IQQC
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M-W>3&]$8N#*<Q)@OYASA\Y!QVQCJ:+^8BM=Z%IOB6:>X@U&&1"$RT: NA5<
M;LYV$9R._K5R;PK:SZ9:VC3*JV\4JJRH.#(,;ESG&.WY5#;^&KJ+3;RW:Z@$
MUQ"D0P'9?D[DLQ;G., @#ZU''X,'V94FN5D==HW$-C:$=0O7IE@?PHOY@(/
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M"".#UHK*B\064\R1QEV+R&-<8P<=^O\ ]?GI5F;4(X+D6XCFE?:"PC3=M!.
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M4 %%%% !1CUHHH 3'.:,#&*6B@!"!CIQZ48 /O2T4 )T[48!]*6B@ Q1110
M4444 %%%% !1110 4444 %%%% !1110 444$ C!&10 9YQ3>.V,^HH) ;&>2
M.F>U(,>83GYNX]/K0(0*03SQVXZ?YXI,-Y9!;!^O:A=@+8;/J?2F@((>'^7/
M#9IB',KE1AL-GK00Q=2K?+WYZTUE0HH+D < ^M*X0RJ2QW=E]: %"MYA.[*$
M=,TBI( Y+ GMFA503LP?+8Z>E-14"OMDX/4CM^- A=D@AQO^<'K[4,DF$VN
M5^_[TPI&+;;Y@VYZ]J<Z(1$#)@*1CG[U,18JK=V$%\ +A20 R@ ]F&#114FA
M!'HUM$C1J\_DLA3RO,.T9&"<>I_J:;-H=M.[L9)T+@ [),=@"?J0 #110 U_
M#UD[[R9-_9LC(S][''?O^F*4^'[(N&S*" %&'Z)S\G^Z<GW]Z** $7P_9(,
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M'(Q_*BB@!%T&R6*:/$A65][#?WP1_4TK:'9O.96\TDG(4OP"1@D#WP/RHHH
M#H=F8UC D55D,F W4G&<^W J.;PYI\R!71N"I'.<84*.H] *** ))=#LY9%8
MB10JJH16PO P#CU )%.FT:SGN))G5M[C!PWNI_FBT44 0?\ "-V&%'[[:I!"
M^8<<=/RJQ_9%N&0J\R*J*A19" X7IN]:** )++3;;3R_V9"BN%W*.A(&,X]<
M5;HHI %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *:V%'08SZ=S110)C2%W@=^3^O\ ]>C \P\?, #[
M?YXHHI@"!2&VC@D@Y_*F;D\@D!@I[]^F:** %?RP%!4D9.!]*&V><@*_-V(Z
M?YXHHH0-(%VF=P!\XQGTIJ^6$EX. 2&]3110*PTM"+8$J=C'IWS_ )%.D$0,
-2NN>?EQVHHIA9'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I G # 2(  A$! Q$!_\0
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M_=7@TV_T>^F:XGT>\>S6=NLL8 *$^^"!^%%DU=!=WLSL:***D84444 %%%%
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MNMWNFS7BQRPV3R.;>6(2++N7;SGTZU*M?4;OT,[3?'.FWUK;&7_1[VY\X);
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MR2NP[_CVKC_!G_(?\7\@_P#$U[?]<DJH[,3W1V5%%%2,**** "BBB@ HHHH
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MJ#HME:M'%$AO)RK>4AR0VP=R> /<5';0:==Q!H+4+]G)9A,".3D!7;^+L>G
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MP<9V7WG&:??16ME)%*2T<TH66,9^:,J03]1D$?2K4VK06]U+'$9+B,!%$B;
M'PBKT92>WK74?\*XL>]_<?\ ?(_PI?\ A7%C_P _UQU_NC_"N26*PDI.3;.Z
M.7YA&"@DM/,YFTU***SA>6XA?R03#$8?WD<A?.21C*^OKZ9JMK-U9O!;VMDJ
ME4DDE8JS%<N<X&>?\.E==_PKBR_Y_KC_ +Y6E_X5Q9=[^X_[Y%*&)PD9\Z;^
MXJ> S"=/V;BOO/..IXHKT?\ X5Q9?\_]QCZ+1_PKBQZ?;[C_ +Y6NS^U,/W?
MW'G_ -@XSLOO/-VX4GVKVW1QC1K(>D* 9&#]T=JYVW^'NFQ3J\MQ/,H.3&V
M#SWKKU7:H"C Z"O)S'%TZ_*H=#W\FRZMA'*57J<;\1%8Z1:$*<"?KZ<&O.*]
MUN;:&[MV@GB66)P R.,@UC_\(;H!Q_Q+UZ<?.W^-7@LPA0I\DD1F63U,56]K
M"27J>14O?^5>N_\ "&Z#_P ^"_\ ?9_QI/\ A#-!QQ8+_P!]G_&NW^UZ7\K/
M,_U<K_S+\3@[+5+0?8X;B9EB@A5E8*2$E&X$8QT(/YBJAUA9+2.VFAF>,;=R
MF?@@$$C&WIQZUZ.?!N@X(^P)SZN?\:0^#= Y_P! 3_OL_P"-<:Q>&O>S.]Y7
MC&DN:)Q%UK>FRBWF$5VTJK*%^=08"Q^7;D8X'3KBLO7+JVO-7GN+4N8G"\OG
M)(4 GGZ5Z7_PAN@ _P#(/3K_ 'F_QI?^$-T 8_XEZX_WV_QJJ6.P].7-%,FM
ME.+K0Y92C]QY%1_GFO7?^$,T'H=/3_OMO\:#X-T#_H'KCW=N/UKJ_M>E_*SB
M_P!7*_\ ,OQ/-/#\3R^(K!4!+"96('H.37M YXK.L-!TS2Y&DL[1(G(P6')Q
MZ9.:T2,'K^%>1CL4L1-22M8^BRO 2P=)PD[ML7&>_-&.?\*"?I0,UPGJG(^*
MO^1N\&KG/^FS<?\ ;%JZ[&1_]:N2\5X_X2[P<,\?;)N/^V+5UP_GZ5<MD2MV
M)MK*\10O/X?OXXP6<PM@#J>#6O32N12C+EDI=A5(<\'%]3P3@C@YHKV:7PUH
MTTK2R:; 78Y)V 9^N*9_PBVBC/\ Q+83CVKZ%9Q"VL6?'/ARK?2:_$\<ZUIZ
M?J$=G:21N"PDF7S$_P">D>"&!_/_ #BO4/\ A%M$'_,-A_*C_A%M$Q_R#8/R
MK.KFE*I'EE%FE+(<12ES1FOQ/.I==BM[F5;5)I8#L"/YS19 4#E<>U45O%?3
M)K:624EKB-U7);:@W;L9]S^M>IGPKHG?38/RH_X1;1.O]FP\>W^?2L5C<.EI
M%G1+*<7)MN:Z]'U/+[^YMFTZUM()FG\EW97,>S:IQA3ZGOFLSZ5['_PBVB\?
M\2V'\J!X5T/&/[-A_*MZ>:4J:Y5%G/5R&O5ES.:_$\<H)"KD]!7L9\*Z+_T#
M8?RJ2'PYI%O.DL6GP+(IRIVYP?7FK><0MI%F<>'*MU>:_$DT2%[?1+&*5=KI
M BL,=#C'I6B*!P./TI:^=D[ML^RA'EBHKH-[BN/\&_\ (?\ %W_85_\ :25V
M'?\ &N/\&_\ (?\ %_\ V%?_ &DE..S&]T=E115'4]4L='LVO-1NX;6W7 ,D
MK;1GT'K4C+V:*Y/_ (65X-_Z&"T'XG_"C_A97@WOX@M/S/\ A5<LNQ//'N=9
M17)_\+*\&]]?M/S/^%'_  LGP;T_X2"S/XG_  HY)=@YX]SJN,= .*@O;V"P
MMI+FXE6.*,99B>E<X?B5X.(X\06A]LG_  KFU\;>&=<U$7.J:Y;Q6,#?N+-B
M?WA'\;\<^PJX4F]9;&-6LHJT-V=):VEQXFNEU#4$,>F1MNMK5A@R$9Q(X_D/
M\GJ=H QP *Y4?$CP8% &OVGX$_X4O_"RO!PZ>(+3\S_A1/FETT"E&$%O=O=G
M5_C17*?\+*\'?]#!:<^Y_P */^%D^#O^@_:?F?\ "HY)=C;GCW.KV_\ UJ,>
M]9ND:_I>O6[3Z5?P74:G#&)\E3[CM6D*G8:=]@Q1M%+10,3'U_.C:/QI:* $
MQ1CBEHH 3%&,#%+10 48XQVHHH 3'^11BEHH 3'O1M%+10 @%&VEHH 3'\J,
M4M% "8'?FC''/.:6B@ I",TM% ";1Z4;?QI:* $Q1M%+10 FT48ZTM% "8YH
MV_E2T4 5KMVCLYG4E66-B"/I7%+K6JK;6[W#%=UC"Z[922Y,B NW P<&N\V@
MY'6HW2-4),:D =,#H.U7&26C1G.+>J=CBK[Q/?RV%X$\JWD$3R+LSOB*RA0&
MSQD@Y_'\:L'7=2.I.HV,UO#<;XUR$<H\8W>H.UCW_G4NGZEHJRK>M$\,ES$K
M!9&:1AN+':%YZ[<\>E7;G6M(O+1T23S$<JC%"8VVN2 0<9.=N./0UH[?RF/F
MY#7UR\_X1U=2CABS-.%@5MV/+9]JL>_0YJI_PDNH?:+^'[-;EK9) H=]F64#
M!.3]TD^G'K6A8Z[I$MI9QJRP"2-3%#(I&U>0N>P^Z<?2I;#5[+4[^>"WB+!8
MD<S,F ZL6 '/)'&?3FIVOH7O;WC _P"$HOF>2X#Q%([*:3R3$4#R*P'J?T)J
M=M?O[>>:-VMD8S*AFE9O*C_=;^GOT_7VK7_MK1S$V98O+CPO^K)^\=HV\<@G
MC(XJO+XETQI'A5/- B65F9<+R^P*<CAL\8-/?[).WVC/BUC4)-1>(3Q2,;HQ
MPHH(4#R-XS_>4MW.*;+XNO?*CFBM(A'(2H,AQAT4%E)) 'S$CKV/!K<;7-(4
MS2&>,>5R[[#S@[<@XYP3CCI2/K>DBW25Y5$32E/FC("N#_%D<')'7UI77\H[
M?WBIK>O7&FO:I$MNGFV\DS><3U7:=HQUSDC\NO2JZ^)+]U9C#!;QO=?9D>4-
M^Z(3<3)T]@/KUHN-=TPW,%Y/:2--"'1%!)89E$9^7IC(ZUM07^GW;B")D=I-
MY*^7UV':Q/I@\<T.R6PU=OXCF[?Q-J#S22/Y4:2+;;$D4A8-^=S$Y!(R/;J/
M>K=IXENKNZAC*6T*D+Q(2#/EF!,7Y C.>O;J;47B/3IA</.@@6.5X SIDL$.
M&)&.%!/>M*TO;*^N)4MRKR6S%&.S&QNX!_PIRM_**-WM(YK_ (2.]NY+55,:
M!Y8&)A)/EAG*F)\_Q?\ U^.,UV0X_P FFB&/'W%Y.X\#KZ_6GX[]ZSDT]D:Q
MBUNSD/%>?^$O\'?]?LW_ *):NO'6N1\5_P#(W^#?^OV;_P!$M76BG+9%+=CJ
M***@88II;G%*:X/QCJEW%XRT/2!KDFDV%]!.)Y8]@)9=I&&8':>HS3BKNPF[
M'=;N/4=^*KWM_::;;FXOKJ"VA&!YDSA%SZ9)_2O-M-UGQAJOAA'TZ=[NV@OK
MBWFOH$C:ZGA0@(\6[]V3]X$\YQQS5>9M%&L^$C>37<FD>==^<VM%MWVG8,>9
MOX!QG';TJ_9ZZD\QZO%*DT:21.KQL 596R"/4$57M-4L+Z2:.SOK:X> XE6*
M4,4/H0#Q7GGA"]V_"^]L;>X47,D=\^G0A_G:$,P5D'4J,C!^E<ENM6L=//A?
MR_/_ .$4N/MWV3&[.%QOQ_%NW8[YIJF)S9[A::II^H+,UG?6]PL+;9#%*K!#
MZ''3O2V.I66I1L]C>P7*(VUF@D#@'TXZ5X?JC61L+IO"C1>7_P (F!>?9/\
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MTG!_$ U].CCWKY:^&G_)1=&_ZZM_Z U?4PZ]:\[%?&>GA/@%HHHKE.L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ IK ,A4D@'(XIU-/3KQ]: .?M_"EI;R6;K<3DVH4*#C!VAQS_WT
M?R%!\-V5O'"TES*J0+$@+, /D8D9^I8C\L5F3Z9KTCSNLEVK,MR4"W' ;?\
MN<#/3'Z=?9)[/Q'-=7#&*14>+:%$JE2P="&P3Q\H;L*Z&G_,<MU_*:2^%+&%
MXI))G811")_,53O122HR1\N,XR,5<TW0XM,F:1;B:8F)(!YF/E1"=H&![_C7
M.WNCZY<VLZ$7$@F:XW1M.,%=X,0'.!\N?Z^E236/B)I+XQ/=*&'[@"1<;<KM
M&2<@@;NWKG/%)IO[0TTG\)=N/"2K;1I9W$@:-XEB\PC$,2R!R%XZ\=_0"ICX
M3M"SL+BXWR*%F8X/F'S/,STXY)Z>M9U]9>(5A:&U6X94FE:.3S_F"Y4IU/(^
M]Z_2G36'B$&1X))P\GG[@TPQC>OEA1T4XW8/'7GV-;?$&E_A-"3PI9R1/$T\
M_E@%8E."(@7#D#CG) Z]JBO?"^GRR22S7LL6^1I3\R@ DJ<C/3D 9'/:JLME
MK;M9?9OML,"[OE:97=3O!!?)P05SQSC/K3O$>CWU[?W$EM;M*LUFL0(< !A*
M&/!/ID].U)7ON-VM\);E\)VDAW?:)U8*5!&.,R^;GI_>P/I5K2])>UU34+^5
M55[AL1HIW;5'4YQU8\D5C2V'B%;Q5CEN1:K+($*RJ64;U*ELGE=N[UQZ=*;=
MV'B Z?(L/VAIY9YF+?:0#&H)\L+R!@@\^GH:+-Z7"]M>4U)/"UJYF(N+A&F:
M7S2I'S)(V63IP..O45I:;IL.F)+%"7*R2M+ANQ..![<5S%JFJ7EW>%KBXA@2
M:>.:=IL*B[1M"KG@ACG/Z]JVO#+7=QIWVR[D9I+AMRJ3P% VC ]\9_&E)-+5
ME0:;T1MXI:08XQTQ2UD;''^*L?\ "7^#?^OV;_T2U=>.M<AXK/\ Q5_@WG_E
M]F_']RU=>/I5RV1*W8M%%%04)6!JOA:TU;Q%I^JW;B1+2"6$VLD89)1)C.<^
MF!704F,GK33ML!%!;PVT*06\4<,,8PB1J%"CV IE[86>I6WV:^M8+J D$QSQ
MAU)'0X/%6/QI<T@*JZ=9+<0W"VL GAC,44@C 9$/55/8<#BDM=+L+&2:2TLK
M>W>=MTK11!#(?5B!S^-6Z*=P*=GI=AIXE^Q65M;"9M\GDQ!=Y[DXZTMEIMAI
MD;I8V=O:HS%W6")4!/J<#K5NBE=@5[:RMK-9!;6\4/F.9)/+0+N<]6..I/K4
MX'X#VI:* "BBB@!O?OUKC_!O_(?\7\<_VK_[22NP[]^M<?X-'_$_\7GUU7_V
MDE5'9B>Z.Q/K7SK\;3_Q7J#_ *<H_P#T)J^B2>17SQ\;XY$\<P2.A"262;&[
M'#-G\LBML-_$.?%+]V<C_P (]G1=.ODU&T+7MR]N49MJPE4#_.YX!PPX]QSV
MJ*XT18/"UMK?VV*0S7+0&! 28R%W?,?7V&>".:AM]8N;>SMK3RK:6WM[EKI8
MYHMRL[($.X=Q@#BHCJ5R=&72B4^R"X-SC;\V\J%Z^F .*[TIGG-T[;&I#X-U
M:>[M;2/[*UQ=0)<11BX7<4?&W([$Y[T+X-UJ2&&2*&&0RB(B)9E+J)&*HS+U
M R",^WI2VGC/6;&Z-S"]OYGDP19>$'B'_5GZC\CZ=*9'XOUB"4RPR01R>7#&
M&6+.%B8LO7/<G/J*G]Z5^Z\R:;P==I#9R175I(DUN9Y)O.40Q_O3$H\S.#N(
M_6D_X0G65C9YEM;?8-TB37"JT:^88\L.PWC'Y5$?%NH$11_9]/%K'%Y0M!:@
M0E?,,@RN>H<D@_GG)IMQXMU>[6;[1-'(\T0BDD:,;F F\[/UW_IQ2M5'^Y+!
M\&:E]IM;/]U%>3></+GE51F)RK8;)Z8SSCIGFC2/!E_JJ6UQY]K#9SLZ^>T@
M(0A&< CW"G^M))XUU6=IC<0V,PF65'$D!^[(^]P,$$ G] !2IXXUE(+>$"S\
MN (%7[.,,%1D //38[+_ /7YH_>@O8D0\)7\WD&#R]LT4+J\TBQJSR@E$4Y(
M).#CI[XJ*[\+ZG9:8U_/'$L:I'(\?FCS(U=BJEEZCYE(^M/A\6ZI"(E"VCI"
MD*Q1R0!EC:($1N ?X@">?S%0W'B/4KNTGMIY(W6>&*"1BGS,L;%U.?7<3D]Z
MI>T$_9=#5^&G_)1=&_ZZM_Z U?4PZ_C7RY\+X9)OB/I'EQERCN[8'10AY/MT
M_2OJ,<'FN/%?&=N$^ 6BBBN4ZPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)P*6B@#!UW6FTB2V8(
M70QSR%0P&=B;L=/;M4)UZ:;1=6N!"MO<62G +AQ]P.#GCL>GM6[/9V]SM,\$
M4A4$#>H; (P0,^HXH^QVH25!;Q[9>)%"C#C&.?7CBK35MC-QE?<YB3Q@UO;O
M*]IYBQ[H\F0!F=4#-E<<*?7].14G_"5O#</'=V<<,:RO"TGGYPRQ^9Z=,<$^
MOK6^VFV+NS/:6Y9UV,3&/F7T/M[4XZ?9EBQM822Q8DH.21M)^N./I3YH=A<L
M^YRI\67<SVKQ6\*_O)DEB:3 ?;&'!#$9'!Z8_2I]2\0R2P:?]@>6)[B11(OE
M#< R%@!NPIZ#OZUO_P!E:=Y0C^PVQ3KM\I<=@>/H!4EQ86EU$D=Q:PRHARJN
M@(7MQFGS0OL+DG;<PK77YE\*KJ4ZI/.K^4ZJ0@W>9MY/0$<9ZCKVJ&3Q>(2B
M-:IYHG\F55ESCYPH9?EY&3WQT]:V[O2;2ZT[[!Y8AMP5(6$!1PP.,8Z<5(-,
ML#Y8-E;_ +O.P>6/EYSQQZTN:'8;C/HSF4\5W$%K%<7<(=FCE;RXF&TD2JB]
MLCKUJP?%DRO%OT[;\J--NE 9-TICX&.>>>W!]:Z :;8@,!9P<@J?W8Y#'+#Z
M$]?I2+IEBJ!!9VX4 *!Y0Z [@/P//UI\T.PN2?<YQ/%%S!:QRW=O;LLEQ-&\
MHD*I&J/M&[@\^_3CKS76 \U6;2[!VW/96Y(<R<QC[QY+?7WJT  ?_K5$FGL7
M!26[' Y%%%%26<?XK/\ Q5_@WG_E\F_]$M77"N1\5G_BK_!O/_+Y-_Z):NO'
M^>:N6R)6[%HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@!I_K7'^#<?V_X
MO_["H_\ 125V!Z@^]<?X-_Y#_B[_ +"O_M)*J.S$]T=B1]:Q_$/AC2/%%FEI
MJUHLR1G=&P8JZ'_98<BMFDQ4IVU0VK[GG?\ PI;PA_SSOO\ P(/^%'_"EO!_
M_/.]_P# DUZ)BEQ6GM9]S/V4.QYU_P *6\'\_N[W_P "3_A1_P *5\(?\\[[
M_P "37HF*,4>UGW#V4.QYU_PI;P@>!'>Y_Z^3_A6#%\,/#.GZHNFZS#=CSC_
M *-=I.0DG^RPQ\K?SKV/%4]2TZUU2QDL[N(20N.G0@]B#V-5&K+JR948[I'#
M_P#"E?"!_P"6=[_X$G_"C_A2W@_M'>_^!)K<LM0NM!NXM+U=_,MY/EM;WH&]
M$?T;T/>NGXQ2<YKJ"A3?0\\_X4MX/_YYWO\ X$FC_A2W@_KY=]Z_\?!KT3@\
M9YHQWI>UGW*]E#L<]X:\%Z%X267^RK/RY91AYY&+R,/3)Z#V'%=$*3 I:AMO
M5EI):(****0PHHHH **** "BBB@ HHHS0 4444 %%%% !1110 4444 %%';T
MHH **** "BBB@ HHHH **** "BBB@ HHHH *#110 48HHH *0],<4M% "8SV
MHQ2T4 '6BBB@!.]+110 4444 <?XJ_Y&_P &\_\ +Y-_Z):NN'X5R/BL_P#%
M7^#?^OR;G_MBU=>.@JY;(E;L6BBBH*"B@<BB@ HHHH **** "BBB@ HHHH *
M*** &]_TKD/!O_(?\7_]A7_VDE=?W_&N/\&_\A_Q<#VU4?\ HI*J.S$]T=E1
M114C"BBB@ HHHH *2EHH J7]A;ZE:26EW$)(9!A@1^H]#6!:W]UX<GCT[5Y3
M+92-LM;[^[Z))[^A[UU./057N[."^M)+6YC$D,@VLI[U2ET>Q,H]5N3@]*YK
MQ7XUL?"PACFBDN;F8%E@B(&%]6)Z"HK6[N/"\T=AJ4IETR1MEI>'K'Z))_0U
MP?Q7.?%=L>O^AJ1_WTU)JP1E<U_^%Q #)T-O?_21_A2#XQ*?NZ&W'I<C_"N%
M\-K"VNQ+*(]YCD\CS0"AEV'R\@\?>Q^.*UTL=1OI(!K\*3W:6TTEM;%Q%/.P
M*C:Y7!V]2HZG! I%'2#XPCMH;^W^DC_"D_X7&IR/[$;/7BX'^%<_)I&D6L$U
MQ<:>7E'V0/9FY.+9Y68,I8')X ..HR :N1Z3IA6+3VL1+:V^K744LXE*R;53
M* D>N,?A0!JGXPCD'0V_\"!_A2#XQ _\P1S]+@?X5R]GI&FWFF6]P;(K;7$$
M\MQ>_:2!8L"VV/'?@#KDMNXIE]8QZGXPL+-RJ026MHTS9VA8Q"K2,3] ?QH
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MHI9F/10.237 3?%W2$F<0Z??2Q!L+( JA_?!.?SKI?&A(\&:N1D?Z,W.:^?
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M(7"C+.QZ #N:Y'_A;NAX_P"/+4?^_:__ !51?%__ ) NF]?^/H]/]PUY'TH
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MTAF))-G%R?\ =%;% #3Q7'^#>/$'B_VU7T_Z9)78=_QKD/!F?[?\7].=5_\
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M>, YZ!:Y7'7BEQ0 4?UH_"CO0 =J](^'VCZMJ'AZ66P\0SZ=&+EU,4=NC@G
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M5>O\.,TS5-.OM+O%BU)"MS+&L[!FW-ALGYO?_&G#5(_[!N;(L_VB2]2X5PW
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M?\PNR_[\+_A1_8.C?] JQ_[\)_A7/?\ "RM$Z_9=;/\ W"Y__B:3_A9.B?\
M/KK?_@KG_P#B:.678+HZ'^P-&QC^RK''_7!?\*7^P=&Z_P!E6.?7R%_PKGO^
M%DZ)_P ^NM_^"N?_ .)I/^%DZ)_SZZW_ ."N?_XFCDEV"Z.B_L#1O^@58_\
M@.G^%/AT?2[>998-.M(I <AT@4,/H<5S7_"R=$_Y]=:_'2YS_P"RT?\ "R=$
M_P"?76O7_D%3_P#Q-')+L%T=D,>HS3"Q&,#J>17('XD:*>!::U_X*I^?_':#
M\2-&(&+76NG/_$JG_P#B:.6787,CK\G.,9![]JY#P4XEUWQ>ZG<O]K%<]LB-
M,U7N?&^H:ONLO"VA:A-=OP+J^MFMX(,_Q,7&3CG@"MSPGX?7PSHL=@)3/,S-
M-<W#=9IF.6;Z=A[ 4[6CJ*]V;]%%%06%%%% !1110 4444 %%%% !12>QYS5
M0ZA#]H>#Y@RLL9)&%#,,CGOZ?6@"Y14-Q<);6\D\A.R-2Y '.!UJHFL6;1%G
M<1MD@J^,Y SVSGMWH T:*I0:I9W,4KQS+M1=SEOEP.Q/MCO0=5L1C-W$,J7'
M/44 7:*J2:C:0R&.2X1750Q4]0*C.L6"OL-R@SNY'08Z\T 7Z*I'5+$#+74>
M H8_0D8_'GI2KJ5JT32&51%YGE[FZ$^WM[T 7**H2:M9QQ,YN$.UMI"G)SZ8
MITVIVELTBS3*C)DE>IP!G@"@"[15$:M8$#-W'G(R#[C(I!J]D8X)#, LV[82
M" =OWJ +]%4GU.S3R=TZ;9E+(>2&&0.OXCBE.J66TL+J,@,5XYY':@"Y15,:
ME9F.)_/11,GF1ECC*]>_2D;5;-45Q<*P8%E"\E@#@T 7:*IMJ-HI"&X4N5W;
M0>2!U-/CO;:6,R+-&4#!<[N,^E %FBJ+:M9H"3.I(&=J\DC.,BA-6LGD*?:%
MSOV#GAC[4 7J*SSK%DL/F^;F/?Y8*@D%MI;C\*EBU&TF:)8[B,O*,HN>3_\
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M^:TZ* ,Y](AGOI;J5V;?L(0' 4KT/N>333H5F>0TP(/RD2'Y!G( ]@>:TZ*
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G](Z+$MCF*><,YWT+Y?GD@#=W-(?]<O\ GO2+_P ?K_0?UH'?4__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $6 G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I#U_QI:0]10 M%%% !1110 AQ[9[5QGC'
MQ'J6B7\'V-HC'Y7F" *K/</O"[.6!48Z$ \_3GM*ADM;>::*66".22$DQ.Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTE+2&@"ID#5'R0/W Z_4U9WIS\R_G51H4DU(^9&''D+U&1]XU-]DMNGV>/\
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M-Y#\(6T[2+'4H+W"A8Y"L=PS><"[?*< GEL ]*[?_B8 _>M<?\"HQJ![VO\
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MLTG1-;TO0]2O9-$N;Z58K2&PL[N./>DD6<.RH<$)D?-G)QGBN@T6.YL/!_\
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MVQJS@%SZ#U-3]^E<IXJT>[U>ZM88=.BEMV4K<70=5F0 @JJYZ#/S$CGC ]:
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MQ)X#N97EE93(TD,F\-(&#1#;&01TP../6G+<>!4$)#(?)DGE3/F'#3 ^8?\
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MG )]* .9_P"$FU,:B+ ^&;L7+0F<+]J@QL! )SN]35@:SKG_ $*MU_X%P?\
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M_P "X/\ XJM^B@#F[;Q#J]U;1W$/A6^\N10RB2YA5A]06R*E_MK7/^A5NO\
MP,@_^+K?HH P/[:US_H5;K_P,@_^+JO>^)=3T^V>YN?#%VL*$ L+J GE@!_'
MZD5T]<_>^(-/EU\^'I[8RMM5Y&D>,1J,%APS9.-N> <4 +_;.M_]"K=_^!<'
M_P 74EOJNKRW,<<OANY@C9@&D:ZA(09ZD!LG\*MZ/K%MKEDUW:"3R1*\0,B;
M2Q5BI('H2./:M"@ HHHH **** "BBB@ K)UK08-:\HR7-S;21J\8DMW 8HX
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D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) G # 2(  A$! Q$!_\0
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M_+1_PEGA[_H-6/\ W^6M3R(?^>2?]\BCR(?^>2?]\B@#+_X2SP]_T&K'_O\
M+1_PEGA[_H-6/_?Y:U/)@'_+./\ [Y%(88@/]7']2HH S/\ A+/#W_0:L?\
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MP]_T&K'_ +_+1_PEGA[_ *#5C_W^6M3R(?\ GDG_ 'R*/(A_YY)_WR* ,O\
MX2SP]_T&K'_O\M'_  EGA[_H-6/_ '^6M3R(?^>2?]\BCR(?^>2?]\B@#+_X
M2SP]_P!!JQ_[_+1_PEGA[_H-6/\ W^6M3R(?^>2?]\BCR(?^>2?]\B@#+_X2
MSP]_T&K'_O\ +1_PEGA[_H-6/_?Y:U/(A_YY)_WR*/(A_P">2?\ ?(H R_\
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MT->A 8)P.IYHX^8E?KQUI <%JOBVXMK[3%M[1H8;B+>\=RI#N2Z+A.<GAR>
M3QTQ5NZ\3SP^(+BSBTYYK4.EM;N2RB2XW*'!;D8 ?T_A:NRP"0<<BCMC.,T
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M&:+4M/2%[&X$#-:,0(A+&3&?GY?!'/3CI7IF#CK2 Y[41'IZWT5W]FM-+O
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L:=XU\5VBX=I6MW)/\
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M%&><@$'I[UP^@^,[_4-?M+*748IXIG*XCT>>(/\ *6&)&; X&>G(KT)P"I!
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MW<"E@(Y=Y1X6ZJX/(^O&?I5WN 3S2V =12;LXQSGFEI@%%%% !1110 4444
M%%%% !1110 4444 %!HH- ',>)/^1'U?_=?_ -"KI8_]6OT'2N:\2?\ (D:O
MU'RR?^A5TL?^K7Z#I0!%=P23PA(KAX'W [T )P""1R#P<8K@-"O'TOQ+:Z+?
MZCJ%C<2,YAT\PVQAF !Z-"N5'?YL'ZUZ'(-R,NXJ2#\P[5YEX'UBWL-2MM'A
M_P"$>\V9F6::VEE^T7# $ECNC&3W.6X[4 >GCCC/X48X/;/<4#H.OXTM &9=
M>'M)O=1%_=6,4UP%VY?)!'(&5Z$@$X)&1DU)I6CV&B6YM].ME@B9MS88L2<
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MRI:09]<TM9G2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR;F9=4;?*4"%OW478<#BNEKF_",LTTFOO/;_ &>4ZHVZ(N'*_NHNXX]ZZ2@
MHHHH **** "N?U;3]7;6[34](^P.8K:2!TNW<<,RD$%0?[M=!10!D^'M1N-5
MTA+F[BBCN%EEB=8F++E'9,J3@X.,_C3]1MYS+;7-E!#)<)*$>1Q\RPDCS #Z
MG:/R'I6&UKJ7AN^TZ.#4UFL;W4F1K=[8!@)!)(?G!SP1Z5UOXGKU%&S SA-#
MK6E)>6=S.L3!FC>-BA.,CD?45:L&F?3K9ILB4PH7W#!W8YR/K5".XDT[5&M;
MERT5U*#9I#;MMB4* 58@8'S9.3ZU#;W,Z7-Y;Q7C$6[M))YED_0DG"MG#8Z<
M4V@-TG'//X4AP,#H*Y75WU+5[6TN=*?_ $4W,1\M[=UD4AN6;)'R]R,=.];7
ME:G_ &;+')<P&\*_(Z1E5!^A)I):V)D[*Y1U^8@PJIR=COCWP$'_ *%6S;1>
M1;11 8$:!1GO@5P.AZ5KD&MQ)J#E$9\GS&W,^SG(YX!/\Z[6ZBU1]_V.[MH@
M<;!) 6QZY^89KHKP5.T4[G%@ZDJO-4E%Q\F7^AX!I:YKPY::S#IC)<7$*'>Y
MC1XB6'SG).6Y![>E:%GJT9T>XO+MU46KRI,Z(0%V,0<#Z#WKG.\U:*8CAXU=
M<[6&X'VZT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&<8]JG-_"L<+L)$6=_+3=&0=Q]?2@"W11S10 4444 %%%% !12>QQS2@Y^E
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 87C/_ )$[5/\
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MGMYDFB?5&*R(P96_<Q="*Q?$V/\ A;?@OGK'>?\ H X_G5T_B$Q?^$"\0?\
M10]<_P"_<?7\J#X"\0?]%$US\8X_\*[ON<<G/K6;KUC?ZAI<EMI^IMILKD;[
MA(@[JG\07/ 8C@'G'I1SR"QRO_"!Z^>?^%B:WM_ZYQ?SQ2CP%X@[_$37/?\
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MF9FD8.K8Z* ,$=.I%54IN$G&Z=@N7<]L&EJCIMW/=V0FN+9K=S(Z^66R<!B
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MMI)=;752B$#:"0-Q)[#\36;8^*A=>*[C1!:!%B9U60/R2H4DD8Q@[N,$G@Y
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M ,=_6KNWQ;G[^A_]\2_XU3U+Q7=:?K1TR32D:6;'V/\ ?\.=X4;N,#.<\$D
M<@5M:-J1U33EN)(3#*))(I(]V[:Z.58 CJ,CK0!0V>+?[VA_]\2_XT;?%W][
M1,_2;_&N@HH YJU?QE/;1RS1:)!(X!:)A*Q3VR#S4NSQ;_>T/_OB7_&N@HH
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2M(V['! [4^HXNW^XO]:86/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ G # 2(  A$! Q$!_\0
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M'4(8H=XB\L.J) 9&N'W8,8.?EX[^^>U %O\ M'5O^@&W_@4E']HZM_T V_\
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M[$941GW%C@?PGY1GZT<D@YD=]GGI29KE-0\90Z4=)BN+;SI;Z*-W6*0 IN(
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M0A)Z *<DXJ[HNO7&K7#1RZ9-:+Y?F*[L&STXZ<'YA^M;=% !1110 5SVD_\
M(Z>(_P#<M?\ T!JZ&N>TG_D=/$?^Y:_^@-0!T-%%% #)98X(FEE=8XT&6=C@
M >I-8UOXNT.YNEMX[]0[':C.C*CG_98@!OP-7-<N8[/0[RYE>)$BB+%IHC(@
MQZJ",_3(KC_#5[J.M^(9+B]E9K"0.@A5&>$LFT%>?E7!&1D!CD]A0!W^<]12
MT@I: ,[5]8@T:"*2:.65II1#%%" 7=R"V!D@=%)Y/:J6G>+=/U*\AMX8[E%G
M#&&>2+$<C* 74-G[P!.>W!P3BK.OZ'#XATMK">>2%"ZONC5200?1@0?R]ZIZ
M?X0L=.OXIXY[A[>!"+>TD93%"S##L.,DL.N21R<#F@ @FBG\>S-%*DBC3$!*
M,#@^:WI70US%AI]GIWCJXCLK6&VC;3(V988P@)\U^3BNG- &/JG_ "%]"S_S
M]2?^B)*TIH(;B%X)XDEB==KHZAE8>A!ZUFZISK&@]1_I<G'_ &PEJ]??;/[/
MN/[/\C[9Y9\GS\^7OQQNQSC/I20$-MHVE6:HMMIME JR>8HB@50'QC<,#KCC
M/I3ETC35#[=.M1YA8OB%>2PPV>.XX/KBK$'F^1%]H*&?:/,,>=N[OC/.,YKD
M95\06OEF%;F0-//)DC>8E)(P5S\PQ\RCVQZ52NQ'4MI]BT4\;6=N8YVW3*8Q
MMD/'+#')X')]*C.C:7\G_$ML_DC:)?W"_*AZJ.. ?2L.QFUOS=1GN!=/_H2F
MW4PJH9@\O..SD;"5^E4X[KQ-/8.EPMPLK1R+&8[7!D/.-QX*8^7!XSD\4:@=
M6VF6+;RUE;,7^\6A4[NG7U^ZOY#TICZ+I3I)&^F6;)))YKJ8%(9_[QXZ^]<W
M>3>);6,1VZR3%"JM<F#DJ0"3M /?(Z=*FEG\2^408%9HF7#)%Q*64G.,C 7@
M8/4GVHLP.BETZRG>)I;.VD:$;8R\0)0<<#TZ#\J;!I>GVHC^SV-M#Y;%T\N%
M5VDC!(P."1Q7+7>JZS8ZA%:371SO3RS]F4M-N90=P!^4 $@$=3GTYGU**^\W
M40(=4DOF+_99+=R(EC\L[1UQUZ@\[N1VHL&AUW04=ZXO^S]?A\^UA>178K(C
MPLWEX5&/#.Q(9G(!!XPM+-9WEV8X],MK^.,$EUU"20([;#Z,&'.,GIGL:+!<
M[/-+7(Z/=ZL=2BLWDN)(X1&LHFM\84Q!B6?KOW$ #T]>M=8!Q2>@QU%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5SVD_P#(Z>(^GW;7_P! :NAKGM)_Y'/Q&?\ 8M?_ $!J .AH
MHHH @O+5+VSFMI&=4E0H6C;# 'T-<YI>ESW0'D^*OM.FQ/\ +#8Q11'(/W6=
M/?J %_I71WMR+.SFN" WEJ3M+A,GL,D@#\:\Q\.VFGZUXB\]UFMM88L[2QZC
M;J\.UON"*$X;T.\'@GGF@#U3'IBEI !VI: *]W?6UA T]W<100KUDE<*!GIR
M:9%J5C<W36L-Y;R7"H)#$D@+!3R#CKCD?F*SO$^D3ZS86\5NZAX;A9MK.8]X
M"L,!P"5/.<X/3'>LG1O"5[87=@)IK406(D=)H 1+*TB!-K9&,+CKSG"\#% %
M^WMTA^(5VZ;\RZ;&S;G9@#YC#@$X ]ABNBKEM,L&T_QQ<1M>W=WNTU#ON7#,
M/WK<# %=41D4 8VJ\:QH('0W<F?^_$E7K^>6UL+BX@MI+J:*-G2",@-(0.%!
M/&35+5#_ ,3C0@3UNY,?]^):NW][%IVGW%[/O\J",R/Y:%FP/11R3[4D!+ [
M2V\4DD31,Z!FC;&4)'0X].E<HWB&[@6:Y>]@DGWR(-+,>&CVM@$L.1_"23P<
M\=JZN"9;B".=-VR1 Z[E*G!YY!Y'T-<Y_P )0D<H$]DHD>>2+:ARTB*2$(SC
M.2,$'H>]4D(AN?%]Q DS?98':,D$"4YCP^TAP1PQP2!W%'_"92---&(((\/A
M))92(U7!.7;'RYQ@#KDU=B\00S/J9DL66&TMUEER%+,^Z163'<CR^#WI@\46
M4MU+;+82M=$A#%A"S2 #Y"<X&,CD\<'%/Y"*LOC*98 1IS))N53YK$*A8%DR
M<=U'YG%;6BZE/J<,\\L*0QB39&H?<W !.3T[]JH-XKLKAIX%MI7:,@,C*IRV
M4!4@'@C>N,\'MG%./BJV>6%;6WFN!-\J",*"S?+W) P,X/TI-#-UHT=E9D0N
MOW2P!*_2I/:L2T\1P7MS''#;7 CDW*)6"A=ZJ&*D9ST/7&.M8Z^,YT@CEGM8
MMLGDN?EDC"HSA7^^!NVCG(X_.BS"YV9QSZT=ZYB'7K^\G@%M#:I'->RVJ&3<
M20J,X?CU"]/>NF'3-*PP"@$D  GKQUIU%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]I/_
M ".GB/\ W+7_ - :NAKGM)_Y'3Q'_NVO_H#4 =#1110!5U*"6YTZ>" J)9$*
MJ2[+C\5Y'X5P?A.XU$^*%6Y5A92+,+>5Y+EO.VG'&_Y2< GM[9%>@75K#>VL
MMM.I:*52KA6*DCZ@@C\*\S\'V$MEXUBC^PQ0".*4^6D4I,"DC@NTC*#D8(P"
M>".,T >I4444 )WHZBLGQ)',^B3"U2X>X+(L0@E9#N9@H)((^49R1Z U@Z;!
MJ]KXEBMTEU.81>:MQ)=NS0/$$'E%2>-Q8#..?OY[4 :-M'.GQ"O#-.LJMIR&
M-1'M\M?,;@G/S<\YXKHSTKE=);5&\;W)U6*SCE_LY-@M9&==OF-U+*.<UU?:
M@#'U3!UC0N^+N3_T1+6A=W<&GV<UW=S+#;PH7ED<X"*.236?JG.L:%@X'VN3
MC_MA)6JR+(C(ZJRL,,I&01W%(!L4L=Q#'-$ZO'(H9&4Y#*>0:Y)M;T6>Z>&\
MTZ)88?/'F;UD*?-AMRCE=QZ>IQWKKU 4*J@*!@  =*S9] TVXB,<D!*D."0Q
M!(9MQR?][D>A%4K"9D+K'ARW$@$&VW:"-&D$9(*L\@*L.V"K9)_O=Z?<ZAX8
MW7#SQ?-.VQB(G'FE3@E?7!7&1Z#VJ]+X8TR?894F8JH3=YS L!NX)SS]YJC7
MPK8&U:&X::4LSL&\PKL#,20O/ .<'UHN@U&VMQX<-S=>0L2M;1AI2%(7:A'(
M'3@J >^0!3[2ZT6YN;6*"WQ.-\D:F!E,>""Q/]W)8'WS5F#0--MA<I% 1%<*
M4>(N2F#UP.V3S4MGI-I8S":+S6F"E#)+*SLP.W.23S]U?P%%T!S"7WARR\0-
M>%KA0D(>+*?N@IRA*C&2,)DGIBK:7GARWF-M;V+2N)1&5V$[0 Q!&[HORGIQ
M5_\ X172O.64)/O7A#YS?(N2=J\\+R1CWJ2/PUIL4ID19@Y;</WS<=>!ST^9
MN/0T[H5A-#ETO4;"WGL[7R?+"RK&\94Q,T8 //\ L'&1VK9_.JMI86]@I2W0
MJ"JKRQ/"J%'7V JU4%"T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[2?^1T\1_[EK_Z
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M5S8HQ2#@#I^%+4##%%%% !28I:* "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH *Y[2?^1S\1]?NVO_H#5T-<]I/_ ".GB/\
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MBG3D,86/;L7S&X)R<G/?BNCH QM7_P"0WX?_ .OR3_TGEK9K&U?_ )#?A_\
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MC\<5T= &-J__ "&_#_\ U^2?^D\M;-8VK_\ (;\/_P#7Y)_Z3RULT %%%%
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MM.LM8O-6MK<Q7EZJK<.K-B3;T)7.,CGGKS6B":,B@D5-[C*VH:?::M83V%_
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M4F60* VY""O/7J* +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 =Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y[2?\
MD<_$?7[MK_Z U=#7/:3_ ,CIXC_W+7_T!J .AHHHH **** "BBB@ HHHH P4
M_P"1_F_[!:?^C7K>K&O-)O7UO^U+&]AA<VPMV26 N" Q8$$,,=<4OV;Q!G_D
M)V./^O1O_BZ -BBN9NI/$UOJ6GVJ7-I)%<LXDE%FV(=J;@3\_<C%7OLWB'_H
M)6'_ ("-_P#%T ;%%8_V;Q!_T$K'_P !&_\ BZ/LWB#G.IV./^O-O_BZ -BB
ML&W@\4.DAN+W38V$C! ELQW(#\I/S\$CM4WV;Q!G_D)V/_@&W_Q= &Q16/\
M9O$/_02L?_ 1O_BZI:F_B:PLQ-!<V=P_FQ(8UM')PSJI;A^P)/X4 =+16/\
M9?$'_02L?K]D;I_WW1]F\0_]!*Q_\!&_^+H V**Q_LWB'_H)6/\ X"-_\74*
M0>)S<S(][IRPJ%,<@MFRY.=V1OXQQB@#>HK'^S>(?^@E8_\ @(W_ ,71]F\0
M_P#02L?_  $;_P"+H V**Y^_'B2TT^YN8KRRFDBB9UC%HV7(&0/O]ZD@B\12
MV\4C7]BC.@8JUHWRDCI]^@#<HK'^S>(?^@E8_P#@(W_Q='V;Q#S_ ,3*Q_\
M 1O_ (N@#8HK":#Q.+I$6^TXP%&+2&V;*L"NT8W\@@M^0]:E^R^(/^@G8_\
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M+H^S>(?^@E8_^ C?_%T ;%%8-S!XG2UD>VO=.DN I,:O;, Q]"=_ J46WB#
M_P")C8#V%HW'_C] &S16/]F\0_\ 02L?_ 1O_BZ/LWB'_H)6/_@(W_Q= &Q1
M7,&7Q.-?33_/M# UJTYN?LC;5<.JA/O^A)_"K_V;Q#_T$K'_ ,!&_P#BZ -B
MBL?[-XA_Z"5C_P" C?\ Q= MO$'?4['_ ,!&_P#BZ -BBL"RA\4R6<3WE[IL
M-R1^\CCMV=5/L2_/:I_LWB#_ *"=C_X"-_\ %T ;%%8_V;Q#_P!!*Q_\!&_^
M+JEJ$GB6SFL5BN+.<7%R(9"+-_W:;6;></ZJ!Z?-0!TM%8_V;Q#_ -!*Q_\
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MDEC5VB-FV4) )'+]N:G^S>(?^@E8_P#@(W_Q= &Q16/]F\0_]!*Q_P# 1O\
MXNHI(/$PDB$=]IS(S$2DVS H,'!'S\\X]* -VBL?[-X@_P"@E8_^ C?_ !='
MV;Q#_P!!*Q_\!&_^+H V**QS:^(.G]I6)'O:-_\ %U4L3XEN_M7FW-E#Y5P\
M2[K-OWBC&'^_W_I0!T=<]I/_ ".GB/\ W+7_ - :K/V;Q!_T$K'_ ,!&_P#B
MZ72=)N;+4=0O[NZCGGO?+!$46Q4" @=22<Y- &O1110 4444 %%%% !1110
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M!PRKALOR<-DYVCIR<XKML54?3-/DDFDDL;9Y)UVRLT*DR#T8XY''>@"OX?U
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D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #A G # 2(  A$! Q$!_\0
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MV_JG_/\ W'_?9ZT?V15[H/\ 6*C_ "/\#V?</44;AZBO&/[?U4#'VZ?\7/\
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MSF<;?QX].:DFUV]G-UO$1^TPK#)\O\*],>_-')6ON'-2ML9U%%%=1SA1110
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M%&'_ ,(3H/7[&W_?YO\ &C_A"=!!_P"/-_\ O\W^-;?V:/IYLW_?9I?LJ?\
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M\:!X)T'_ )\W_P"_K?XUN?9D_P">LW_?9H^RQ_\ /6?_ +[-'MJG\S#V-/\
ME1A_\(3H/'^AM_W^;_&C_A"-!_Y\W_[_ #?XUM_9H_\ GK-_WV:#;1\_O9O^
M^S1[:I_,P]C3_E1B_P#"$:#G_CT;K_SV;_&E7P1H2MN^R'CL9&/]:VOLJ?\
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M=_W8?^^F_P *,W?I#^9_PHL%RQQZ4<>GZ57S=_W8O^^F_P *,W7]V+_OIO\
M"BP7+%''3%5\W6/NP_\ ?1_PI0;K/"P_]]'_  H"Y8I.#5<&ZX^6'\S_ (4
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M-U_=B_[Z/^%&;O\ NQ?]]'_"@+ECCTHX]/TJOF[[+%_WTW^%&;K^[%_WT?\
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MGOBE[.0U5BSL>_&*,^]<1!XWN@8KF\TZ*/3YKF:V62.?>P:/?R1C&#L(Z_\
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M/Q[4<>U0?:5Q]V;_ +]-_A1]I7^[-_WZ;_"@+HG_ "HX]J@^TKG[LW_?IO\
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MQ[@>N/TJ#^VEA$CW2;%!RBKDLW./H?J#BBX6-#R9_P#GX/\ WP*/)G_Y[_\
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M*<\#I^OZU8CTNUC2!/+WBW0K'YGS=<<_7BHYM(M)IXII%8O$Q8<CG)S_ #H
MKVL^CO K((D!1WPPYVG@D_45)&VC,BV\?DE)/E"#//>E.B61N//V'?M"]?U]
M<XJ2;1K.>>*6169XSD9.<Y.>?QH K)-IB)/=V=J)3 H1S$H'RX[9('2I$;3+
M?]TT45O)'^^,1QN0XQNXR.AJ>+3H8K:>#?(Z3KM8L^2!C  _"F3:1:SWSW;(
MQE; /3Z9]>@H A@ET6,M%"8%)/*CCW_I^E/1M'B5+M?)57!1''?/4"K#:?;D
ML"&^8Y//OG^9J!=&MTM$MT>955F8,I&3GJ.F,&@")+ZRCB\R& E%D:WXP <<
MGDD#'7KUI-VBR>7 RQY238JL""&P./Y>U7)=/B> QJ\T8#%LHW//4<\8J,Z/
M;<8,R+T*A^"..#[<"@"%IM%F8 F!C'EA[;:KQR:%%!Y:^5(GRY."<DXP?Y=.
ME:$FDVLD/E$R*!CH_/ P*C31+2-%5'F 0<8;H<YSTZT .MTTR<&W@2(^6 3&
MO\.<?X"JL9TJ;3+FY6S!MXW9F4)R2.N,?RJ[#I-M;SO,H<ET\L@M_#3(-(M8
M(YT!E(F 5][9Z<"@!CRZ==2202JI"JI)88XP2,'V'\Z<UQI*QL2T(17\L\<9
M/;_QW]*#HMKM*J94+$L2KX/.<CZ<TITJ$Q^6)IE /RX?[@/! XZ&@"#_ (D<
M2.Y$"K X#$=%;_(_2I96L)'CNI8QDN4#L.!MW')[8X-1S:!92^;N,H\S&0I&
M. 1Z>YZU;_L^W^SI ,[$8L/FYR00?YF@#,\S1GN#'M68W!,ID(X'S'OVYS4K
M2:"T/S&W*,,_E_\ JJ[)I=M)OW>9\PYPU,MM'M;50B&3KG);OS_B: &-/I!D
M6 O;EMPPON>G]*;;7FE0.(;5HE+$\+P-V0#D^O(J==*M!%Y:[MF"/O>N/\!4
M$6A6D2;%:4C.<,W7IUX]J 'I>Z:TL#I<1Y9V" 'JQZG_ #ZT7C6GVBU>XM_,
M,K!4D*\ GH#ZTZ/2K=,DM*[$#YW?)(!!'Y8%2RV0F,3/)*3'@D!L!\<C(^M
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M$?\ 8UO;<-"563!8CG?_ )S[5,='MP-B @/()'W'/ ).!^>/I3FTJ(ICSIT
M8D8?[H/51QT- %>6YT6**2%O(\OS?G7'W6]?T[5(\VD1Q21L;<(@&\8XYX'U
MZT^'2((7W%Y&PQ* MP@.>!^=-AT2RM[DRQHP8X.>.,8_'M0 TOI*NJJL+.H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
F**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# G # 2(  A$! Q$!_\0
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MUT=% &!H.CW&F7^M7%PR%;V\,T>#T7WJ+7/#W]LZ]I5U+'!-9VPE$T<HSNW
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MB@ HHH/2@!O3)KR7QE?&\\03*.8X,(OX=?US7K#L!&QZ#;FO#;J?[1=33_\
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M5M>B58_W8BV("2WL5((J?PGIU]IWB1U33G6%TD\^>Y@V2QMNR%,@.V?/9L9
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MD-W%):06^IBTCE*AEE7RA)DDGY>I.?3%*?B#I26D]S-;WB1);FZCW1 F>,$
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M&]:]-A:FY9Q(9?*&[<.C9]?>N?\ !%DEK=Z[);Z9<V%G/=J]O'/&4++Y:@D
M\@9S7+:=:S3W4L^EZ7>MJ4.JWKS73;A'+"'D'EA\XY.T #H1F@#O[R'1-&LK
MB]FM+:.+E)2L0.1(P!! '=L9J/28]#DQ#IMA"L4$\A!2#:J2HVQN<?>SG\*\
MXCT757^V?9],NT2?3HUDC^QM"C3"XC)&&8EF"[OF/45I7.F:Q"U\Z:7<S(PU
M >7A@"'NT8'"D%OER0 >0* .]O(]%LC:R7,5LA>ZVV[%!_KI"<X]SSFI=+M-
M.M()&L+&.S620EU6(1DD'&2*\RM]!N7,OFZ1=RV46LV5S&ILC$-FW#LD>20
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M,KNXPO08ZU=\/>&;_1M7>Y:>"*TV.K6]J[[)V)!#^6?EC(&>%SG- '94444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JI96%KIZ2QVD"1++*TTFT?>=CEF/N35NB@ JG:Z?:64UU);0+')=2^
M=,RY^=\ 9/X 5<HH **** "BBB@ K/M](L+6>\N(K55ENWW7#DDF3C')/;';
MI6A10!#%%'!"D42K'&@"JJC  '8"IJ** "BBB@ HHHH **** "BBB@ HHHH
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M5]/7F@#;HK&%_>+;7<@C@E,6,,C$+[C/?'M6LOS(,J,E>G:@!]%%% !1110
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M:5);R1M'')':#)5?F"^P_P *FELM+5V22* /.W1C@L?;_P"M4$6C-':W-O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $I G # 2(  A$! Q$!_\0
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M^-;?J>P]J/;'Y]Z/:/R^X/J\>[^]F)_9VN?]!P?^ B_XT?V?KG_0<'_@*O\
MC6UUQGD?YYHQP>.3[FG[1^7W!]7CW?WLQ?[.US_H.#_P%7_&C^SM<_Z#B_\
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MO*^H/O\ L@.](Y0L0Y''#=>^*@&N:UJ=K:3W496.+4[*Q>-X.LP8^?(.^,D
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M4S_R +O'_7:/_&MO XQQ]/\ /M2 #CIUXYHYU_*'LY_SO\#%_MG5/^@!=?\
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MP:/#;2,Y SSCO]#4*_$7PQ);B9;X$LVQH]A#+P3E@>@P,_B/6M-=.ND<R!+
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MD\=L]\51U30)KN[)A^S^1);BW/FJ2T0!.2OU!_0'G%/L=%N+;6I[R0P")@V
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MK96\#:)?%HT"$J8R"0,?WO:K']MW>?\ D!W^3QR8^?\ QZDZ4KZ%1Q$6E?\
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MB#&_X22+I_96L$8QS82?X4?\)+$?^85K'XV#_P"%;7F)_?4?C1YB_P!]?SI
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M[_YS1M;(&TY/0>O^-!4X. <4Q!G/L#UYHSSUZ>II2KCJI'U'O1M88RK#ZBD
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M].Q(/8D5+0C;T_\ UC?[OY5H5GV'^M;D?=%:%8RW.F&P4445)84444 %%%%
M%.__ -4G;GO5#@_2MDHK@!U! /'>F^1'SE%_ 8JU*R,I0N[F2#^M)VQQ_G K
M7\F/J$7/N*/(B_N+^5/G)]DS(/(X[UC>(M*N=7&FK;3>5]GOEGDDPI9%".,@
M,""<L."/6NP,,0ZHOXBL34/$-AIWB"QTB6VD>2Y W2HJ[(2Q(3?SD;F4@?2F
MI]@=,Y"Z\*ZA!=Z9:Z4ZKI=FBJ6>X99&+,YDW#H00P/ ]1V%4K?PGKMOI$-G
M%(D445O:Q/;QW1Q+Y9D\S![9W(?0XQVKM]$\2V.N:C+9PV<L3QQ-(6?;@@2M
M%V/JA/T(IMIXOT"[6'?.EN]PV(4D'++O9$?@$ ,5."3Z57.]K!R>9R4GA36I
M ?,O'F=F2-GDNV(>'[,R.&' .7*D\<XSQ5C2- U>PU?2YBJI:06L<$T373.(
M]J%2(U&.K<\@@]>"*Z*Y\8:0MC+<V%O/J+1, \<$)0H,$EF9]H"@*><^@[U"
MWC*R69%_LF]\J2S:\BE\M0)%5 Y4#.> 0,XQGCK1SOL+V?F:F<_C[TN>,DUH
MVS6]W;0W,2JT4J"1&QU4C(_0U+Y,8_Y9KZ#"U'./V;[F1T^M''J.G7%:_D1?
M\\U_*CR(NGEK^5'./V;,N,_O!Z\_R/\ A3!VY''^?ZUL"&,'(0#\*3R8A_ O
MY4<P>S9R/B?2!KGAV\L1#'+.R$P"1L*).Q/Z]:SH-'U(>*;J^6SLK6(0LEK<
MHRL?,8+ODD0<NS%0!R, >]=_Y$?:-<?2CR8NR+^5/VF@O9/N>77'A/6IY[N5
M[LR22_:R&2\>-265?((4'"@,&..V1UITGASQ(\=W_IA^TRP3*\XNV_?E@OEJ
M%_Y9^7SR/PSDUZ7-Y$$,DTB*$C4LQ(Z #)-<?!X_LKC1+?5TT2]:SFF\O<AB
M?8ORX9L-U)8 +]X\\4U-O9 X>9SNH^#=4GFNS&L4L1CNX;7S;HDQ+)&FWKDX
MWJ_'O6NOAR];0?$&DFY$<5VX^QDRLXC7RT# YY +A\C/1CZUO6/B:PO]6ETR
M*S=9X[AX"6"XPJY+]>!G P<')%=#Y,9X\M<?2AS[@J;[GFUYX=U#49+B[?3;
M&U9H[>-+."XVY\IR^\.%P&&<*"",=:WO#MI>:?HL5O?M#]H#.Q\D*!AF)&=H
M"ENY( &:ZOR8A_ OY4>3%T\L<>U+VF@_9,R1]X=#SG]:63[[@_WC_G_/I6KY
M,8Z(N?<4IAC.<HO/?%+F#V9SNJ123Z5=Q16L%W*\;!+><XCD;L&]LBN,B\(Z
MTQT2Y=[6*2RO/M$MNS;E+LY:28%<#D<!<<#O7JGD1Y^XN/I1Y,7/R+^5-5+"
M]DSSG5_#VN7]]/,=0$AV0"!HY6MPF)MS@JK<GRR1N[YZ5#%X;UZ*Z^6[(C2Y
M)M'^UM_H<0N"WW?X]T1"8.<=*]+,,0',:D#VKFY_%4$&I:A8?V'J#SVB"2-4
MC4F<%P@*\\#<>K8& 3T%-3OL'L[=3D9/"&KR(HE(E!9)I8I+MB'D2ZWKC/3$
M7R\?2M/PUH%_HNII/*0L+1W!G19RX9VG+QG:>!A">F,9Q6C#XZTR;R NGSAI
MH/,52$'S;MFSKSR.&^[[UURQ1$9V)^ XH=1K1H%3OU/-K;POJ$:V-G);Z>(K
M&XN)S>ER7N?,#@*R@ C._P";)_AXJ_X2T;4-'%RMW'#% 8X8XHUD65UV @YD
M"@LN,!=V6X.37=^1'C_5)G'3'%'D1<?NUI>T'[-]S([=>?K6E9_\>ZGW/\ZE
M\F/^XOY4Y4"@  #'3 J).Z*C#E=RIJ'W4^M4B<?G6A>1O*JA%)P>:J_99\_<
M/MR*J+T(FFY%&^N18Z==7>PR+;PO*4!P6VC./QQ7.:9XYM;R">>Z@2WABCB<
M207 N%+R'"Q$@#$G3Y?2NKN],:[L[BTFC8PSQ-$X5@#M88./SK*G\%V$X.8)
MX\QPH?+EQEHB#')_OC&,]QP0:M.-B.5D4'BO1KJ>.&WNFE9X//!1"0J<\L>W
MW3^(ID?B[2)(M\<LQ<["D(MW\QU92RLJXR5VJQS_ +)J:?P5;3-!+_I336T9
M2 R3Y4,0PW$=3]XY&0#W%06/@.VM;*W61[QKZ&*-!>QW3"1=B,@5#V7#-Q_M
M'VIWB'*Q\?BW1)+@1)=EE./WHC;R^8_, W8QDISCVJ-O&>AQZ?!?273I!.28
MF:(C<% 8O_N@$'-6H?!6GVQ4V]O/$%E29%2<@*R1>4N.^-OOUYJ%/ .FQJ-D
M5VLJRM)YXN,/E@ PZ8P0!T'7G.>:+Q#E9M#!48.5(!!'<>M&<@Y[U,+28* L
M8  P!F@VL_78?P-3=!RL8?\ 4+_O'UIG&.?K5C[--Y:C8-P8GK31:S_W#^?^
M?\FA- XLAP,YP"?7C-175Q#9V5Q=7&U8(8VED)48V@$D\_2K?V2<D_N_PR,5
M#=Z6;ZQN+.:-O)N(GB?&,X8$']#1=!ROL8,7B_3F\I+E9X+IHU+1>66*,8O.
M\O<!@MLYQ]:I:AXZLK2"VGM+&:Y6>5HMS 0D$!6P-P.YB#P.,X//%:MOX-A7
M[/+=HUQ=QNDLC;OW<DBP^3G:1C!4]/6GZAX*TS45B62Q,"Q[@1:-Y.]6QN5@
MO4':/RX-5S1N'*R?3M1COGOE6(12VETUO*IQG(PRG/NK ^W-7,#&,#CH,#CG
MKTJ#3M%FL)+Z4_/->737#D<8&T*JCZ*H_&KOV6;_ )YGZ4FT'*R+D\]SWQUI
MT/\ K/P/X<4_[)/_ '.?K3X[:8.,IQS2N@465^U']:E%K-@9C.#QVH^RS=?+
M]S1=!RLP+GQ+8V=]<VLT<F(9%A5HHS)YDAC,A0*!D;5 )/O[4ZV\3:7>WT5M
M;M-)),@EC<0$JXV[@<]^/\*F;PFLNL37\JL0\RW"(K;=LOE-$Q/J"I_.K%AX
M;M--AMH[;3X0T$8CCF=%:7 &!E\9)QQ5.40Y7V.:N_$D6HZ0)[CP_/)9KJ?V
M:59)51HGCD4*Q'KN.=N?X3DUMV;VFIZA/>-;E;S3YY;+);[G3E1T&Y2I]><4
MV?P1I]RC)+#<E'N9;F11<L [2,&96 ZKN4''MUJ]IVBS6!O7/SRWET]S(1P!
MG  'T55_6ES(.5D_OW^E/3^/V4\T_P"RS8_U=.2VF4M\G\/YTKH%%D'?/;KZ
M51U+4ETV.V/EF62YN8[:-%.W+.>3] H9C[#%:?V6?IY9]N:H:IH<NI):$#9+
M:W<=U&QY&5R"/Q5F&?>BZ#E9DCQCHCVYF1YFC4(R@6S9*ON"L >H.TC/M2MX
MF9]4M[:#2IYHKN%I8)@ZAY-J;O\ 5GD+G"[B<;B!5ZT\'Z?9;%2R,RQVR6JI
M<$2J$0LR\,,9RQYIK^#[5M4DOL7:&2#[,]O%/L@,6TKMV#H.2>HY.:J\047V
M*>F>)A?W%K;W&GFUFN);B#!E5PLD6&*9 YRI)SQ]T^QK>&.W QT QZUE6G@Z
M*QOK&:'SF2U:68^?(9'EF=%0.S'^Z@(K;^RS$\H?SI-H.5]B6P/[QN<_*.]:
M!X&:I6D4D3L77 (X&>IJYT&!U [UE+<WAL+1114EA1110 4444 %(6 ZL!]:
M6N3\?:=>ZGI.G6UE TS'4[<R+ABOEACN+XYV^M-:L3.KS@<G\:/8D=.<5YM<
MZ3XETFQ;2+>YN+FTATNXFQ';J\<DYD^2$%\M@*V ,\@"B[OO&\*WRVD5SYD:
M2A(A;)Y<: +Y31G&6<G.5)(Z\# JN3LQ<QZ1GW!^E<UJ7@G3M4U*[U&>>Y^V
M3-"8I4D(\CRCE0HZ$;LGD'DFJ'BVSUBSL],U'3?M6H:A:B2VD"* T@E0@.P7
M ^5]AXZ#-8L@\9:-]JT[3_M!@LK79:JMN)1)MC7:X<C[Y??D$G/H.M$5U3!O
MN=AHWA2ST749KV&XFE>6-XRKXQAI7D/0=<N1]!63IWP_A@TU+6ZNI,Q+%"OE
MD8,<-P9HR<CJ<X-9EU>>.893#$;EH8[V6-;DVJL[H%C,>Y57E"3("0!TZC',
M$+>+]/L9XH3J?G?:+QT)@60R3>;F)22.(BF3D?3(QBGKW%IV.HU/P1I=[ILM
ME9O+IJSR(\SP<F0*20IW9!&3DC'-,O\ PBT[&Z74[J:YCMFBA2>0"-9&C\LR
M$ <?+SM'&><9KG]6'B74(+ZUN(]0:5;N%EMX;=1 L2W$1#)(,,3M#$C)[YQB
M@ZIXXE@UAH;:]CF+0G3XI8$(5R\@=6; &S:%.>V1@FFD^X:=CO\ 3;)--TNT
ML(VREO"L2D]3M &:MYST(-<;K=Q>-IOAHYNAYMP#+YJ!)&D$+L@=1QDN!QC&
M:SK!?'5Y:B)[R>.;R+>9I)HXXL.R'S$!\LCAL<8R/6HY;ZW'>QZ'G/(QCUI,
M\$;AGID5PFM:5J;:]I5U*NHWR#3;F.YCMYMJ!]B !2 H5F.[#<>V*I^&X;^Q
MU#P];>5=6X,E\OESDAC;<,A*$G;AMH )./QQ1R^87/2,]0",TM(.":6I*"BB
MD/T!'>@"*>)9X)(9,[9$*,5X.#P<&N5'P^LOL#VO]JZC^]DS<.)%!F3:J!&
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MP,8RY#N#C#$ #'7(!/'3%=%W[U,KWU&A:***0Q,\9 I#Q[ 4[OUII.!].YH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M32'=EAD(!QU/4D?@#[4 =#D4F>I_2L 7^N@7$;64#7*Q[H4#85SN]=WIU';
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M &%!X7MH+62!;B?YR"6W#)PX<?K_ #I5\,6R,0MQ.$RQ";N.?Y__ *JW.]%
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MX&*EB\-Q02I)]KG=8YUF5'P0,# '^?:MRFK]Y_\ >_H* '#I28SU//M2T4
M&.E)D@9Q2TUOO)_O?T- #6960DGY>YI&";0,D#GVI(^DG^^:9)_J$^A_D:JQ
M/6Q(VS>I)(/84 +YI/\ %CD T/\ ZU/][^E(/]:_X_TI"N(HCVOM.1WS2'RS
M <L=F>IIJ?<?_<%(G_'H/J/YU5B6[#W$15,MP.!^E*=AG!S^\QPN:CDZ6WX?
MTHF_X^X_P_F:$AMZCU$7FOM)W=^::BPB%P'.WO20_P#'T_T_J*CB_P"/*7_>
)_K18F^OWG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608375776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACTINIUM PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATNM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,997,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">74-2963609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">677-3870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">275 Madison Avenue, 7th&#160;Fl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523609234112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,276<span></span>
</td>
<td class="nump">$ 108,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">95,537<span></span>
</td>
<td class="nump">110,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $590 and $487</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash &#8211; long term</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">2,581<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance leases right-of-use assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">99,051<span></span>
</td>
<td class="nump">114,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">8,637<span></span>
</td>
<td class="nump">10,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating leases current liability</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance leases current liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">9,151<span></span>
</td>
<td class="nump">10,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Long-term license revenue deferred</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LongtermOperatingLeaseObligationsNoncurrent', window );">Long-term operating lease obligations</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">45,974<span></span>
</td>
<td class="nump">47,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 shares authorized; 26,984,443 and 25,674,823 shares issued and outstanding, respectively</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">368,033<span></span>
</td>
<td class="nump">355,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(314,983)<span></span>
</td>
<td class="num">(288,765)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">53,077<span></span>
</td>
<td class="nump">66,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 99,051<span></span>
</td>
<td class="nump">$ 114,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermOperatingLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term operating lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermOperatingLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608342864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, net of accumulated depreciation (in Dollars)</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">26,984,443<span></span>
</td>
<td class="nump">25,674,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">26,984,443<span></span>
</td>
<td class="nump">25,674,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523607625008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Other revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
<td class="nump">11,081<span></span>
</td>
<td class="nump">4,662<span></span>
</td>
<td class="nump">18,930<span></span>
</td>
<td class="nump">9,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,561<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">8,296<span></span>
</td>
<td class="nump">4,968<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">15,642<span></span>
</td>
<td class="nump">7,895<span></span>
</td>
<td class="nump">27,226<span></span>
</td>
<td class="nump">13,999<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(15,642)<span></span>
</td>
<td class="num">(7,850)<span></span>
</td>
<td class="num">(27,226)<span></span>
</td>
<td class="num">(13,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income - net</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,181)<span></span>
</td>
<td class="num">$ (7,767)<span></span>
</td>
<td class="num">$ (26,218)<span></span>
</td>
<td class="num">$ (12,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">26,217,910<span></span>
</td>
<td class="nump">23,731,886<span></span>
</td>
<td class="nump">25,958,706<span></span>
</td>
<td class="nump">22,942,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608304496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share &#8211; basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.58)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding &#8211; basic and diluted (in Shares)</a></td>
<td class="nump">26,217,910<span></span>
</td>
<td class="nump">23,731,886<span></span>
</td>
<td class="nump">25,958,706<span></span>
</td>
<td class="nump">22,942,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608049248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 329,271<span></span>
</td>
<td class="num">$ (255,748)<span></span>
</td>
<td class="nump">$ 73,545<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
<td class="num">(5,129)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,692<span></span>
</td>
<td class="num">(260,877)<span></span>
</td>
<td class="nump">68,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,271<span></span>
</td>
<td class="num">(255,748)<span></span>
</td>
<td class="nump">73,545<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,896)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">346,800<span></span>
</td>
<td class="num">(268,644)<span></span>
</td>
<td class="nump">78,181<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">24,870,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">329,692<span></span>
</td>
<td class="num">(260,877)<span></span>
</td>
<td class="nump">68,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">22,143,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">16,683<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in Shares)</a></td>
<td class="nump">2,726,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,767)<span></span>
</td>
<td class="num">(7,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">346,800<span></span>
</td>
<td class="num">(268,644)<span></span>
</td>
<td class="nump">78,181<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="nump">24,870,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">355,220<span></span>
</td>
<td class="num">(288,765)<span></span>
</td>
<td class="nump">66,481<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">54,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,037)<span></span>
</td>
<td class="num">(11,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">356,984<span></span>
</td>
<td class="num">(299,802)<span></span>
</td>
<td class="nump">57,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">25,729,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">355,220<span></span>
</td>
<td class="num">(288,765)<span></span>
</td>
<td class="nump">66,481<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">25,674,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,218)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">368,033<span></span>
</td>
<td class="num">(314,983)<span></span>
</td>
<td class="nump">53,077<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">26,984,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">356,984<span></span>
</td>
<td class="num">(299,802)<span></span>
</td>
<td class="nump">57,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">25,729,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,787<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">1,210,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options (in Shares)</a></td>
<td class="nump">44,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,181)<span></span>
</td>
<td class="num">(15,181)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 368,033<span></span>
</td>
<td class="num">$ (314,983)<span></span>
</td>
<td class="nump">$ 53,077<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">26,984,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523609192768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,218)<span></span>
</td>
<td class="num">$ (12,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation &amp; amortization expenses</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,625)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Payment of security deposit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,493)<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Other revenue deferred &#8211; current liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred', window );">Long-term license revenue deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(527)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In/Provided By Operating Activities</a></td>
<td class="num">(28,720)<span></span>
</td>
<td class="nump">22,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Used In Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Provided By Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SalesOfSharesOfCommonStockNetOfCosts', window );">Sales of shares of common stock, net of costs</a></td>
<td class="nump">10,558<span></span>
</td>
<td class="nump">16,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">262<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">10,818<span></span>
</td>
<td class="nump">16,641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(18,025)<span></span>
</td>
<td class="nump">38,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">109,608<span></span>
</td>
<td class="nump">78,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">91,583<span></span>
</td>
<td class="nump">116,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term license revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SalesOfSharesOfCommonStockNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales of shares of common stock, net of costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SalesOfSharesOfCommonStockNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523610738544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Description of Business and Summary
of Significant Accounting Policies</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. develops targeted radiotherapies to meaningfully improve survival for patients with relapsed or refractory
disease who have failed existing oncology therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2023 and December 31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">91,276</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,583</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from the National Institutes of Health (&#8220;NIH&#8221;) for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement include payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
June 30, 2023 and 2022, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,418</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,431</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, FASB issued ASU
2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock
Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523611516416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#8220;FHCRC&#8221;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608372496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Leases </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#8217;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lease term for all of
the Company&#8217;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#8217;s leases as the reasonably certain threshold is not met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company entered into a lease for corporate office space effective
June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date on July 30, 2027 and current annual rent of $0.6 million.
The Company is also responsible for certain other costs, such as insurance, utilities and maintenance. As of June 30, 2023, the Company
has two leases, a corporate office lease and an office equipment lease. Both of these leases have been capitalized in accordance with
ASC842. During the six months ended June 30, 2023, the Company spent $0.5 million on improvements at its corporate office space, which
has been included in the value of the operating right-to-use asset as of June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The components of lease expense
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">183</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">141</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">345</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">234</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Supplemental cash flow information
related to leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash flow information:</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,605</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Weighted average remaining lease terms are as follows
at June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">4.1 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right">0.5 year</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#8217;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rates: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Maturities of lease liabilities
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2023 (excluding six months ended June 30, 2023)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">305</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(242</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523603442976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OtherRevenueTextBlock', window );">Other revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 &#8211; Other revenue </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#8217;s ability to terminate
the module. The consideration is recognized as revenue over each module and revenue of $0.9 million was recognized during the six months
ended June 30, 2022. There was no other revenue recognized from a collaboration during the six months ended June 30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had a grant from
the National Institutes of Health for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognized revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Other revenue recognized
from this grant for the six months ended June 30, 2022 was $0.1 million. There was no corresponding revenue for the six months ended June
30, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2022, the Company
entered into a license and supply agreement (the &#8220;License Agreement&#8221;) with Immedica Pharma AB (&#8220;Immedica&#8221;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s contract
liabilities are recorded within Other revenue deferred &#8211; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#8217;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#8211; current liability at June
30, 2023 and December 31, 2022. Long-term license revenue deferred was $35.0 million at June 30, 2023 and December 31, 2022; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OtherRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OtherRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523607331392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Equity&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2020, the Company
entered into the Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which
the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of
common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. On June 28, 2022,
the Company entered into an Amended and Restated Capital on Demand&#8482; Sales Agreement (the &#8220;A&amp;R Sales Agreement&#8221;)
with JonesTrading and B. Riley Securities, Inc. (&#8220;B. Riley Securities&#8221;). The A&amp;R Sales Agreement modifies the original
Capital on Demand&#8482; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the six months ended June
30, 2023, the Company sold 1.3 million shares of common stock, resulting in gross proceeds of $10.9 million and net proceeds of $10.6
million. For the six months ended June 30, 2022, the Company sold 2.7 million shares of common stock, resulting in gross proceeds of $17.2
million and net proceeds of $16.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of stock option activity for the six months ended June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/>
 of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,204</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(85</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,418</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.12</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.42</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5,293</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,306</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the six months ended
June 30, 2023, the Company granted stock options to new employees to purchase 151 thousand shares of common stock with an exercise price
ranging from $8.05 to $11.60 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated fair
value of $1.0 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 3.5% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.1% to 81.6%,
and (4) zero expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2023
was $9.0 million related to unvested options, which is expected to be expensed over a weighted average of 3.0 years. During the six months
ended June 30, 2023 and 2022, the Company recorded compensation expense related to stock options of $1.7 million and $0.8 million, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Restricted Stock Units</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of restricted stock unit, or RSU, activity for the six months ended June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">330</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#8217;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $2.0 million, was determined based on the stock
prices on the dates of the grants and each RSU grant is being recognized over its respective three-year period. The unrecognized compensation
expense at June 30, 2023 of $1.4 million is expected to be expensed over a weighted average of 2.2 years. During the six months ended
June 30, 2023, the Company recorded compensation expense related to RSUs of $0.3 million. There was no compensation expense related to
RSUs for the six months ended June 30, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following is a summary of
warrant activity for the six months ended June 30, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/>
 of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,445</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">16.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">0.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,440</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15.94</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">0.83</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523603027888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Nature of Business</b>
- Actinium Pharmaceuticals, Inc. develops targeted radiotherapies to meaningfully improve survival for patients with relapsed or refractory
disease who have failed existing oncology therapies.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Basis of Presentation -
Unaudited Interim Financial Information -</b> The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Principles of Consolidation
-</b> The basis of consolidation is unchanged from the disclosure in the Company&#8217;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Cash, Cash Equivalents
and Restricted Cash -</b> The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2023 and December 31, 2022:</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">91,276</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,583</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#8217;s lease of corporate office
space.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Leases </b>&#8211; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Fair Value Measurement
- </b>Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Revenue Recognition </b>-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, <i>Revenue From Contracts With Customers</i>
(&#8220;ASC 606&#8221;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#8217;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Collaborative Arrangements</b>
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606<i>.</i></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_GrantRevenuePolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Grant Revenue <i>&#8211;
</i></b>The Company had a grant from the National Institutes of Health (&#8220;NIH&#8221;) for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LicenseRevenuePolicyTextBlock', window );">License Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>License Revenue <i>&#8211;
</i></b>The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#8217;s trademarks. The terms of this arrangement include payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Upfront license fees</i>:
If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Development, regulatory
or commercial milestone payments</i>: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#8217;s or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#8217;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sales-based milestone payments
and royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#8217;s right to consideration is unconditional.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Research and Development
Costs -</b> Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Share-Based Payments -</b>
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Net Loss Per Common Share</b>
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
June 30, 2023 and 2022, the Company&#8217;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,418</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,431</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting
Pronouncements &#8211; </b>In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#8217;s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, FASB issued
ASU 2021-08, <i>Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers</i>,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#8217;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2021, FASB issued ASU
2021-04, <i>Earnings Per Share (topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8211; Stock
Compensation (Topic 718) and Derivatives and Hedging &#8211; Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40) &#8211; Issuer&#8217;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grant revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LicenseRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LicenseRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523607712352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash, cash equivalents and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">91,276</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">108,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Restricted cash - current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash &#8211; long-term</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">307</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash, cash equivalents and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,583</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">109,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of diluted net loss per share anti-dilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Options</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,418</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,431</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">330</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,445</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,193</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,484</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608119792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">183</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">141</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">345</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">234</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Amortization of right-to-use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total finance lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&#160;30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flow use from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing cash flow use from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,605</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm', window );">Schedule of weighted average remaining lease terms</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average remaining lease term:</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">4.1 years</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: right">0.5 year</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfWeightedAverageDiscountRate', window );">Schedule of weighted average discount rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td>Weighted average discount rates: </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance Leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)<br/> Year ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Finance <br/> Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2023 (excluding six months ended June 30, 2023)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">305</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">631</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">643</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">380</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(242</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOrDescriptionOfWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Weighted average remaining lease terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOrDescriptionOfWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523607690576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/>
 of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,204</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(85</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">5.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,418</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.12</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.42</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5,293</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,306</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of summary of restricted stock unit activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amount)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Grant date Fair Value <br/> Per Share ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">325</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">330</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">6.00</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per-share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<br/>
 of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Exercise <br/> Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> Average <br/> Remaining <br/> Contractual <br/> Term <br/> (in&#160;years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> Intrinsic <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding, January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,443</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,445</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">16.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">0.84</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Exercisable, June 30, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,440</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">15.94</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">0.83</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523604255520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 91,276<span></span>
</td>
<td class="nump">$ 108,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash - current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Restricted cash &#8211; long-term</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 91,583<span></span>
</td>
<td class="nump">$ 109,608<span></span>
</td>
<td class="nump">$ 116,722<span></span>
</td>
<td class="nump">$ 78,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523607709776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,193<span></span>
</td>
<td class="nump">3,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,418<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">330<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,445<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608333424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 15, 2012 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNetAssetsPercentage', window );">Net sales percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetAssetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of value of derivative contract to net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetAssetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608012800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">5 years 2 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Current annual rate</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember', window );">Corporate Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsLineItems', window );"><strong>Leases (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandImprovements', window );">Landlord assets</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523604255952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of components of lease expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems', window );"><strong>Schedule Of Components Of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-to-use assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523612370864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow use from operating leases</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flow use from finance leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow use from finance leases</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance Leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523611547008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average remaining lease terms<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Leases</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523610593312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average discount rates<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageDiscountRatesAbstract', window );"><strong>Weighted average discount rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Leases</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageDiscountRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageDiscountRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523609157680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember', window );">Operating Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023 (excluding six months ended June 30, 2023)</a></td>
<td class="nump">$ 305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2024</a></td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2025</a></td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2026</a></td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems', window );"><strong>Leases (Details) - Schedule of maturities of lease liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023 (excluding six months ended June 30, 2023)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_PaymentWithImputedInterestPremium', window );">Less imputed interest</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_MaturitiesOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_MaturitiesOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of present value of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_MaturitiesOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_PaymentWithImputedInterestPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment with imputed interest premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_PaymentWithImputedInterestPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_OperatingLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LeaseAxis=atnm_FinanceLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523603078384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Other revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_LongtermLicenseRevenueDeferred', window );">Long-term license revenue deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_LongtermLicenseRevenueDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term license revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_LongtermLicenseRevenueDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523605250240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Expected term year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_GrantOfStockOptionsToEmployees', window );">Grant of stock options to employees (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_DescriptionOfExercisePriceRange', window );">Exercise price ranging, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$8.05 to $11.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_StockOptionTerm', window );">Stock option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_VestingPeriodOfStockOption', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AggregateFairValue', window );">Aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageTerm', window );">Weighted average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_CompensationExpenseRelatedToStockOptions', window );">Compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription', window );">Discount rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.5% to 4.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription', window );">Expected volatility rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">81.1% to 81.6%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember', window );">Capital on Demand Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate value of common stock</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock, shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 16.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_CompensationExpenseRelatedToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation expense related to stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_CompensationExpenseRelatedToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_DescriptionOfExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_DescriptionOfExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_GrantOfStockOptionsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant of stock options to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_GrantOfStockOptionsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_StockOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_StockOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_VestingPeriodOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting period of stock option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_VestingPeriodOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482014/830-20-35-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_AgreementAxis=atnm_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523609064768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of summary of stock option activity<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfSummaryOfStockOptionActivityAbstract', window );"><strong>Schedule of Summary of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning balance | shares</a></td>
<td class="nump">3,396,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning balance | $ / shares</a></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Beginning balance</a></td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Beginning balance | $</a></td>
<td class="nump">$ 15,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">151,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 8.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Exercised | shares</a></td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 5.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="num">(85,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 5.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending balance | shares</a></td>
<td class="nump">3,418,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">$ 8.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance</a></td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Ending balance | $</a></td>
<td class="nump">$ 5,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable | shares</a></td>
<td class="nump">1,126,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 12.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 1,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSummaryOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSummaryOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523612374384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of summary of restricted stock unit activity<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract', window );"><strong>Schedule of Summary of Restricted Stock Unit Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RSUsOutstandingBeginningBalance', window );">RSUs Outstanding, Beginning balance | shares</a></td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_RSUsOutstandingBeginningBalance', window );">RSUs Outstanding, Ending balance | shares</a></td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs, Granted | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 8.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">RSUs, Vested | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_RSUsOutstandingBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>RSUs Outstanding, Beginning balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_RSUsOutstandingBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140523608024160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity  (Details) - Schedule of warrant activities - Warrant [Member]<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Shares, Outstanding Beginning | shares</a></td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Outstanding Beginning | $ / shares</a></td>
<td class="nump">$ 16.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term (in years), Outstanding beginning</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Beginning | $</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_NumberOfWarrantsOutstandings', window );">Number of Shares, Outstanding Ending | shares</a></td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price,Outstanding Ending | $ / shares</a></td>
<td class="nump">$ 16.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Outstanding Ending</a></td>
<td class="text">10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Exercisable Ending | shares</a></td>
<td class="nump">1,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable Ending | $ / shares</a></td>
<td class="nump">$ 15.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term (in years), Exercisable Ending</a></td>
<td class="text">9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_atnm_WeightedAverageRemainingContractualTermGranted', window );">Weighted average remaining contractual term, Granted</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Cancelled/Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled/Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_NumberOfWarrantsOutstandings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares, outstanding beginning.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_NumberOfWarrantsOutstandings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atnm_WeightedAverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atnm_WeightedAverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atnm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>f10q0623_actiniumphar_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:atnm="http://actiniumpharmaceuticals.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="atnm-20230630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2012-05-16</startDate>
            <endDate>2012-06-15</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <instant>2012-06-15</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:OperatingLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:LeaseAxis">atnm:FinanceLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="atnm:AgreementAxis">atnm:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-36374</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">ACTINIUM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">74-2963609</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c0">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">677-3870</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">275 Madison Avenue, 7th&#160;Fl</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">10016</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c0">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">ATNM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">26997587</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">91276000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">108910000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">4261000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">95537000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">110942000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">590000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">624000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">604000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" unitRef="usd">307000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">2581000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">2341000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">3000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">99051000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">114192000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">8637000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">10130000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">512000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">494000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">4000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">9151000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">10628000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="c2" decimals="-3" unitRef="usd">35000000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="c3" decimals="-3" unitRef="usd">35000000</us-gaap:DeferredRevenue>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">1823000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <atnm:LongtermOperatingLeaseObligationsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">2083000</atnm:LongtermOperatingLeaseObligationsNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" unitRef="usd">45974000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">47711000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">26984443</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">26984443</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">25674823</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">25674823</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">26000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">368033000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">355220000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-314983000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-288765000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">53077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">66481000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">99051000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">114192000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SubleaseIncome contextRef="c5" decimals="-3" unitRef="usd">45000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c6" decimals="-3" unitRef="usd">985000</us-gaap:SubleaseIncome>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">45000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="-3" unitRef="usd">985000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">11081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">4662000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">18930000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" unitRef="usd">9031000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">4561000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">3233000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">8296000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" unitRef="usd">4968000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="-3" unitRef="usd">15642000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="-3" unitRef="usd">7895000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">27226000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" unitRef="usd">13999000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-15642000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-7850000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-27226000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-13014000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c4" decimals="-3" unitRef="usd">461000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="-3" unitRef="usd">83000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="-3" unitRef="usd">1008000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c6" decimals="-3" unitRef="usd">118000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">461000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">83000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">1008000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" unitRef="usd">118000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-15181000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-7767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-26218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12896000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-1.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c6" decimals="2" unitRef="usdPershares">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="shares">26217910</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">23731886</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">25958706</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c6" decimals="0" unitRef="shares">22942317</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c7" decimals="0" unitRef="shares">25674823</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" unitRef="usd">355220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">-288765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">66481000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c11" decimals="-3" unitRef="usd">993000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c13" decimals="-3" unitRef="usd">993000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c10" decimals="0" unitRef="shares">54414</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c11" decimals="-3" unitRef="usd">770000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c13" decimals="-3" unitRef="usd">770000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c10" decimals="0" unitRef="shares">133</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c11" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c13" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" unitRef="usd">-11037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" unitRef="usd">-11037000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="0" unitRef="shares">25729370</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" unitRef="usd">26000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" unitRef="usd">356984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">-299802000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">57208000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c19" decimals="-3" unitRef="usd">1001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c4" decimals="-3" unitRef="usd">1001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c18" decimals="0" unitRef="shares">1210965</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c18" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c19" decimals="-3" unitRef="usd">9787000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c4" decimals="-3" unitRef="usd">9788000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c18" decimals="0" unitRef="shares">44108</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c19" decimals="-3" unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c4" decimals="-3" unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="-3" unitRef="usd">-15181000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-15181000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c21" decimals="0" unitRef="shares">26984443</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" unitRef="usd">368033000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" unitRef="usd">-314983000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">53077000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c24" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">329271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" unitRef="usd">-255748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">73545000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c29" decimals="-3" unitRef="usd">421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c31" decimals="-3" unitRef="usd">421000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" unitRef="usd">-5129000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c32" decimals="0" unitRef="shares">22143974</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">329692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" unitRef="usd">-260877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" unitRef="usd">68837000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c37" decimals="-3" unitRef="usd">425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c5" decimals="-3" unitRef="usd">425000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c36" decimals="0" unitRef="shares">2726649</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c37" decimals="-3" unitRef="usd">16683000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" unitRef="usd">16686000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" unitRef="usd">-7767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-7767000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c39" decimals="0" unitRef="shares">24870623</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c39" decimals="-3" unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" unitRef="usd">346800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" unitRef="usd">-268644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" unitRef="usd">78181000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-26218000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" unitRef="usd">-12896000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">1994000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" unitRef="usd">846000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" unitRef="usd">391000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" unitRef="usd">317000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">2625000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c6" decimals="-3" unitRef="usd">47000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="c6" decimals="-3" unitRef="usd">-299000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">-1493000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c6" decimals="-3" unitRef="usd">232000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c6" decimals="-3" unitRef="usd">-794000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <atnm:IncreaseDecreaseInLongtermLicenseRevenuesDeferred contextRef="c6" decimals="-3" unitRef="usd">35000000</atnm:IncreaseDecreaseInLongtermLicenseRevenuesDeferred>
    <atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets contextRef="c0" decimals="-3" unitRef="usd">-527000</atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">-242000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c6" decimals="-3" unitRef="usd">-222000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-28720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" unitRef="usd">22137000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" unitRef="usd">277000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" unitRef="usd">-277000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c6" decimals="-3" unitRef="usd">45000</us-gaap:FinanceLeasePrincipalPayments>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c0" decimals="-3" unitRef="usd">10558000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <atnm:SalesOfSharesOfCommonStockNetOfCosts contextRef="c6" decimals="-3" unitRef="usd">16686000</atnm:SalesOfSharesOfCommonStockNetOfCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">262000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">10818000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="-3" unitRef="usd">16641000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-18025000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" unitRef="usd">38501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">109608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="-3" unitRef="usd">78221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">91583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c42" decimals="-3" unitRef="usd">116722000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 1 - Description of Business and Summary
of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. develops targeted radiotherapies to meaningfully improve survival for patients with relapsed or refractory
disease who have failed existing oncology therapies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2023 and December 31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;91,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash - current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91,583&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;
(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements&lt;/b&gt;
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company had a grant from the National Institutes of Health (&#x201c;NIH&#x201d;) for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement include payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -&lt;/b&gt;
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
June 30, 2023 and 2022, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Adopted Accounting
Pronouncements &#x2013; &lt;/b&gt;In November 2021, the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance&lt;/i&gt;, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In October 2021, FASB issued
ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/i&gt;,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#x2019;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2021, FASB issued ASU
2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock
Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts in an Entity&#x2019;s Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Nature of Business&lt;/b&gt;
- Actinium Pharmaceuticals, Inc. develops targeted radiotherapies to meaningfully improve survival for patients with relapsed or refractory
disease who have failed existing oncology therapies.&lt;/p&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Basis of Presentation -
Unaudited Interim Financial Information -&lt;/b&gt; The accompanying unaudited interim condensed consolidated financial statements and related
notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) with respect to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished
reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement
of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements
and notes thereto contained in the Company&#x2019;s annual report on Form 10-K for the year ended December 31, 2022.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Principles of Consolidation
-&lt;/b&gt; The basis of consolidation is unchanged from the disclosure in the Company&#x2019;s Notes to the Consolidated Financial Statements
section in its Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated financial statements include
the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Use of Estimates &lt;/b&gt;-
The preparation of these unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial
statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Cash, Cash Equivalents
and Restricted Cash -&lt;/b&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash
equivalents. Balances held by the Company are typically in excess of Federal Deposit Insurance Corporation insured limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of cash, cash equivalents and restricted cash at June 30, 2023 and December 31, 2022:&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;91,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash - current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91,583&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Restricted cash relates to
a certificate of deposit held as collateral for a letter of credit issued in connection with the Company&#x2019;s lease of corporate office
space.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;91,276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;108,910&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Restricted cash - current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;396&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash &#x2013; long-term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;307&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Cash, cash equivalents and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91,583&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;109,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">91276000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">108910000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c3" decimals="-3" unitRef="usd">396000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">307000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:OtherRestrictedAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">302000</us-gaap:OtherRestrictedAssetsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">91583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">109608000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Leases &lt;/b&gt;&#x2013; The
Company has operating and finance leases for corporate office space and office equipment located at the corporate office space. Leases
with an initial term of 12 months or less are not recorded on the balance sheet; lease expense for these leases is recognized on a straight-line
basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Fair Value Measurement
- &lt;/b&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction
between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted
prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Revenue Recognition &lt;/b&gt;-
The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;
(&#x201c;ASC 606&#x201d;). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services,
in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable
consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as
the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the
entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;At contract inception, once
the contract is determined to be within the scope of ASC 606, the Company assesses whether the promised goods or services promised within
each contract are distinct and, therefore, represent a separate performance obligation.&#160;Goods and services that are determined not
to be distinct are combined with other promised goods and services until a distinct bundle is identified. In determining whether goods
or services are distinct, the Company evaluates certain criteria, including whether (i)&#160;the customer can benefit from the good or
service either on its own or together with other resources that are readily available to the customer (capable of being distinct) and
(ii)&#160;the good or service is separately identifiable from other goods or services in the contract (distinct in the context of the
contract).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company then determines
the transaction price, which is the amount of consideration it expects to be entitled from a customer in exchange for the promised goods
or services for each performance obligation and recognizes the associated revenue as each performance obligation is satisfied. The Company&#x2019;s
estimate of the transaction price for each contract includes all variable consideration to which it expects to be entitled. Variable consideration
includes payments in the form of collaboration milestone payments. If an arrangement includes collaboration milestone payments, the Company
evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value
is included in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;ASC 606 requires the Company
to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining
the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative
standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately
to a customer. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance
obligation as each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based
on the use of an output or input method.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Collaborative Arrangements&lt;/b&gt;
- The Company follows the accounting guidance for collaboration agreements with third parties, which requires that certain transactions
between the Company and collaborators be recorded in its consolidated statements of operations on either a gross basis or net basis, depending
on the characteristics of the collaborative relationship, and requires enhanced disclosure of collaborative relationships. The Company
evaluates its collaboration agreements for proper classification in its consolidated statements of operations based on the nature of the
underlying activity. When the Company has concluded that it has a customer relationship with one of its collaborators, the Company follows
the guidance of ASC 606&lt;i&gt;.&lt;/i&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <atnm:GrantRevenuePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Grant Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company had a grant from the National Institutes of Health (&#x201c;NIH&#x201d;) for research and development related activities that provided for payments
for reimbursed costs, which included overhead and general and administrative costs as well as an administrative fee. The Company recognized
revenue from grants as it performed services under this arrangement. Associated expenses were recognized when incurred as research and
development expense. Revenue and related expenses are presented gross in the consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</atnm:GrantRevenuePolicyTextBlock>
    <atnm:LicenseRevenuePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;License Revenue &lt;i&gt;&#x2013;
&lt;/i&gt;&lt;/b&gt;The Company entered into a product licensing agreement whereby the Company allowed a third party to commercialize a certain product
in specified territories using the Company&#x2019;s trademarks. The terms of this arrangement include payment to the Company for a combination
of one or more of the following: upfront license fees; development, regulatory and sales-based milestone payments; and royalties on net
sales of licensed products. The Company uses its judgment to determine whether milestones or other variable consideration should be included
in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Upfront license fees&lt;/i&gt;:
If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company will recognize revenue from upfront license fees allocated to the license when the license is transferred
to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
determines whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Development, regulatory
or commercial milestone payments&lt;/i&gt;: At the inception of each arrangement that includes payments based on the achievement of certain
development, regulatory and sales-based or commercial events, the Company evaluates whether the milestones are considered probable of
being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments
that are not within the Company&#x2019;s or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of
being achieved until regulatory approval is received. At the end of each subsequent reporting period, the Company will re-evaluate the
probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust the Company&#x2019;s
estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis and recorded as part of license
revenue during the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Sales-based milestone payments
and royalties&lt;/i&gt;: For arrangements that include sales-based royalties, including milestone payments based on the volume of sales, the
Company will determine whether the license is deemed to be the predominant item to which the royalties or sales-based milestones relate
and if such is the case, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Upfront payments and fees
may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements or
when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur or when the uncertainty
associated with any variable consideration is subsequently resolved. Amounts payable to the Company are recorded as accounts receivable
when the Company&#x2019;s right to consideration is unconditional.&lt;/p&gt;</atnm:LicenseRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Research and Development
Costs -&lt;/b&gt; Research and development costs are expensed as incurred. These costs include the costs of manufacturing drug product, the
costs of clinical trials, costs of employees and associated overhead, and depreciation and amortization costs related to facilities and
equipment. Research and development reimbursements are recorded by the Company as a reduction of research and development costs.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Share-Based Payments -&lt;/b&gt;
The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model. The
fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required
to provide service in exchange for the award. The Company accounts for forfeitures of stock options as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Net Loss Per Common Share&lt;/b&gt;
- Basic loss per common share is computed by dividing the net loss available to common stockholders by the weighted average number of
shares of common stock outstanding during the reporting period. For periods of net loss, diluted loss per share is calculated similarly
to basic loss per share because the impact of all potential dilutive common shares is anti-dilutive. For the three and nine months ended
June 30, 2023 and 2022, the Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, restricted stock
units and warrants, have not been included in the computation of diluted net loss per share as the result would have been anti-dilutive.&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June 30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,431&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;330&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,445&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,193&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,484&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c43" decimals="-3" unitRef="shares">3418000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c44" decimals="-3" unitRef="shares">1431000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c45" decimals="-3" unitRef="shares">330000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c47" decimals="-3" unitRef="shares">1445000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c48" decimals="-3" unitRef="shares">2053000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="-3" unitRef="shares">5193000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c6" decimals="-3" unitRef="shares">3484000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Recently Adopted Accounting
Pronouncements &#x2013; &lt;/b&gt;In November 2021, the FASB issued ASU 2021-10, &lt;i&gt;Government Assistance (Topic 832), Disclosures by Business
Entities about Government Assistance&lt;/i&gt;, which provides guidance on disclosure requirements to entities other than not-for-profit entities
about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10
requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to
account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included
in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions,
including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In October 2021, FASB issued
ASU 2021-08, &lt;i&gt;Business Combinations (Topic 805), Account for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/i&gt;,
which provides guidance on accounting for contract assets and contract liabilities acquired in a business combination in accordance with
ASC 606. To achieve this, an acquirer may assess how the acquiree applied ASC 606 to determine what to record for the acquired revenue
contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities
consistent with how they were recognized and measured in the acquiree&#x2019;s financial statements. The amendments of ASU 2021-08 are
effective January 1, 2023, including interim periods. The Company will evaluate the impact of ASU 2021-08 on any future business combinations
the Company may enter in the future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In May 2021, FASB issued ASU
2021-04, &lt;i&gt;Earnings Per Share (topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2013; Stock
Compensation (Topic 718) and Derivatives and Hedging &#x2013; Contracts in an Entity&#x2019;s Own Equity (Subtopic 815-40) &#x2013; Issuer&#x2019;s
Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/i&gt;, which provides guidance
of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification
or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if
so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company
adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 2 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On June 15, 2012, the Company
entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (&#x201c;FHCRC&#x201d;) to build upon
previous and ongoing clinical trials with apamistamab (licensed antibody). FHCRC has completed both a Phase 1 and Phase 2 clinical trial
with apamistamab. The Company has been granted exclusive rights to the antibody and related master cell bank developed by FHCRC. A milestone
payment of $1 million will be due to FHCRC upon U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of the first drug utilizing
the licensed antibody. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <atnm:MilestonePayment contextRef="c49" decimals="-6" unitRef="usd">1000000</atnm:MilestonePayment>
    <us-gaap:DerivativeNetAssetsPercentage contextRef="c50" decimals="2" unitRef="pure">0.02</us-gaap:DerivativeNetAssetsPercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 3 - Leases &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determines if
an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right
to control the use of a fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to
the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using
the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company has elected to
account for as a single lease component for all classes of underlying assets. Lease expense for variable lease components are recognized
when the obligation is probable. The Company made an accounting policy election to exclude from balance sheet reporting those leases with
initial terms of 12 months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Right-of-use assets and liabilities
are recognized at commencement date based on the present value of lease payments over the lease term. ASC 842 requires a lessee to discount
its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental
borrowing rate. As an implicit interest rate was not readily determinable in the Company&#x2019;s leases, the incremental borrowing rate
was used based on the information available at commencement date in determining the present value of lease payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The lease term for all of
the Company&#x2019;s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option
to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate)
the lease controlled by the lessor. Options for lease renewals have been excluded from the lease term (and lease liability) for the majority
of the Company&#x2019;s leases as the reasonably certain threshold is not met.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company entered into a lease for corporate office space effective
June 1, 2022. The lease has a term of 5 years 2 months, with an expiration date on July 30, 2027 and current annual rent of $0.6 million.
The Company is also responsible for certain other costs, such as insurance, utilities and maintenance. As of June 30, 2023, the Company
has two leases, a corporate office lease and an office equipment lease. Both of these leases have been capitalized in accordance with
ASC842. During the six months ended June 30, 2023, the Company spent $0.5 million on improvements at its corporate office space, which
has been included in the value of the operating right-to-use asset as of June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The components of lease expense
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;183&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;345&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;234&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Supplemental cash flow information
related to leases are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Cash flow information:&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Weighted average remaining lease terms are as follows
at June 30, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;4.1 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.5 year&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As the interest rate implicit
in the leases was not readily determinable at the time that the leases were evaluated, the Company used its incremental borrowing rate
based on the information available in determining the present value of lease payments. The Company&#x2019;s incremental borrowing rate
was based on the term of the lease, the economic environment of the lease and reflects the rate the Company would have had to pay to borrow
on a secured basis. Below is information on the weighted average discount rates used at the time that the leases were evaluated:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average discount rates: &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Maturities of lease liabilities
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2023 (excluding six months ended June 30, 2023)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c0">5 years 2 months</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="c0">2027-07-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseCost contextRef="c0" decimals="-5" unitRef="usd">600000</us-gaap:LeaseCost>
    <us-gaap:LandImprovements contextRef="c51" decimals="-5" unitRef="usd">500000</us-gaap:LandImprovements>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;183&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;141&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;345&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;234&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Amortization of right-to-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total finance lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense contextRef="c4" decimals="-3" unitRef="usd">183000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c5" decimals="-3" unitRef="usd">141000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" unitRef="usd">345000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c6" decimals="-3" unitRef="usd">234000</us-gaap:OperatingLeaseExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c4" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c5" decimals="-3" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c6" decimals="-3" unitRef="usd">41000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c5" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c0" decimals="-3" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c6" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">1000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="-3" unitRef="usd">21000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">3000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c6" decimals="-3" unitRef="usd">43000</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Six months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;June&#160;30,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flow use from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flow use from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Non-cash activity:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" unitRef="usd">300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="-3" unitRef="usd">239000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c6" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c0" decimals="-3" unitRef="usd">2000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c6" decimals="-3" unitRef="usd">45000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c6" decimals="-3" unitRef="usd">2605000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <atnm:ScheduleOrDescriptionOfWeightedAverageTerm contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average remaining lease term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: right"&gt;4.1 years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.5 year&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:ScheduleOrDescriptionOfWeightedAverageTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P0Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <atnm:ScheduleOfWeightedAverageDiscountRate contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted average discount rates: &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Finance Leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:ScheduleOfWeightedAverageDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" unitRef="pure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" unitRef="pure">0.08</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands)&lt;br/&gt; Year ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Finance &lt;br/&gt; Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2023 (excluding six months ended June 30, 2023)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;305&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;380&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c52" decimals="-3" unitRef="usd">305000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c53" decimals="-3" unitRef="usd">2000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo contextRef="c52" decimals="-3" unitRef="usd">618000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree contextRef="c52" decimals="-3" unitRef="usd">631000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour contextRef="c52" decimals="-3" unitRef="usd">643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive contextRef="c52" decimals="-3" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c52" decimals="-3" unitRef="usd">2577000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c53" decimals="-3" unitRef="usd">2000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <atnm:PaymentWithImputedInterestPremium contextRef="c52" decimals="-3" unitRef="usd">242000</atnm:PaymentWithImputedInterestPremium>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c52" decimals="-3" unitRef="usd">2335000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:MaturitiesOfLeaseLiabilities contextRef="c53" decimals="-3" unitRef="usd">2000</atnm:MaturitiesOfLeaseLiabilities>
    <atnm:OtherRevenueTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4 &#x2013; Other revenue &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company determined that
certain collaborations with a third party are within the scope of ASC 606. The collaboration agreement is made up of multiple modules
related to various research activities. The Company identified a single performance obligation to provide research services within each
module for which the Company receives monetary consideration. The third party can choose to proceed with each module or can terminate
the agreement at any time. The Company recognizes revenue for each module on a straight-line basis over the expected module period. Revenue
for succeeding modules is not recognized until all contingencies are resolved, inclusive of the third party&#x2019;s ability to terminate
the module. The consideration is recognized as revenue over each module and revenue of $0.9 million was recognized during the six months
ended June 30, 2022. There was no other revenue recognized from a collaboration during the six months ended June 30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company had a grant from
the National Institutes of Health for research and development related activities that provides payments for reimbursed costs, which included
overhead and general and administrative costs, as well as an administrative fee. The Company recognized revenue from grants as it performed
services under this arrangement. Associated expenses are recognized when incurred as research and development expense. Other revenue recognized
from this grant for the six months ended June 30, 2022 was $0.1 million. There was no corresponding revenue for the six months ended June
30, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On April 7, 2022, the Company
entered into a license and supply agreement (the &#x201c;License Agreement&#x201d;) with Immedica Pharma AB (&#x201c;Immedica&#x201d;), pursuant
to which Immedica licensed the exclusive product rights for commercialization of Iomab-B (I-131 apamistamab) in the European Economic
Area, Middle East and North Africa (EUMENA) including Algeria, Andorra, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Monaco, Morocco, Oman, Palestine, Qatar, San Marino, Saudi Arabia, Switzerland, Syria, Tunisia, Turkey, the United Arab Emirates,
the United Kingdom, the Vatican City and Yemen. Upon signing, the Company was entitled to an upfront payment of $35 million from Immedica,
which was received in May 2022. Under the terms of the License Agreement, the Company is eligible to receive regulatory and commercial
milestone payments and is entitled to receive royalties in the mid-20 percent range on net sales of the product in certain countries that
may result from the License Agreement. The Company will continue to be responsible for certain clinical development activities and the
manufacturing of Iomab-B and will retain commercialization rights in the U.S. and rest of the world.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s contract
liabilities are recorded within Other revenue deferred &#x2013; current liability or Long-term license revenue deferred in its condensed
consolidated balance sheets, depending on the short-term or long-term nature of the payments to be recognized. The Company&#x2019;s contract
liabilities primarily consist of advanced payments from licensees. There was no Other revenue deferred &#x2013; current liability at June
30, 2023 and December 31, 2022. Long-term license revenue deferred was $35.0 million at June 30, 2023 and December 31, 2022; this deferred
revenue will be recognized upon European Union regulatory approval of Iomab-B.&lt;/p&gt;</atnm:OtherRevenueTextBlock>
    <atnm:RevenueRecognized contextRef="c0" decimals="-5" unitRef="usd">900000</atnm:RevenueRecognized>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-5" unitRef="usd">100000</us-gaap:DeferredRevenueCurrent>
    <atnm:UpfrontPayment contextRef="c54" decimals="-6" unitRef="usd">35000000</atnm:UpfrontPayment>
    <atnm:LongtermLicenseRevenueDeferred contextRef="c2" decimals="-5" unitRef="usd">35000000</atnm:LongtermLicenseRevenueDeferred>
    <atnm:LongtermLicenseRevenueDeferred contextRef="c3" decimals="-5" unitRef="usd">35000000</atnm:LongtermLicenseRevenueDeferred>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 5 - Equity&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;In August 2020, the Company
entered into the Capital on Demand&#x2122; Sales Agreement with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which
the Company may sell, from time to time, through or to JonesTrading, up to an aggregate of $200 million of its common stock. Shares of
common stock are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on August 7, 2020. On June 28, 2022,
the Company entered into an Amended and Restated Capital on Demand&#x2122; Sales Agreement (the &#x201c;A&amp;amp;R Sales Agreement&#x201d;)
with JonesTrading and B. Riley Securities, Inc. (&#x201c;B. Riley Securities&#x201d;). The A&amp;amp;R Sales Agreement modifies the original
Capital on Demand&#x2122; Sales Agreement to include B. Riley Securities as an additional sales agent thereunder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;For the six months ended June
30, 2023, the Company sold 1.3 million shares of common stock, resulting in gross proceeds of $10.9 million and net proceeds of $10.6
million. For the six months ended June 30, 2022, the Company sold 2.7 million shares of common stock, resulting in gross proceeds of $17.2
million and net proceeds of $16.7 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of stock option activity for the six months ended June 30, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt;
 of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.12&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.42&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5,293&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;During the six months ended
June 30, 2023, the Company granted stock options to new employees to purchase 151 thousand shares of common stock with an exercise price
ranging from $8.05 to $11.60 per share, a term of 10 years, and a vesting period of 4 years.&#160;The options have an aggregated fair
value of $1.0 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing
model include: (1) discount rate range from 3.5% to 4.21% (2) expected life of 6 years, (3) expected volatility range from 81.1% to 81.6%,
and (4) zero expected dividends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The fair values of all options
issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2023
was $9.0 million related to unvested options, which is expected to be expensed over a weighted average of 3.0 years. During the six months
ended June 30, 2023 and 2022, the Company recorded compensation expense related to stock options of $1.7 million and $0.8 million, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The following is a summary
of restricted stock unit, or RSU, activity for the six months ended June 30, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;330&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The RSUs vest at the earliest
of a change of control event, the termination of the recipient&#x2019;s continuous service status for any reason other than by the Company
for cause and the third anniversary of the date of the grant. The fair value of the RSUs, $2.0 million, was determined based on the stock
prices on the dates of the grants and each RSU grant is being recognized over its respective three-year period. The unrecognized compensation
expense at June 30, 2023 of $1.4 million is expected to be expensed over a weighted average of 2.2 years. During the six months ended
June 30, 2023, the Company recorded compensation expense related to RSUs of $0.3 million. There was no compensation expense related to
RSUs for the six months ended June 30, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Following is a summary of
warrant activity for the six months ended June 30, 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt;
 of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,445&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,440&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15.94&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.83&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c55" decimals="-6" unitRef="usd">200000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c56" decimals="-5" unitRef="shares">1300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c56" decimals="-5" unitRef="usd">10900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c56" decimals="-5" unitRef="usd">10600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c57" decimals="-5" unitRef="shares">2700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c57" decimals="-5" unitRef="usd">17200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c57" decimals="-5" unitRef="usd">16700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt;
 of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(44&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;5.76&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.12&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.42&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5,293&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,126&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">3396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c3" decimals="-3" unitRef="usd">15204000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c0" decimals="INF" unitRef="shares">151000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">8.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="c0" decimals="INF" unitRef="shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="INF" unitRef="shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">5.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="INF" unitRef="shares">3418000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">8.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c0">P8Y5M1D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c2" decimals="-3" unitRef="usd">5293000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="INF" unitRef="shares">1126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">12.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted contextRef="c0">P7Y6M</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c2" decimals="-3" unitRef="usd">1306000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <atnm:GrantOfStockOptionsToEmployees contextRef="c58" decimals="-3" unitRef="shares">151000</atnm:GrantOfStockOptionsToEmployees>
    <atnm:DescriptionOfExercisePriceRange contextRef="c58">$8.05 to $11.60</atnm:DescriptionOfExercisePriceRange>
    <atnm:StockOptionTerm contextRef="c58">P10Y</atnm:StockOptionTerm>
    <atnm:VestingPeriodOfStockOption contextRef="c58">P4Y</atnm:VestingPeriodOfStockOption>
    <atnm:AggregateFairValue contextRef="c58" decimals="-5" unitRef="usd">1000000</atnm:AggregateFairValue>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription contextRef="c58">3.5% to 4.21%</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription contextRef="c58">81.1% to 81.6%</atnm:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription>
    <atnm:UnrecognizedCompensationExpense contextRef="c58" decimals="-5" unitRef="usd">9000000</atnm:UnrecognizedCompensationExpense>
    <atnm:WeightedAverageTerm contextRef="c58">P3Y</atnm:WeightedAverageTerm>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c58" decimals="-5" unitRef="usd">1700000</atnm:CompensationExpenseRelatedToStockOptions>
    <atnm:CompensationExpenseRelatedToStockOptions contextRef="c59" decimals="-5" unitRef="usd">800000</atnm:CompensationExpenseRelatedToStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amount)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Grant date Fair Value &lt;br/&gt; Per Share ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;325&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;330&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.00&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <atnm:RSUsOutstandingBeginningBalance contextRef="c3" decimals="-3" unitRef="shares">325000</atnm:RSUsOutstandingBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c3" decimals="INF" unitRef="usdPershares">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="-3" unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c0" decimals="INF" unitRef="usdPershares">8.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <atnm:RSUsOutstandingBeginningBalance contextRef="c2" decimals="-3" unitRef="shares">330000</atnm:RSUsOutstandingBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c2" decimals="INF" unitRef="usdPershares">6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="c60" decimals="-5" unitRef="usd">2000000</us-gaap:RestrictedInvestmentsAtFairValue>
    <atnm:UnrecognizedCompensationExpense contextRef="c61" decimals="-5" unitRef="usd">1400000</atnm:UnrecognizedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c61">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax contextRef="c61" decimals="-5" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;(in thousands, except for per-share amounts)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;br/&gt;
 of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price ($)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual &lt;br/&gt; Term &lt;br/&gt; (in&#160;years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding, January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,445&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;16.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.84&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable, June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,440&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;15.94&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.83&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <atnm:NumberOfWarrantsOutstandings contextRef="c62" decimals="-3" unitRef="shares">1443000</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c63" decimals="2" unitRef="usdPershares">16.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c64">P1Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c62" decimals="-3" unitRef="usd">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c64" decimals="-3" unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c64" decimals="2" unitRef="usdPershares">8.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <atnm:WeightedAverageRemainingContractualTermGranted contextRef="c64">P10Y</atnm:WeightedAverageRemainingContractualTermGranted>
    <atnm:NumberOfWarrantsOutstandings contextRef="c63" decimals="-3" unitRef="shares">1445000</atnm:NumberOfWarrantsOutstandings>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c63" decimals="2" unitRef="usdPershares">16.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c64">P0Y10M2D</atnm:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c63" decimals="-3" unitRef="shares">1440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c63" decimals="2" unitRef="usdPershares">15.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c64">P0Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:RestrictedCashCurrent
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c0"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="c6"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubleaseIncome
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SubleaseIncome
      contextRef="c0"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c4"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c0"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="hidden-fact-13"
      unitRef="usdPershares">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-14"
      unitRef="usdPershares">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c4"
      decimals="2"
      id="hidden-fact-15"
      unitRef="usdPershares">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-16"
      unitRef="usdPershares">-1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="hidden-fact-17"
      unitRef="shares">22942317</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="hidden-fact-18"
      unitRef="shares">23731886</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-19"
      unitRef="shares">25958706</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="hidden-fact-20"
      unitRef="shares">26217910</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c10"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c12"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c10"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c12"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c10"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c12"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c10"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c18"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c18"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c28"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c30"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c36"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c38"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c38"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="c0"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:IncreaseDecreaseInLongtermLicenseRevenuesDeferred
      contextRef="c0"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:IncreaseDecreaseInOperatingLeaseRightofuseAssets
      contextRef="c6"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c6"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="c2"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c46"
      id="hidden-fact-55"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c0"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="c6"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="c53"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="c53"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="c53"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="c53"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <atnm:PaymentWithImputedInterestPremium
      contextRef="c53"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      id="hidden-fact-64"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c64"
      id="hidden-fact-66"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c64"
      id="hidden-fact-67"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001388320</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MM:2^J*@OP-(N.0FB=(T6+\DCBTVT</QD.;LS,8%1+9G<BLD%RU2UXN7+QIA
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M+W-H965T-2YX;6RM5FUOVC 0_BM6.E6MM)(W I1"I!:8UDG=4%'7#],^F,2
M52?.; >Z?[^S$U) +JNV\H'8SCW/W3WG^#S8</$D5X0H])RQ7 Z=E5)%WW5E
MLB(9EBU>D!S>++C(L(*I6+JR$ 2G!I0Q-_"\CIMAFCOQP*Q-13S@I6(T)U.!
M9)EE6/R^(8QOAH[O;!?NZ7*E]((;#PJ\)#.B'HJI@)G;L*0T([FD/$>"+(;.
MM=^?1-K>&'RG9"-WQDAG,N?\24]NTZ'CZ8 ((XG2#!@>:S(BC&DB".-7S>DT
M+C5P=[QE_V1RAUSF6)(19X\T5:NATW-02A:X9.J>;SZ3.A\38,*9-/]H4]MZ
M#DI*J7A6@R&"C.;5$S_7.NP @,<."&I < AHOP((:T#X5@_M&M!^JX>H!IC4
MW2IW(]P8*QP/!-\@H:V!30^,^@8->M%<[Y.9$O"6 D[%(YZG4'62(AA)SFB*
M%4QF"AZP'91$?(&^%41@75>)SAYR7*84;,[1V10+,%D111/,Y#FZ0!^0B^0*
MEN7 51">=N(F=2@W52C!*Z&$Z(X#FT03""FUX,?'\9TC>!=D:;0)MMK<!$<)
MOY1Y"X7>1Q1X06B)9_1V>&!+Y_^\3_[9^YX88;-10L,7OL)WFR<\(R\; _VX
MGDLEX$/_:2MU1=:VD^G#KR\+G)"A Z>;)&)-G/CTQ.]X5S:=WY-L_)YDDW<B
MVZM(NZE(^QA[_!6Z".-2(O@Z$10G@W/7?'OH]*07^/Z5/D%I@G">HI2R4G_7
M9S1'8\X8%A7,V)_;"ECY[AG?NMFLXPNO%?4&[GJW,E:K,-RW&ENL_);G[UM-
M[!X[WN[O!;,G6=1(%AV5[-'T#= !K^%$6Y(]V>"H*Y54(!?-EW_1<&8 5N&J
M"**=-().X'<O?>] .XMAV W]7J]S()_%,+J,>EWOP'!B,0PNVT'H=P]D<W<:
M1D;$TG1J"6J4N:J.A&:UN0Q<FQYXL'[C]T>^97T,EX>JU[_05S>/.RR6%!H)
M(PMPY;6Z$*ZHNGDU4;PP[6K.%30_,US!!8@(;0#O%YRK[40[:*Y4\1]02P,$
M%     @ &H@.5U_2J&KI!P  7SP  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6RUFVN/TS@4AO]*5! "B=+XDAO,C 1M5LM*NQHQL/LYI.XT(DU*DL[
MOU\GS32U?>(DQ7R!MG/\VGYS;)\G3:\>\^);N66LLG[LTJR\GFVK:O]VL2CC
M+=M%Y9M\SS+^ETU>[***ORWN%^6^8-&Z:;1+%]BVW<4N2K+9S57SV6UQ<Y4?
MJC3)V&UAE8?=+BI^?F!I_G@]0[.G#SXE]]NJ_F!Q<[6/[MD=J[[L;PO^;G%2
M62<[EI5)GED%VUS/WJ.W(77J!DW$OPE[+,]>6_54ON;YM_K-Q_7US*Y'Q%(6
M5[5$Q/][8$N6IK42'\?W5G1VZK-N>/[Z2?V/9O)\,E^CDBWS]+]D76VO9_[,
M6K--=$BK3_GCGZR=4#/ .$_+YE_KL8VU9U9\**M\US;F(]@EV?'_Z$=KQ%D#
M1'H:X+8!EAI@KZ<!:1L0N4'?D&C;@(X=DM,V:*:^.,Z],6X55='-59$_6D4=
MS=7J%XW[36ON5Y+5B7)7%?RO"6]7W2SS;,TO.UM;_%69I\DZJOB;NXK_Q_.A
MLO*-M=Q&V3TKK23CG^?QMVV>KEE1OGCF8^2]L\+OAZ3Z:;W\DD6'=<);O[+F
MUI>[E?7R^2OK>=WJ\S8_E%&V+J\6%1]SW?,B;L?WX3@^W#N^W2YO^P5:+_6M
MWZ_Y@'@^1JEU&R7K^<?,6D;[I(I20&LUH!7'A]TA;>Q9L4T2)Q4@$NI%/N=*
MWPM^Q4Z7#9\N&VYT:(_.ARB-LIA94<7'$K^Q"'IM81LCR."CDMLHU?O&PPW&
M5XN'<Q?5$((#["$Q;*6&S;'C>-07XT(USB,.=4Y1PI3):<IDU)1?UFFXC0I6
MOAHU_:.J(TP?41)X5#)!VWV]8;\M]U',KF=\1RY9\<!F-R^>(==^!^622;'0
MD)A@.SW93K6V-RMO7N_%:RO.=_R *J-Z24%6:Y7@<5K0HJ;*):-8SD5#?87Z
MO@3+G)-ECM:R?_CYGN8EN-MI6TZPR)#.RE&F/W<0#J0%/10EV.2>;'+'[F%_
M1\5I$6/(-G=X#W.5,?(]S VDL)4:-L>N[7N>-&4USO5]XL%3]DY3]B[9PP:G
M[XW=P[3=3]W#3(J%AL0$V_V3[;ZQT](?SC0?RC3UM%3#X--2C=.<EL%IRL%O
M.2V#L9FF[7YJIID4"PV)";8CNZNG[8LW?WW3B?-<&E5;&54+6S4A^1'V Q?.
M:G2&*VCL4O[KD/%<MOMWS59*6,N.E,9MC+"8J>O;MK28@3A^;O@NE=9%" 1Z
M/O)[2@K4%?QH7,4O+>AA$["ZHJGOV2XFLA7: 4S.)Y-JH2DUT?P./= X]AAS
M5K=2VA,$J5 "%BM '%RM (&:<@5UQ3_25_^7%BQ(+:M[SA'] "9GG4FUT)2:
M:'Z'$4C/$5/02R\U 2R06NM3>==<F>HM'.A--*X#"Z0GB[LH9?6-J_AX\ZBL
M?7QM9:RYFY64Y:')Z3@O*_B85FE#V2M5/$"NZQ/9)^TXI_@$]]=WG'8\@O1
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M&DJ W91@_7SS$5'HCFY9END0Z:9#!>-6,HHM@P%O.?=Z(>K++4)@"0.H&HZ
MW?.!%Z*B^@3JQ-,?""S]6=CM/Q8QWY\OAH@;;EH]=@\/;HH\3\RXEB0H9C)*
MN"R$J00&PP::$R1C.?2'DF!O0T<=(1Q+6]LC#9/ ;B9ABH>9(P!H@ [G)8BK
M%;93T0L.1D=0U)XM-P0D<(\>NF"AD5&DR(.]/+J5O0#P$125@"<'KR]2*K;F
MK8Y$9@!1COSKI_6;HPOSOJ3S_-(_79?O?QHUY>NHST1 99) 13:@TGN_@$TH
MRC<\Y8WBN7E)<L>5XJFYW%$24Z$%X/L-Y^KI1O] _9YM]1]02P,$%     @
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M+T./"&1-Z8O2$S&=TT,=@?,VOT"36>O63J#7L11_=5=8M=711^"2._5D_;9
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M4W!2<U$>O*5=27Y^OC15)3UEV3L0.H>ET5[J G4FT4UC3Q1L&&<=W%4+E_X
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MFER3X:^G45O$_<2;.G1B.CS4U\.PI(<4+1O0_MK0#>PF3- _S?,O4$L#!!0
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M&U[K\-'N?I$IGA/2EUOMXW^V:\XN3D8LKWVP91*&!Z4RS2?_G/+0$W@]^X[
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M) C ZIM0-8]W-N'9XC7N3HZ#?1AL"]4:6(7Z%/>9:*SC;H0>.7\9KU1;6W/
M?FNK&Z'9-W=S0];JX:('DN!3:]%JM0>:C[QN826+O38V&4Z.9FR/S4- S3R<
M3_$<3X=)E 8_:: &),73V)T$'^Z%SJ3!UGZ:L@,V#8\2E'B= ?%H$\RT>3A[
MHG+=/2A,XSGDQ0E^TH1!U]&D%\UO2O&4(1[&R8S%23B+V6$XC; QB6;L/7H#
MH=\6T&!#P&;]+#NGUE-DJ/UJ#%^B:DKU((3; &YF!68EYW^?CV?*S>,D6E1T
M(4(EX1()H&Q)5KK;8 \QGI+DO3@.9Q%ETXL;HGH E!5)C2/V(+A&WDD;9[>
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M');"P1D@L/85D,%-C7<[<8NAPV>40 MSCNW&4]I"<F4CNU$L/CPQCD_6+6+
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M0B#:2M)=5"I4E0 ZP*JT@LJLS X,*KT2*1)%-\K<<KG@Q[63[=16:JV(!X>
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M7 >H^1EC\JVCBY^ZF@[_ %!+ P04    "  :B Y7NV/S&&T#   W#@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R]5UUOVS84_2N$!@PML$9?MN-D
MM@ [[K -S6;$[?I0](&6KBTB$JF15-S]^UY2LF(YBK 40EXLD;KG\-S#:^)R
M=A#R7J4 FGS+,Z[F3JIU<>VZ*DXAI^I"%,#QRT[(G&H<RKVK"@DTL: \<P//
MF[@Y9=R)9G9N+:.9*'7&.*PE466>4_G?$C)QF#N^<YRX8_M4FPDWFA5T#QO0
MGXJUQ)';L"0L!ZZ8X$3";NXL_.L;/S0 &_$/@X,Z>2<FE:T0]V;P1S)W/*,(
M,HBUH:#X>( ;R#+#A#K^K4F=9DT#/'T_LO]FD\=DME3!C<@^LT2G<V?JD 1V
MM,STG3C\#G5"8\,7BTS97W*H8SV'Q*72(J_!J"!GO'K2;[41)P#DZ08$-2 X
M!XR> 80UP#KG5LIL6BNJ:323XD"DB48V\V*]L6C,AG&SC1LM\2M#G(Y6H&+)
M"FNIV)%EJ3! *4)Y0C;5UIKY#=MSMF,QY9HLXEB47#.^)VN1L9B!(F]6H"G+
MU%ORCFRPU)(R X-+6%9J2 C'@LP$\A: -912";B"9N_L=]Q'A-E9=7PP3CZF
MHE2H0\U<C9D:O6Y<9[6LL@J>R6I";@77J2+O>0))&^^B0XU-P=&F9=!+^&?)
M+TCH_4("+P@[]-S\?WC0(R=L=BVT?.$S?*<6KVJ+_T*+/QB+UVCQQEJ\,!:O
MCA9_66R5EOB_^=IE:+7@J'M!<YA<JX+&,'?PM% @'\")?O[)GWB_=KDQ$%G+
MFU'CS:B//?HH-,VZ,JQ@8PLSI]M#-/:O<#,?3I4_#0I'TU$3U%(T;A2->Q7]
M;?]>BGRYA7P+LM/^7H:7VC\062O929/LY+5+<S*D-P.1M;RY;+RY_+'2O.RH
M.G]Z5II/@_Q1Z'>7YK11-.U5= ?H.XO-)FVTB._))\YT?Z7V$KYT-P8B:^5^
MU>1^]=J5>C6D-P.1M;SQO<>^P/NQ6JUQK6(-O;-:[2?O%D_Z=)_T,WZO[L]4
M2FPM^FNXG^.E&S446SOCX#'CX+7KN%YQ*'\&8FO[\]@K^;WM1D\EAQTGZFA\
M7LI/HP)O')Z=N^Y)"YZ#W-N;B2*V4Z[:S&:VN?TL;,]_-K\TMR+;VC_25%>J
M6RKW#-N(#'9(Z5U<HB19W5*J@1:%;?2W0N.UP;ZF>+,#:0+P^TX(?1R8!9J[
M8O0=4$L#!!0    ( !J(#E<L[11?20(  # %   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;)U4VX[3,!#]%2NLT*Z$FLNV!4H2J1?0@E14;;7P@'AP
MDVEBK2_!=MK=OV?LM*&@;A]XB3WVS#EG)IY)]TH_FAK DB?!I<F"VMIF$H:F
MJ$%0,U -2+S9*BVH15-7H6DTT-('"1XF430.!64RR%-_MM)YJEK+F825)J85
M@NKG&7"USX(X.![<LZJV[B#,TX96L ;[T*PT6F&/4C(!TC EB89M%DSCR6SD
M_+W#-P9[<[(G+I.-4H_.^%QF0>0$ 8?".@2*RP[FP+D#0AF_#IA!3^D"3_='
M]$\^=\QE0PW,%?_.2EMGP;N E+"E+;?W:G\'AWR\P$)QX[]DW_F.A@$I6F.5
M. 2C L%DM]*G0QU. I+DA8#D$)!XW1V15[F@EN:I5GNBG3>BN8U/U4>C.";=
M3UE;C;<,XVP^5T(PBU6VAE!9DKF2ELD*9,' D.L%6,JXN2%7A$FR9)QC*4T:
M6J1V &%QH)EU-,D+-#%9(G!MR$=90OEW?(B2>]W)4?<LN0CXI94#$H_>D"2*
M$_*P7I#KJYL+N+=]/6X][NU_U>/'=&.LQI?T\UP).N3A>63771/3T *R -O'
M@-Y!D+]^%8^C#Q=T#WO=PTOH.?X:P,<B@33TV<D_)["#&'L(UZV[/$[#W1G6
M4<\ZNLCZ%:>&H<A,&M %LF(?GR/N4-Z?$$>#*/F'.SQYQ0)TY7O5D$*UTG8/
MNC_MQ\&TZX(_[MTL65)=,6D(ARV&1H.W*$!W_=D95C6^)S;*8H?Y;8TC#;1S
MP/NM4O9H.()^2.:_ 5!+ P04    "  :B Y7!>_H,J$"  "2!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6RUE6UOFS 0Q[_*B553*TV!D.:I(TA-
MVZFM&JUJU.U%M1<.',&JL9EMDO;;SS8)RR:*IFE[ [:Y^]W_\/D<;85\5CFB
MAI>"<37S<JW+,]]728X%43U1(C=?,B$+HLU4KGU52B2I<RJ8'P;!R"\(Y5X<
MN;5[&4>BTHQRO)>@JJ(@\G6.3&QG7M_;+SS0=:[M@A]')5GC$O5C>2_-S&\H
M*2V0*RHX2,QFWGG_;#ZU]L[@"\6M.AB#S60EQ+.=W*0S+[""D&&B+8&8UP8O
MD#$+,C*^[YA>$](Z'H[W]$\N=Y/+BBB\$.PK374^\R8>I)B1BND'L;W&73Y#
MRTL$4^X)V]IV$'J05$J+8N=L%!24UV_RLOL/!P[A6P[ASB%TNNM 3N4ET22.
MI-B"M-:&9@<N5>=MQ%%N-V6II?E*C9^.[]"DI.#X$C6A3)W $5 ."\J8^6<J
M\K6)82W]9,>;U[SP#=X(%H+K7,$53S']U=\WVAJ!X5[@/.P$WE:\!X/@ X1!
M.(#'Y24<'YUT< =-X@/''?QIXD]WQ@)N-!;J6UO>->ZT'6?/SIDJ28(SSQP.
MA7*#7OS^77\4?.P0>]J(/>VBUV)-L:E$TM)6<YO ;L007I%(!2$4;H,Z5 T;
M5<-.Y-5+225QARLE&MLT=0-N*U;OK=W<<8>B4:-HU F\J*1$KH%P7A$&\@U5
M-:0?.(IM6YLXZ(TB?],2>MR$'G>'%K(4-B!\SC*:("QM-<#3 HL5RM:*Z@3^
M945-&KF3?UO^D_\@=MJ(G7:7/^$I$S(%HA3JUJXT;=O2X6];ZA_TR0+EVMT&
M"A)1<5VWS&:UN7#.ZS[[T[R^K19$KBE7P# SKD%O;"I=UC= /=&B=%UW);3I
MX6Z8FTL3I34PWS,A]'YB S37</P#4$L#!!0    ( !J(#E=MW\U96 ,  & ,
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*U788^;.!#]*Q975:W4
M70B0;+1-D'8#U?74JJMNV_MPZ@<')HE5L#G;;/;NUW=L6)H 2_>N^1*P>?/&
M;_S D\5>R&]J!Z#)?9%SM71V6I>7KJO2'114G8L2.#[9"%E0C4.Y=54I@68V
MJ,A=W_-F;D$9=Z*%G;N1T4)4.F<<;B1155%0^<\UY&*_=";.P\1'MMUI,^%&
MBY)NX1;TY_)&XLAM63)6 %=,<")ALW2N)I?)W. MX N#O3JX)T;)6HAO9O V
M6SJ>61#DD&K#0/%R!RO(<T.$R_B[X73:E";P\/Z!_8W5CEK65,%*Y'^R3.^6
MSMPA&6QHE>N/8O\[-'JFAB\5N;*_9-]@/8>DE=*B:()Q!07C]97>-W4X"$">
MX0"_"?"[ >$C 4$3$#PU0]@$A$_-,&T"K'2WUFX+%U--HX44>R(-&MG,C:V^
MC<9Z,6Y\<JLE/F48IZ-W@%56Y$4,FK)<O21GY!:]F%4Y$+$AJ2A*P8%K94:Y
M 1.X1Y/B]8Q\OHW)BV<OR3/"./FT$Y6B/%,+5^/"#+V;-HNXKA?A/[*(@+P7
M7.\427@&V4!\/!X_&XEWL2!M5?R'JES[HX1_5/R<!-XKXGM^,+">U=/#_2$Y
MOY8]^=_9CXH1M!8)+%_P"%_KAP\;LOKA!QQ9\Y"D\<-?5VNE);[Y7X<<4.<(
MAW.8K^&E*FD*2P<_=PKD'3C1\]\F,^_U4/E/21:?DBPY$=G11H7M1H5C[-&'
M$B35C&^/7]2AW:B)9I;('"5WT62.5KL[+/( )IP<8^(^)@BGQYBDC_&#L,4<
M*9VV2J>CEGS#..4I-#I3H?20R.DI+7=*LOB49,F)R(XV8M9NQ&S4<E>%D)K]
M2^VACR>$-.?RF19G%>X+50KTX'%0DTX/K=4Q7Q_A>QWO#4 ZSNLC#@Q\I/>B
MU7LQJO<MUX!5U 3EUN;+&5VSG&D&@TI'Z?ZK!R]^5K;XIXBDC_"'2S)O2S(?
M+<DGH6E.-D]Z(^?]3TIGW_L(OZNQ#^E\N9(^(@PZ(MV#EJD N;6]JL*%5US7
M1V,[V[;#5[8+[,Q?3RY7DX'Y&-OGNMO]05_WWN^IW#*NL%0;3.6=7^!FR+J?
MK0=:E+9A6PN-[9^]W>%? ) &@,\W0NB'@4G0_JF(O@-02P,$%     @ &H@.
M5X-D*3TM P  .PH  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULK59M
M;]LV$/XK!ZTH6F")%,EV7F8+:)P57=%B0;-VGVGI9!&E2)6DXNS?]T@ZFIW(
M6M;FBRV2=P^?>XY'WGRC]%=3(UJX:X0TBZBVMKV(8U/4V#!SK%J4M%(IW3!+
M0[V.3:N1E=ZI$7&:)+.X85Q&^=S/7>M\KCHKN,1K#:9K&J;_N42A-HOH)+J?
M^,37M743<3YOV1IOT'YNKS6-XAZEY U*PY4$C=4B>G-RL3QW]M[@"\>-V?D&
M%\E*J:]N\$>YB!)'" 46UB$P^KO%)0KA@(C&MRUFU&_I''>_[]'?^M@IEA4S
MN%3B;U[:>A&=15!BQ3IA/ZG-.]S&,W5XA1+&_\)F:YM$4'3&JF;K3 P:+L,_
MN]OJL.- .,,.Z=8A?>@P.>"0;1TR'VA@YL.Z8I;E<ZTVH)TUH;D/KXWWIFBX
M=%F\L9I6.?G9_ .2!@9>7:%E7)C7< 0W=%+*3B"HBI+;M@(I:Y8)*)BIH:*\
M Y?A_(14"F:Q!*M !+ C^'QS!:]>O(879 E_U:HS3)9F'EMB[/:-BRV[R\ N
M/<!N!A^5M+6!WV6)Y;Y_3)'VX:;WX5ZFHX#O.WD,6?(KI$F:#?!9/MT]':&3
M]>IG'B\[@+=TBK:,ET!Z FM4)ZTAS0K14;Q./%LC-"1KIWT67$Z\RB X6W'!
M+4=S,21LV'@RO+&[&RY,RPI<1%3\!O4M1OG+7TYFR6]#JCP3V)Y&DUZCR1AZ
M_F>+FDZ:7.^<OXX$J+1J0/6+X>P-*1'@9Q[>76JW>98D\_AV-\#'-FEVWMOL
M\9[VO*<_SKOBDLD"1U@'\.DNHP><QRSV&,]ZQK-1QF\]J1]F//M/QH\M)M-A
MRJ<]Y=/1 O*OSI&JCAQ/9@Q2^:@5764RE _>%363:_3U%0I'K01?^ZMKN'!.
MG[-PG@EL3YNS7INS)Q[ PSD;11CF!T-QGCW._2PYD-OSGO_Y$XXCPH>#[$?]
M_P?[G\<) <8[[W"#>NW;$P.%N];#&]7/]AW0&__P/YB_I,XH-#+_PH2VZB/3
M:RX-I;0BR.3XE#37H54) ZM:_]JOE*7>P7_6U-VA=@:T7BEE[P=N@[Y?S+\#
M4$L#!!0    ( !J(#E<7:WS,$@(  -X$   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;(U486^;,!#]*R=/FC9I"P32=,H :6E5;5.G18VV?G;@"%:-
MS6P3FG\_VQ"420G:%_#9?N_>\_F<=%*]Z K1P&O-A4Y)94RS"@*=5UA3/9,-
M"KM22E538T.U#W2CD!8>5/,@"L-E4%,F2);XN8W*$MD:S@1N%.BVKJDZKI'+
M+B5S<IIX8OO*N(D@2QJZQRV:7\U&V2@860I6H]!,"E!8IN3+?+5>N/U^PV^&
MG3X;@W.RD_+%!=^*E(1.$'+,C6.@]G? .^3<$5D9?P9.,J9TP//QB?W!>[=>
M=E3CG>3/K#!52CX1*+"D+3=/LON*@Y\;QY=+KOT7NG[O;4@@;[61]0"V"FHF
M^C]]'<[A#!#%5P#1 (B\[CZ15WE/#<T2)3M0;K=E<P-OU:.M."9<4;9&V55F
M<29[1&M)P[M[-)1Q_1X^PM86OF@Y@BRA\ZZP 'I 98MDZ^ JS<0>N$."057K
M)#!6BB,,\B'MND\;74G[O14SB,,/$(51_"\\L Y&&]%H(_)\\16^Y__1N;JD
ML^==7.9U+;'2#<TQ)?;.:U0')-G;-_-E^'E"=3RJCJ?8LY^-%6M&D1?/<9IA
M 4>D2L,<:BE,!4LHZ%%/2%N,TA:3Q ],4)$C/%X5-HU?]H(N2@G.KJOK_!]4
M[9G0]A!*RQ7.;F\(J+Z;^L#(QM_@G32V'_RPL@\0*K?!KI=2FE/@FF)\TK*_
M4$L#!!0    ( !J(#E>8:NP%#P(  )L$   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;'U4;6^;,!#^*Y8G39NT!0(TZS) 6EI5Z]1I4:.MGQTX@E5C
M,]N$[M_O; A*IR1?L,^^Y^7PV6FO]+.I 2QY:80T&:VM;9=!8(H:&F9FJ@6)
M.Y72#;,8ZEU@6@VL]*!&!%$8+H*&<4GSU*^M=9ZJS@HN8:V)Z9J&Z;\K$*K/
MZ)P>%A[YKK9N(<C3ENU@ _97N]88!1-+R1N0ABM)-%09_3I?KA*7[Q-^<^C-
MT9RX2K9*/;O@OLQHZ R!@,(Z!H;#'FY "$>$-OZ,G'22=,#C^8']SM>.M6R9
M@1LEGGAIZXQ>4U)"Q3IA'U7_#<9ZKAQ?H83Q7](/N8N8DJ(S5C4C&!TT7 XC
M>QG_PQ%@GIP!1",@\KX'(>_REEF6IUKU1+ML9',37ZI'HSDNW:%LK,9=CCB;
M/P"69,B[6[","_.>?"0;//BR$T!417I?%92$[4'C(9&2FT)UTA+-+)@TL.C!
M,07%J+<:]*(S>M\[.2-Q^(%$812_A@=H??(?3?XCSQ>?X7NZ;'!YRN' F)QF
M=+=@:5I60$:QS0WH/=#\[9OY(OQRP6\\^8TOL><_6[1IN=P1X?_\*7\#PWPX
M,G>K]GDX"Y/K--B?4$XFY>2B\AV73!9 'L[J#OC/KV7_5PV.>LU=VQ],[[@T
M6$Z%L'#VZ8H2/5R%(;"J]>VW51:;V4]K?#U NP3<KY2RA\!U]/0>Y?\ 4$L#
M!!0    ( !J(#E>D*,:"6 ,  '(.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;,6776_3,!2&_XH5$-HD6&*G3;O15F*;)D!#3(S!Q<2%VYRV%HX=
M;*<=_QX[R9*BNAE45-RTL>/S/N?XXXT\6DOU72\!#'K(N-#C8&E,?A:&>K:$
MC.H3F8.P;^929=38IEJ$.E= TS(HXR&)HB3,*!/!9%3VW:C)2!:&,P$W"NDB
MRZCZ>0Y<KL<!#AX[/K'%TKB.<#+*Z0)NP=SE-\JVPD8E91D(S:1 "N;CX T^
M.R=E0#GB"X.UWGA&KI2IE-]=XUTZ#B*7$7"8&2=![=\*+H!SIV3S^%&+!@W3
M!6X^/ZI?E<7;8J94PX7D7UEJEN-@&* 4YK3@YI-<OX6ZH+[3FTFNRU^TKL8.
M[.!9H8W,ZF";0<9$]4\?ZHG8""!D1P"I TB9=P4JL[RDADY&2JZ1<J.MFGLH
M2RVC;7),N%6Y-<J^93;.3*[!EJ31T248RK@^1J_0K5WYM." Y-R23*&887:(
M;7$W&'%&IXQ7G<\1$^CS4A::BE2/0F-3<L+AK,:?5WBR _^^$"<HCEXB$I$8
MW=U>HJ/GQ[_+A+:BIBS2E$5*W=X.W8\Y*&J86*"ZP/L/D$U!??.EV"GECL69
MSND,QH'=]QK4"H+)BV<XB5YW)!HWB<:E>GR8^;^_MGKHG8%,>TN+#U!:KRFM
MU[D&Y9(>P<.,%ZE;"<T>4":%66H$(H44V<6'9O&/?>E7@*0$.']93>*H/PI7
MGJSZ35;]I[+J^5!55'\#E>"A'Y4TJ.0I5-^'2K91,?:C!@UJ\!0J\:$&VZA>
M[$<-&]3P*=3 AQINH>)AY$>=-JC33M1G:2BO=WU.?]J/@?%ZS.D6FO0' S\;
M1ZTS1IWT:] :L2POC-VK3!BP1\1X+2[:XK\B/;*#O^',N)-_XXZD,&A%>0'>
MX^]-!F]/1ASO.#2X]5/<;:A73% Q@S^QTVZE/4T'MX:*_ZNCXD-8*FX]%1_<
M5&O";SMDQ_9H317OYZK=8?[90ET3U7HOWL]\N\/VR*BU:+R?1W>'[9%1Z^1X
M/ROO#MLCH];P\;]Q?.RQ?/\>)JW?DW_D]]TZ?S\]I/TDD$-\$FK1I&.RPHT;
MA+N-?:!JP82V^G,;$YT,[$RKZH)3-8S,RTO%5!I[12D?E_92",H-L._G4IK'
MAKNG--?,R2]02P,$%     @ &H@.5^ *D:_6 @   PH  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&ULK59;;],P%/XK5IC0D%ASZP5&&VEM0("HF#8-
M'A /;GK:6'/L8+OMQJ_'=M+03)FA4E\27\[W'9_/EW/&.R[N90Z@T$-!F9QX
MN5+EI>_++(<"RQXO@>F9%1<%5KHKUKXL!>"E!174CX)@Z!>8,"\9V[%KD8SY
M1E'"X%H@N2D*+!ZG0/ENXH7>?N"&K'-E!OQD7.(UW(*Z*Z^%[OD-RY(4P"3A
M# E83;RK\#(=&7MK\(W 3AZTD8EDP?F]Z7Q:3KS + @H9,HP8/W;P@PH-41Z
M&;]J3J]Q:8"'[3W[!QN[CF6!)<PX_4Z6*I]X;SRTA!7>4'7#=Q^ACF=@^#).
MI?VB767;U\;91BI>U&"]@H*PZH\?:AT. )JG&Q#5@.A_ 7$-B)\"^L\ ^C6@
M;Y6I0K$ZI%CA9"SX#@ECK=E,PXIIT3I\PLRVWRJA9XG&J>2KRD&@&]@"VP Z
M3T%A0N4K=('N;E-T?O8*G2'"T)Q0JK=)CGVEG1JHG]4.II6#Z!D'(9ISIG*)
MWK,E+#OP,S=^Z,#[.M@FXF@?\31R$L[Q(XK#UR@*HJAK.6[TYPWKH3BP\+@#
MGKKA*62]9[RW@HF;[8LM7^S</E%OWX^KA51"7Z6?7?M4,?6[F<SS<BE+G,'$
MT^^'!+$%+WGY(AP&[[I4.B59>B*REH+]1L&^BSW9'WT!&5\S\KOSC$Z=',=J
M5Y&%@64S[_(V"7IOQ_[V4),3>6QI,F@T&3@U:9VJ+CF<\&/EJ,C"J"5'^$2.
M$WELR3%LY!@ZY;@K5T*_0:C$CSKAJ2Y!*H+A00CQH!W!S.GCV!MS(K*6'*-&
MCI%3CB^<K2\4B )1DND" )KW1^=;$*+[!CDYCSTRHW_*G3I-JKC]@[19@%C;
M\D.BC&^8JC)H,]I4.%<VL?M_S:OR:([%FC")**PT-.B-]'D55<E1=10O;1)>
M<*53NFWFNDH#80ST_(ISM>\8!TW=E_P!4$L#!!0    ( !J(#E?R#B\SQ04
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M&^S?(0>XN8J/8?QQY?SQ(>L/?!X+0&OE;@$IA,LX6YZB",2<QQJA$933BN!
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M0F$FZ/$%YVK7, '*EUOX#U!+ P04    "  :B Y7#*:#W.P#  #=#@  &0
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M'B2X('FJ/O'MSU@ZU#7Z8I[*XA^VY=[ @SB7BF>EL$:046:?Y+$,Q)Y YY!
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M$D7V/;CW/@K7[ZEP\Y_!T1]02P,$%     @ &H@.5Y>*NQS     $P(   L
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M4,GI23?6K4G#@G:0.:&5KZPK[@4\V=_M=9'LA!5K(85[7B3-O82$E$*)4KQ
MODA&";$;_?1%&_&BE>-RE1DMY2*A;<,]&">ROZI7->0WOK9-C>/K.^Y!%LEL
MY <LA+&NZ=&,SSWC#GSGME0Y_4E(!V;)'7PVNMH*]5 /XV>1!M-HXM!=VR#.
MS?^$41>%R&"ILZH$Y=HX&I UH+(;L;4)4;R$1=)U(6<J)Y?*^2"1*]4.Y?O6
M,_6/OLK;63N/&\30S(5O,%=Y QX/\D*K')2%G/@[JZ7(/4=.SKGD*@,20#($
MD@T(^9T%D&,$<CP(Y*K&\3\-("<(Y&1 R%XDIPCD=$C(<0 Y0R!G0T). LA#
M!/(P+N02;&;$MJXGNB#GE14*K"7<9Z1550:01PCD4>Q(EJ5P=:<6S,?3^9P-
M*A-@ \1C!/$X+N(U<-MCH2,L98_BTMRX#1AR!SM0%810J$<BB^3R1^4%%])@
MPJ"1C7&69;IJEA&Y]7NS7DGOR?JY+3R'6J.8,FAD9Z#[LY>.*28-&MD:[?(G
M!_Z0)<&^"[$P3=#(GFB7W%XL3 PTLAGPEQKJBV)JH$.ZH2<PBLF!#FD'<A!B
M8H*@;V((<K $QX7L+4:&N8)%=L6?7.0#6?EA\TI"_=9#3,P>++(]4,Q>(F3H
M_Y#(6L$QPZW-,*VPR%K!,<.MS3"ML#?2RG[,:8B):89%UDSON+5_AV.Z89%U
MTUEP'Q?F%Q;9+[^X_I5Z0DS,+RRR7U#,?N;!_,(B^P7'##//&-/-N-%-VGW\
MRJ'PTL^_^D=87Y]QF=T:4E_:$_QD6DNUJ*2\\'4WZEKSO/N6UGT'/'T%4$L#
M!!0    ( !J(#E=DA-5Z5P$  )$2   :    >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'/-V,V.@C 4AN%;(;T RSDHZD1<S<;MQ!L@6'XB4$([&;W[(;C
MS\QB-J9G15K"Z;MZ(!R^3)O[QO:N;@87W;JV=YFJO1\^M'9%;;K<K>Q@^NE.
M:<<N]]-RK/20%]>\,IKC.-7C\PQU/#S/C,[WP?QGHBW+IC"?MOCN3.__&*Q_
M['AUM3%>1>=\K(S/E+ZUR[;3\X56TV05G2Z9&D\74CIT$$,0AP]*("@)'[2&
MH'7XH T$;<('I1"4A@_:0M V?- .@G;A@_80M \?1#'*& M(>L%:@-:$7),
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M2=9WYY9__7^G70LCE3WXL^XGVNP34$L! A0#%     @ &H@.5P=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  :B Y7(; RL>X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  :B Y7F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !J(
M#E>.X+MY[ 4  /H>   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  :B Y7J::+[K\%  !X%P  &
M        @($O#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ &H@.5]:5TJM0 P  !0L  !@              ("!)!0  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !J(#E?_570K]@0  ,P6   8
M              " @:H7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  :B Y7G+Y\!AL#  !>"0  &               @('6'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ &H@.5U_2J&KI!P
M7SP  !@              ("!)R   'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( !J(#E=;X-3':08  ',;   8              " @48H
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  :B Y7,)I;
MXZP)  ":&   &               @('E+@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ &H@.5Y[E*CYU P  I@<  !@
M ("!QS@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !J(
M#E?K6LGC=@@  )\6   9              " @7(\  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ &H@.5Y&GA.^H!P  (Q(  !D
M         ("!'T4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  :B Y7*_!QH[L'  !1%   &0              @('^3   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !J(#E?2<<&YI H  $D@
M   9              " @?!4  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ &H@.5U51*><" P  2@<  !D              ("!RU\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  :B Y7\SLZ
M$BT$  #8"P  &0              @($$8P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( !J(#E<')AIY30,  .,(   9
M  " @6AG  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M&H@.5RC<WYTD P  60L  !D              ("![&H  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  :B Y7NV/S&&T#   W#@  &0
M            @(%';@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( !J(#E<L[11?20(  # %   9              " @>MQ  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ &H@.5P7OZ#*A @
MD@<  !D              ("!:W0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  :B Y7;=_-65@#  !@#   &0              @(%#
M=P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !J(#E>#
M9"D]+0,  #L*   9              " @=)Z  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ &H@.5Q=K?,P2 @  W@0  !D
M     ("!-GX  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !J(#E=WWFGU+00  '@0   9              "
M@5V/  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ &H@.
M5Z#&XF(7 P  Q0D  !D              ("!P9,  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  :B Y7#*:#W.P#  #=#@  &0
M        @($/EP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( !J(#E=U_U8T0@,  "84   -              "  3*;  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ &H@.5Y>*NQS     $P(   L
M ( !GYX  %]R96QS+RYR96QS4$L! A0#%     @ &H@.5P*Q]>[A @  BQ0
M  \              ( !B)\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M !J(#E=DA-5Z5P$  )$2   :              "  9:B  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !J(#E<Y:2-U@@$  $P3   3
M              "  26D  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     F
- "8 00H  -BE      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>65</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>13</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statement of Changes in Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenue</Role>
      <ShortName>Other Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Leases</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/Equity</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Leases (Details) - Schedule of components of lease expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable</Role>
      <ShortName>Leases (Details) - Schedule of components of lease expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average remaining lease terms</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Leases (Details) - Schedule of weighted average discount rates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average discount rates</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/LeasesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/OtherRevenueDetails</Role>
      <ShortName>Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/OtherRevenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Equity  (Details) - Schedule of summary of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable</Role>
      <ShortName>Equity  (Details) - Schedule of summary of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Equity  (Details) - Schedule of summary of restricted stock unit activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable</Role>
      <ShortName>Equity  (Details) - Schedule of summary of restricted stock unit activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10q0623_actiniumphar.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Equity  (Details) - Schedule of warrant activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable</Role>
      <ShortName>Equity  (Details) - Schedule of warrant activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://actiniumpharmaceuticals.com/role/EquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="f10q0623_actiniumphar.htm">f10q0623_actiniumphar.htm</File>
    <File>atnm-20230630.xsd</File>
    <File>atnm-20230630_cal.xml</File>
    <File>atnm-20230630_def.xml</File>
    <File>atnm-20230630_lab.xml</File>
    <File>atnm-20230630_pre.xml</File>
    <File>f10q0623ex31-1_actiniumphar.htm</File>
    <File>f10q0623ex31-2_actiniumphar.htm</File>
    <File>f10q0623ex32-1_actiniumphar.htm</File>
    <File>f10q0623ex32-2_actiniumphar.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="374">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0623_actiniumphar.htm": {
   "axisCustom": 2,
   "axisStandard": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 374,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 65,
   "dts": {
    "calculationLink": {
     "local": [
      "atnm-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "atnm-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0623_actiniumphar.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atnm-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atnm-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atnm-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd"
     ]
    }
   },
   "elementCount": 291,
   "entityCount": 1,
   "hidden": {
    "http://actiniumpharmaceuticals.com/20230630": 3,
    "http://fasb.org/us-gaap/2023": 65,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 72
   },
   "keyCustom": 31,
   "keyStandard": 178,
   "memberCustom": 3,
   "memberStandard": 8,
   "nsprefix": "atnm",
   "nsuri": "http://actiniumpharmaceuticals.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://actiniumpharmaceuticals.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Other Revenue",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenue",
     "shortName": "Other Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "atnm:OtherRevenueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://actiniumpharmaceuticals.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "13",
     "role": "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "14",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://actiniumpharmaceuticals.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "menuCat": "Details",
     "order": "17",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents and restricted cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "menuCat": "Details",
     "order": "18",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
     "shortName": "Description of Business and Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share anti-dilutive",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c49",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c49",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "atnm:MilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://actiniumpharmaceuticals.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Leases (Details) - Schedule of components of lease expense",
     "menuCat": "Details",
     "order": "21",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
     "shortName": "Leases (Details) - Schedule of components of lease expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "menuCat": "Details",
     "order": "22",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information related to leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease terms",
     "menuCat": "Details",
     "order": "23",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable",
     "shortName": "Leases (Details) - Schedule of weighted average remaining lease terms",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOrDescriptionOfWeightedAverageTerm",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Leases (Details) - Schedule of weighted average discount rates",
     "menuCat": "Details",
     "order": "24",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable",
     "shortName": "Leases (Details) - Schedule of weighted average discount rates",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:ScheduleOfWeightedAverageDiscountRate",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c52",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "menuCat": "Details",
     "order": "25",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "atnm:OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c52",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Other Revenue (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails",
     "shortName": "Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "atnm:OtherRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "atnm:RevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://actiniumpharmaceuticals.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Equity  (Details) - Schedule of summary of stock option activity",
     "menuCat": "Details",
     "order": "28",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
     "shortName": "Equity  (Details) - Schedule of summary of stock option activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atnm:RSUsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Equity  (Details) - Schedule of summary of restricted stock unit activity",
     "menuCat": "Details",
     "order": "29",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable",
     "shortName": "Equity  (Details) - Schedule of summary of restricted stock unit activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atnm:RSUsOutstandingBeginningBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c62",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Equity  (Details) - Schedule of warrant activities",
     "menuCat": "Details",
     "order": "30",
     "role": "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
     "shortName": "Equity  (Details) - Schedule of warrant activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c62",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "atnm:NumberOfWarrantsOutstandings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c24",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statement of Changes in Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c29",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Description of Business and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies",
     "shortName": "Description of Business and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0623_actiniumphar.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 13,
   "tag": {
    "atnm_AggregateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of aggregate fair value.",
        "label": "Aggregate Fair Value",
        "terseLabel": "Aggregate fair value"
       }
      }
     },
     "localname": "AggregateFairValue",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement Axis",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_AgreementDomainDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementDomain [Domain]"
       }
      }
     },
     "localname": "AgreementDomainDomain",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_CapitalOnDemandSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital On Demand Sales Agreement Member",
        "terseLabel": "Capital on Demand Sales Agreement [Member]"
       }
      }
     },
     "localname": "CapitalOnDemandSalesAgreementMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_CompensationExpenseRelatedToStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation expense related to stock options.",
        "label": "Compensation Expense Related To Stock Options",
        "terseLabel": "Compensation expense related to stock options"
       }
      }
     },
     "localname": "CompensationExpenseRelatedToStockOptions",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_DescriptionOfExercisePriceRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of exercise price range.",
        "label": "Description Of Exercise Price Range",
        "terseLabel": "Exercise price ranging, description"
       }
      }
     },
     "localname": "DescriptionOfExercisePriceRange",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_EquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "localname": "EquityDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_FinanceLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Cost Abstract",
        "terseLabel": "Finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCostAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_FinanceLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liabilities Member",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_GrantOfStockOptionsToEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant of stock options to employees.",
        "label": "Grant Of Stock Options To Employees",
        "terseLabel": "Grant of stock options to employees (in Shares)"
       }
      }
     },
     "localname": "GrantOfStockOptionsToEmployees",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grant revenue.",
        "label": "Grant Revenue Policy Text Block",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_IncreaseDecreaseInLongtermLicenseRevenuesDeferred": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term license revenue deferred.",
        "label": "Increase Decrease In Longterm License Revenues Deferred",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongtermLicenseRevenuesDeferred",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_IncreaseDecreaseInOperatingLeaseRightofuseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Increase Decrease In Operating Lease Rightofuse Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightofuseAssets",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LeaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease.",
        "label": "Lease Axis",
        "terseLabel": "Lease [Axis]"
       }
      }
     },
     "localname": "LeaseAxis",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Details Scheduleofcomponentsofleaseexpense Line Items",
        "terseLabel": "Schedule Of Components Of Lease Expense [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofcomponentsofleaseexpenseLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofcomponentsofleaseexpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Lease Expense [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofcomponentsofleaseexpenseTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Line Items]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) - Schedule of maturities of lease liabilities [Table]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofmaturitiesofleaseliabilitiesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Details Scheduleofsupplementalcashflowinformationrelatedtoleases Line Items",
        "terseLabel": "Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesLineItems",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesDetailsScheduleofsupplementalcashflowinformationrelatedtoleasesTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LeasesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "localname": "LeasesDetailsTable",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_LicenseRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for license revenue.",
        "label": "License Revenue Policy Text Block",
        "terseLabel": "License Revenue"
       }
      }
     },
     "localname": "LicenseRevenuePolicyTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_LongtermLicenseRevenueDeferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of long-term license revenue deferred.",
        "label": "Longterm License Revenue Deferred",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "LongtermLicenseRevenueDeferred",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_LongtermOperatingLeaseObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term operating lease obligations.",
        "label": "Longterm Operating Lease Obligations Noncurrent",
        "terseLabel": "Long-term operating lease obligations"
       }
      }
     },
     "localname": "LongtermOperatingLeaseObligationsNoncurrent",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MaturitiesOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of present value of lease liabilities.",
        "label": "Maturities Of Lease Liabilities",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "MaturitiesOfLeaseLiabilities",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_NumberOfWarrantsOutstandings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares, outstanding beginning.",
        "label": "Number Of Warrants Outstandings",
        "periodEndLabel": "Number of Shares, Outstanding Ending",
        "periodStartLabel": "Number of Shares, Outstanding Beginning"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstandings",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of lease liabilities.",
        "label": "Operating And Finance Lease Liability Maturity Table Text Block",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_OperatingLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Member",
        "terseLabel": "Operating Leases [Member]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesMember",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "atnm_OtherRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other revenue.",
        "label": "Other Revenue Text Block",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherRevenueTextBlock",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_PaymentWithImputedInterestPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payment with imputed interest premium.",
        "label": "Payment With Imputed Interest Premium",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "PaymentWithImputedInterestPremium",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_RSUsOutstandingBeginningBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RSUs Outstanding, Beginning balance.",
        "label": "RSUs Outstanding Beginning Balance",
        "periodEndLabel": "RSUs Outstanding, Ending balance",
        "periodStartLabel": "RSUs Outstanding, Beginning balance"
       }
      }
     },
     "localname": "RSUsOutstandingBeginningBalance",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "atnm_RevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of revenue recognized.",
        "label": "Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueRecognized",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_SalesOfSharesOfCommonStockNetOfCosts": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales of shares of common stock, net of costs.",
        "label": "Sales Of Shares Of Common Stock Net Of Costs",
        "terseLabel": "Sales of shares of common stock, net of costs"
       }
      }
     },
     "localname": "SalesOfSharesOfCommonStockNetOfCosts",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Abstract"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Components Of Lease Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Anti Dilutive Abstract"
       }
      }
     },
     "localname": "ScheduleOfDilutedNetLossPerShareAntiDilutiveAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturities Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summary of Restricted Stock Unit Activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSummaryOfRestrictedStockUnitActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSummaryOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summary of Stock Option Activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSummaryOfStockOptionActivityAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Abstract"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWarrantActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrant Activities Abstract"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivitiesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Weighted average discount rate.",
        "label": "Schedule Of Weighted Average Discount Rate",
        "terseLabel": "Schedule of weighted average discount rates"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRate",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_ScheduleOfWeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Discount Rates Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOfWeightedAverageRemainingLeaseTermsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Remaining Lease Terms Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "xbrltype": "stringItemType"
    },
    "atnm_ScheduleOrDescriptionOfWeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Weighted average remaining lease terms.",
        "label": "Schedule Or Description Of Weighted Average Term",
        "terseLabel": "Schedule of weighted average remaining lease terms"
       }
      }
     },
     "localname": "ScheduleOrDescriptionOfWeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions Description",
        "terseLabel": "Discount rate, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictionsDescription",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Description",
        "terseLabel": "Expected volatility rate, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term Granted",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Ending balance",
        "verboseLabel": "Weighted average remaining contractual term (in years), Outstanding Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_StockOptionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option term.",
        "label": "Stock Option Term",
        "terseLabel": "Stock option term"
       }
      }
     },
     "localname": "StockOptionTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_UnrecognizedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation expense.",
        "label": "Unrecognized Compensation Expense",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "UnrecognizedCompensationExpense",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "atnm_VestingPeriodOfStockOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of stock option.",
        "label": "Vesting Period Of Stock Option",
        "terseLabel": "Vesting period of stock option"
       }
      }
     },
     "localname": "VestingPeriodOfStockOption",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_WeightedAverageDiscountRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rates Abstract",
        "terseLabel": "Weighted average discount rates:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRatesAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageRemainingContractualTermGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term, granted.",
        "label": "Weighted Average Remaining Contractual Term Granted",
        "terseLabel": "Weighted average remaining contractual term, Granted"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermGranted",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "atnm_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Lease Term Abstract",
        "terseLabel": "Weighted average remaining lease term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "atnm_WeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average term",
        "label": "Weighted Average Term",
        "terseLabel": "Weighted average term"
       }
      }
     },
     "localname": "WeightedAverageTerm",
     "nsuri": "http://actiniumpharmaceuticals.com/20230630",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r110",
      "r189",
      "r383",
      "r399"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r110",
      "r189",
      "r383",
      "r384",
      "r399"
     ],
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r80",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net of accumulated depreciation (in Dollars)"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r42",
      "r365",
      "r417"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r284",
      "r396",
      "r397",
      "r398",
      "r405",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r6",
      "r27",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Diluted Net Loss Per Share Anti-Dilutive [Abstract]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r64",
      "r81",
      "r96",
      "r122",
      "r136",
      "r142",
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r208",
      "r210",
      "r222",
      "r255",
      "r311",
      "r365",
      "r376",
      "r403",
      "r404",
      "r410"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r77",
      "r82",
      "r96",
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r208",
      "r210",
      "r222",
      "r365",
      "r403",
      "r404",
      "r410"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation - Unaudited Interim Financial Information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r17",
      "r79",
      "r355"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r18",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r17",
      "r52",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r52"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r387",
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r37",
      "r256",
      "r298"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r162",
      "r163",
      "r352",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r396",
      "r397",
      "r405",
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r41",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r41",
      "r299",
      "r317",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r41",
      "r258",
      "r365"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 1,000,000,000 shares authorized; 26,984,443 and 25,674,823 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateAndOtherMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate and Other [Member]",
        "terseLabel": "Corporate Office Space [Member]"
       }
      }
     },
     "localname": "CorporateAndOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Long-term license revenue deferred"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/OtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r4",
      "r25"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation &amp; amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [
      "r289",
      "r290",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r343",
      "r344",
      "r345",
      "r346",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r289",
      "r290",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332",
      "r333",
      "r343",
      "r344",
      "r345",
      "r346",
      "r356",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetAssetsPercentage": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r368",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of value of derivative contract to net assets.",
        "label": "Derivative, Net Assets, Percentage",
        "terseLabel": "Net sales percentage"
       }
      }
     },
     "localname": "DerivativeNetAssetsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r89",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r111",
      "r113",
      "r115",
      "r116",
      "r117",
      "r119",
      "r220",
      "r221",
      "r252",
      "r264",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share \u2013 basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r89",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r113",
      "r115",
      "r116",
      "r117",
      "r119",
      "r220",
      "r221",
      "r252",
      "r264",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share \u2013 basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r20",
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r6",
      "r74",
      "r85",
      "r86",
      "r87",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r120",
      "r148",
      "r149",
      "r186",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r250",
      "r276",
      "r277",
      "r278",
      "r284",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r235",
      "r242",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r237",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance leases current liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r236",
      "r245"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance leases",
        "terseLabel": "Financing cash flow use from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance leases right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r235",
      "r242",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-to-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r248",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r247",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49",
      "r321"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r16",
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Other revenue deferred \u2013 current liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r385",
      "r393"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Payment of security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income - net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r90",
      "r92",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots.",
        "label": "Land Improvements",
        "terseLabel": "Landlord assets"
       }
      }
     },
     "localname": "LandImprovements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r241",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Current annual rate"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023 (excluding six months ended June 30, 2023)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r96",
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r209",
      "r210",
      "r211",
      "r222",
      "r297",
      "r360",
      "r376",
      "r403",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r46",
      "r65",
      "r260",
      "r365",
      "r395",
      "r401",
      "r406"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r78",
      "r96",
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r209",
      "r210",
      "r211",
      "r222",
      "r365",
      "r403",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided By Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used In Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used In/Provided By Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r48",
      "r54",
      "r66",
      "r76",
      "r83",
      "r84",
      "r87",
      "r96",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r114",
      "r122",
      "r135",
      "r141",
      "r143",
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r221",
      "r222",
      "r263",
      "r319",
      "r334",
      "r335",
      "r361",
      "r374",
      "r403"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow",
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r135",
      "r141",
      "r143",
      "r361"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r243",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcomponentsofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating leases current liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r238",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flow use from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating leases right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r248",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaveragediscountratesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r247",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofweightedaverageremainingleasetermsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r39",
      "r55",
      "r56",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r1",
      "r47",
      "r223",
      "r224",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestrictedAssetsCurrent": {
     "auth_ref": [
      "r350",
      "r351",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.",
        "label": "Other Restricted Assets, Current",
        "terseLabel": "Restricted cash \u2013 long-term"
       }
      }
     },
     "localname": "OtherRestrictedAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r40",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r40",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r299",
      "r317",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r40",
      "r257",
      "r365"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r2",
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r10"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r254",
      "r262",
      "r365"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $590 and $487"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r38",
      "r205",
      "r412"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net of reimbursements"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r387",
      "r394"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r68",
      "r388",
      "r394"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash \u2013 long term"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "auth_ref": [
      "r341",
      "r342",
      "r347",
      "r350",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of all restricted investments.",
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "RestrictedInvestmentsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails",
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r60",
      "r259",
      "r279",
      "r280",
      "r283",
      "r300",
      "r365"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r74",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r148",
      "r149",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r212",
      "r214",
      "r215",
      "r217",
      "r219",
      "r276",
      "r278",
      "r284",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r123",
      "r124",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r187",
      "r188",
      "r251"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r320",
      "r354",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r88",
      "r96",
      "r123",
      "r124",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r147",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r222",
      "r253",
      "r403"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r246",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r246",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsupplementalcashflowinformationrelatedtoleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate value of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of common stock, shares (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of diluted net loss per share anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrant activities"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r362",
      "r386",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Expected term year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant date Fair Value Per Share, Outstanding Ending balance",
        "periodStartLabel": "Weighted Average Grant date Fair Value Per Share Outstanding, Beginning",
        "terseLabel": "Weighted Average Exercise Price, Outstanding Beginning",
        "verboseLabel": "Weighted Average Exercise Price,Outstanding Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Number of Shares, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Exercisable",
        "verboseLabel": "Number of Shares, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "terseLabel": "Weighted Average Exercise Price, Exercisable Ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Cancelled",
        "terseLabel": "Number of Shares, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "RSUs, Granted",
        "verboseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance",
        "terseLabel": "Weighted Average Exercise Price Outstanding, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Cancelled",
        "verboseLabel": "Weighted Average Exercise Price, Cancelled/Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term (in years), Exercisable Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Outstanding, Beginning balance",
        "verboseLabel": "Weighted average remaining contractual term (in years), Outstanding beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofstockoptionactivityTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "RSUs, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofsummaryofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r75",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r362",
      "r386",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r6",
      "r15",
      "r74",
      "r85",
      "r86",
      "r87",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r120",
      "r148",
      "r149",
      "r186",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r250",
      "r276",
      "r277",
      "r278",
      "r284",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r120",
      "r251",
      "r281",
      "r285",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r120",
      "r251",
      "r281",
      "r285",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r40",
      "r41",
      "r60",
      "r282",
      "r336",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Sale of common stock, net of offering costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r40",
      "r41",
      "r60",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock from exercise of stock options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r40",
      "r41",
      "r60",
      "r284",
      "r336",
      "r348",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r15",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r41",
      "r44",
      "r45",
      "r57",
      "r301",
      "r317",
      "r337",
      "r338",
      "r365",
      "r376",
      "r395",
      "r401",
      "r406",
      "r418"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet",
      "http://actiniumpharmaceuticals.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r95",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r218",
      "r339",
      "r340",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r244",
      "r364"
     ],
     "calculation": {
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r69",
      "r70",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ScheduleofdilutednetlosspershareantidilutiveTable",
      "http://actiniumpharmaceuticals.com/role/ScheduleofwarrantactivitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r111",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://actiniumpharmaceuticals.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r381": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r382": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(3)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001213900-23-067199-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-067199-xbrl.zip
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M#T-[)RT8LA=P9ALZ"Q OO[F(KG@[#1LW(U+/*); UHB,CTK*F(NX.U.M*20
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M*$0E=^;$]9K>_7\BX/T?4$L#!!0    ( !J(#E<_(O0U$ D  !E8   5
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MOT2>KKES6#/9-4 2K,)I&N"@)7GF"52P4A33&Y*;(H$>S .^<>"1GP0T2OJ
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M1?3Q(W;]T+59;\'<U/NBQ#JF8NKBRZ N:]$ F1),W3H,PFE]9&W-S_UKA-W
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M+<_+"A1KL/3%\89DZ7>0D,F14(/\=(GPG.SA'W'P&"UHJ-KR=6RRU>/V/Z#
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MP56>+'Z]2Z(ET65/_KD-\Z>1V2Y9 .(TZ(*A%83ZY__U'^\.]M_^ ?%A-;D
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M2,'SU8\!A3BO/]GLDNFT$_@/D3/"9!G6;#SE 9[@-KPJW]]&&DP3$:(SBYA
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M[IP_6>/TEMP\WZ?)0WY'([:#>(R]+Y_7IU-* X=>&HHAB(]!8A"T-4'+J::
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M/C1CQU1"1Q?2A8*F9@0@9#WX7!<Y6ZHX%8_[$K-_X66OG@_=4?YN,CD "KF
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ME-7IXZR<_HAIB6IR*-X3!?@6?]ZN;W!ZONI$.4UQMO5;&\!ZWPM A9P6<Z"
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M?T!!;52W:S2$*%FPL]F544\%1Z$BIV!**X@<8_YG[=P3@0L37?T]%O8O<O;
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ML& U+;DK^Z42+_>R#[39V5T2+0E!:3W]_.ESDN/I2\+:K^N]!8@M9 J!XF-
M7ZV]F=JHO] +?W<C2Q7!P<H<?R GUY(60L9QQC*4&!SG+, W*W+(/-4><08(
MKEV-*\A6Y4C*-E 9G0\EO%U4D8L(K6N-)TCR,B2#2#M@?]!E;]K+'J8IS;6@
M.N"'I^H3H18>/@3I4@!UOLVS/(BIVT,5@$?+.-/PEFT0T3"\@[$W%  &$(6
M_*-I"LX2XU$Y :K-@.@4Z.LP1D_D/9M]@VH [* /^#:,V9";(*(>4O#M#;</
M&N<!$)?'3O<D:]XDLQ1H60=J38[)HB;1>5.B=^HBC6X*B?Y=DF'9Z_Y(D=[
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M87*P+<7$XI0;_1$B7<1_EJ8<$)4/C7;^)'+!/H6^ZO5\:CXUE#BZI$M^V1!
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MC2YB5?HV^YHN3%Y<W]3*SE2+*Z+.0>H+C$]2V1Z>CG7>[F7O*2O*F(5J'77
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MPD<RL;@5R$_(/^C#C'[Q_P-02P,$%     @ &H@.5UN@=Y?K)P  4(\" !4
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MZA%I$S;,V$1*IHULP^Z.*ZU&MY%%3G])2:^".5"NL96L8@=QZ?K:I)7!@&I
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MJ>^1'J<5TN1+)B,3]U;N*2\@CQ\U$R]WKE=@+NS^DE<'P[?\\;Q 8K(_M.F
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M&9.DQ],Y.[6C86M<% BB7MNIRL@9AO_(!]Y\V']C;)8:NF9JD."81LAM4W^
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M4HA//\8R=,B"E08K[FQ>AE9(A%P 6-(3UDXF'3X+8#N?L(<++)>&MZ$_L$G
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MP>C#^_<O+R_5'ESC]RR/^V[H];B/7[!*13[NW./XL _L/G18-WQB]2:KGWR
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MI-(\/:D5SRMV'%LQ?_V?TT;]Y*//'KC-1[A\:7:"]>+T[!!U:@V!I.BKB%9
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MI//3M+&2P8M</UT4?(V:>V3MD)+!VDRT0UG94;#+@KM&1V_45VI,D\$)4#2
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M-W1$8"4B;?6*I0\D4I$&/[!Y#@2*?-0 F14=S'/!2:CO[,E'/ %.2 @;N5Z
MM5J*I/\WVC5N&(.?\) O *[A(_=8LZXS''3W>J1(2HW<M^RXC7DLSEU-+DV+
MY<*CDC"]Y 4,O@,:(IYFQJ46B=#"'%*X3KJ*EMI2FL\%G<+3+"#FNW4I:((S
MK7* ).?49A*VZF".AR(8N'YTJB>O!*4)19C[@L?$#Q]]R[2 (^Q716J<I!-A
M-J3N[SZ_Z5_ BX8H G=.S]\%]*,%,*3ABH:8%UJ'H8R> /GJADJ.8*0H07%V
M O'16%1* >HGY(V&BKCQ.V<\6A^UN_?]<"B*:V!9!L@^RMJ3D@&I'1:@1@3#
MTF?/JL',$3I_\%Q%@;.WH$WH:?/>$\U7,4,2L?%UI)Z1\$-U(Q",78BP'HD:
MTX(M>(HIX)F(MEP 3AXY+M+NBZ6$G_99R$R!99D$D\F;Q/&S^A\V><?.#Y](
M<Z(@5&(QI"S$*Q:_Q[)%,DDB5<ODGD^:W\!Z&@"KM"UXCAFS6#IBKF?!"H'D
MAF@O"]HG>O<X9T,Q11GD@<W%'$?0>C"^K24RKZKLLV&C6@]6";=)Q4WP:]+9
M@O$(36S2UN @H/*&+[GD)AHB3,[D '4/!!T9".>N!R=#"D;\EN/I!,90!(*?
M9.Z2D(THL29GJFX<,<O,[XCLE)"1*/L@J-T7Y'*@XQ@@JR.?V.SZ@'F9?&J"
M-RH@3;IH2BWY$%%'$BF'J=K>]\"" _OXIC\;L0\8#$TJNSL@Q6:>I-B -5-$
ME_6X;<L0_"]'*!K@LS\R>NIS.A>N!_2$[K0/3/WUD:GIN+7:3R+]*PN*CS*E
M':R<1Q01Q_*XWC$I]6[H S7[.;==VN:T].@H_OSHO?_$WM:H>,5UQ'N!]41
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M 0U06/LESD+J<>L9K@E<YG-,]')$4%MGE(AJT2^ ?<?'*+(13ZNF?"ZXFC0
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M@2$;.(9*8Q]:-FS"!8U/70],M$^J=JS2QFM>=G.*E6HQ*TT*L.@N7TH"L7S
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M+YOX_-T I'IC)D<P)S-LL63*LX8JCI3N#&+(8TTEB%&'HP7/5<B/KC4M46-
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M=NYM)G3%#?7F>9M?+;:R%.^\!M=T6V^<+6]%O4$KL95\U(6U5<O%',1BMNO
MQ(RP.1KC/AQM>]7I$B#)H-/5]7ICN8%8Q,#)'A6O!(@W5+SJC6JGZ'&K?:I'
M\R$]3SV2P=2C3R?5=FV9DE1XNMZ5)C,-[K3&4E\00M>;M4TYR&1WTV(TCIK=
M2.JP.DFURTY2JI-4L^PDM:7J]JD>4FN5L>]T-U_F]ZG44GIDNB;L24@7EBS?
MH+8:#BR0#T>V.^:<OAB%7F^ ;<\75R"=KMN;FN2<K!^3W/O!O5 K6#E5)JHS
MF%,Q)KOZ.HRK!/41JC@:2A8$)!6(+U(8<*>)Y7_A?L^S:-TW_936=(>RZNC3
M7TZKM38"\B_U>K4S)<FQ D(L5<=>P]0 I;]T 9E4EABBJ$]@:>'4RRFK7!>-
M,=DS-;!ZDNUO\UK&/\5311 HA>>C3ZW9"ZJ*(XJ%1XHR!\8S3]7AFZQO6)X6
MM>9?4B!WNFX7DLCS<0FO(Q5B037<C,8C40$C=3/%YBUP<R\4S4Y#7YU=$D25
M^QZP&J19VG4%*5,V'.9VE?W3\"Q4*WRX3W3<67:G1G>J@O /[+C^CIERNC;#
M;F*RM]2J1+^VW1$!L>O[X5#@5HW[OG2]6]</)!5B53\L0UP1G[&C3\UJ^R<\
M3JUJH_[3%/T<-][%[9QMJ\^7D?$.\G%G;?I"KA%/)DB,SKR3>=Q,[.?9!;(1
M#84*@#>UA7]&J\*![2E<G=:K=4(6_-&90I:N(=\Y;KUC?W+/C;<)TAC[FIO^
M&^I"0$66 &0Q:X2D%K81E^Q/LZB4FOBT&_M<J3O'(Z>_AJX74/LAU=7<HF;+
M"%+L,9?F[;*+?.@DVA;U$A2AF@A/-4?2EG>?6I_5?D\L)TF?%V(Q\_GNV2*^
MFVBK'SH(!H21 &O4-=J/B4]T%I/[E] TV(NJY3)D%5=.PG'"%R#D=+,Z1U!7
MV4QM;T;O<]'%:KH50-0,;B:V$Z!*ZX5;E*\S$'TGEO'@)G7"15)W0=L !,.2
MI9_M;^FUZG086BU=3QQ?>_PJ62%5UBM!#W0GBNRQM>G62^R+6D[OQ= 01Q )
MAOI=W=U_U\L">W7>8JHAHB&:(4VEK+9?H=K^@(KM@?S+TGKQB3PF#!NK,M3+
M12FTJK,'=85.3'ZU]CLICS[IO+;RZ%5\8$C<B<U_YL!Z,23T6;3-79S,UEB>
M_'QPI;-%*C]?FAQS[4J[8D*;IW/Z9:;K:&$]2(YEZ_E-RCQ#-EBT L]UHHH;
MA,O398:_8K.QA4>SL&6$Q:W\6%C)N=:!.JTV-TU,V&T&N93*,X[?/XG+''SA
M4>:QP:U\QP8?1.%#9N"TBS=3N:R!V(L"V%S>.^4M)U&_4D6QDZ5G3OX#FE^;
M#W*^DP[/),5-, I"0Z\,S[;@,_KI#-8;B+$\?3%FQ+49CH20DX/4R%9+M%O'
MKSR@MI$E6XM'XTDL)\1!OW)$),-.YJ&8HB7<]8:/3Z!Q(P&\D#V.4_WV:1:/
M$<HQ8?$L60.X!]"6CP:T?+\IF]?CWY3](6) <=!)_8C[UI<XS3OK#(55!RSV
MW5W1>:"ST@TR!-@;"P(].@77$Z.=*0X;S9=!+Z%&J1Z^^@XAXJ= (@86T:1<
M@((<CVGY,L:6")916 B;Z"=";,' X[R"@9IH@/#"()LV+\BV/-S2J>\\QE:O
M3K>)B*(L^0?0<(>KQ.77X=?T3RH]I8XD-E61M##XMCS5*G/,C1C.=G"O8$42
M"1?F\0&\'LCVRH%E\4O7 P0Y8NIJ;YSHV-UU3/IDT[)_-2SG*YB]7<_"U!4!
M$0&[:Q[<]!^,'XNB7?.[T4^-;%T(*HU E6UN[58C9S031@@I):JV.PJ&0F:_
MT?3@[0?))F1CXT282=&6]S/WYG)F\ PGE[P(N!0Y2J9@F'^8;&:BJJ*4&^^.
MQNB5 ;&R_?2;B)&5[:=S;3\M%E_VH"Y[4.\]"-A9V\FFIM-$0C&&Q)(Z [W5
M6E[!?OAM<3O[:":]6Z]9O5-M+V_]<G#Q\MDV=*O8O:;KU69S66'K*SA4&]?!
MYM-9)UT'NZ!=1Q&S#VK5>H.,OP)D('1:!Y2"4-C>HBN ^+";26>(SA6P+4(&
MV3&K@&%I,X-Z+1&V*E@W@^*T@UG(!.>:1Q<_1I;WEO)#.F5^R'S@G+Q!X)1=
M4LO\GWWF_W36S@#?R#>Q>O?K(N3_3!E9N:3^E#Z, J-\>UU.L^JK>VES6JN>
M3G6Z. 1TK7U"DQ'Q?/^MY)CAEG,+Q\+:*.5B#F(QN6M@RWN*EAK87CN6MEJ'
MF;G]BC2W_!NAMJMGRP=J%1&K>U7.MM#X,Z-^5B?];&D@JH@86_L<YJE%S:D3
MH,_)?HHY-WR<D8:8^PM6:E#:*1N4J@:EK;)!Z>KT2O\8U'74^$^MUD3Z,SYM
MLSTJ+>GJX>(;:U296-JW[G7WUXMO%]</LDKEGGVYNC__?G]_=7.M=:^_,+C@
MZ[_OK^[9S26[O+KN7I]?=;^R\YOK+U</< W#:^XN[K]_?:!+;FXO[KKXPW8.
MJ?BW2E&1F3M,8'[[_68)H)<W=[]U[[Y4OM[<_._5]:_L_J'[0!!EUS</5^<7
M6P1$/0*#2C>NJ%[+V^65*U5663Z[!&4 WE+Y!^D)()9]X$H>_H$532C.*[;K
M_H[YB5@1)<*V5;P-ZYM\[$D[<GWLF.J,$U>HIZGFF*DW4?]-S/1UW"!YC]MG
M<&'@>FAI,8R=P-[&VB,'910N404MB]8E0/N;A3G& ;.MH16H0A%D84\N^<!?
M@+/[S ][ V;X#,]7H_817J73G_6/ZJL7R[;5=YK\3E373%[YR&V+/_/)KPT0
MNCUK!.N;_ 5K74 +X^IK@*?\14KJY"]8@V%X*-PU45/EVN[3F$!H@02A/'J
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M?<\MNOP!9'Y1Y3&M5."M%#<-[3J58)/,D(JFHO,8D1^>]<3$X2^8TA>T(L5
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MM@MB5^B"8M>5PW(GZ[)6/JPP'X/^*$WW$7I&D<R1P!$%*(^*/FFX582%EW0
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MAK>TNINRYWNWTL;G^VH7]$D07<.:#;Q$AG"\YEY7R;@B1D&U9C3CB0'-///
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MOZ*$UX@Z/F XF\O)*/[TG4J$Z\96CK:Q%8VM'&QC*W?R2'^B)!UO/YR,C,F
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MK@LO+E%=T'UV/VXSV=P@S/R2<Z;"CS$!BW3^G1J>&UW1)A)7W498*SP&'CF
MN'PM)X\#.PP'T)XAX:3 CLVB-D$ )UVA!0>/S.0I74YA8%%53HD(@0R,*BWD
M^ZXOJ>1,'HY*<_G7&[.KH3$A3Y@K,_1.3[9KT+2:?D$F%\](>[RFS^U,[X+0
M3QE55Y65XL_1=4/&I!O3]+<=:;W,67J\=9;463K<.DMW\T!S<^,V=L\7M/]F
M02L&:  &Z/=I9GTJP;.[<U^3RE1"R>$Q)X@)YDIR3C;F!'5QPO93Z?,%.2AE
M)^FK+#VV-"C-QMBVF7'H9;)2,!05Y%4T+2YSZ]#;U3RF'[K^<_B0?.]S>-O@
M<?\0TQTO,]/N.N+*6\*\<]308'JU$*XQ*4)[FQ%0^,#QGEV _#09%:#3@RRI
M83"K)$OC\.'^'N;+<30'8/P^>(2E#6,JRBK#A[L':*K24'?[^P\><3::.)ZX
M=E1,G3FR0VD%H<+(?O_WBV<&1_9P8&:]=] _@EG?,!/S;?J(OQ?Q)$&O^O'.
MP=.]\$RWM/=\F11$ 3J4/2611[C@,_>@FH#UF=0[/HO7U ,):;EZ+X[/[JG<
MV]TFMK]RHQFW;*%=RQ(%GDU/90!:%='!%!M)SW>W2J:C#[10V+3*PZD,G:2\
M6@/"4O >7=/ :=NWH%(9JMXF_[G.5NC;3ACBV]%AFDMFA 1"^7@LN)CZKKD?
MF>1@Y'9.,4@0.9W%0@ K %[KB%/)2^KD-IW7.!!N#)76I0.'PH00%TK[HT3D
M^#0F2+1K&T4H0Q;<T \6@+HN4_8T729>,,++*9&/="U66]-3SFON8UAL@[B;
MN=;I>B&DF*!WN*8'*>TT2CLE5'KI%TAAP13.W^V3MXFGCW<H(!_0Y/Y=_WD>
MRZX8Z)4]71*+9JI@,"PRQ:AI>5+G<?/*@!O]U .;UO/X"1W&YDVTA,YLD=32
MT0Z1 XO'N31H*@PEMG!F4"PNV-!&WJ-0@$7&*D<I?59'W;0#Y.<W8^P1,S4J
M0[DC,_3(.!781GQL'7-PS)]L'7-US(^VCODWDP%I]CC!)VJ+"Y0A[[%K-NJI
M8&B9')175K6 DLC>4T-V\)T8LG>6$/.WFIJD/W-Z^.$Q?(6M[8^IM?V)(>8/
MG&SY/26_;#1!$"*.H$$GRM6YH/RI!QI]LI/8Q<0BV(Y&,XI,B;02$F]C+S8L
M=<N,Z1AX#TT[H\ 425M8_(H[;EPX%$5E/$V$?:M)$=6F%(H8JC<5W!F/S^5'
M!C/5!GD(*9%<!"T#UT-%L.7%DLXTTV2_ 1Z(]&E2%V_:/(?/I06 9_5-,2,3
MA[^^&OIY43;O\RD2:^_Q*J=30Q% /<^Q:<PX7>DV.3VIY9TN0H3XR ?[]RK'
MYW5D=]N2)R[;#*[=^_ZI*1?7172;@"*TE]-.#)?6]MZ):?\=P0>6,%#"E0J@
M6H)F9U0A_Y:5Y-E%'AZ7$D/[Z<LO#_\7YW^5A>KM] >7=E)C7P9;#JTPG)G-
M_OG#S@_<@F@5C_7OUQ[R13JIYOC1G0<_4$_OJM"':$92!PZVW0]BE543_9!\
MO]$&KIIL_B!/TU,M.-S>%'9OL?[I4P.FSR+RG.>'[WQR>/3DJ=N@O/GN3RNW
MOS4",-,TAH@6UD],X992Y7.^3$OI,(L"QK*WF/Y&)&:=$SZE7I:NH"8*"FO=
MB> UT1M7&HK[;&_%!O%\8^W<M[?@/MT")1F2>X ]7F<Y,Z\A!VJR6%DBHI*5
M/;?E<SE58K!SRLH+\S0YY1A;;AHOHL:OL\T11N4"F*1E4?.+'))2C04YT/78
MB486"1BW2E"94INGI*!8D#,50]Y $4-"#/7J520\C1K\0N-E>_.V-^]KZ)]U
M4LBM,QK&L:OK;)&//R@UI!)[:L<G<ZU06RRXT[H6B$7><XPK8&^7ZIPV?RA7
MUW)/MLN4D2K'[=787HTO?S606#NIR%T6ZTRQ=\JM1<7JIHDF96"D!3E[>=CR
M#=LO@0(R<'FB^U,><ZI8CYCUC?E@4NH:.*[+1KMR;/"$_4--!P6Y/$H(-+:#
M9?IR+WU@^AGY[8S(ZYWDW-8JT4;F(?=ZY#^?IU+A[CR_X93BK Z0KV9WA\L/
MYJ!^_V)5B16!:=%T;L5]=H(0VQO\-6[P_N/5QZM<X,$^?NZ[N[X91E2Y*/(8
MPT=OJ<24[[(?*4C_BELG^R)=+)J-Q\;N,Y?4ATL(X_-5>+ C(=P2 >J8BU-R
M,KAJ0HTGD8Q1XC\*;M$R0?1/#FH-EB#&RZI<@%-J%5,R(R<-L3UPY/,_)V*J
MT1HIVE&"P%_V#B3\?[#3@S&55$]MPR/%+,[D"?WPQJ[@W8TVX4Y:#]A9*0T1
M!1VBCP)/%%R4BE(OS,34 D6.0"^LU8\U^CJF%GHD59-LC"RA$XZ"(_-:76BF
MULFF)Q^3,17+!UULC'%%#03P>\1!>YXOZB5[27(J2=K;3K83@8U)O).M+2+'
M@T.*XCRA0.=JM:#N0"FL<H9J*R0\."([3"'")$<420N.P06TASL/F,/.H@7F
M3*3(+:\GEOF *  M#J3-*$!3T,.-Z[A*.*D0+X+D(XI=2D@JX9I6I*#[%)F(
M+E'_%E4&2S)/5Z)&9>G^>//*D%BBWDKB)2E++^#+&V'6'\ER46)C +F(U[@[
M9L4]GH(+-1N*/)XPR8T6#>K[G>T2&MXQ40/3M=_;46D2\NXJZ5VY2N(/I5,+
M+Y+%.2OX)5=@F<;*/E<]/K\SV._QO,?HF?+"(=P2+TIJVH8X>Q+:/0DD;(4
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MOHMO"#N*KI.:%V[4DC"FL/(?@BD8<V"#(B=CJ>4(8-QCI(Q#=VIZFSL9:3V
M"5TW(U:(VO@[,:N 8U9I@>:L]*M"TB=VQ,VRJT?>#]_]^(Z;QA,Q,SK^OD/J
M+S,ET<HR'Z>Q<2PV]5F/@JMYR.1JV:Y'[35BM\0-S%K9)MVUNKRH)ZX7%32\
M*&_WT0R7D$=S]YNG3%D82**63 &GP&F3K*TP!BQ 4)/?5(_@YCBF;@WD^1FJ
MRHF 2%#KQX$?+KR'*DJ8.42$,B\<K4Z JT-)WQZ;(PH>HEOCIQN\M85#2'T$
M4'[@Y:@S_).Y"*!KN)4H@9Y)\;ERGV[;:!V^A\L72L RX*QU/WR&$I=2I+F7
M4/+>W[[6&+2TW<X_%93Y4X#DGLC$!(21F0&Y]U[*R9,<3-QH!D1/ZTPV<2Y<
MP""2&3HY?M7;)1PF@5_B5;ZJ<OP6I7\Q4.O)1U&:-F.$: IO,XB Q0[N0XH8
MDJI>8M4+ TKH$9@J\9(GFCAA),)%)O W.(0R1)%3,-*'H&\?20;TKX30A/QD
MI+TCS 2_<.,X.39TA0TUR 1L'=?CY+W1$B:\XC  !T0^*1UEXZ*2*!['FF!U
MI"T/1I+$HDJICH>"2J0V\*CEV2RG-*-B.Q7>PK>'^\9I$A"+YE%;T4/=@Q$%
MC9YW\ F.97/.3'"6SGRYJH1B;&PWT"%N9Y'HFTC"PIJYBR@'#_S>]ZL/KA79
M&6PC.Q+9V=O91G;NZI&^,LT;5\:Y/&_H!1JQ<P^MFC=9^%LR*FKLGG08A<P1
M1I1@65YC6IU5./R$+AA#^G(B*AX^&WII]8C4ALKFUR]?1 P<I<5N0!5\]E>/
M")=\-/2!LHDZ>80@7>2S=!PHMG1L\B3P9JX%*!-L-B,*PX&@DPJ#=S)V?=U0
M39BTJ6IR\)03#:TJ;O"$:I"1+JPO7 4EV$==A\5"*9&<8@K%CO.K&6C'BIBU
MFG,0?;MH00V<"BGZ,$J=<T=.7"$*" 6;6\=;O4IAR[:KF,'4%ATP%IZ "1-P
MN3$!/ZF=H #K<96[015:74"ATZ.G9=!9UH&%=-IYT-0CS'6S,)O$7#7G:<*5
M+TI=0-$,[;)5&J0?ED#:[U&."TQ>Z2%(E8V!/]8E(G+M\OMFL3O29#I%BT:#
M0LI3  N@,V1^'["Z$)1*S1@0ISG <HS&X0K!SDM*.BN8>J3P#ISE,>(U":?5
M#U_%Y#'@L-':I\OGG:9Z->&F#VQ@T1>I%)+ E<N<&BP1/6"%!BG*>7<Z?LPC
M4%_=ZRK,!\3YEB+#ZN)R?X$@EWSG\;,&]>4.@!V#V?H[M:@N=19]<Y>.95($
M+EN:66=[&!7"IQ+&(BWKAIE,;2S1?A*GP04:*S 8G_WN?^+EZNDS/=I]@H/V
MU)L"T__DV>DQYVK5<)8N[22GZ=G+=%SD27:>%GEF&%*3CPGL/HL@E'6:,V'V
MG;+%Z4FZQ X?/:+5@J#R"#J&L6$!7)$O3,^P#>\>87]0S%_CTO+@*0!GJQ-
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MW@1/GS9/)'D@)3/Q&(8NX?01^AZT"I;DQRH[,?;4D"-14JI5$@T!&R 8<_B
MI$;8Y!T5*OA)DP)C\%HG=_SNU-3)<8LO>B$_)^="=RD"<1Q"\  +&_QM/?3E
M\?"U>6P4V 50?]WK?SOR/*F2J>$:;8[I//(\G9L&@V=2/'P?5NXA]QU6RA+L
M&V.I9%+1,%,NI&L\0XP1M%(PCHP%=@__9U8]Y2;D>X]"ROG"4_&' R9ZM5V&
MX=53V/Z%E@,BPJRZP&_L]'9W'O3#9WSQ,=?)*PJ:,*#^[S"R''8G*7]<8CA[
M-8=IEEY<V5L$IT\OKB,G1!V5K%@YCS,/I^NNT'=Z1Z^+X=K;8K@4P[6[Q7#=
MR2/=K7;>9XOT0^+C71Q#(G68\D!B953_85+.@@5-JZ:W@:G2O$JL7\<BDK([
MQO&,Q%,3HFY;CLQLV%+4G!"J)R!*ADE-=.U>F!=395:(.3%0J8ANQ&0OI%C%
MY FGBWH2XUD6FCOT]T!TYB6(SR6J/\-.MJA_/%ZK!@J0QYI\/W?II'C",/N8
MF5 ("DEHM4VE:2Y.+@P'$1K*VYAG3E+L7B(\"!>&I\0YEYTPJ9/3/XZ/(TEZ
M.IJN8>AJ8K.C1:@R59"5;@K'?NW1%G#U&F_3")N[I.- _5US3'[M#5^]LC0!
M!1U M+87>(_T4>H<FZ\]>_7KL?F:0*P8#S>M*<M!S1Y>OWS!I&U>3@.QUV .
M], JFT@Y%/,CA7$KW2$GU%L>17S3$GA+9.L/E,M@XD,**3">5ER*@2AUAB86
MB:WZL43"&FI#:*/ P?E+WGP[ZR/:I1$H,IXEXX12[U0^068>!760YE,Q7!0W
MN@)H?6*J.:Z$79>N;?D'/$47 @4IYS$!D4A8"9;,GEDI_W .JD.N/^7VR%X^
M9Q%G!KTB]O@J'B<W&._X!H+]BKO"_7!]J!N+]]]=\?FF#4L+UVCG!+Y2C*2-
MB'KVM&ZLNUQB%SS-#E=Z$S&C7:B5/-9DP)E.C-*Y_)<Q!1890$KM;_!2<2<L
MA\&.ND1TP5S;8S!A4Q><ZXJXR(7P"60N@Q6C@(-TS_!I["C':A>#LI=I1IU^
M*'W-A&@J!NU%_S5R43DV*.P8)Z65JA)]FM #JF0\SV@6 5S]BM]E(SS>>F#,
M=@I3RHGYT4S?<BM(/!@'X**$LG:HR>F!*>&"V$7;1($MK%UPZAE--29P]72P
MHA3*"C0<\JR^^IWJLWD9GJ^P%4#U[J/3:QRG1/A>:0[HPX8XA>+M' ES- FT
MP0NFAZ7!F@O<,_OF478)/)ORQC&8;3Z]8C(Q)U8C=B^>OQO0,. />RZ:-^ G
MZ>?IJA!&$.: _0X:3+ MS($=0C]\C[)LE6:9'OJ.G'Z)^E[N'X,>F(4UL.?
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M)DH%BYR,W#A#I#8WFN<$0<\FGOAT$OL-R*4*G+00V4MA$[#*J9$GSNCE6QY
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M9[B"I!G0H(HDP">0S"JXS=N$^T[QZYQ'TQ&*&\?BZN^[L9+!.ZLD#$'V$6\
MGM! 61J):3L.%]B)14JSFSP$TA445 NBF)'O!4YQ./R5BD#UQQ$R+I4U,47G
M<D#-5^3I?,.2CW1ON'4#\4R0 =3D+A R$+?<3D005RO&6?@<3G:^1"E4)#"
MDW0R@5/[/"Z98>0U@K'#X;3 (3Q\_O[D^>OA([<,;#&#A84O#I%7H8BCX-=X
M7H!8C,+C]:JH8>6?S]:K*@I?%K@;\-__PG_+(DX64?@OT+KXTS_JBSB%S[Q*
M1G&&Y4.OTM$:1Y-G\3C'_Q?Y&/_PAK;T+9+'5"")H_#_B^'&PN["3$ZP25B.
M?X:A!52X 8\XA87_*RD6,!GXRYK&>E9G:<E_*#XD:^YL_1ZD+:PN?B]\ODRI
M1ZSWFS]@OI-\R3_[=TQLT.$Q,GC@0OU?W.9^^![I/HA?!<O>X8R0[$=!5BVD
M>P%2_<-]Q"+F>*UE2?_8.PB72'.G\MZ>"1%4+"M84J4XV[5( J+LY%OL%)#"
M$O)I'.H1I$)7K M-X+RGTO1=:8&D]P V"V"*1$-_ :."Q<:N\#)<KMB*&],R
M#\K7\8**SN2D+=-);["#DAN!KURI', L,6],+$ Z8*T\1)5J5&L-6B]-G/IH
M[EMB"Z1;TZ0:1*I;<ZED1XDVPJ29TS7AEP2=S;"LLC-\+:VB,[<9%+VP2&34
MS?LGE[-9*$CQ3YY]0"7Y]U[,7J\<[7!;CJ;E:/O;<K1O_.B_(6HK(?I:I(;N
M&B5M8!Q4,68]]PP$US0IT!#1)(KR-.ICUM2=(L]F/501QE!I?5^();"NGFT-
M-'MS[3\XBA=D>)?S!.NT)HE6[0HE;XD]1_D-V';7O(Z[&QLQKUI$I;(:J<SO
MT;D$EB9$&A; PP(AQ9[8)Y)2D,E)AP-TO-A&[EZR7GNI0-&TO7K3$G5O5RUP
MLY[!QO7$5X-F[^\8W7ZUA[LMG(VF(PV[JGSSX"FS:>H;3<B"])&WO"$QD1F[
M#XP:5$R.VE=^,JO9[@$/IX=K<^GUGC.<9".^;1LWVP0)-$@<)._XQ^YN?]=:
MME<-I(&#@4P6\/-_'/;W?<OX'_O]H^L\,>#K^H)9$8I/C9JC-5;B3-B M",Z
M/CFVQ(,-0@?L]XD!HE]?#<-INM!>H'*?@LU]C]TNF,Z[B. \*XT7]P\P2\S<
M&S)":!^06HOLYN_3F*1;NQFAJ-N(%_0V[\B="5QN7JK G'B*2_4/_\XU':WQ
M;#9OZEY_<(6'!HW0EMS4*U_(UB79N?HEB?0GR"PTCLMY *8S7NS+'NI=5OD^
M*,\IMTZ2Q49+1=^<^'1YH)0+>(G^ZMLG+W)2!HJ4N/<9 W<Y/.(^5(MH5*0-
M!%0J+%M%@L1NQ(;#U <<@8Z7>%ZO?C>;%\'>%[Z;._W=X)H7?J!W+]93'PNE
MNYD+ALWN@N+YJB?=@@.V5J"N!5LG!U;@!Y^I18Y:6N2H__BZJFE@]44@9W9^
M5?L/?S'[I(%QRPQ2=V#GKQ>K.]K&ZC16=["-U7WK1W\#6U2@ ;C3].-5N:(N
M_>B6*6K+%+5EBFHC-^\F4Q1<9?[)EB?J]IF3MCQ16YZH+4_4]4L0MDQ07[3>
M8$OYM*5\^J*+]>3Q-\;Y=,V"NRVYTW=2:==Q4+?L3G=K,%MVI^]HBZZR 7>,
MQNEQ]&1OYXYLSI-H9^^:E%)W1&]^QWQ-L#9/#N^[(MV/GAP^OC55^IEFW'=(
MS#0XB@:#>W\:=_>B)T^>W/!QW)(HW''#8LO,].W9#=\S!=-NM+/S973FM[P(
MN]^>V? ]T2UM#^&M',*ML7"GC87OE7%I<!@-/GW6OSO&I=U!]/C3/OJ6<FE+
MN?0YE$ME^G%+N'0?RR>^#N'2WR%)"CZ+)"G\LB1)P?5(DL(O3)(4;.)(\JNK
MN?;DB4'M;R8ZNO1^#_P2[N!OTQQ=+DWN/:(?+\7KF-MSAR\S^&155UP?^"*)
M%WC-+F(2VG#DX_!T&2\6X:_:9?[,=$H/SHHX*Z<)5O-C39#DE C!.BN$W@@9
MDO*BPNU2 A9_W^A>GR3+O$ :FM-%'F?A'PDV<L?M/*8^WN$Q@>2(1>GD](^(
M'ES5D[64W Z/SZ( (;_'S_8/>G!P9TG%M ;<J)RJK(H<!K6DNJ;QG-JK+];+
MU3R?)'#K:2@KN.4%?<!)KPAI&3QZ]XE]]/'P77C60URN-)I?:YXMF01PHV&4
MQ%#CG-K<NSM2[Y^6LE17TH0#N7*FU+I!?N#=G*#KYEQ)W]ZC&[)E![@1=H#'
MCI:XHLWG< ,\<;]-M6)/'*Z-J]V<?G 'F '@(<'?9 88W'=F@*]6NO9X6[JF
MI6N'V]*UNWCTMZ087X<4XW%_[_.U$Q8S[[D/( 5U<%4%%7Q10@RK)_URZ,U$
M&"$38027/2RB%=PR8&P9,+INV5=FP/C$162VI)UK\5]\PL?:LE]LV2\N8;\8
M'':P7UQ+7>RV]<7NX+H>TI;[XN^<[E<IJ+V)LCH?QZL480G@S>9U,4YN\=#?
M&;%^>3E^4":+9$Q!-C0BIO Q..04CZ[<(]PJUO_I3IZI;=E]EX-YI\KNPTO*
M[N6VAE]O.-N:_L[SLZWIW];T__UO?UV@[&6EV1L"3B@(KBZ]CU$#/JQ+8M9^
M]*-D7\G4L^41-F/<)3Y,:>]5"Y6O /-Q*I [<4R/HZ-!JRKKTE>TI,C-#WLP
MB';W6IW?+GW#UT/#T\;+OL,_Y]2MQ-_JKPKQ>[C;%I67[-K7&L7@J+4AGX2
MW3(FGG;.N:@\V6F:Q=FX>PN_76#N3O3X"V%SO^55.(P.][],5]QMH?H=P!]_
M'>F@"&4>TWB.38RH41&(BR@TX?+S>&$:)&% L$B-)_SMXGL?1SN#3S(Y?&^P
M9C@K!SN?VSZWZ^1^K]#F:P9+QZYE9(S@P&FW=8WP_N"QTPG"CZ0>[+BDP=I"
MA7!<O742%Q)_XL<,+&XJ"F*$MDF7,6E9HYDQC^K8#=5JBS!MT2+?\UN_U*N>
MW_;-:^0BR3%>&&P(UAKK]QET_3OGQUC6[OFAGCL.$HXV!WYP[4PN?L\TXUDE
M^(9DL8XT"T3GJ2Y %Y0$>$7Y3]'TKP)!OTO+[_JQQC+^S"N\Z]Y37/%KP!UW
M#YV>%;CM-N]A;CQV&,0/E_.XX*0^-[A:+K%/8Y6//]S[:_4R"X?U##Z!*[N#
M8&_I:QI07U-<14V#P)H]2^#5D__Y/X_W'P^>AJ?4P''H=SG]5YXEY5D14Z9?
M8<0,"SA5O/FK5\<$VG4_V]7^]"()L.MCF2P6D<AQF#3=/_@_]N($6V\V#QF>
MZS^M7DF_S7@& YPAP)[$_8Z5R5WG(7R3\6$;/-[8ZQ66;,G'$L_LNX08A2=7
M7B>:.BZL/J7U^_9"XHM^[0?OTD6RAG4<UP5=M@A6>,SY\0T/0SP_5@B47'8
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M"[[:>7.8I/0$M+/0&+K( LJ'SOC!SFK80*Q95N,UGX-SQ%?=OWCAPW&\HE_
M.1HE.&2=Y".63:D[\L;8 EA,W7MXBZXK/<_QS]N+V1"#X4.S2\YOX.IH;%H_
M^.A^"0J^U\W0G&H@$A:.<FY(:XQG,E$-*U_8S7B19PGY$Q)I'+LQ&[K\&_CE
MXFF%T0OGIG2KO\9^T1%2[:W?VJ0;C7KAX\M&4#E7ETBG/>'(YB4SD[$XGI:&
M!6"'5+WRUPKUPF0U4 _2&.!FDGI;BT_&3I@O<=Q;ZEP#JB(WFBWXDTR%S-'P
M1)C'HZALZ;LL7<M"X>6 R9@%T$MLH4L;MZUL[:IC,^%#V;Y(L9^R"!I<^W"5
MIQE?1D1DP#SS<]0F!,N@/9VZ/W$M1C=2CH.L.5N!'FE=@4>&#R/7+%B"!+MM
MY-O=<4BNE8/>W]GFH#4'_7B;@_YFHF.<X+1,D""YAHYW>?L!BCN@]?]4QYF5
M@\T,SNJ4 Q.4C>KFMS5Y1V,SD/90$]51+J6)!M:2RC)/Q 31R&%Q[LJXV>AY
MX&=*832J2 29Q!9&SAAK^DL$BGF5,-.KJ GP'M%@@*6#I1F7UI!PSPKK?'C+
M/%U%DJV5:2;9'-=F$MAT(L.F-GV_),_9&/$\P>XU)>L(-/\*3?8%>%B4F9#0
MYS66QM.+65S)&$E+9A2M=:K0UL@Q#+MSH23!$^NG4U+9VAC>O,0CR!*+?W3V
M-0HNO..E9\IQ(W].?P&=G'XM+NP;5[?,GT9TJQH3O>FWWQ$3X\^$"*IC)9]5
MC_-R6F \_!O)990(TP&(TR$U,'*Z.EP34<JCA$UU0@3"1F"9$@FT*Y&YS.6K
M"3KX:NC;+G\F@5:]CTR3I,G'VV#B5<YB#K:)F9QX803.A*/];355/QB693Y.
M:>X^=9OS+@ZU9>.Z*#C;\RF.GKXYH2S;%O[S8V*&HZ +>B $3;7^<I< \E$L
M-^<\W]H]?P6;!FOUE6_Z7;$3?-PZ7KI)/:Z"!2T"Z1(+WL?(W6A-(4*4_L0I
M[U+75VZK!O)2C=4@ST5EAPXG,]+#FPL$S*04ER!-#LH&;MXDP6Q>V0_02\=X
M06FP>VZP0F'G6C"%Z3N6$+'$^@QJB929  5%7YK4PD]AO>+*JX5L/7(./O7Z
MWP9%,JL7J/^8^(GP[#W6QLL4_ESA&U1*<4R^R-<@_5*&WJ#APB!X>+V\9Z++
MPH8$NKF*=L&YV+2#A@#-FTH,X'%DK#OCX 0]&H5C[>C /0(9;/";TU_>=YP
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M&X6=80DP]V,O,!.TWTG<KZ30,&9=L62*O(@B08!=$^QOH6U #$H:N7!HTEF
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MY?RYN:; [V EADAK2IOFX":"T;DNB8(']R1'OKAJ&(_"^J8-12>+DFG)*)^
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M+:,9'XFT5H)!Z98[42]BN[>' L<"0]B,%M1UL0LGQYSB_8N"U[GT"_;O2'H
M&R-'C^8XLJX/II#7@&ZRR#1(*1A(Z9*U<Z>O"S7E658M+'31MK276#H1*6T
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M_%SK"X,_9KP*852KW45;+6BQ_$JAA^*<&MJ%Y<E%06LG;-'E$A"-]0A)@K_
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M*PSHKB4L3U6PWHVJY1K1A$LVA;0][J;C;GH?XV]9KHBRC>50I)1*$J@^Y*N
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MF'75@:<*C4FN(SYW5+)A=8-ZJJDO3\B>ZS;AGI*387O'*0_/K"*68IO&"1N
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M?2+3+J%MV5+Z0;#GNO$HPR6";-KI=8&FDD3D2+X$2/DF,BS1EJ/7X7)J*:.
M%/VL%[WK"^);7[BH052($'7XM@2"LD8'4[O=U!@*89)UR=,G,0\V%(W8L5,K
M-D0-5SHR&T9B,?#)7:+^8F2J<>![U8.*2L-NZ8BIMP7!L5C:^<@\E=G-0O1S
MQQGIM*ND&I-R1D8<0HS=)\%U>1J' )N3*3;G1CB.XN0M9'-'"R=/XS)=C-+/
MZJ #"3Q [<[3(O0^#,LT7+>V-6T.+4B7#^<G\:9>T56NB\ZK?XD4561WG3==
MKP)QUFU@*:9%$UD.',(9S"CNT;/)A]&2-UW!FXN2QS^B12P[2JP2 PRJ9->C
M6R Y@#54,0V+F@G:7K:\*.2Y&"K2W1ZXF?%=EPW_THNF++D,EO<'OZ+EO.5Q
M&[M+IBY;-*>SGYOK$@R*ADGP*4*OU)LFW5V$)<4_^W.2"1O'?9JUU$.?=YK&
M@=H\H_?7,NS>[M(/^/KL5$I6%IFUD^^EUZ3%7X\7#^G0WHB)1JLOG>Q7BX?/
MH )-S(H#A4OHB:2^6$PH5X\%N,@]"(>,X6'>C_A^YIKX<** KM-UQ/![1 <[
M=+#0%BN]*R?2QL[4A#X:GWRF?B;>2S?A2PE2P%>,G51@Y&Q<&4.()FE@_4&5
M04*EKH7-&'&<U4[65R2#]-P*TTM,2,JO"DK<(3MKBJ*?6K[PYH5R5.KX(RIU
M('SEJ'#!92E'A,!+=MMLQ?L\J@P=E]GO7V9F L-=%#<Y#]XWN=7!8"^KFE&C
MTBL)2WY<<<<5]P\:-B4J _M)M&5.B<'X98S1D,]B5T=+Z?N.$H#'9?F/&,*V
M>5MMI/9N'B=E'J*6ZG&%'5?8[U]A+%B0&+/C@CHNJ-\W@E$ W9;S=JCZ/18Q
MUSG01=B?Y_7B]B&7.D>\W%==>5R<Q\7Y^T806]*F\B@JZ$P>GF '43UJBRU4
M^V)'W/' /2[!W[L$L?"JHK9X ;E\\>NT\A<L'>'9E?AZ#]Z%\G /'!]*?)[/
MIDG$ !W# >,2N5L)L3-W$3-O(I>"'7X:Z_XS$3#_QZ]\.SC7-T<XE\*YOC["
MN8XV^0NWR0<(2%$DKVK\H.E(:EV! T!__@PLXW'!_1$77,K#;DF==U+9@:'.
MN-T_F1XZ_OO@_K>?1]'^@ *HZQ%PNHXZUWG&0"5K?&=4O*,5L#)_+L1*U;90
MB>XI&H(NC)?5%X"L6U+_@<![T%2P7JO03<MT%0+ R>R%[G-H*BA(44"Q,R%\
MJ6DOJD6D)6:QNCDC1)C27.D.%0,$HI0(E2(Q\%I^4'6 &)A+5X<TP+!:1PA_
M5E&Y3ELO%&/Z?K7R0UB)B"N;J'X+]%8Q:&$>:$J(G*#IF*A9!)"E04)H*]'@
M)S"9*8#:N_23%87)6;*4;G.2QO*+AK0J.H8H!VCQHO-99,!]$T^8EG43]@WS
ME!+Q:4?XBCR%98[WT#OYH*-\)_.47C'=EZAA.(33B '&8YL:IW9]4715=T33
M*)KF!@0\J%5&BIL'\"C6QIWT8PO?,S=4JMPP-4::;DZW)^')E*R*0\QY(,Q#
M2XLA^>[!NY[.SH6[.OT"]*SVR9111>8.2#><8"O(BHXD4D00%_ ^[7>\V%2]
M Z%B .!C&H-HV:#(6EX5:V&:'8WH&AA5P%G=Z-%I:2)&67+2,9()&X!O(GT#
MNPG$A@KGT>/FPNE,H\2VYG2#<)3AO77$68S4F GVIDLBDT['?<$(<EN&#J_E
MHF3"8R.#L5DG."Q_L+2.D&;HXX*0J>06<NLT7I7^G&B6F6M)%#3WR.BG;T$4
M*R(UX(1NK?&LT!M+-)NG^8&))-O8D4E_.=@JL9#<UE=Y2=BJ&U67O0R'?_$Y
M]770'DU7SH%E$SZKJZ3+#F@D)V3JLB ^$7/"@^].OWL\5CCX](;Q!C;M+$'L
MMF.M7?,-HP"7B?0&UY_(1S9A4$RD0;+B7E&#G2$8602CV-&MA:/<3,YK)M.%
M)"?ALU<_F#<UC27DENZE= ^,JLH>5AW]7@#+QPN-V[O$;]LG&W_'1$1SFUAF
MV@#BMHJ[.CX8A :)[4@1G<'PCXS=P3BLJ+EV$Y.Y;O#<R8/?K"UQV%LAXL*1
MWEN<Z'W[\A[^Z(1822*5Z52N?BGKRWZU<[ZTTDU&?*PGX]D[O=\]BO26KD/$
M$]G/\3ZBJN$7JKWCN*;@!O!>162U79&=IL8MKJYC'I@S@0X%] )>-\;)+U;D
M "]^9/IA4@%E'K0+<RL5DQN,OQI5"9(NKCPC5H3KPRQ9XWNP@D<34V)TK8MP
M^"_I3 L.8S-G^C?L*+"S3<]"9UTWJLZ82?>6=AZ,60_O'*/6W\H]^5*;RFS\
MWHW_M5XX0A^L,&/PI-Z4Y[_0Q%XT8N]2%0MU<Y[^]33\A5B?Z*<7?-LG] ;/
MYG)P2/B7@9G51N8&!><:;YVT]"JBD:CFLHC%.::!T6F WL&J8W/1QF2&4Q4N
M)C\@37A<\LJ6Y35&' ;R\/[]_/[]^UCX5]5BD!: O2=6-:O*KL*"A;>\B..W
MS3A+@VW$[3]%'"G;X:YWU*7*L[@IP%7K1++W)X][AUEJC=7JIN:$PJ ,3=!@
M!E<.(6HXGAZ_7#>,;WS'T]EKKH8+7]KLZ?,SYN+M#NUK(17:-)S*RD8)$^,C
MM_9)6Q':&;VHBLLZ!!T0X<+ICZ4P7LE$UK,L3X@,CKAYQ3>:AY"A%AFZ18D<
M#L[*+,X/OVCZ/ 4:\74OQ>@\X+<>CJW.V<NP)>Z0Z7EQX.76945K/>M634L1
MTUY.C+(J]!Y<VY@H&/-?EE/KN@X_7%8<'97[?Z93Q$K=^C[B#3*5Z7;1E+1Z
M@B5F<M-//QY88&B;%-(^" ILU7XCKH":6E@[E?'IG(PT\671$F:#N!PX %<J
MG%%P!@\U;*GBK2OBLR?M>*1G2]*_*JHK4#HG(7XU&7+J4=%E[.X2^TLB;K0O
M4^2$EH038=^6R^/J[2CSP!-%BC_;IG:B3.#LH\PP*)K!,(?+G6"NR[=H?Z+&
MUUP]>KZW.U)8$1)7+)U$E)\7K]'DZ60CN<+&/V.>#;40, >GGW47J'M6;K+P
M3Z8OBOG;2F5,]"L&$U9*VL&WMM/WHP>%[)FG;\CT-I:.D;4LCW:QGFJ@L37\
M]*__^,)EV>R"<@U."R$L,Y8YC,N-70%]CRS @ EWKS!,-U%:(%(=[=E8,XA=
MHYRXP92B[YC/*&*?6S#5]ENY6<4ATJ%GM?X/5FN:498YS/VF['WLS&^HPCL-
MUNK:G<#N;<>7L]YET''BO"$MP3 F,9'L[9:UBL3N3\47>C;<%C'SYR-B1A$S
MCX^(F<]R2=^HCGFMT?OL'O*J5V6FT?Q7!^T1&'ZEOC!9M[(B+T78\6".03;;
MDR2ES)1+E!*R*V5ZNKGCP@?V4B6F3PRUJFQP*_$*:M:QY)"XY'4X M?1VW)D
MAU2M(ZE"]^!1!E&?2</U ^=\ZB#0)*>/A>!.SV%.?'-E@%DW+]JF6&A4M^^Y
M9.:Y[ 7)\0V-7"<=7.GFO:5RPH'H2%(C:XK;Y&@B3X6E/4VF6LA2V34-F[UC
MVBR_4*BVX9B0%J6J;7(,>DMO8D0&Y0ZV3/ENZ7=,F9FTJ6NN\V#<?<=IDW^L
MA)2_C&8A:KX&1T&V[:$5S\V!T]MF["]C,_@OZ[;R7%TB]I4X+Q339X)DQ^K2
MFMJ]ZJLH8(^[RRN/ORQXV6V:JF3R":[X)MO0W&A;%<P=?*\*U]<]$#[W]/D9
ME=:9677*NTZ<;AM^*H7F![0SVO0)3QXPZ)%O*%L'^_%$GR'3/RV([VEQR*T?
M7>O+=>.0H7;'W WT+EK4.G"6115D(\E2HAIWL>9B+? AK0YP06FQGQDX@B^L
MQCCQ-CA3EKE7-M)A\KE^ 4@I;V![589?*'/8I@G'FFTK+Y#,JNR'.@:89%CS
MO=CG>HMB]NKI\]<H4+8XI1O;]3>C>+A81'33E0V8:=G8!6"L&G;\Y5 1,F&[
MVG7HF$ 9;JCESQD!NZ1>:,7M<BT7 QZ-STW2N [F,69NVI(HL??8L57[*K=0
M/+P4_+WTU/; ;9)PUD8E'?JF64]D:9RI+(0R#$>ZJ)XGKUP$T,UT=@=G\2"Y
M6?AC!CIP@2S.?RTN\4__C'E:7"7R[Z;M\;$NC"3X_O*)'H*1N21T^9$V]%GR
MHE@5HUX@T=PN?BU+)+-E>6:'EF=J.@1X(?)S$X;$+PZE!DP6C*B:)>5<TC)B
MT9SXQK;!?SN)'I\'0/!#T/-TN;YN27R!-8SPC)TS88Z1#^?8_*?G+WEQ_'3^
M4I9PO2<UGZG\@1(^8D0Q/9*L'%TV\VG.,\ZLU/QD3%/@(.L.^\+[G#,S>/@V
M<T]^.ON%O5B2#@KOF[O+R2PSAG6HB6L/84U8LQMQ) XMRIA\&=7NPT6#(ULK
MBF#!>%M"5U+2J>78>(<4O]U@FGP-)<+I98\$UHU<B./EY(64PJSD)&80E9-6
MX?+=D37IB/;_)XU SQLV4+68<#5'>PO[)B!L6-.+MK@NUN,SV]B8^<+8$U?-
M>JA!Y\_W6/!&T*\$XQV\XL^BO^^XKO^(ZYHXF&A1%BUJL.N2M$9AJ5?-FNGT
M1@?A<:T=U]KOM:'+H0OK2##&Y""YD&-2B5>IZV-$8&F.Y'.D= R9ED&^0]T*
MC BF:O95,S?(7_A2^%,$!QX7]'%!_\X1Z"G<E=5O0(=R1CE"7G3%$ZJ&$LV<
M!.0@3)1E\*]#WL*Q0_6X/'__"*KZ[T,]-T.J2R^*UL^KJXHE=-L*/8YDA LP
MV'Z\1M0_4I9/4FD)[8=DE"*@21-!81:-"D2E1 !Z1XN&P(5BL._4!CS[O]2O
MPGN9F\[<7%KT$*#GX40CRP+CLRYVR5!&@E$3S8X0,"UJ*#2TE+=3&;M?RW6U
M:II%;BU'+>=[8*\F1\NCHQ$7I$K- 0TC@+,U)6;D8\CW1=WZ*^U S&<,4)NN
MY-&W4%"DUAQM7.U(E05-L%9J6Q1;)*>T-RI<K'PKXM1)[DD+LHMFZQ7<QI_1
MEZ=H4[DS<$YR3\-3NUQ%3#-9$7G=H-MAETV4C$U=L]BE0'03X#%PU7Q%S4CB
MYVCA&M@7-+W>\?K?[3 OWQXQ+XIY^>:(>?FC+'PM"9XWK 0I.?!J<T%=KK#*
MBGN@LX&[,X*)-'@Z\1]H4RW#X;KR,I9P#A6H7/5'#AV2O"E$4?9@9GEI4=NQ
M6FA^A->>9WB"S.%4[46;/A;-AJ@=YM92U#(Z!5+I]!Z3,@VI!O4*5W'B3M>K
M4K/DEJ6?'UQ*I&<<5PXMC]AK2(<6P1;<J^^<, N.5_XJ,_.09%JM;>F';XF[
MA+/8H7P)IC#GEA;F-&. C:SB/.7ER*<?3?9$;,VEB5'9!E>"4>2(?RJFR=#!
MN!0&Z=!1>=)58ZG^<AI,J\P2==U=F@\2,QCQ4>C:W(--[\JF8L&-VBU&O%?A
M;;J>QO$<Q5;VSYJ]U[HM=@W!S_53N?RK"G[%J@R^_BJ%Q[:712TU4>_>[E]2
MNC_0MAF>:AV<S;XO-]N><?.HM]%<\DTP0&[L#$.&[:#/84TGRP"^)R'<6 ?#
MKPEQSX")P?O.?3LJ%AL .!DS[$"1"^_OBICU3+TG#-^66(^"9%RXKZT*B5Z'
M),.$<-Z/QURW^.9(VID%F8C#)=MZH(IK7YW]\,M9;-LQJ+43= JK%)T(80E
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M9RKX\+LF"QN73M5))Q"7-W!@1MLGU 9A:5\QOT,'C<Z#H] 'Z#(_#S@BN\@
MQ>M4A1['O %QK>4BDU$1VK:IV;#+X9/TK>T)TC9U>;.S._$FP])GIU+/26#9
M'+M!'!A=X9J8(ZXMMQ5%%R7+=3J>GXSF9SP5N,\$@8+ EA+0"58;97CX_>#
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M>*!&H1"I'>>Q.R4[#1(9;38%L.^-"$ SL"F.=U=_-[15?"$0?U,+ R)4R%A
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MQ!,=*//&*22-?<5%3.;ZQ;;WN'FCH07 -E#^C(Z**JL U&*4+D.48#F$"K0
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M4C45T#=T.Q@4Z#C$.3/PV@*I> 8"6OR8CM<XZ'N* 1^Y P%UK7*JM5EDSG7
MY]JB)"$+]0.'N71DJPY @YE*Y;8K(2$#3MJYV/@AC-GA.;1C'UZ*R!K((G(V
MQ<N^ AC=,Y?<H>GC2.G(IJ3@0BB)B,.1HYG5-7X%JZL3XZE@SQD=-\8("!G
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MO/!=RLN_3&/_Q$GX9,RQZ]@Z(^KF,:.6>-*+Q4GZTE(O[XVCHR>O#Z-QF<B
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M*3J[5S0(@Z.;/,&QY=_"Y4J)_SMOO"^H0C$3=@'QD49=>'"S</=\!"I5EA[
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M[F  DJUS[[_ZX:>CXY\?)OFA*_#_["N8^P+I13"] "[>"-.+XW\ 4$L#!!0
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M'[NPV^V^B</][<FL<.;XD3.GKN!?^QW&/Z207B+3R^/\;3*]=/X+4$L#!!0
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MF>OE*/=?O)7AM7%[CU37S:]02P,$%     @ &H@.5^+9,@K3 P  6PX  !\
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M/F+BYN%]PL<O(/9<7$)22EI&645535U#4\O0R-C$U,S<PL'1R=G%U<W=_VW
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MF.+-_L$!#/"C^)ORZ!_YQQ\D5=?58XXY-V==K4ULI[._+^]<C/3^S6B N8I
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MH9X$F?(IAZ+6UW8SS6F' 7A?HTGJ4+NRM<M7S(-K,5?!A!,WM]:RBJ\H_JQ
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M\;Z\-\<11Q8A)YOC"N\2M/TT]TB^&4:HODW:T#C>NU Q+>3+/;,0A&;NF7B
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M8@P\,CG#>VL01)5!S7^;+ Z+Z:;KPF5&O"OM7*IT3"V&TM2^J."@KE#'GNM
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M71L!FFM3$_#; %-OSQ=[AZ]TJ5VIC;CE+?971LO_34%;-*2"6\FJA<LGM_1
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MY.3:+$JCEF+J_^ACPW^G,%R,_AM02P,$%     @ &H@.5W,!$.']90  *VH
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MAC.;B).H8R_AEI@?*)]A;TRJ5WH#8Q'?P%G.FU"V!"(3/S\Y5I-^3#BN8#-
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MQ/4",;8DYUDQ09F;'XZK Q 72[OHIE^L!?U "PD\W QP$B<OD?7%9"5G'W[
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M-';M"Q/#$JJ>%3W"+S_E3UX)H2;R=E+XW%R5G:E]@.YQ\%RIH;+&&3]6!_Q
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M\(=4+;Z2NXZNN9ZN?0*\7$A)O=4WR\$N^1:GW]Q%M<#0=38!!E%EE!HV9EZ
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MFK]>(=57$]\KFS?E(]6QI=<=@!UB@>IE7/E9"_#8<^#2=!O'NN5X'?T=0 H
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MIF'B%P9S"G%P<7,^=(* CH&!C85-AH-#QOD8])CS?WW<M0$$Z @IB!)("'0
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MJ8RT]"6'SX!A_ [G;%L[Z; O%T%Q*E+ ]"H3$GB8F%M5^BD+@V(Y98&)"6T
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M2@?]B$4 +54F-;@L0O%(N"[(IL86'SY0N*OS\?P)?W93JLS%ZP;Z.# #BI@
M@$:\X;C=R!<&<SZ*#CY[2_#=M.&#2"RW306$9</V8_]01/T3\I=)_%;.M!3
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MW++;J1]5' MOAM=@75\C626=JQ)=<X]PAT>&\V[Z?A=UDV5"O@"<\'<7IQ?
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MO##&*OQA#+]]674 J,8,@>.T:?-U!\3>&5*^$U/ QWF 7P$Z:+?A.C,0#O9
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M5(/_2'-6WT>@CI=-<!A(^JP+#X%%C3A=C[8^5<T(V%S5?;M0C.0\K@9_6C:
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MSUCIV[]JYR4PB31^CS[^#=^I(!5EUB?X6GU]=']Y5&U64R;@HO">*J'EY4?
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M\T6EBNW OA[2DWW;9U>FR C:%R6?GA9#;IHMP4(3#:%%S]99W51L>LV:S6_
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M->@#GS1:'6ESN(I=U#"?)H9 L"4^>JXJF[R!'DW4=K9G7HI8 EK7W(&E5%A
MA+/BH4F7C[U+J?Z8O1^FF@OO40HK.84U-.J8/8^!*/"YQ)[.K.\_W]/^YVN
M\VS]DL8;IJVG=-#E.W&8M+&0;-H,1LJ2_O,WO@QO7A7^J6M-@+$K#U).;-30
MK"_9N96;.-P*%#7G.4_TC+?I4X-=LH7QXO G,0#[S*^[1/<5YZJ_-L5L#:\I
M5.XH5LTD65"JM8Z*/5NF8WT]RW^8J[G^/FMX3?G.FI5P()^;"BH-+_@8+ K8
M@# 5&NK=R^8I-?..$4<T^CKYC$Q/N0[KO^ICWC/+3^&9#X.SFR+>FC@&$<[,
M)[\:KF_Q.ZI?I9:9)"*21B?X[7A5-Z_US\XZ9E8=%<089I"J_LH'T0"LX/N
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M4R&HA@#_SE4,)Y<7RX= @6#TRVV=AR5/A<K?_!6V-I(R^/COG*1"?*Q<\7>
M\:LV['26PP8Y2Z;17(%\6S!1BA8//KD9HUY):P^R%)"4.]\P_HXMQ;*].&CZ
MXGER8R[]\$@AE7=+J,87?U(<A:L"G=/)\!IE\JSN1$L8APS>-0E[&GU(<DZ
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MXI0WW@BUAO1%#2<^DP1?+-&5<\HL_3X@%I_YV)G@Q8Y;+X7A0/?SN6[&V$<
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M'JX[.4TE:K8@A!WN>YF38P[Y;>E=8!.1.-]/Z [O6BUNMP^OP]G1<,P#.71
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M;S&8W8J0=9<ZW#6Y2N<=>$-K0NA8D$'@=./!'.'P>M3)')-$O;K6T/-GH56
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M0.1U6+^HXG-MJT2B\H/\C'._C^T'!/5O/BW,T,#+8/KUWS'+%#K.HSB7\E2
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M"*=A?9-Z=FTE_&_TEF&I!TNZ<UX!Y11XFO.N7*("DJD'']V:4ABX]EB'6<R
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M$%:)F0M0M'0,US*S,"G$S'6H"3A(RYP5MTMZRI+:/QKG=Q (F9,B::YB'PC
M73"#<SO=>M+DMA1!UB.W[GN/3AE=2\P3AZ ;KGD]*+&]-I;91B\$GN<K54U-
M56EEM8M+3+A6,KQDK1'@([$.5R30A>=PN*>N.3!)/Q;+4=KYS-'R3MWDHB[>
MHOW(J_E$E@*^@U+L+^%>?;>G:, ,F4*Q[/C8HYU?[8A*USZ--LAZ.CY]<AM
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M5;&-Z3;WV,L<OB)LD>(N#U9?EJ[(!]ZF*G^3UZ@:[COZ7*H$WN@@^;@'^U#
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MI*#X;,')8V:4Q >Y?:/V([M"XN=*=4Q00 ('"O@4WWR=F^3Z%.+#  7@C*
M<6N1OWS1Z+$;HKOQ-&L8B@UM$A?1O0=Q$0)3) V<(_D*I-HL4E:GHZ513ZB"
M/_0[=]28803QFS:!@]D?.ANK,;L8V.=# 90S/_%O\*!]?(Z#M-^8UOSZE9PB
M\9"(;T*64 /[P5$\)OT4H:F_L.#6[BVATWD9:S*CL'PT_,&9S_*E:R8@GHMG
MC.+W:*:S,DB+MENFU,IW&U9@M7"SUZ+2)9 $OO4>;+%_?M6<Z& LS1E_#05*
M.@ZO]JT0)"%?2GW-I\!EVA'7T=S-")^M5SZ@3/"7Q$.!4EW'=J.8-%I.&6;Y
M^->O@P++Y>]./Q4T8I9FR)H)33>.V(%'28W4%L1QN*>?[".M5*&T%WJU5EHF
M?@&W(7ZRF72)G"^_X,X]$?)YF:_K^@ *> [] $FQENRC,Y_:Q:+N+.:*)D)O
M86Y40?Z2I:<_-4DM.M;Z)+=(FNN>7M\W[M%]2UDCQ1*0)VB>QSKB:AERD?YV
MB<2GG4A%(@O)&.&UCQL863R8N8_DT0%KH(G$'4J1;,%VV0:,50G-WRGF]GRV
MV)>S)QW_>E!?9F0QE@&T)\T93MBY\0SL)'#W:3:667MV/' R$'10Z\<,<>=<
M<!_$9]OY3C%3GO9PH%\H=/$L)R<"E"NN#-Y(+O8O/'\O-T3,>"+WL3:XB]#?
MK:.PW @$T[4!"(Q88+S4" Z*FC_9;KS$T;BE5_:M75DQ4>V%ZK)RFX[4I/BB
MV'YA(P1>^;OMO:# /G:=3;GLVQ/UD>$+Z\ADU]:T%Y]U# 70- 011 _4O]VW
MZ?W*GCO)474,!6#NR')S'^CC'[0*::J*:\IJ/;22G1((<R2XPX66R4"H_CT1
M5OQ15ZJ+(2,^7M].,3'RQ[8;EB<:_X:R?5@$R5@T#8U=NVR^@1!^9HJ+5DUT
MI56&^L*G5TTOG,!"0]N4-;YM8QYT9^0Y?ZT+_8.3R.4W>$9YR#2^R$VX'[WT
MX2]7E6@F(SH:\,Q0-=D?<UD+X(UI=YBYV)+U54ZF!]ZO)J-!Q#+@'U=:Y""<
M/;=<[K$>T12\7A'<V&WPOQA5PLBJL5(@VM-.'3R%>6C6&344:#0*_>-#7)8E
M7TU^D$O44]:B3@&:RN)C7LNJ<MGLO+$A@^V<Z\[&O8FTG^^YN,KVDWB0[J29
M]Y#K0+&?[\72!'>H&R>?7H6!YHME?[ZK,Z8NFFA<,8,<.*Y.&7^^,[?AZK(&
MPI*DTJXT%/!N>YC=G:+V$6[P5@X,VC#.!'(.!1K,IQG..JZ/E%(_:#Z?%&\0
MWXO]Z74CWY)9N5\DS5.<]9'\ +4X?H)/],,7@W_X\R7C'<PPAG@Q^S.E_6NF
MJY\8_VS\_PLPTZVW/P(@[0=:L>QY*Z'GT;3*\YOX%84<E^6Q:I+SCY+L+_[T
MVY^ ZGH:CZVERTX:*_@_\Y/8,U_X&(N["&[TL87D9&UZFTUPY!?4I54HT:MY
M9<TC!<*W!?\:;5E#$G](9I)RZK 0]$<4P/:I3)\C*!#8N/E2_!(,\2TY(<PO
M..' ,9 H[N#!DK-VQ-Q]\+Y$0O0+Y56H^S<(]3E(9;SLBBJSE2X<Y3W7'JJ=
M#!>W/@@*(%.\K^R$G1>]AKU.K^17(8W\/&\MSV/9F)*K("-1NYB\5J$<VT,L
M.(>R\2M!:L+)\_NE'-1J3U]<*&1$^%V)1_'O'C<?G<#GRBV($\ASTD54S>BL
M5S_MVG2S*<]">B7R8,IVDAP[FOACJO!T5(QFBTVZ9[V# L7C+ZB/O@:I?J:=
MC?:>'U?B3CFW8D^=0Z[%XHBS)0TOB#);Z(S?N;N3M*5-O==J=6J,%Q0A6PX9
M/9(FM9$C?/(9@TI)7/Z;3!Q9P]N7/:02[VT,_2F:#A?(63[%-0OU=# 'FR;H
M:7X6KD)>'3W9K=+WG_\:&3.]8S&6(UC+TE!Y+08%5!0LP$\.9<E3GM,$<>7R
MUC%>]8\)-HDPT97.8#TJJSXP"9_@^=K($>L]UD!+(K-*ZB)BEK6EOKJ?WYID
MWC;QE._0;O?VH_NR1,L846 +^OWZE5P1"FOXB?8Y^3VO[FU,QX'[16&0@XSG
MXA9R4(!C!@H4GAMG8\D4Z"E+D><AT2=HUK"'VF=:$K\IZ2Z1MJ?_YNU,1U!R
MM*&C9I;$$U'B@LJ8Z@M_TUR!#8S;,(\&AUQ&7W5!@60VNL8W?4O2;&7]!TK/
MPUN=?;2?6R<:7)\D>MUR:KBW?SLWU_6MEV33@NLZJGSM#K/DJXT=U1TPQ;*.
M HF5 'WY0^L"L1%,;#3_R^6L<G?4U!5ULV!FKM-PA_?FZR1-[A\=A11XT^5%
MZN1H(M7GVE31N4>Q.M/]F]SC)"-ZJ=_2<$2M!M#)7/M5$;9['>EQGTNULYM0
MO3S&%E'A2@%L@M\S;6P^]K(8<55JC\9Z\W&B6 LM\(+D8_2\C_V(BT#6CGB=
MW[9X3;_*>K.+LI+=AP%K1MG(9WKG;JT@U^P.VV_VL0_V>^A:!V=FIP.,*J+,
M @EF#DKH=_*$S41EK HCFB%\'Q2@ .6)&;M4P>#0WM45NICNV66LU?G3=EN:
MAQJ*V'76)-TI4IU$D@D=I/&HHEEG'SPP=DLCR+%&B794!*U-K,I!M*S^ZZ;
MQQ5T.^_$DU G&VL.N@HN6:J ;H*@53DR.ZOA=-C),R0CDHXM*R];-SV@C*O4
MA^A5APJP5E(@1NH:=7F]:Z9#ZY;D^-'K,\JFW2V!,0.+5#/_R/J)TI'C7S?>
M+%.K4Q8%%KWIND\//.KM@#[=0B&=Q%&UR!!FV*' /:$CD+XZ4.=^EJZ!SGQG
MKTZ?;."]5T [LO#]?AG!A:]TA2V*DLALQAZ?*+HTXW=C9:[W*\/Y[1-78S#
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M0C9V0;^WFMT5VJ4)'HC-*TI7CKK'I$H#9<J-8@*BM/<+,IZ%,?Z/U-2S!EE
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MY)&.H+?;0ARU7_OL;1?)!RVRKYCU? >B=?&[\5WV#<&A=V+@?.W[.(V$M;G
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M4,3,UFI7$V$5DI[UJ'Y??DNFB%,AND=@I#6P]7#C$5B5_'7,\.#JJO/PH/"
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MK46D-T>V1K#=R>9(?HT67,%:E>>J'6@D$^6Y=MC^:H4UT3$3(YO=J/T-5W>
M8W?S<+[NJ[S'UD18@/88Y\!NX\J7TS4+@I7.-AS&;M4RA_/>0M5";JOXMQ(O
M)9-_P%D$I'-@PX9)YX3B7N%-J?D45RL>4T%3>P0LOTJCT14%3E.L>WOOF<+#
MF.:3T_&TYF"2O&FB+Q*BL=_^0*1SB)FYV\)NGL"W<N;[J-+#"J.)8 5XP14.
M<? T9.X/9 8WU9T5\=JMK(GK1DV1XO&(F?WE2%ZO9^]:H), H](H%MMXHM\,
M8@NF75K1.R>E"UM<.+>5K[%931Q%&UGPAN2N3O&(8>3/+L-=2*O*V&=]K=+!
MGQ>JUNG3M2!%)ND[MG>YQT,L3R[MP[TPZ6N0:)CVX#::V.&H0Y*V6&3^! 1X
M+ZDYECHGHA2K !A-3INDAW)\WVVMTE[JH5M8=;MN26M^(V<'211ONC6.H*@/
M":5 H#,VRK6K*&G0@:-<OSW<$Y@BK&I'D_IVQD/A'3\F\\.,<&D+A>$%GXHT
M>/+LO<>+Z>CRP^DZBW/9J0D!Y5V/=QYN%[]=,+IY5GS2C_*AES.P<XCO%$-M
MF)Z@7KBQ27*I)(77/:.FFY//]"-0D,9']NI>KVQTOZY;.(\1B7)14GCKN(R7
M]"#?+G]N]CY/><3I+;, SRF%2@8HSVUW7[YNBC-$@/^=1V%,5I/46FJJ2R4E
M5SUE4-E.Y8'D13B_8.2)[*VFK6%5[.?:%T%LW>[EY&EO?M,*0^RXF7URK&"J
M[_4'7!_D!LOJ)0>=8[,I*B8@:D2P'Z2<^2'"U<9)6GF*%_DH[TMF8: OR*S%
M2T/"NS=B-R??+96>[K_KU%N^H@0& "-NNDBTV.+R71L'MQ*?_/P7ZOO3!;0_
M^SY0)RJ<G=QJK?6:JI_<,=W$8/@>$]X<BQ/*T4:L@:[DVR&^(%T3U&&I=9+S
MHD@2P>5SJQ@!#W6[J',/RO1H27COOCQ(X)RR^O>"I79$>>-HRQR_@2",[H5=
MD\05[]T[<1>EUU+Q]II%ZPZ4"M/U.RI?J[SD83R!:M"$3JB2N*GC/UPA>L$*
M67' \*JXO8:291PY\%:6*I%F".FH9NYEC/O[=.T>Z)55=FE<B=:.RI)EG!6"
M^)_%@2BV]OM!'(#L*^J-AH4X8.^->T21_NV@M$PBTZ?08$$BNGIHSV_NBT'#
M]Q[$.V2NT]_.B1<-.PO+\C/N3<>#,]3 :$@O&TUDL@9)VV[<KIX3/D+P:A16
MSRJ$R\K0X=7");>RWL*"5.:GRE[[(;_?3]8Y/LF;"MX^T3D-=W'_OD;R*?%3
M*2*]0W3*5U0ZA[3J&241\JD1?\>!*!QS[>[K<3U"PB 8AV%YH5XK-V6Z3'J7
M$$'5,3@5DI;)L0M&[M?EL,-!RG5GLNL_U9E4!'%#KIADIO],F,Y:'W#LYC3X
MZZBI6I<=I?&"ZDKT)%?I PJW9[1U3Y?<N$F3=TP"(@9HC0E 5"Z@W4.]<^(N
MP(XTL?W^A6K==%ZL!_1ANC8(9A(QB205%C_70_75?3*)JJ-SC)/?:O*8.\0F
M 6._IJ%I^04&#H*N\PA<+Q4?,$+\[_]@0]J?G*)0;W,2?+,V-(PT%HV=N2>Y
MK@'/P: 4OCF;J&J@5U*6$\J3]RL0O$AJ-2>SI192:_=QZJ$J QT30&:H<9,Z
M)L\&?I8-0W*1;_5'JW[W6"Y0;S_?ZZBXPU3(MYK6]GN7\&Z1]6; HD5#Y>SP
MRDZ#9WDI<CEF1#Z?X6#']CKIY[W'>$K:9'(@6?U:%9]-(.+=9J27,)^-A' B
M1:&]X#9ZIEV/V*$$)OWJ\C*'S?DC0/IL6^G!3L;+HK&53\3=)Q#!4> L^RC/
MYB*CENK>\MFV%S&\BZ-V.NXK!<\-]D,U@B/_T64N/&7=3Z[WJ5UNX1\CHB#4
MZ[GTJS?W%MP^:>;HF??=C#VT8:8KH*?X./'K_5--;!OY,7%>A'%$$!H/!NIE
MCC^,3/.;XH<8Z@TZ2WSO'_<+'MX<-C?>JI9,3 O.P@)*/2#A"/H]I<:T,ZQM
M%Q^%]DBV@!'\Q:7-.!>J>YL?R*./P.EYSCJ%%YS;8<E_T6?D^E!$#ZM''MM
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M_8_R^O-__$K]?P/=?6WMG9+%<H<0;K3ZS_!%^LKYO]OD'WK5@#A25_XSO/\
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MX'1&] 1B.T(7=IZPX'(#J!E%;D=H009$C\ G745ELSH8Z[/LT,T3V&^(&V<
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M&QJA=U1-:7(3-3_12AD+1_?$6PQY"1?VIUG"18H\A5116=%#"T)C:*R'"]-
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M[]_6B[B-2;KTT-MN8$"HR?E2J=HE\J1)\M"R71%ILH7=-1I;_W;H8-/^-*E
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MQ;=@DU"#ATH6"JZ<!^3*,80I',ZKP3RCIRH/2(M=*K@$W:8>'6P[*"([!6X
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MM2]A)()X+\\_*;O_@E?U9&H"L?S[=YV17J1IH=SL@*H?-9I4$V-SJUG3^SZ
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MR+(*F!:&0W!JJ9L:8UZWWWN+G6!PL<JVK;?"(0B]#,G6(=$?-.:&D@G^T/D
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M&LL1HW<-%T?',U!KP$T;*GQV(,,#(L(,@JACM/H /<7FB3 G:@2#>^R8$(^
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M<9+F;4UEM<+1Q0UG4<2.-<XH"RV[#V50[9G?19ER!:G]FTR]7GT/UZ[ >N)
M"X5Q]D]H[[Y_5!OV41\:,&5#UJV9$O!U3+0U9JJK"Z7#7]B<0GH35!/"0)!Z
M$GQ+[> 'UI\\SDG#A%*4*Q).W4ZQV;%[*WX0"G!!%U#IU;9^=E-D,N=,V_QQ
MDPW!P,'"(N%*U59XMY/3EAN&\8+(GC8[U&$3I:$^O.SB(/E5I:*E'16Y(N=+
MX!2#5)AIOL[>X,!/(AVM_M2I 5/+@X(_F51'Q.R"X9&]L( *UAP=(376'#B*
M_QV11S(RLZ+,#8&K3*(_:K9;1L?CRY>4VJ=[<R>!T1[/ 05(1SQ7LI<C2O1
M1A;):IG!S=+;QHXH.&!C(&NY&.7GJT?5NNW[#"\_: !E/>J!N7'&@Z)8/#(6
MQ8&W;Z=UR42!P=D]62I<_&X&;#3U<AQ*M_A;TF_9-;_R83.*+>#%9A+XEU?
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M=-UHR.BB06^19Z0<+[%QX+N'Z6[H"I^1R.R8,JB;HF0K26H_9TSG.+MCJ:&
MVSZ"W)L:<\;;$,)S1HMF<MT>"")_/WFHDNV>,?->OJ*M;+8VY<IKVL!XKZ^<
M[O/W6_>DX<<&.1*JOF2D1,X]::NEU&4.C@(_A01U%I,NL$B?/GO'WADZQM/_
M"!P4XV"O8C"FJ*&&NJ^:$$* %OJ(DFME?'Q,S*;(WNV @TQ.#=W>7CV23O?;
M<-6^_'@7OSN;?I=%.H0KW!/34_%P#K8X3&&D/S5C@,;F*FPMQXD7N#=$.D!G
M(" 8[.OL_CR[V%Z2MB78,.M*M[#R*8G&2]<MTB:L',#;0MQ&?&ZKN2+;A?/Y
MJ74!P_ZC<')2;*0,,..#;P%Y$TGHJ0^?)HFL=&HOMS/]M!=T,\;* ;5.N )]
MV1Z_Y,:SG*FUCJ1*Z<A= OJ%XP8IM#/LDVM/ %*_;\7+T_XDR=C"<0<^/NLS
MW\>U(;_R%/2\GZZA6)=$FWURR3EU*J0/:>AM?PO0NP]2W(AG9=5)01E2OL*!
M> ,]J#8-3$1)HW&J:N*ZH-P;$<M_@@8KRD!KW'  ,MQ6:#^]SR>JG&_RZY-A
M6!-FZ!6%[DRBW9/+<JFN1CCP*;AO-\93'6&R"2UXL(QYFO7Q6_R;CB6M(SA@
MF/!=C$=B<D%=EHC^_[T[2Q C^L:'4INZ;=- !9/^/*D@3:V%P(+![QZK45HS
MA5UK(5._LH!$I(7!R3IJ'DN203\*U-L>*#$/M84#(?'.L;?H:B?G7#?S:C.N
M-,,N( =3.+"[*?8#?)H7Y;79Z'RC1[QV@9]=<9WRSP..<.#%+1PX*8 #Y))Y
MGV%O8'-=<&"\UQME:BM XB#T/S #4$Q0_Q<8L6S# _(NS2DC')"PO8NAOY6Y
M-T"'_CZNR=;G.S+DN8EWG+$[!S]L(\B]A#Q;@@5-7]+T=H#E_W!#L_A+ZO8F
MYG?V^8&<FT/(7]((?E4EHSK !HOHX8X"VY[AQB)Y_3?9Q>,N\NISN87$=<+G
MJH)RM34X G9NFFGOEN_4XU68HN8Y2F]V!I3;_-^&*H<_WA@V9<U^G5587:3D
M:<).M-#V7I;UR4XI&WWI8,&H2_9I-4?';QI)R5(8/ZA[H'[O(5MHIP-L1*/>
M"V(9>"C[" >R/Q]7L[@;,D'9(RW@ /?>P":"8T3'^0Y]_(87#D3_P3(C=-GQ
M1Y41R#9M+AT(JBU[YW!@37GO,@^AEGK?Z2(XT(Y0ZQ^M(-\;H,(!J2<KUE&Q
M^AN@#8LEK^E=Z%SLC>Y5QP5>-G7+OW R_\99JL]';'1L6!I8VJAFX-U8@2_+
M:U[/'-49D!Z7F7@X9O%\Q#B*U1\NIRYC].T?D,5QHGF\;*=TV)+AF2= .97/
MTYK ^[UXA$<8,&\<:J=?8!^CJ\EZA;[]/JC1;S.)E8@5BK6MTS?9L[0X/"_V
M[N[J0#GCHIP0JE /!W+>PX'K*820Z)L2B+G]1P@'Y^)-J<1MA#& $+8@5K6L
ML9NA@PT'L)_]\IC>_0NQ R&X]9HN_-L)3 R0?P+]]E 6#//PI@N[46]9;31!
MV-I*[7WL_1ZH/_9?=@>[I_E/6]B5]XS?D_.;Q_U#%V$JUZ3C"+.TDT+0!4U(
M(MAJ;80%UOZ+\#_3U* ./8@(WN2(2L&JT1_'>AI,UX5]"<Q;QE#)L QG?3W1
MU?JFD=+_P_--GWKO\SVE*YJL6DLML0>E)94ZA_0F;>&4IEW)7U0J9J#N@&\(
M,U=$6/XT*.1QGH;]::1%:42>XF)^@HUF&B];LJ3DQ#BT+AWV('2C\6]T$QPH
MY-"YU(<#@S P5\4&:'?S?JR4OZG\K<^]S!'[VO5>B=2&Q*34;OZ*U&ZD^J7^
MVG#/P8W)[4W[>>DHHUO':;8MZ'S*^?YL!M3MGPL:5VS\0U!^U@$.L-T'_POY
M?92,:!@1</\9LN-D1 /1\?]W!Q1"HU4!C9+L0"R?[,@3T8QS.56) _S7$-64
M4L. K$7WG4N,_;?9A7YSJZ"[Y3F^3SE'C-8>TZ5853O!S52RA)9OTRA!$7!@
MR^741NKL5@@6;G\01@/[OM6J#=JL/$7XA**%C@ME'7VI<2*W!8(&BQ)>%GNA
M>'5E/B#'ABGB8]@QH5.YA@G-[\GAX5 [8%U4SB4PM1#4W34%:G&% X'-\VJS
M;&V^>MWGE,^\/$E6/1>N^)V(!A$B=$[Q<C>@PQ8F$;.-KB#5XSK^P)>WGX3P
MM)'WRIA_%L&\4YZGF]1II4?V\3+^O<WT)1P0SH&^G))J<3VZ;Y8L,;DE!=F9
M2>UNBAX^V"ZS(4KFD.!\SZ4_PY: -DSM:%80^NSP@/T7X-'R9+QA&)2=BKYY
M&=]D!0X@:(ZQ*HC[YRF+RHVRF\4(#7[5DMRM8_I47N=BH1=#U,+Z^8!/EH=2
MX5OB%O>@R-&16KE%H]W!#<)_K_WQW[#N]NR+(;;*DYLKA)_//J.!@&CA0.]\
MPX.;4O%A[[6\E2SAVRCFW C@/UM<=G$.BO/YJ&]L+\TMOLS>5NRN<;2O+VI(
M;0H) <9&E-77K.S=J=:\/IUS>[]$';<ETB?@A^&JVU2^Z\]':9>\C0U&RM_6
M;6:?5993.7WF'^6V%W1[YJ@7!<EML<'*YQ'WWE.-5&A(>^J5HA$0;1X_0AKX
MOI"7)\,]"\]!4*QD0R->Z;=0V*V/6)C,75JRH^K5QM<1,1[;GS9!T47%R/6N
MBVU#4Q4_EZWR)%6)*H<Q547SY, O%98L=;C8?I10!&$.X@D] A@2T$U@=8H/
M\5:H=;WG*O32IN?JW8_VPA]E(75='.A9:';PAI'P^H;,GK4I(]4&9EBTZ2>?
MZW^T2]:SD@_BH65MU&**X8FRG.,M^CPIDI>;^9JS^NV"^9)T@H0;LW74J"VC
MEIW\, 9;?/R,)Q%Q$>JW:?KF>@.W;J\8N0;KQ3PR('17\E)U8FUE7]I?XVSU
MD=4RQC@5'"C0;PXV:(U;,LPOGPBB>T&()V\LFH6_99^65D+"4H895=*L$677
M]CY22)17-@?S%0%V,5@Y[$L&+X^(.NQW5_'2JWKE]*]I9Z\-V /-=-V\Q4R9
MR7:+=VIP'Q:R%-,V?B:P:(NL?^26$[6@?.-<GEI@P4><[OQ55=*Q<>G65.N[
M<.3[5TKM1$O+'/:BYGHR;9PX+3;^WL..MS,V,7ZFL-!Z<20X0/\4$20XCZ!]
M[FXKX\)F["'!"E8BQP,?04J_3A-UI@YPF@-^NJAL)1A-N_3+DY;T2CM@,ZKO
M:Q-XK H2%%!Q51W8" \>7%8\F<7S=.AV_WDR_[!_46.Q&32O4RN,6*S.L#;?
MZ-,X>Y)GVKBT2<'<I"B[:>O#IGDB]EEA5;U$E"7=$ >=)N,H]0@^DQ?O/[N(
M3NKK$[:K%C(L%EEJ"%):$A!>EF%N5D9,S2F^%<@_4^8'\;E@: 8W9.')NFGU
MGJFE).]ZLC/5%HV/6F0.4BF0Y45=E><I61(8EF?C'UOY3"E:)%H3;27?]BOL
M2F9H&-[*2Z<NJBW?LE9Q3M9MXP6Z]&1D*5)#+WYD\9R?G:6S/W+9V37@^YI'
M2&//-B%>6?'ZQA<.T+)T'+2 Z(QM#HP:/G'4I7H4.4K>83P[5]56\*9<=\^8
M3TTMG9A=TEP:W )'-.M,'GJV,S'X.+_9BEUN4"OPV:WSDVRPVV2^,.AOFCG*
M_R#GG=OYDO[73NMF];!Y'J9#@&H,;7J2KI% D<F;/M+<B"O\#/[:WQS6-3,X
M58/S3PQJJ^)<2J/<]]6D"NP7]XAU^.2MS:QLDS&IWPSP.M]WQJSX])F^:+!S
M=.5GW01:GIL*+ZK)7':6,+9U1 B7%63)ZBJUVJL*0I+HSS=;]VN+6"05EW:W
M_&K9-#^1B'.=G0O0![_V:&A,(XI:D>NBD^YUPM/9/DG@B8)DS.*JJ0E:B[,>
M:KVU)GBD!TEPS4+:I>[.DJKGE-[/;HN3[QX)"MFEQ"\Y%)TA67/^*.S(A?*Y
MN"F:U&O+\R0F:Z9$VK6X[?Y:A[5U;SC]FOSPZ#:Q Y%"MM$/DL,!U\9#AZ7:
M&(](2?R[I#'02@6!!/YTG9]7MM6FX+1C&I7VK#D/BZS@"AJ:V'QXNJP U;L
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MU<*!3L1:?'_L@++/Y%$K.4!;#)93E&WSH^*B#N9W(NMS1P!5I;9X[*6.EN!
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M#FQU;.B-/ U.J%NHY1:),CIL/Q_+*(D?1L/234+9"LJ2HM0,<)@,ZTFGC[U
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M7,8A*5U L\>/,ZB5Z!/7;,UW8(ZRB P;Y<*P=#?F"KD_3/Y5E]0_ZDH&@>_
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M=&X*,PW$N)+TTU^PI)_P+NOVQWB!/PWTV2(7#80C["S'1T>F7ZK&#%KJYUO
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M)3!K8Q?=*\B'F?S6E0']>/!^&>?Q"Z8+0*,H1B#QX^IC=FCC(U23FBCNMY;
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M\<UB^VXF'.A./@V#GK?#@<Y@&"$(T0-!S]L0O2_&X1&&VEES 3\?$L6H/>$
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MW;7[-7OO<\[>Y]YWQ_N]=^X8;S'J'[I6S:JOOEFS:O5J^!1\$<!_*2TG#8!
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M8[X#]&G1M^^AZH9&K?8S)%^@6Y$J:.<6_5+KCP5G:\17;J^']-%[]#V/,>&
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MU<5?T#O1Y/7K#3E_XJ-B83.JYGT[+1UQ[M_7%ND@2".I(E-TZ:BK*Q)_8&-
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MKQMM UF"ADHG=SKR&@ 9\146MCQ0RH9%@SJVYRDFGAP13J<@1GZ*<2TFD5K
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M8A+.,T_OM.(8>*^P]GU#7<WCT'S2_-"3(&_<FG**$3;1>"%(Y7#0RR _OH_
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M)T?$I'K2+L?+3]I<%R[K7BE<V- 6-T39O)S;;2,*^,IM6!Q5(X+ 83R&G*.
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M4_H56%.9['^I=!^'2=MIEW@%R$6_OQQE/^ XU;P"Y;I/2$!Y:?@O?89YJJ:
M/92"9 0=;-,,/Z']4VW^0 C/L_"7^MIDA3"W(H?F:+$LTE> 1C\4OYH3?W_@
M^R<[I!C!#Z*H'@;MOW[]DI)[NV!^:DRQHF6#\&!\N;Q(H[,DG7.)+]^KS&Z?
MX8(-=0!^F)R$"H+Q/Z*V6C_/HH;RYBRP"N(1I*KF.XP^!X4Y$V&IISNGO?F
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MGUH*?K) .#DI:D^;,:XS-^@V^K7EFT4K_ZCTB90R2#NKF,@,.D='C,^:K]G
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M^J7F;Z=8HZ=CB<O(2T/F_6_PT)[#S*00T?7\7C9C,8\X2D(_!6_0'OK(9)/
M9R%P0KFFNG5%M3=1[7T#<^3^.\TJ_I6LQU_/>0BOY#<M>!N<Y;ACJ2#2$_6^
M(:-1AR;6W7>*#[)B0%Z49C%TV 9) DXQ$9RABU='5)?%[<A)-RU1VN7TP!MS
MI<Q1F73Z@UFU'@H)QH/0FPP9-NXRF/&2UC',A[C7C\39,"??*V WNHK(MH[8
M2G$JV&.I)0$=4>38@CH6;G/T,1JZNJC:FU^H^\R0Q10,AA^KS.^%5J)WB?/R
MO"O&)6V(^F!!S\5X'7Y)MB<-]+RQUU-IAY3V5N^E=>=<$#N<A.\9$.[ZA4-O
M#@ZW^2Z>!.O!#I3!DV>7(J)=TQF:KH79Y4O%J[%O)L+=6;IV7*HA]#]!OR2J
MPMGRU*]=/)JPIL/PQ]6L2JZ\M^KXL)98=++U6,%^]E:"OTUTX792+(&_G2=8
M^=;!:* XF^A+45S24UJ&T06F#BZ==9.]GBW8JV"5(H=*YX%KG>#FXSN:X![4
M&6P9EVNQ6$R=B\YNV*G)'SLNDQ=D1E_/NDV6'2[P[$-M=1^[YCR:Z0F<&G[A
M;&OOL_'+Z@A$AMG3*>CQ2?6;W?&3(H6C7:V#@YA$!*HER "]3HM<M3JBKS]Y
M[7BP7WM\Y]%*5F ,9*!QLK2Q.?HGA4S;"Q%'>8>'8/5/E_2.H;>_(8Y-[\Y2
MV\++=@?42_O,K,7RI9&UX"<1U65B>KEIK2"Z_K6[RL#,V;1/U"M@=;;>X"UA
MZ8;&DYSGZG8')S@?MH+/Z/RB!IRR?,\]G('<UG/8]$S&R:K4^V2Y8^&$\YLI
MNAV6_;BBO1)(XUA^O3J'Z0RDG>/&0D'=(Y,N^ES/7X'K8](P5%]]O1!E7!,?
M791S]M4D8T4?_:F+YA&%]ZA#L#5"ONLI1DCT8'%'EYM(@-?<8UK(T_,)C^=E
MSN0Y30_:S'5;;W1KUZEF=DW 9I_M4;V@*&:@OJ=J(94+TU>:$' W#2W2=OM<
M@/_U3?@L8B.D[7 5-J'W(*U;HBO 313^Z\R"Y:^ZEDR>;DNZ".2=!SJ-=AR6
M+0%'PXR%2KM6XA$U;=;>BZSV;8WPH/=*F4WY:AMR>7..7Y+!\KVN-;X5H0VS
M?"8(!^&7+TL?_IQ>+J0_/U9QR5BH2:=W95K,>LB-W:+DS;<AB#U_4X,K1/+F
M+X</7JSAT'-2^(FO6S>/>2P2X:P;Z7G4/!6E@X'[AR4*2I"UP$)*OG/JN-K"
M/25,PL%%9,IC,.1A98EW_[+R"K!O;! %,+2=L=FG_/B5):#?V_.J'OW;CUP,
M&A4;RII\+)E3AG?>ZW-6@W[YG'9;<P,]6_9^AA\;ISL-FJJ_.+OCI4"F^0Z4
MP!T&!]9V87L/('[*Y7V?L)SVL#V@F>VP%$5+K_8MP0,I0S^5.3G613^&Y!CL
M>026%YON!TTEY+Q2]IT.N.@":AW14C@H#C]WA'UM7%<PF+KL9K2#$]HA 2S
M]^/=(^.ZOLK:Z9ZSW3LEG^D)37,!N(AD16Y*P'RH]G45"5B+C<2NRY4E0)%?
M?(]&M<UET$[=,(/J>9_,/KY+GXYVG$#@>(6]OPN[-]K^^Z_59D>5/AL)Z,NK
MA$XQ$7K<D<3JX"U!BO$_2TB.\\N3%NE;_1 .G:4>D2L0SDO)E%Y0BLF243\.
MY:NTF!>#>65>HU_\!;(WPT]%ZC\$0"OXR?Q09U8/P[++YQ.&J:BCTZ]-Q1H#
M/-O2;H \3W-\,Y3C9P"[5O<FM8V+G+>%)1\D>.EE9/DO@),H,XH'SUJJ?*3)
M-+_EDK3[=6F6^%.L=)^\%4^UC<+7;VL=K-*YYN5>SKE\[+N2BZD4%2@O2"%[
M,SJ!3[9[4BL%AP1#:&?_E@&KBL"8ZB;^4AD)H$'$]*MN7QUK7B7&%RR2-PN:
MQI@A:\9[9*))]F3"8;AL%V]?%U7:&B55]Z+^"F?J>_7N6[?%/F>_XENRDET(
M4F9\FC]FA3>WX\\YR*E)HG..5'?^@#LE2@)"L$IIL[DYJ]!%YBVB[TE,&71!
M$AK%LQ6/#V8E=HUYDP";"N+%X'R[BB&+0.3B1&99:(6E*\H* D&KC DV]Z<Y
M=7YGB@@/-J;+<UU,_%8]R[2*"@ZMW%Q/[1/73AL G?GTJ:\# !@ 3"LC7K--
M=8B@#<>BB<II!://%J&,:23@LK(<":!((P@>*G4]8-3?GNHZ$;X7V8GL9C>2
M;5CFA<GDVAD%E'TC@+<>SPS&8:QOU"9&$@F^/6[DK45T<7?H@#MOE01P]Q.Y
MQQGI D/\AO<V"93Z6\5;NV?O,#Z'[NCY*4&'9$G ,*K5)1J%FAO\YK[^,)XF
M.:3V=I%Q6+C1A"3$/4&P.%[MGT5'=>6,ZC&JIH;H1VT@/KO:7^.V,S<]3T#K
MJIN?R;&A57&X$ FP7T'L,<+)T: P\2+T'Y-+/O% V4G:&_(G5<:(A'=X@W].
MC#\+GDK($<N0?B+D]T4N8=\D@H90:XYB? 9W!^G&]]+)7YMIE>P_Y>E6ZZ'-
MB95!: *^1[AGTM9/4:R.'QIC>Y1\:7DCY+@2.#RTC\M8>8=SQNYRZ,6=TGHS
M4RS881RAQO/:^@_N')SG=Q==D2<2MELEQP+WR(%LZ+N37[9;;]/O4ZJNY2D2
M(PX0ATO0S@][K(^>V6Y?T& '1V)X,BX*D@##]HQA;NH[QR8,B22 ER<6L8KA
M.;D I_A(S@L ,/AWG\^=!$=>T$=1\IQ*"!&!G<O3!*2#'Q[#J)SU[PDY%=(O
M[_7J-S VSLNA?+_HJOJ3+17_^[J;.Z%\]8EM/"B+R.QLN1Q^BN\'CV%:,F5#
MG*%.RX*MIPJF]0^*VE@@E]W0!Z'8ST?K2-O>0FN^UQD#M>/^5+MH%=<[=,BA
MV_(+)@5/)2(B(C2GV7:<'2:_AK:?A'T-ZF[:1<QC\_,G\MX%^KA;S*UI5+ED
M#ETGU';)&U%[2"1X,;+5Q%P\G^.=7CRFYCW'NA4UF;&P#'^5YVIH&1T'DI9B
MW LP_F0&FV-1AKD@HD+.AQ:[/HU:GZPK[^?,<A<Q>#F1Z7"=:H5JSC(A%*CY
M#A-$\M<'QB>].D;']]#LC28%8(C[47T=5/=OJVYX(VW#,CB<*:NNPHDCXT8E
M'E)Q,=G$K]Y]U4J^.3<C8"K%M:UL=Z;3*JIQJ)KH"?0!]$:0UFR"3]#J_9KT
MQ_4M,<?@D_;A[CAVNQ9Q>_F%,/\RF+,BI_]AR7UY\?.!S"3@P>3>J[>A$",S
M]Z63%3E 6F\I@[Y ?$[@737D7*]=I/S,]^3B<.M!O7,2:1M/Q]L8G%UU)M(Q
M)6*1[_..1D<TG]SX71@"@4[5O?,47=M<D.HD =+N#5Y1#3LJ-A2K)\+@M/&D
MR7 %]#LVYTQ4NFROW5(RT2^*E36V=R3!-W?J-@/8M,SC.JW;8N8!7<.= <".
M;3;PVU129UDO[65?-;K_/XN4(@$7PWZ[;\;=?^>1?]R01AYGV,=-?9T@VV;-
MELA&;UKJTRIC"=RSAS60KH"G&1]AI7ZK ;6)2PDHC?*W#9WG;S^O\?WBL=F/
M^Q@@SS;TE%$76/R>U$WDC#_8#$N2;V]/G#V=$5#WR]L[,I!UP.W2-N0^BC\L
M#9JH@^'R";U6&#_9XRD0N)1;HO>>!@O4#C(JA:O4OW7TY]K/^#AKOH.+<[@#
M\^HX3U@&\7"+$8DQ9'^I1Y1^%6*)O"FP)(>?4B=;I^PF5B@%9>:G;6[O<#]D
MK D4/A^+0\O(SC,?$+N0QQ](0*(?*")>$%2 ?('X6!SV )IHU(38MFXO<[ '
MQULL:VL\LA+K8%PM&&UI^5$38E0;6"UMW A&C936*69TR5^[M:4NST7+-L16
M2!N A^,$-+Y# VRW"]^]"/73[]:%5ON!4G($0;E-4-8>=Y&4-R^$BYFUIP8H
M^SCI<0A='VCGPY&W<@?LM4"&L! J5"IGV:F0 >KX OJQB 3,7R SQZ%D>;+.
M2,1G$5P+RW$918VIFG%+#H:WG1,'UJ34..O;BS"M>29''6()W%]OF_=E,;9=
MD!AB[;%&8S8WG:"'7\N.)B0PZ)(W*Q8)3[6/9983;KA&_(@)0)UGX5&DZ%^^
MP2@S>9]:M:X',3=, C;CH+W%>00'QJREGN*!%K4RSYQ6BI_(?.^536O1BQ1#
M:]N>AW#58XSM]FLT9GYS&7K8C<!:[OU!H"T$Q;I"^,WR@]'--O/*:5$4_PM6
MQQ39]^DG2.$" D2F[IW+4/&*^].&5&MW?\-8-10MR%O@/>'NDVE\N75@#?8V
M<P0SO[\Y:$<WBB\EX>$&]G0^@QH9UL!&GF -$M!^C9Q36+>+_B5H&<2XO8$:
M9S^4C6X\7*,X.\&!K,T?*;0O4_;Z#OKBC="_D:-G//S]VK+$X'\#:SR^J63^
MQAEB.M@B4CS'>T63Z=0TE]2 OW%4M2N$W?I;"P?-4EW&J&S*&XJ7V5B:;,6&
MI&P<I^/P\&EG$D#K6MQ^PO@#..F']F;]DZI>82!,_%Q_.4>@^>6&7$W.!.B4
MD-JGCC6&P /<1_=A:M7&/Y%^J;5?7@1ET^/[N;U<6ZE3SQJGGWV#8<T1=D]B
MS?4U.8J2Q<-Y_D4V:=5H'3Y_R6+>YAM?CI3,]]@-FG1W5%$@+C]C8M1O\.8P
MM5!H,*:5321EZK9GO16=UZTO.ZE5,R0 ";5H;>QI/C[B.=D6QT\HZ_5 +,+@
M?OW2I<Y/D-,D -J5MPC>N"&5NZ4#^%"Z.Z%2)J27FE*9Z(MUKJ8JHQM:%$P
M6 EO-7!_ABQMIS^D#9YG@0;?'AKUW*Z)C =^5-OV/D!KB8PX)6LO,,<]KWJ
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MR=8J1P>J'5,@*S)1C26-1?B\CR_(9F?I!-'Y&N-I><Z1A/(=8%)]!XQ6Z$^
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M""(.XC$D[C'9[[[;?#;X?JQD$!?O74KYE%4@":ZP@@_Y:/_2])E4E/5NJRN
MJVI4,P7J9LSM5;_?8O\.TA;+OP/ZMN'B.5Z_.=@M^^RQH#7W0]([P.P/'C?T
M:)+38:,V,4OC!9,>?R<0@.V>890N-D*E&OUUO+#K#F#CYY;%[Y/PS!+[&4S\
M4UO>WXWM^T8]C4!:_A[' \;/_32X/<V]G;49@35P3K$I>T?3-R)*5'E.%3A3
M5Z%,*N0C!ZBAOAO!8L^IWA;D UX%N1CGWE-3>'SGWOA2&*=)VA@H?FZVB79:
M @+*]MCKS>D8H3($"IC(HJ_BZM<"S:J:5?-5(3/ZW4X[5.1A[^V%XGTP.D%M
M#*I"4-QGWI L\@[M6F(O!-NR)P_IY!5SD918%4+X:^6XZG>A+LU8:LA7_AX1
M<**YPNO!PIZAAME@<7,<D"#BC%DCRWKU(,KXM:LKN='"POZXVD&#RS<)OWDL
MD*$Z*2$HMN008D/C(>!F?7NMJ%VQF3;5 8=CVG(41O-[A/(@*DBN2(E:3+*K
MW0%=J])(ITW)U.=PO:8@_X=91?-&PZT#H;STES:ZG\4(W51KP$B?192<"9.>
MC/+F6L56IH ]!$^V#?)\PO>1,]8/3)("CFC&OOG8G-6"V(2H.Q1%*0YAC?6/
M]"/ILP0<$A'+UUE<?->HY$>FA>X =&EYI@>S3(F;2>S%;F-T27@QJT+T2%01
M+1K2M V' 5WHO %IJ#;]2.@JYIU[M.T4W.TTWH1!'9;TRGQF:/2=*^ T#7K-
M=B&OWL%,$YR&QUZ<>#*\.U9*#W4<V:=TW0BKQ+>)DBG[CB[$ME]U/]184'*H
M):@9I<72D1ZB05QC%"3I6SML[Y9(B/YR,6 9C%_$H]CPXA(B_<%$E\=U07[#
M55^/HT"\".MX$$.&)-G"CMK=!20D)G)6@@UO8@W/1JY-A?$@TK-DUJH1T5"A
M+=8/H]:ZJHBSU/J:ZNO[EB,ML:!UA X=G8.QL)9OF/EX/?/D+:V><+1Z?$:J
M&,L_@RBIXK?[NU.XS!F@K<U_U,(@]BLVR[<6PS4P+S.OB-E4H$_SUZGM7VNX
MM(AAX0T+^HJREY<9)R',UK%IY3I<1KG[-L*HM3D;Y(A=(O_X>VVQQ;PB1LS*
MQ2GF^&*CZ3@?A L#! ;0=WOU/ G_Y"O_'?2?^^.]W_TQ2%LC5#]+V(>&A2$1
MXQ/'8'RW+W682^"#^@G5:"(GS;"4-UQUJ6L-SB*VO>2W&B[H>WN)1B&>]MA[
MD-KQ3S8%&N5$T4GBN:$2&,<2J#-*EJLZ>5=8:FCPE$M;PORV_#C,ZIC<-9,8
M!!_ZF!'43[\.CJRM'5;&KL1O/\$=DQQ4RU_8I-%U<39,<I/0+N7<Y',?ORIL
M+X5=I+%ZI#]_*[M1UI7N-(38A><KJ[CJ:L(;%WCKKX826^U>U,7:R;?+4IL9
M_AA_[VCZFQ/Z\-"P$+R1=ZS!D*%&[K"E?]*L*L[X^]H,NX6UX5=S3[:\S&EM
M6##WZ3-*<^F#-PT2)T]J/GA[H^18/UZ8'\1N9C+2I5BFBU-\G%/B#K'1$:2V
M3XZ_,F6P^\(6V;<#@7 -R$E1=M.0$U;.RU","C>[,5E8"F$5)=@G.3K+9F^O
M-(]_U#$][GW78L%\;%K'M.Y-E5U$N5NA1LA2C($" !Z0V1-L?C@]10)!OB"8
M&RG<L9?Q9E_^ ]'3#BOI72J*.@(0RIQ7*)\MDD4HY @!(F)2:I%SX%TTOT-%
MLN!RW'VL,D<2F>E;H()N;$#4(Y][5CIV8?XLQS3UD5G) ^_,ML_D]8RB-QO%
MTQVU*),?ZFT+V*#MS1U-B-Q@3E'$3&H]CE?JM754% ("1M)=98XDM@H:Q';X
M?92"+*"#!&3QL5W9AH:::,R7*@+]9&])G_G05$HL])L$'&N9C/#-F;HE2C[1
MQE"'<SPU.6W;2QY2LLZ'Z7Q[]&;(-C2%1XE5A$O$/4E5PC,()#M"T6'LXS;8
MA>VCMR(M3<56M!^:^8&%.XGK'6,A"\S(QVW1W-'9;*P^14[;5$022XJ\D7/
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MN>U3 (J'"T>'(\%N <Q,_ *L5.]SGO?E?@D'$I-'J$XWA:??U"@Z)XTIA?V
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M]HA+P3+R#D-<9S= > I #[?Z8::=9;<&DX8.?ITX'"DGN&XK'<D6PDYPQY#
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M'20P]3!A5N_CL S\("87OL?K$0SK-*\";YU'.DOL.9KNG&L41 +![@E'UY'
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MB/AGU^+(R&RJ)?(GQSGWO85NH]MBNS18G*7);"D@@3<Q<&;%EL6-UHNE@_Q
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M.3P7)O3"%*OXEL*W)AY#>O4MI(9QGL L&M3ZN-#?W+.DI?M16;ZY,45,N6
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M*GT,L_NE8E3'R2E)$2EWF[-%C+RROG9X!PY&FEXF#=Y(4 MC%NAA(O'7U<6
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M?<E BCVW^!P;AE[KX'; F^+'A'>,';7TQ<K,N"%F15>[*:E2<:?<\>?@1![
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M[@10S['[5R[.LH_I\5;L5)[TY0BT&"S\+)VO!!$/9>%FW8F\ 6=Y#N$FS$U
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M,N;1R]B8 LR%><X:<QR&X0@)N&=S*(PW0"1/3H?<37KGSC[W&,X1_,2L<R8
MN=-H96K6J)QW+\SXRHI<8R$P@Z:N/H*'4?W%B(LZ:-)]_L9\O+;)($)'C3$=
MC^"6L$/9*/8-L)"[3RAG/T.P0(H=PL&]PAXC1GLG'@;P0?77%0B_P8O/; JB
M%5DFLQF2./#.R1<:Y^PU*)[4F9YS(TCZ-AU(JU/9[)5L5M!&$#U!OC ?\<>'
MEYGOEO!RS)ZHT#'2^WE^/ @6:E1"/D[MJR)[]2_5(:H/,,YJ%XA +,H3'L%\
M7ZKW(Q4JYI+KM^W-B]: ],Q&W(J.&,4IF58RN#B*I9;Y2,,Q7>"8R <;^'O
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M<G+.*A\C/GDEQ1>P:.WAY[W$6W/<7E3=4/U WLEW"4]U,1RT&2F<F/S%(G^
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MMDZ=*AC0O@IC:*V0Y=HX/94OBP*S&SSEXUZUK*@ZU6T^+#H13'I6\LDD^CL
MK>UT2*6L&NJ2G;,TP8WE3JZ9;9BR'O&E;<%6WPZN;YMD\V08GPHA=<V/:Q<5
M/9ZXP3S5[MOIKS5$K]ZY8G=V7*U[V>2LY>0OPQ*XI>T25UVL<O"5MBU6^>93
M6I1@Z8'QG0 $NA.L- @@Z_5QM'FT2@!#W+GD:0V&5$D+9%ATZP3(Z *%EN+T
M*\N5Q@S"R*.99M6"2?JZ:;H6G-:A1PKV%9X-L9Y>/YD2.CA1B)&S$QX6' ,4
ME(0N*=_Z3W.PAM3G'HFE>/P%#%S#?^M-Y%)TK7B/!%H)K%B:!U:B'Y]KW$=
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M!^U9[&!F1VM37\1V89<_"(4V#4XT$^B.W2F>[A746=*T=Z_N9%M7&39>^,[
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M;" R=#QX.'<C*!^[_3W+L5Y+<T,DO, C5BV>"(+4+4V]6&#%U-S@/$5'BA1
M#YZNR\>V>\_&*W7+Q&#O"7FW^LFF<]/]6#%+/\9Q5H[.UK-55<@"G/3X&Z6+
M*.VELI@>;"O(E;?&CF)H+@AZU R N:2^$[;-Y>!WUB*E!JCX]_Q&&21*<:[2
M-Q3MHVVF49\8]#(1$"B.^2Q???HC=JV ?5=A'R$%P1,GO%L:8#^C*S7 *8W8
M>2%7#VY$Z#\0B7O:G9^L&IX5UMLU:L,JY_ W6C[^5Y<;;;KCBX=]4I.$9:[
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MA.B =G&6,"5$?E6Z=!D/HK'\ _J\8^7FV=RI49I8-3K65Y<'C^M5=[$;P&A
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MD9&PM2]H7J/T_^AS[_\A2']7_A-02P,$%     @ &H@.5Q:"L\+YC   AY
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M;F<B[M-1F)TA_QN>6HC$=A?ES?EYSJP$5[UX&<WAH07SA4<3$I"J00)M[Y#
M$XFJFJ$;(N*_IDI*0X2$8"W6/CYIQ(/_PSN0?Q!/_>-Z:\@_\ES_P)^BQI/(
MU.,1.1%-$2OZ+_#_CBSMW^C(77@TH(RU_]L]PZX9(O%R&"#0V?\"*."O3-?_
M"1"V$"S?QL!Y_LE_.^<#2O]N1VR)+&RD1%9"6CW= @DHQC[6K55WF/>OG(X+
M]W70[+OW)F_Q9HY6L2XC57S*\+-20)H5!!K;;.T,W3-P_YB...ZEB\5@)22F
M"XF1*P&#H.&;;B6S6F4"X3#W!FFQ#$BHZR?5+$;3Z2G)7.=3BQ]O_DRF74\V
M17T/?Z&,'LZ2]=^3E7?(T0<PJV+DKHX3>JVFR"T$$)T'-Y;F%0NX?29E0X4.
MMM C(73^>B<@'SU27:6B6":G-J#W"=Y!V&5WP%OQ&2J)-XMOWTEF?9 #T*!:
M*5*&!ZY&[\Q&/12/N3\E%]4J[I82^3 U&@=XYT/,;9*10,S>TN6*Q.]:C\TR
MOGIJ:U]9B2+8T%\G&A6([%9!ECXB 7R)RAI)/)&SI??/4(+!4$)"7XU0:N<0
M.7#(SM'I[<QGMQ(U2P1SE6\ 2E%(WK^TSI_==T)6]'TA$GH"4/5]2G\C&H@O
M-Z2R1@6RZBM8=\" TDN4\-,5"3R:^=7J3'NE-8CCX+V9HH0Q5U9",Q(VL;)Y
M645[R_9VZ,G>TA51YHK<A58A[$[5XO+^-R34[AXMMPTC'^2&BOLV*HDV+UM/
MN5LKSU5OB ;BD8#27^WO]THTP;95D&4P"H?XDM%9FO-X )^O+"J+,A>1P!\8
MHF]"" E\V4-=U*L>95GKY?M[F"(!NT=W;*88]?N#.'JX:VN$YV1_EX3]LZ0;
MT3_> S=,1=S)(<A:9WPR5/AG&I' $"XJYVI5B$&@8SD[N-BU&,L%5+R,6.(7
M$DB.N$_XZ3F%VE.M> @RE,N__77.#!(HQ4.05P6*$/JSM)U1;UU Q3Z"$9<(
M"XD+HWS4YOTOK?$H#Z#2%16D58FCDE(?> 'U]DON83A-]7^C@CW1*OR[IO40
MY1G:&;T?$FNB@O=7JD<E(=#;B]Y=60!!([SFGC/[\J;9#W&!HFANDWE&C6+!
M?*6.@@<9]G#(/&U'Q=9);/LE+Y0P/O.?",#_%0'-?]E'Q3;^EDL3+K*W -D,
M=KW1:O"Z&V*/;8:&#@F=P_0"Q' FHZWI_F4!\M< 31(JP\?N6%!NEM@2%8#L
M!D-"[;%HOJ;*N>\/@/8@?\/PQQ$5)$3(?^^SOP%$)?<V@KRF6L,>)T[D/"<]
M8EH.M2,%4?&/OO[/7:JZ8ZRL)?*]QUDTIBD2[+%[':TK^G-R><]Q\E?DJOVE
MI^5R;#<LME/&M3?DS<(5;>M;)^?Z.[CJQ2A]P\>+N1[JE@?:>!1%S#W[A8O@
M0S RUS-(1+%I#:X[[)O41W]-D";R)7D=5\=#+:R8_%N_K#,-3BFT40E6,:,!
MC?NUM$CM;B^=E827N3HD:8W.]?#$/9/MV<'M4C+,37:G7\>.20RBZ*/^ALM@
MF%_+;4 <Y7C^--))^H>,/YO5$<$??=878XF$A<P,+]3?1U^$NAM1-[D'53=]
MISCH7S.&1$J$PL8A>K-MPHSNNUWZEV8'R@+Y6*;!$5V>>M&?R>DGC*MJ$U;T
M]9DKK6DV6!\*IA"YO%2@?BEPMV";,M8L7:2SO>]2]WWCA)K'\S3O8Q5CIBW^
MNT^^&&-E#"D7=.&4#Q\[;7F<D=FI$;V"E[TQZ*_(2][8['IRD>GI>M'?X\"Q
M7WI@3\GT97Z%[O3U1XS>H?YJ=YKS* 3;!#]YH(%-3Z%CX1S/>UQ)_#*RT) 7
M I- M)'H6=F'V9:(C%^B-V-OGG/72&)0X[P1GC*N.G"FR.!M#>D@75J8'G*K
M^-+I>=1-015<H3-G+?RTAQH--!X U#=7M#:.N).UZC*%<N78=CV+B*$P)E+M
MH\4DOMC]]8(8A_(L!R/8&U;#:6ZKP^[=&K8YMC9N3X.X55<EX]_K=<:7WP0H
MK@W%MSYRCA*/X? -/.Z:O( 0<"0NGAG:6IN1<$STOS&WP&^@=FU(XM^6DK1;
M=H MPI['R% ^"^;T]P@7CM$Y:?*=6Q"5_C6<)Y)&<3'E<:K /A?:7AF#. [J
M!0LYR6_]J&GF+LHK&:Q-T4KW]C8GBZ6,&STRD'5M8B+8;U^F>/JY%_[+!QN'
ML6RJE2SHG;9-8,BTIHMJEAXL<D=CAX.HP2INH5@;-=8[H>!L!WD68F/]OF7G
M252&/YT;\"V]\AAD<ZPI_KY6TS3?C'\ET\Z> _9GJWG1?)<S?JP8E'9[F3U4
MX)*A6V [._017C$J43VIWR3_P7ID>?$Y,2LE$<P5RX P*!8:/Z 59CA1O>+.
M,_] Y69ZQ](LEKI'0P8?5[-GUM-T+"C(J/:=3F0;K5*4%7[6IA6A*B.^\$0M
MT7O>/WO-JF5+-0EI3])S. :V0_:7++69_#ZY)FA6OZ0SS0A+J5HI,=68 !OF
M#/D7V.FG4[;.?/354*!X5:PM1HP6G07/\WGR$\!5>^GR4LQWF$26&$1()*+^
MIPFK>4AX;+,BWL!RDHMKY9AN(H/O$Q6MN,KI>NF@=B_W<GS4VMJ3H1$_F9];
MLT_ 4RWVQ;5)5;)E=J-\'*!;*69A)\\S(0#MT*CXH0/AJT0,*AB?/<A<&_!1
M'PR&I5@MLDVY4VL,=MJ\;'YU\BYQ69^-KX*1[3F@64VJ0$4%GW\G"J&U?:3@
M9-(2NK\6+NQW63UW\7(,TT1=9^U%K;QI;#O_S@IZ4" /-@Y&.#J@ !#&>9&Y
MRI7K7H);U:;.K4KY^F_MS=U)R 07U<+'8=1[G[.^P\'Q0VSM[3 ?C]35,I+W
M\]:3%3L><1P#-Z^F;!TH0T^,9#5^=J+C!Q+YT/AHYV,:%M5H$UP*+:N1R$EB
M$TOB8$>Y3[-[@S,X)]SJV:&/9!XT#;F=R(#$S2H3ZE^@AWVHM]_+]U!5TCQP
M3]?JT&LU_[;S^.'.&)] G*PT_7U,(UI(&@W.LF_*N6%$]SLO80S:$K3'3G8/
M%NLW4'HY-KR_(C@F3(>ADQG/RG]Y)-+R?+!>QPTIHI#4V5MHN^TDZ0%/N:_\
MDCEW)-)94C([98(^YI%93Q3CK6.FVGEIJVA"-E?SAL8YBE71GFKE+7%?O/6V
M\9SK(U3MCTV5Z9;.% *YS55;GG<Y8$RUCC;<\[?6\O>>JR=6!SWX5;&W*2%*
M;!>(=E$::/'31]>#.Z>,KZEB7%W&P@V+3%WR/Q/755Z>T85U/(R1IO4-T#XF
M=_>V<4-6_U+HQ@X)G$]N'4+=2R'O'/?2':AUH+-*WQ>WHJ\MXT^$+WK;Q<^;
MHZBDM#2(I>>.2I[76HH]MNTZ^(; $=Y53)%T'900X2%VUDU''U&(W6&U G(9
MP,[A>M)0T%D7X((0/R4.U?\0(SC'@7-PFN;_'0RGF2DUV7Q_S)VA%:W)G0.Q
MJLRJE#WI:O(+!+DVM?BZ;::<G4C<OWWHLWG$_T:!32>Q!MPWUM4XT-WXX=:+
MD\O>6%F8 YN&.?*)UA(TN.G;.1QTGEMSS-GH5L)IKZEC2^G(4)]\*!-<.Z4U
M&Q/:C4-E%QL/)=3^/KM]4:O]6'.NDR'NX+V !V;Z836G-]@I*X#<F B 1TVO
MIL;M45AFSGB%=8[M/+&''E$Z<)F$7UK5_>XBS3XU[=U2Q.SV1E>UZ:D\#OMB
M7N7-6"_3UW7QXY;SO>J?5)U0@IYW>YVQT!.VB;8AX<W)J!G8U&*4^33[;8;C
M#W"=./:Q623$SZ]_^\)(RF'16HEYL."E,_2H'LYH4K#]I'-6.70MT5F:O-)(
M-R*BB)<]L>2ID/9L'&$.UGI%!DRX3 LF,0EUSI KSTGV(. =XAOP?3]Y'J'H
MQ?\(J[FL0!P)5&+\8OC*+AT+>S#5\@*MU%8OO23W4CTABD.EKPON)?*'\OJ$
MZ*H7\%A>_<6%,R?Q1LD4@\X?1T\XR;ABD]0KU3!X],YP?H!D;,8N+YD](61P
M])@+C'5RD7:&U3#(K;CBKZHV<??NAZH_8QR?T](KQKEJD>+8?48 V\DGD-<H
M,HI[+GN R^\X=O(OY:$7X^%X[JXO417V8[6-T%CPX5!2O;<^<.WW*WDA\Z)J
MD.W-86=CU>XCJVU71FV.G[T GGW?G']:Y4M&TT,X3N:;,TZTW2&ET65XF9T3
MRX9A,"S^RK93),U')=Y1H$JL7E_1D8D&-FA;2+GZECGD)#,I&'='H8BYJ_$F
M=Y2C^W;HQ7YI\8,?V)GKP>IUIAN]^,+,'GM0DU^B.&,9XZ:9HU'F_L%_3F6F
M[M1M?:1^"0:+%NGXU5:]/6W>\HR1!P'3W2*6:1.BCH^OX@SI-SY <-VB,%CC
M@!*[O2LW@!6?NXTKC63(8*H(SB#FSZN8Z8-R8=6!4PMUB/J4PUGT0Q4&;*P$
MQD2KYH:\V_Y G#[M@Y@.:F+0\0):"!1!%FA\Z]'%,E0'>I)XP,=!YCI ]HE,
M708@2]Z-<IY6C_$-?^4O3U._+TGXU4)P/L  M#E:"69& O0#8?>N</%DH7O6
M%KIFQV=N<YJI<_,PRAUUU473+6!H6V_2H]#2^D&S*1XIYOLL<H]J_AW7_ %M
ME<\5RG0NJC2(KSLJO(=J;E0I&=$TV8RN,+8YHX[,%ZM@!XSA*/CT!-.OJ;W*
M)!$3([116]U7B:@C7IWJ8%U5+RJS[,-34S]B@(_#:\38)_XPR0@./+8PA=@O
M'",!TJ>(E@HD</SV@<-I]%7,$A)84D==NGMP6"JELV<\O;547)7)UJ9M:6/<
M/V_#/-[66H\3]:*QUC4-YV<_V$1[2Z3 YRIW+;.W Q%<AD+V^YLW;_&1P%0Q
MY.X=AGXS','H$[9)BP3(]8Y4R?\8V?%\>>3\-"E#JIV<[LX'\1;UM+A/0P*I
M1[+,%Q,SM"?HK3?Q?Z7E+A8V[X$R&/SOA;X7#M40PW"XR-D9JEE)$0N9&4=
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M+)/N:CAWFI?O+V_^Q>4?5Z#LHL#5M&V67V9!">$IJ)1O_?8+M2+SY*\-U1O
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M*&6V[@:IT*MP!<"W#B?:QO]'Y:5(9Z+L>'=X@[;G>B!&>GZ=4(^8SVJ),%.
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MS7!\:IIZ"G 9BX)Q#,S@4=\#1?6)<;8:S8Z5[1WI$EG!/8L*Z7UW>:^".U<
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M%-]'#X:;710<.7X7Z$[0FI+394"U0T)ZBDZO,F5JFYKJ4JXU]/D>."?85X1
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M[WCA/D5^7*"7I(=AW8+VE1R9@9=C>[_8<-,D9(1P9%[95""KU5);Z,6;1TO
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M)#[!B@3JK"6N4H1U#)]ZPS0'6+>[/M ^MLHR6V@1V=P[B;Y/K'V6S/SE.?1
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MRK=WORVMD;UKI>I*_L-P8MT>A4GYA3P+S2_M6$#5ME;J._!>.WT)/M(<C\B
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MDXA%%JA=YPA5]Z3 YXL9322_ \;CUWV?%],*7OTK'T0F2Z_-WW?>-?9%"P$
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M]?-2J\!!8W5U"DU7S4(C-[@FR5<A_G'U8BD[7!"F;+C80MN>_L^L[\XN:CJ
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M3)RQF=E?HAQ*HL0I:/M<R"G1V%;D8*ZQR]E/%3O'6FYD7!VQKHAF9'_.=&D
MP]3F5,6K*@A$MZ"&A2K%[DY45)K^)^_"Z@3$9%V\-IG1<L]<^*DMSYO2(I%=
M6LH-YYUF\7#NE8M]S&+,W^L^XYO*@1P@$5!<2$(ZBC_%6W>OLYN/&R^[J)/G
M\J<7V\3?Y+[*U*-)7Q;;84'UMSTQ)J(,20=1>Q*X5LW6 U.&8WL3XQC#7O6(
M?SX&9*J+",8;D,O;9#,("5^=JPNP;X8KKR]5B5E2\(^J,XU8.%"G&"+_Q)0N
MP@>W=L<55.9#TT5]WO=%"DL-3]WW>:ZRO#NP,#\TD=C;?6="B07MQ.OZV"O=
M*Y&RP,HZSD)G,-#H/L5VC>" %RXL294EYE7"L5QG8WW,R;'N)Z11,FJJ9UR$
M>UIY$HU9N] <>-!1><897=:.B]/"+OM7>.Y ^D<CBO3KM>A#Q2)8_ 6O12%
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M@#:#;R'P;K5ISW.T=O@QH:Q7&5+K9 (]4;?\6J-M5XUE@HH<0?A5KIM<3]]
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MJ.+_ (\I?][^M%B;Z_>?_]E02P$"% ,4    "  :B Y7R57B]J0.  "[D@
M$0              @ $     871N;2TR,#(S,#8S,"YX<V102P$"% ,4
M"  :B Y7/R+T-1 )   96   %0              @ '3#@  871N;2TR,#(S
M,#8S,%]C86PN>&UL4$L! A0#%     @ &H@.5T:3HOX#)P  !%<" !4
M         ( !%A@  &%T;FTM,C R,S V,S!?9&5F+GAM;%!+ 0(4 Q0    (
M !J(#E?@QW38ZF<  *Q*!0 5              "  4P_  !A=&YM+3(P,C,P
M-C,P7VQA8BYX;6Q02P$"% ,4    "  :B Y76Z!WE^LG  !0CP( %0
M        @ %IIP  871N;2TR,#(S,#8S,%]P<F4N>&UL4$L! A0#%     @
M&H@.5WY%<ASRN0$ 5E , !D              ( !A\\  &8Q,'$P-C(S7V%C
M=&EN:75M<&AA<BYH=&U02P$"% ,4    "  :B Y74WT2I1\'   _'@  'P
M            @ &PB0( 9C$P<3 V,C-E>#,Q+3%?86-T:6YI=6UP:&%R+FAT
M;5!+ 0(4 Q0    ( !J(#E?G'H5\)0<  'L>   ?              "  0R1
M @!F,3!Q,#8R,V5X,S$M,E]A8W1I;FEU;7!H87(N:'1M4$L! A0#%     @
M&H@.5SZB5]+E P  =0X  !\              ( !;I@" &8Q,'$P-C(S97@S
M,BTQ7V%C=&EN:75M<&AA<BYH=&U02P$"% ,4    "  :B Y7XMDR"M,#  !;
M#@  'P              @ &0G ( 9C$P<3 V,C-E>#,R+3)?86-T:6YI=6UP
M:&%R+FAT;5!+ 0(4 Q0    ( !J(#E=S7W@A#EL  ,EL   -
M  "  :"@ @!I;6%G95\P,#$N:G!G4$L! A0#%     @ &H@.5W,!$.']90
M*VH   T              ( !V?L" &EM86=E7S P,BYJ<&=02P$"% ,4
M"  :B Y7N?-GN;US  "-?0  #0              @ $!8@, :6UA9V5?,# S
M+FIP9U!+ 0(4 Q0    ( !J(#E=3@P#B^5L   EO   -              "
M >G5 P!I;6%G95\P,#0N:G!G4$L! A0#%     @ &H@.5Y^1HS4#1   'DD
M  T              ( !#3($ &EM86=E7S P-2YJ<&=02P$"% ,4    "  :
MB Y7Z#.QT@-B   !9@  #0              @ $[=@0 :6UA9V5?,# V+FIP
M9U!+ 0(4 Q0    ( !J(#E=R-Y>=YEP  %QA   -              "  6G8
M! !I;6%G95\P,#<N:G!G4$L! A0#%     @ &H@.5R^='&R9.0  M4$   T
M             ( !>C4% &EM86=E7S P."YJ<&=02P$"% ,4    "  :B Y7
M9GLNL(A:   V8P  #0              @ $^;P4 :6UA9V5?,# Y+FIP9U!+
M 0(4 Q0    ( !J(#E=KPGK6ES   (X[   -              "  ?')!0!I
M;6%G95\P,3 N:G!G4$L! A0#%     @ &H@.5YJCY,].20  650   T
M         ( !L_H% &EM86=E7S Q,2YJ<&=02P$"% ,4    "  :B Y7@H1S
M.Q=J  #6;@  #0              @ $L1 8 :6UA9V5?,#$R+FIP9U!+ 0(4
M Q0    ( !J(#E<6@K/"^8P  (>0   -              "  6ZN!@!I;6%G
?95\P,3,N:G!G4$L%!@     7 !< Q04  )([!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
